New Somatostatin Receptor Type 2 (SSTR2) Antagonism and … · 2021. 3. 9. · ii Somatostatin...
Transcript of New Somatostatin Receptor Type 2 (SSTR2) Antagonism and … · 2021. 3. 9. · ii Somatostatin...
Somatostatin Receptor Type 2 (SSTR2) Antagonism and Hypoglycemia
in Diabetes
by
Jessica Tin Yan Yue
A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy
Graduate Department of Physiology University of Toronto
© Copyright by Jessica Tin Yan Yue, 2011
ii
Somatostatin Receptor Type 2 (SSTR2) Antagonism and Hypoglycemia in Diabetes
Jessica Tin Yan Yue
Doctor of Philosophy
Graduate Department of Physiology University of Toronto
2011
Abstract
Hypoglycemia is one of the most serious acute complications in intensively treated diabetes.
Recurrent hypoglycemia predisposes individuals to subsequent hypoglycemia, and
diminished counterregulatory hormone responses increase this threat. Elevated pancreatic
and/or circulating somatostatin has been reported in diabetic humans and animals, and we
postulated that excessive somatostatin contributes to the attenuation of counterregulatory
hormone release during hypoglycemia in diabetes. It is known that somatostatin
suppresses stimulated secretion of glucagon, epinephrine, and corticosterone. We
hypothesized that selective somatostatin receptor type 2 (SSTR2) antagonism would:
(Study 1) improve hormone counterregulation to hypoglycemia, and (Study 2) ameliorate
hypoglycemia in recurrently hypoglycemic rats. Using both high (10 U/kg) and low (5 U/kg)
dose insulin to induce hypoglycemia, we demonstrate that inhibiting the action of
somatostatin on SSTR2 normalizes the severely attenuated glucagon and corticosterone
responses to acute hypoglycemia in diabetic rats. These improvements were specific to
iii
diabetes since SSTR2 antagonism did not increase these hormones in non-diabetic rats in
response to hypoglycemia. In the absence of hypoglycemia, SSTR2 antagonist neither
markedly alters glycemia nor causes sustained elevations in counterregulatory hormones in
diabetic animals. Diabetic rats exhibit up to 65% and 75% more pancreatic and plasma
somatostatin than non-diabetic rats following hypoglycemia, respectively. Despite
improvements of glucagon and corticosterone, expression of gluconeogenic enzymes
PEPCK1 and G6Pase was unaltered. SSTR2 antagonism reduced the glucose requirement
during a hypoglycemic clamp induced with a lower dose of insulin. In recurrently
hypoglycemic diabetic rats, we demonstrate that SSTR2 antagonist treatment reduces the
depth and duration of hypoglycemia and promotes the recovery to euglycemia, without
affecting the glycemia-lowering effect of insulin. This amelioration of hypoglycemia by
SSTR2 antagonism may be attributable in part to the observed modest improvements of
glucagon, epinephrine, and corticosterone counterregulation following recurrent
hypoglycemia. These results implicate an important role for increased pancreatic, and
possibly circulating, somatostatin in defective hypoglycemic counterregulation in diabetes.
iv
Acknowledgments
I would fist like to thank my supervisor, Dr. Mladen Vranic, and co-supervisor, Dr. Adria
Giacca, for their support and direction throughout my PhD studies. Dr. Vranic – it has truly
been an honour to have been mentored by you. You provided me with so many
opportunities to further my research, and I have learned so much as a result of your
teaching. You allowed me to be independent while providing me with your wise counsel. It
is a great privilege to have been your student. I will look back with much fondness on the
nine years spent in your laboratory, first as a third-year undergraduate student and
subsequently earning my Master’s and Doctoral degrees under your supervision. Adria –
your expertise, sincerity, and kindness have meant so much to me over the years. Your
genuine care and selfless giving of your time and knowledge have made a deep and lasting
imprint on me. I am extremely thankful to have had the both of you as my supervisors. I
extend my appreciation to the members of my supervisory committee, Dr. Daniel Drucker
and Dr. Qinghua Wang. Thank you for your guidance, your generous expertise, and your
encouragement. I am deeply grateful for your scientific insights and for all your help with
progressing my studies. You have demonstrated much kindness and have been very
generous with your time and advice.
I would like to acknowledge and thank Dr. Suad Efendic (Karolinska Insitute) and Dr. David
Coy (Tulane University) for their collaboration. I would like to thank Dr. Ian Stewart (The
Innovations Group, University of Toronto) for his help and expertise in filing our patent. I
would like to thank Judy Blumstock (MaRS Innovations) and Ian for introducing me to the
area of commercialization in research and for their help in connecting us with people
interested in seeing our hard work translated.
v
I would like to thank Elena Burdett and Loretta Lam not only for their excellent and
valuable technical assistance and knowledge, but also for their much appreciated support,
thoughtfulness and constant camaraderie over the years. Elena – I will always cherish your
friendship and the laughter we shared together. Thank you for taking such great care of me
and for involving me in your life. I would like to thank Dr. Holly Bates, Dr. Christine
Longuet, and members of the Drucker laboratory for their helpful advice and for sharing
their time and methods of RNA isolation RT-PCR with me. Holly – I truly treasure your
friendship and support and will take with me many happy memories of our time together.
To former project students who participated in this project – Eric Chan, Andrea Kokorovic,
Jamila Husein, Adam Sirek, Angela Chung, and Garry Thomas – thank you for all your help
and youthful inspiration! I am indebted to their hard work and dedication to make this
project succeed.
To Bryan – thank you for your constant optimism and your support of me. Thank you for
the late-night pick-ups at the lab, for bringing food, and for lending an extra set of hands on
the weekends when I needed them. Just for understanding – thank you. You enrich my life
in so many ways, and I am so appreciative of all your encouragement, patience, and love.
Lastly and most importantly, I would like to acknowledge my family for their unceasing
support and encouragement in all that I do, whether I deserve it not. To my sister and
brother-in-law, Josephine and Karwin – thank you for always helping to keep my spirits up
and for keeping me real. And especially to my parents, Suzanna and Edwin – I thank you
for your constant affirmation, your prayers, and your love. Thank you for continually
teaching me and reminding me to always keep my focus on the most important things in
life. Truly, the impact of the lessons I have learned at home far surpass the knowledge
acquired from my studies.
Jessica T.Y. Yue
vi
Table of Contents
Acknowledgments .................................................................................................. iv
Table of Contents ................................................................................................... vi
List of Tables .......................................................................................................... xi
List of Figures ....................................................................................................... xii
List of Abbreviations ............................................................................................. xv
Chapter 1 General Introduction ...............................................................................1
1.1 Hypoglycemia ................................................................................................ 1
1.1.1 Normal sensing of hypoglycemia: sites of glucose detection ........................ 2
1.1.2 Normal counterregulatory hormone responses to hypoglycemia .................. 4
1.1.2.1 Insulin. ................................................................................... 4
1.1.2.2 Glucagon. ................................................................................ 4
1.1.2.3 Epinephrine. ............................................................................ 7
1.1.2.4 Norepinephrine. ....................................................................... 8
1.1.2.5 Growth hormone and glucocorticoids. .......................................... 9
1.1.2.6 Glucose autoregulation. ........................................................... 10
1.2 Hypoglycemia in diabetes .............................................................................. 11
1.2.1 Clinical Significance – Hypoglycemia in type 1 diabetes mellitus ................ 11
1.2.2 Clinical Significance – Hypoglycemia in type 2 diabetes mellitus ................ 12
1.3 Defective counterregulation in diabetes ........................................................... 14
1.4 Mechanisms of defective counterregulation in diabetes ...................................... 14
1.4.1 Glucagon counterregulation in impaired in diabetes ................................. 15
1.4.2 Epinephrine counterregulation in diabetes .............................................. 18
1.4.3 Norepinephrine, growth hormone, and glucocorticoid counterregulation in diabetes ............................................................................................ 20
1.4.4 Hypoglycemia unawareness in diabetes ................................................. 21
1.4.5 Hypoglycemia-associated autonomic failure (HAAF) in diabetes ................. 22
1.5 Recurrent hypoglycemia in non-diabetic subjects .............................................. 23
1.6 Recurrent hypoglycemia in diabetes ................................................................ 23
1.7 Somatostatin ............................................................................................... 25
1.7.1 Functions .......................................................................................... 26
1.7.1.1 General somatostatin effects in pancreatic islets. ........................ 26
vii
1.7.1.2 Arguments against local somatostatin effects on pancreatic islets. . 27
1.7.1.3 General somatostatin effects in the brain and pituitary gland. ....... 27
1.7.1.4 General somatostatin effects in the gastrointestinal tract. ............. 28
1.7.1.5 Other effects of somatostatin relating to glucose homeostasis. ...... 28
1.7.2 Localization of somatostatin-producing cells ........................................... 29
1.7.2.1 Pancreatic somatostatin-producing cells. .................................... 29
1.7.2.2 Brain somatostatin-producing cells. ........................................... 30
1.7.2.3 Gastrointestinal somatostatin-producing cells. ............................ 31
1.7.2.4 Other somatostatin-producing cells. .......................................... 31
1.7.3 Synthesis and structure ....................................................................... 31
1.7.3.1 Cortistatin. ............................................................................ 32
1.7.3.2 Neuronostatin. ....................................................................... 33
1.7.3.3 Apelin ................................................................................... 33
1.7.4 Regulation of somatostatin synthesis ..................................................... 34
1.7.5 Regulation of somatostatin secretion ..................................................... 36
1.7.5.1 Regulation of pancreatic somatostatin. ...................................... 36
1.7.5.2 Regulation of brain somatostatin. .............................................. 37
1.7.5.3 Regulation of gastrointestinal somatostatin. ............................... 37
1.8 Somatostatin receptors (SSTRs) ..................................................................... 38
1.8.1 General localization of SSTRs ............................................................... 39
1.8.2 General functions of SSTRs .................................................................. 41
1.8.3 Specific localization, ligand binding, and signalling of SSTR2 ..................... 42
1.9 Somatostatin in type 1 diabetic humans and animal models ............................... 44
1.9.1 Brain somatostatin in experimental diabetes .......................................... 47
1.10 Somatostatin in type 2 diabetic humans and animal models.............................. 48
1.11 Diabetes-induced changes in SSTR expression ................................................ 48
1.12 Somatostatin: hypoglycemia-induced changes ................................................ 49
1.12.1 Hypoglycemia-induced somatostatin and SSTR changes in the brain .......... 51
1.13 Somatostatin and its analogues in diabetic therapy ......................................... 51
1.14 Somatostatin antagonist – PRL-2903 ............................................................. 52
Chapter 2 Objectives ............................................................................................. 54
2.1 Specific Aim: Study 1 ................................................................................... 54
2.2 Specific Aim: Study 2 ................................................................................... 55
Chapter 3 General Materials and Methods ............................................................. 56
3.1 Experimental animals ................................................................................... 56
3.1.1 Care and maintenance ........................................................................ 56
viii
3.1.2 Streptozotocin-diabetic rat model of diabetes mellitus ............................. 56
3.1.3 Induction of diabetes using streptozotocin .............................................. 58
3.1.4 Chronic vessel catheterization .............................................................. 59
3.1.4.1 Pre-operative preparation. ....................................................... 59
3.1.4.2 Surgical procedure. ................................................................. 59
3.1.4.3 Post-operative care. ................................................................ 61
3.1.4.4 Catheter patency and blood sampling. ....................................... 62
3.2 General laboratory methods ........................................................................... 62
3.2.1 Blood Glucose Determination ............................................................... 62
3.2.2 Preparation of blood sample collection tubes .......................................... 63
3.2.3 Radioimmunoassays (RIA) for plasma hormone levels ............................. 64
3.2.3.1 Plasma corticosterone assay. .................................................... 65
3.2.3.2 Plasma glucagon assay. ........................................................... 66
3.2.3.3 Plasma catecholamine assay. ................................................... 68
3.2.3.4 Plasma somatostatin assay. ..................................................... 70
3.2.3.5 Plasma insulin assay ............................................................... 72
3.2.3.6 Plasma growth hormone assay ................................................. 74
3.2.4 Pancreatic protein determination .......................................................... 76
3.2.4.1 Pancreas homogenization for protein isolation ............................. 76
3.2.4.2 Sep-Pak protein extraction ....................................................... 76
3.2.5 Liver mRNA expression quantification .................................................... 77
3.2.5.1 Total RNA preparation. ............................................................ 77
3.2.5.2 cDNA synthesis. ..................................................................... 78
3.2.5.3 Polymerase chain reaction (PCR) of -actin. ................................ 79
3.2.5.4 Real-time quantitative PCR. ..................................................... 80
3.3 Preparation of SSTR2 antagonist and saline infusates ........................................ 82
3.4 Statistical analysis ........................................................................................ 82
Chapter 4 Study 1: Effect of SSTR2 antagonism on counterregulation to hypoglycemia .................................................................................................... 84
4.1 Aims .. ....................................................................................................... 84
4.2 Experimental methods .................................................................................. 85
4.2.1 Study design ..................................................................................... 85
4.2.2 Hypoglycemia experiments .................................................................. 86
4.2.3 Control experiments: SSTR2 antagonist in the absence of hypoglycemia .... 87
4.2.4 Effect of SSTR2 antagonist in non-diabetic rats during hypoglycemia ......... 87
4.3 Results ....................................................................................................... 88
ix
4.3.1 Daily blood glucose, body weight, and food intake ................................... 88
4.3.2 Hypoglycemia clamp experiments ......................................................... 89
4.3.2.1 Pilot study: using 10 U/kg insulin and 1500 nmol/kg/h SSTR2 antagonist. ............................................................................ 89
4.3.2.2 Using 10 U/kg insulin and 3000 nmol/kg/h SSTR2 antagonist. ...... 89
4.3.2.3 Using 5 U/kg insulin and 3000 nmol/kg/h SSTR2 antagonist. ........ 91
4.3.3 Effect of SSTR2 antagonist in the absence of hypoglycemia ...................... 92
4.3.4 Pancreatic glucagon and pancreatic and plasma somatostatin measurements ................................................................................... 93
4.3.5 Liver PEPCK1 and G6Pase mRNA expression ........................................... 93
4.3.6 Effect of SSTR2 antagonist in non-diabetic rats during hypoglycemia ......... 94
4.4 Discussion ................................................................................................... 94
4.4.1 Role for SSTR2 in the enhancement of glucagon counterregulation ............ 94
4.4.2 Potential role for SSTR2 in insulin secretion? .......................................... 98
4.4.3 Role for SSTR2 in the enhancement of corticosterone counterregulation ..... 99
4.4.4 Epinephrine responses to hypoglycemia were unaffected ......................... 103
4.4.5 SSTR2 antagonist demonstrated no effect on growth hormone ................. 104
4.4.6 SSTR2 antagonism does not cause hyperglycemia or undesired stress ...... 106
4.4.7 Glucose requirement during hypoglycemia ............................................ 108
4.4.8 Expression of gluconeogenic enzymes .................................................. 109
4.4.9 Effect of SSTR2 antagonism during hypoglycemia in non-diabetic rats ....... 112
4.5 Study 1 Conclusions .................................................................................... 114
Chapter 5 Study 2: Amelioration of hypoglycemia using SSTR2 antagonism ....... 136
5.1 Aims .. ...................................................................................................... 136
5.2 Experimental methods ................................................................................. 137
5.2.1 Study design .................................................................................... 137
5.2.2 Recurrent hypoglycemia treatment ...................................................... 137
5.2.3 Partial overnight fasting prior to hypoglycemia experiments .................... 138
5.2.4 Hypoglycemia on Experimental Days 1 and 2 ......................................... 138
5.3 Results ...................................................................................................... 140
5.3.1 Pilot Studies: How the present method was established .......................... 140
5.3.2 Daily blood glucose, body weight, and food intake .................................. 141
5.3.3 Glycemia during recurrent hypoglycemia treatment ................................ 142
5.3.4 Basal blood glucose and plasma hormone levels after recurrent hypoglycemia treatment ..................................................................... 142
5.3.5 Blood glucose and plasma insulin levels during Experimental Days 1 and 2 142
5.3.6 Counterregulatory hormones levels during Experimental Days 1 and 2 ...... 143
x
5.4 Discussion .................................................................................................. 146
5.4.1 Amelioration of hypoglycemia with SSTR2 antagonism ............................ 146
5.4.2 SSTR2 antagonism improves counterregulation following recurrent hypoglycemia ................................................................................... 150
5.4.2.1 SSTR2 antagonism increases glucagon counterregulation. ........... 150
5.4.2.2 SSTR2 antagonism preserves epinephrine counterregulation. ....... 152
5.4.2.3 SSTR2 antagonism preserves corticosterone counterregulation. ... 154
5.4.3 Discussion of other mechanisms for reduced counterregulation following recurrent hypoglycemia ...................................................................... 155
5.4.4 Why might SSTR2 antagonism not have as great of an effect on recurrent hypoglycemia as acute hypoglycemia? .................................................. 158
5.5 Study 2 Conclusions .................................................................................... 160
Chapter 6 Study Summaries and General Discussion ........................................... 177
6.1 Summary of Study 1 .................................................................................... 178
6.2 Summary of Study 2 .................................................................................... 179
6.3 General discussion ...................................................................................... 180
6.3.1 Limitations of the present study .......................................................... 180
6.3.2 Hypothesizing a mechanism of action: CNS effects? ............................... 182
6.3.2.1 Does peripherally administered SSTR2 antagonist enter the brain?185
6.3.3 Brief evaluation of tachyphylactic effects of SSTR2 antagonism ................ 186
6.3.4 Potential side effects of SSTR2 antagonism ........................................... 187
Chapter 7 Future Directions ................................................................................ 190
7.1 Delineating a mechanism of action for SSTR2 antagonism ................................. 190
7.2 Testing the efficacy of SSTR2 antagonism in other diabetic models ..................... 191
7.3 Effect of SSTR2 antagonism to non-hypoglycemia stimuli .................................. 192
7.4 Interaction between glycemia, insulin, and somatostatin antagonism on glucagon release ...................................................................................................... 192
Chapter 8 Conclusions ......................................................................................... 194
8.1 Importance of contributions to current body of knowledge ................................ 194
8.2 Potential clinical contributions ....................................................................... 195
Chapter 9 References .......................................................................................... 197
xi
List of Tables
Table 4-1. Metabolic parameters of rats that underwent hypoglycemia clamps or control
experiments in the absence of insulin.. ..................................................................... 129
Table 4-2. Basal plasma counterregulatory hormone levels for rats that underwent
hypoglycemia clamp and control experiments in the absence of insulin ......................... 130
Table 4-3. Plasma insulin levels during hypoglycemia clamps .................................... 131
Table 4-4. Plasma counterregulatory hormone and insulin levels during control
experiments in the absence of insulin ....................................................................... 132
Table 4-5. Quantitative mRNA expression of liver PEPCK1 and G6Pase following
hypoglycemia clamp (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist) and control
experiments in the absence of insulin (0 U/kg, 3000 nmol/kg/h) .................................. 133
Table 4-6. Metabolic parameters of non-diabetic rats treated with SSTR2 antagonist
(N+SSTR2a) that underwent hypoglycemia clamp experiments ................................... 134
Table 4-7. Pancreatic somatostatin protein levels (pmol/mg protein) and plasma
somatostatin levels (pmol/mL) in all hypoglycemic rats .............................................. 135
Table 5-1. Metabolic parameters for rats that underwent recurrent hypoglycemia
treatment. ........................................................................................................... 173
Table 5-2. Body weight and amount of insulin administered via iv bolus and iv infusion,
and total insulin administered in both groups on both days ......................................... 174
Table 5-3. Basal plasma hormone levels on Experimental Day 1 (ExptD1) and
Experimental Day 2 (ExptD2) in rats that underwent SSTR2a-treated and control
hypoglycemia experiments ..................................................................................... 175
Table 5-4. Plasma insulin levels (ng/mL) during ExptD1 and ExptD2 in saline-SSTR2a
treatment and saline-saline control groups ............................................................... 176
xii
List of Figures
Figure 1-1. Linear structures of somatostatin, somatostatin-28, and SSTR2 antagonist
PRL-2903. ............................................................................................................. 53
Figure 1-2. Structure of SSTR2 antagonist PRL-2903. ............................................... 53
Figure 3-1. Structure of streptozotocin. .................................................................. 57
Figure 4-1. Study 1 protocol design. ...................................................................... 115
Figure 4-2. Schematic representation of A) hypoglycemia clamp experiments and B)
control experiments in the absence of exogenously administered insulin. ...................... 116
Figure 4-3. Pilot study: Plasma hormone levels during hypoglycemia clamp (10 U/kg
insulin, 1500 nmol/kg/h SSTR2 antagonist). A) Glucagon. B) Corticosterone. .............. 117
Figure 4-4. Blood glucose levels during hypoglycemia clamp (10 U/kg insulin, 3000
nmol/kg SSTR2 antagonist). ................................................................................... 118
Figure 4-5. Plasma hormone levels during hypoglycemia clamp (10 U/kg insulin, 3000
nmol/kg/h SSTR2 antagonist). A) Glucagon. B) Corticosterone. C) Glucose infusion. ... 119
Figure 4-6. Plasma A) epinephrine and B) norepinephrine levels during hypoglycemia
clamp (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist) ........................................ 120
Figure 4-7. Blood glucose levels during hypoglycemia clamp using low insulin dose (5 U/kg
insulin, 3000 nmol/kg SSTR2 antagonist).. ............................................................... 121
Figure 4-8. Plasma hormone levels during hypoglycemia clamp (5 U/kg insulin, 3000
nmol/kg/h SSTR2 antagonist). A) Glucagon. B) Corticosterone. C) Glucose infusion. ... 122
Figure 4-9. Plasma A) epinephrine and B) norepinephrine levels during hypoglycemia
clamp (5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). ......................................... 123
xiii
Figure 4-10. Plasma growth hormone levels during hypoglycemia clamp (5 U/kg insulin,
3000 nmol/kg/h SSTR2 antagonist) ......................................................................... 124
Figure 4-11. Blood glucose levels during control experiments in the absence of insulin (0
U/kg, 3000 nmol/kg/h). ......................................................................................... 125
Figure 4-12. Pancreatic protein content of A) glucagon and B) somatostatin, and C)
plasma somatostatin, following hypoglycemia clamp (10 U/kg insulin, 3000 nmol/kg/h
SSTR2 antagonist) and control experiments in the absence of insulin (0 U/kg, 3000
nmol/kg/h). ......................................................................................................... 126
Figure 4-13. Blood glucose levels during hypoglycemia clamp in non-diabetic rats. A) 10
U/kg insulin, 1500 nmol/kg/h SSTR2 antagonist; B) 10 U/kg insulin 3000 nmol/kg/h SSTR2
antagonist; C) 5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist. ............................... 127
Figure 4-14. Effect of SSTR2 antagonist on plasma glucagon (A-C) and plasma
corticosterone (D-F) at the various dosing combinations of insulin and SSTR2 antagonist in
non-diabetic rats. .................................................................................................. 128
Figure 5-1. Study 2 protocol design. ....................................................................... 161
Figure 5-2. Pilot study: A) Glycemia during 2 consecutive days of hypoglycemia (i.e.
without prior recurrent hypoglycemia). B) Plasma glucagon levels during 2 consecutive
days of hypoglycemia. Insulin administered via s.c. injection. ..................................... 162
Figure 5-3. Pilot study: A) Glycemia during 2 consecutive days of hypoglycemia (i.e.
without prior recurrent hypoglycemia). B) Plasma glucagon levels during 2 consecutive
days of hypoglycemia. Insulin administered via i.v. bolus + infusion. . ........................ 163
Figure 5-4. Blood glucose levels during recurrent hypoglycemia treatment (5 episodes
over 3 days). ........................................................................................................ 164
Figure 5-5. Blood glucose levels during hypoglycemia experiments in saline-SSTR2a
treatment group ................................................................................................... 165
Figure 5-6. Blood glucose levels during hypoglycemia experiments in saline-saline control
group. ................................................................................................................. 166
Figure 5-7. Enlarged scale showing blood glucose levels during hypoglycemia experiments
in the A) saline-SSTR2a treatment group and B) saline-control group ........................... 167
xiv
Figure 5-8. Plasma glucagon during ExptD1 and ExptD2 in A) saline-SSTR2a treatment;
B) saline-SSTR2a treatment with rats that did not experience hypoglycemia omitted; and C)
saline-saline control groups.. .................................................................................. 168
Figure 5-9. Plasma epinephrine during ExptD1and ExptD2 in A) saline-SSTR2a treatment;
B) saline-SSTR2a treatment with rats that did not experience hypoglycemia omitted; and C)
saline-saline control groups. ................................................................................... 169
Figure 5-10. Plasma corticosterone during ExptD1and ExptD2 in A) saline-SSTR2a
treatment; B) saline-SSTR2a treatment with rats that did not experience hypoglycemia
omitted; and C) saline-saline control groups ............................................................. 170
Figure 5-11. Plasma norepinephrine during ExptD1 and ExptD2 in A) saline-SSTR2a
treatment; B) saline-SSTR2a treatment with rats that did not experience hypoglycemia
omitted; and C) saline-saline control groups ............................................................. 171
Figure 5-12. Comparison of peak incremental hormone responses to acute hypoglycemia
(Study 1) and recurrent hypoglycemia (Study 2) in control and SSTR2 antagonist-treatment
groups. A) Plasma glucagon; B) plasma epinephrine; C) plasma corticosterone.. .......... 172
xv
List of Abbreviations
ACCORD Action to Control Cardiovascular Risk in Diabetes
ACTH adrenocorticotrophic hormone
ADVANCE Action in Diabetes and Vascular Disease
ANOVA analysis of variance
AP area postrema
ARC arcuate nucleus
AUC area under the curve
AVP arginine vasopressin
BLA basolateral amygdala
BNST bed nucleus of the stria terminalis
CPE carboxypeptidase E
CRH corticotrophin-releasing hormone
DCCT Diabetes Control and Complications Trial
DMH dorsomedial nucleus
DMNV dorsal motor nucleus of the vagus
EDTA ethylenediamine tetraacetic acid
GABA gamma-aminobutyric acid
GE glucose-excited
GHRH growth hormone releasing hormone
GI glucose-inhibited
GPCR G-protein coupled receptor
HAAF hypoglycemia-associated autonomic failure
HPA hypothalamic-pituitary-adrenal
IML intermediolateral column
ip intraperitoneal
iv intravenuous
LC locus coeruleus
LHA lateral hypothalamic area
MPO medial preoptic area
mRNA messenger ribonucleic acid
NOD non-obese diabetic
xvi
NTS nucleus of the solitary tract
PBN parabrachial nucleus
PC1/2 prohormone convertase-1/-2
PCR polymerase chain reaction
PMV portal-mesenteric veins
POMC proopiomelanocortin
PVN paraventricular nucleus
RIA radioimmunoassay
RVLM rostroventrolateral medulla
sc subcutaneous
SCN suprachiasmatic nucleus
SEM standard error of the mean
SON supraoptic nucleus
SSTR1/2/3/4/5 somatostatin receptor type 1/2/3/4/5
STZ streptozotocin
UKPDS United Kingdom Prospective Diabetes Study
VADT Veterans Affairs Diabetes Trial
VMH ventromedial hypothalamus
VMN ventromedial hypothalamic nucleus
1
1
Chapter 1 General Introduction
1 Introduction
1.1 Hypoglycemia
Hypoglycemia is a perturbation to physiological homeostasis and has potentially devastating
consequences. Hypoglycemia is defined as an “abnormally low plasma glucose
concentration that expose[s] the individual to potential harm” by the American Diabetes
Association Workgroup on Hypoglycemia, and quantitatively, it is a measured plasma
glucose level of 3.9 mM (1). Glucose is the predominant fuel to the brain (2). When
arterial plasma glucose levels fall below the physiological euglycemic range (i.e. 3.9 – 6.1
mM), glucose transport to the brain becomes rate limiting to brain glucose metabolism
(3;4). Thus, it is imperative that blood glucose concentrations are maintained above this
level for brain function and ultimately for survival (3;4).
Symptoms arising from iatrogenic hypoglycemia are conventionally classified into two main
categories: i) neuroglycopenic, and ii) neurogenic or autonomic (5). Neuroglycopenic
symptoms stem from glucose deprivation of the brain and include behavioural changes,
fatigue, and cognitive impairments, and confusion (5). Restoration of blood glucose levels
results in recovery from these deficits in brain function (6). In severe neuroglycopenia,
seizures, loss of consciousness, and brain death can ensue, but this is rare and associated
with profound and prolonged hypoglycemia (7). Neurogenic symptoms arise from the
autonomic nervous system reacting to the perception of hypoglycemia. Adrenergic
2
neurogenic symptoms mediated by catecholamines include shakiness/tremor, a pounding
heart, and nervousness/anxiety, while cholinergic neurogenic symptoms mediated by
acetylcholine include sweatiness, hunger, and a tingling sensation (8). In healthy
individuals, these symptoms of hypoglycemia often do not present until plasma glucose
levels reach a threshold of approximately 3.0 mM (9-11). Neurogenic symptoms are
present (3.2 mM) before neuroglycopenic symptoms (2.8 mM) and cognitive impairment
(2.7 mM) (12).
1.1.1 Normal sensing of hypoglycemia: sites of glucose detection
Hypoglycemia is a fairly uncommon event except in individuals that use glucose-lowering
medications, particularly insulin and sulphonylureas or other insulin secretagogues to treat
diabetes, or in patients with insulinomas (11). This is because the body has several
physiological defense mechanisms to counter decreases in blood glucose to restore blood
glucose from hypoglycemia to euglycemia. In healthy subjects, hypoglycemia elicits a
characteristic succession of responses. Glucose sensors are responsible for the detection of
glycemic decline and initiate an orchestrated series of responses mediated via neural
networks that integrate the various afferent inputs and instigate efferent responses,
particularly as they relate to hypoglycemia. Glucose sensors important for glucose
counterregulation are found in three primary areas: the hepatic portal-mesenteric veins
(PMV), the hypothalamus, and the brainstem (13;14).
The portal vein can also sense a decrease in plasma glucose via a GLUT2-dependent glucose
sensing mechanism and relays this signal to the central nervous system via a vagus nerve
afferent (15-18). It has been demonstrated that normalizing glucose levels in the PMV can
suppress hypoglycemia-induced food intake (19) and sympathoadrenal responses (20;21).
3
Hepatoportal glucose sensors also stimulate glucose storage in the liver, muscle, and
adipose tissue (22).
In the hypothalamus, established key areas involved in glucose detection include the
ventromedial hypothalamus (VMH) (specifically the ventromedial hypothalamic nuclei (VMN)
and arcuate nuclei (ARC)) (23-26), lateral hypothalamic area (LHA) (27-29), and
paraventricular nuclei (PVN) (30-32) in which glucose sensing neurons have been located.
The VMH integrates forebrain neuronal input with ascending information from the brainstem
and then sends output to regions involved in control of various behaviours and physiologic
responses (33). These hypothalamic areas identified for glucose sensing also have critical
roles for glucagon and catecholamine counterregulation in response to hypoglycemia (34-
40), which will be discussed below.
In the brainstem, glucose sensing neurons are abundant in the nucleus of the solitary tract
(NTS) (15;41-43), area postrema (AP) (44), and dorsal motor nucleus of the vagus (DMNV)
(45). These glucose sensing regions of the brainstem have been implicated in the
regulation of glucose homeostasis (46-48).
More recently, nuclei in the medial amygdala have also been implicated as an important
glucose sensing area that also elicits counterregulatory responses (49). Detailed
mechanisms involved with sensing hypoglycemia and neuronal integration have been
recently reviewed (13;14;18). In summary, perturbation of glucose homeostasis triggers
central integration of the various glucose-detection signals, and an autonomic response is
initiated that activates sympathetic (neural and adrenomedullary) and parasympathetic
outflow (50). Taken together, these counterregulatory responses involve inhibition of
4
endogenous insulin secretion and activation of several hormonal and neuroendocrine
systems to restore blood glucose to euglycemia.
1.1.2 Normal counterregulatory hormone responses to hypoglycemia
1.1.2.1 Insulin.
First and foremost, with declining blood glucose levels, insulin secretion must cease
(51;52), and this alleviates both its suppressive effect on hepatic glucose production and its
stimulatory effect of glucose utilization in muscle and adipose tissue. Reduced insulin
secretion also lowers insulin-mediated inhibition of lipolysis and protein catabolism and
stimulation of lipogenesis and protein anabolism, which results in increased plasma levels of
free fatty acids, glycerol, and amino acids, the products of which can serve as substrates or
energy sources for gluconeogenesis (53;54). Reduced insulin secretion is believed to be
due to a direct effect of hypoglycemia on pancreatic -cells (51;55). Typically, the decrease
in pancreatic insulin secretion occurs when the blood glucose threshold reaches 4.6 mM (3).
Sympathoadrenal activation in the form of norepinephrine from pancreatic sympathetic
nerves and epinephrine from the adrenal medulla may also play a role in inhibiting insulin
secretion via 2-adrenergic stimulation (56). It should be noted that the catecholamines
can also stimulate insulin via 2-adrenergic receptors, but the 2-adrenergic effect appears
to predominant, at least in human islets (57)
1.1.2.2 Glucagon.
In addition to the decrement in insulin, several other counterregulatory hormones work
together to normalize blood glucose levels in response to hypoglycemia. It is well known
that glucagon is key in restoring euglycemia during acute hypoglycemia (58;59). Glucose
recovery from hypoglycemia is impaired by approximately 40% when glucagon secretion is
inhibited by somatostatin infusion (60). This dependence on the glucagon response for
5
hypoglycemic recovery is true for both short-term (59-61) and prolonged (62) episodes of
hypoglycemia. Glucagon helps to restore euglycemia by stimulating hepatic glucose
production via glycogenolysis, or it favours gluconeogenesis when precursors (i.e. lactate,
amino acids, and glycerol) are abundant (63).
Increments in glucagon secretion can result from direct effects of hypoglycemia on
pancreatic -cells (64). The glycemic threshold of approximately 3.8 mM triggers glucagon
release (9;10). Other mechanisms of the secretory glucagon response to hypoglycemia
include increased autonomic inputs (i.e. sympathetic neural, parasympathetic neural, and
adrenomedullary) and decreased intraislet insulin (50). During hypoglycemia, the
sympathetic (65;66) and parasympathetic (67;68) nerves and the adrenal medulla are
activated – releasing norepinephrine (69;70), acetylcholine (71), and epinephrine (72;73),
respectively – all of which result in increased glucagon release. Catecholamines stimulate
-cell glucagon secretion via 2- and 2-adrenergic receptors (69;74;75), whereas
acetylcholine acts via M1 and M3 muscarinic receptors (76;77). Decreased intraislet insulin
secretion during hypoglycemia is believed to be one of the signals involved in glucagon
secretion (78-80). More recent work has suggested that a decrement in zinc, a co-secretory
product of insulin release, and not necessarily insulin itself, provides the trigger to initiate
glucagon secretion during hypoglycemia since zinc acts on KATP-channels to hyperpolarize -
cells (81;82), but this view has been challenged (83). -aminobutyric acid (GABA), which is
co-localized in -cells with insulin, also suppresses glucagon release (84). Functional GABAA
receptors are expressed on -cells, and activation of these receptors by GABA secreted by
-cells mediates chloride ion influx thereby hyperpolarizing the -cell and inhibiting
glucagon release (85-87). Intraislet somatostatin exerts a tonic suppressive effect on
glucagon release (88;89). It was first postulated nearly 20 years ago that relative
6
abundance of pancreatic somatostatin in diabetic dogs may contribute to the poor glucagon
response to hypoglycemia (90), and this concept will be discussed in detail throughout this
thesis. Ghrelin is another peptide predominantly produced by the stomach but which is also
synthesized in small amounts in the pancreatic islet. The ghrelin receptor is widely
expressed in the adult rat islet and has been co-localized with glucagon-positive cells (91).
Locally released ghrelin could have a paracrine effect on -cell glucagon release, perhaps
promoting glucagon release during hypoglycemia. However, studies in perfused rat
pancreas indicate that concentrations of ghrelin within the physiological range (0.5–3 nM)
had no effect on basal or arginine-stimulated glucagon release, despite mildly inhibiting
both stimulated insulin and somatostatin release (92). It has also been postulated that the
-cell may sense hypoglycemia directly and secrete glucagon in response to low glucose
concentrations as has been observed in the perfused isolated pancreas (93). However,
lowering glucose levels in isolated -cells failed to stimulate glucagon secretion (94), which
suggested no direct role of hypoglycemia on stimulating glucagon release. More recent
evidence suggests that the direct stimulatory effect of low glucose on glucagon secretion by
the -cell may be of less significance as compared to the stimulatory influences of other
factors (95;96). This is supported by the intraislet insulin hypothesis which involves a
“switch-off” concept in which the -cell reduces insulin secretion as a key mechanism to
initiate the glucagon response to hypoglycemia (80;97). This concept as it pertains to
diabetes will be discussed in section 1.4.1.
In addition to these factors, central nervous system regulation of glucagon release has also
been demonstrated. Lesioning of the VMH caused 50-60% and 75-80% decreases in
glucagon and catecholamine responses during mild (3.0 mM) and severe (2.5 mM)
hypoglycemia, respectively (34). Glucagon secretion can be induced with local
7
glucoprivation in the VMH by direct 2-deoxyglucose injection (35), and hypoglycemia-
induced glucagon secretion can be suppressed by direct VMH injection of glucose (36).
Furthermore, glutamate release by neurons of the VMH has also been implicated as an
important mechanism in glucagon counterregulation to hypoglycemia (98). The VMH has
been shown to be part of the neurocircuitry that links sympathetic and parasympathetic
innervation of the pancreas to regulate glucagon release, and Buijs et al. reports other key
brain centres including the suprachiasmatic nucleus (SCN), ARC, dorsomedial nucleus
(DMH), locus coeruleus (LC), NTS, and DMNV and intermediolateral column (IML) of the
spinal cord to be involved in this neurocircuitry (99).
1.1.2.3 Epinephrine.
Epinephrine has an important role in augmenting blood glucose levels, although the
epinephrine response may not be critical in correcting hypoglycemia unless glucagon
secretion is deficient (59;100;101), which often occurs in type 1 diabetes or long-standing
type 2 diabetes. This will be further discussed below. It has been suggested that in type 1
diabetes, a robust epinephrine response can compensate for an absent glucagon response
(102). Hypoglycemia is one of the most potent stimulators of epinephrine release from the
adrenal medulla (103) and has been demonstrated to elevate plasma epinephrine levels by
more than 60-fold (103;104). Hypoglycemia activates sympathetic nervous activity in
muscle (105;106) and the pancreas (65;67). The release of epinephrine is triggered when
arterialized venous blood glucose levels fall to approximately 3.8 mM, which is similar to the
glycemic threshold for glucagon secretion (9;10). Epinephrine both stimulates glucose
production as well as limits glucose utilization directly by inhibiting glucose uptake by
peripheral tissues and indirectly by suppressing insulin release (107). Epinephrine
stimulates hepatic glycogenolysis via 1- and 2-adrenergic receptors (108). Epinephrine
8
stimulates hepatic, and to some extent renal, gluconeogenesis, also by mobilizing
gluconeogenic substrates. The effect of epinephrine to reduce glucose uptake involves
limiting glucose utilization by insulin-sensitive tissues via direct effects and also by
increasing non-esterified fatting acids levels. Catecholamine release from the adrenal gland
can also stimulate synthesis of glucocorticoids (109).
1.1.2.4 Norepinephrine.
Although some norepinephrine is also released by the adrenal medulla (approximately 20%
of its total catecholamine release is norepinephrine), the primary source of circulating
norepinephrine is from sympathetic nerves innervating blood vessels. Normally, most of the
norepinephrine released by sympathetic nerves is taken back up by the nerves (some is also
taken up by extra-neuronal tissues) where it is metabolized. Thus, only a small amount of
norepinephrine enters the blood into the peripheral circulation. However, at times of high
sympathetic nerve activation, the amount of norepinephrine entering the blood increases
dramatically (108). Norepinephrine has also been shown to increase blood glucose levels
during hypoglycemia via mechanisms similar to those of epinephrine (110). Yet during
hypoglycemia, plasma norepinephrine levels are lower compared with epinephrine (i.e.
approximately 5-fold as compared to 60-fold elevations of epinephrine) (103;111). During
hypoglycemia, norepinephrine is released not only from sympathetic nerve terminals, but
also in smaller quantities from the adrenal medulla (112-114). Increases in norepinephrine
within muscle and adipose tissue are observed in response to hypoglycemia implicating
activation of sympathetic nerves in these glucoregulatory tissues. In muscle,
norepinephrine and epinephrine can stimulate glycogenolysis and release lactate via a 2-
adrenal mechanism and decrease insulin-stimulated glycogen synthesis (108). In adipose
9
tissue, norepinephrine and epinephrine mobilize free fatty acids by stimulating lipolysis also
mediated through -adrenergic receptors (115;116).
1.1.2.5 Growth hormone and glucocorticoids.
Suppression of insulin secretion and activation of glucagon and epinephrine secretions are
the primary defenses to safeguard against hypoglycemia. Growth hormone and
glucocorticoids also help to promote the restoration of euglycemia during prolonged
hypoglycemia (i.e. ≥ 3 hours) (64;117;118), whereas their effects during short term
hypoglycemia are not as strong. Growth hormone and glucocorticoid responses are
triggered at glycemic thresholds of approximately 3.7 and 3.2 mM, respectively (9;10).
Growth hormone and glucocorticoids – cortisol in humans and corticosterone in rodents –
act by decreasing glucose utilization and supporting glucose production (117;118). During
prolonged hypoglycemia, the lack of either growth hormone or glucocorticoid
counterregulation results in a hypoglycemia of greater severity which even enhanced
glucagon or epinephrine counterregulation cannot overcome (117;118). Growth hormone
secretion from the anterior pituitary is primarily regulated by growth hormone release
hormone (GHRH) and somatostatin release from the hypothalamus. Insulin-induced
hypoglycemia, L-dopa administration, and arginine infusion indirectly stimulate growth
hormone secretion, and one study has suggested that unlike the other stimuli,
hypoglycemia can elicit increases in growth hormone secretion independently of GHRH and
somatostatin regulation (119). During hypoglycemia, an increase in growth hormone is
involved in enhancing glucose production, limiting glucose utilization, and stimulating
lipolysis to increase circulating plasma free fatty acids, glycerol, and -hydroxybutyrate,
which can provide gluconeogenic substrates and well as fuels to spare glucose (117).
10
In response to hypoglycemia, the hypothalamic-pituitary-adrenal (HPA) axis is activated,
and this results in the release of cortisol/corticosterone from the adrenal cortex (120).
Activation of the HPA axis involves the release of corticotrophin-releasing hormone (CRH)
and arginine vasopressin (AVP) from neurons of the paraventricular nucleus of the
hypothalamus into the median eminence. Here, these neuropeptides travel via the
hypophyseal portal circulation to the anterior pituitary where they stimulate the production
of adrenocorticotrophic hormone (ACTH) from its precursor, proopiomelanocortin (POMC).
ACTH is released into the peripheral circulation where is acts on the adrenal cortex to
release cortisol/corticosterone, which ultimately inhibit further HPA activity (121;122). This
negative feedback control is mediated by cortisol/corticosterone acting on glucocorticoid
receptors (GRs) in the hippocampus, PVN, and anterior pituitary (for suppressing the stress
response) or on mineralocorticoid receptors at the hippocampus (for tonic basal inhibition of
the HPA axis) (123). During hypoglycemia, glucocorticoids act on glucocorticoid receptors
on the liver to stimulate glucose production directly by enhancing gluconeogenic enzymes
and indirectly by increasing the pool of readily available substrates (124). Glucocorticoids
reduce insulin-mediated glucose uptake and utilization by muscle and adipose tissue
(125;126). In support of the primary counterregulatory defenses, glucocorticoids can
potentiate the effects of glucagon and epinephrine on the liver and suppress insulin’s
inhibitory effect of glucose production (127;128).
1.1.2.6 Glucose autoregulation.
Glucose autoregulation is endogenous glucose production independent of the other
aforementioned hormones and neural glucoregulatory mechanisms, and it is inversely
proportional to ambient plasma glucose levels (50). This has been observed in humans
during marked hypoglycemia (110;129). It is only at very severe hypoglycemia (i.e. 1.7 –
11
1.9 mM) that glucose autoregulation may occur (129;130). It is believed that glucose
autoregulation plays a relatively minor role in glucose counterregulation (3).
1.2 Hypoglycemia in diabetes
1.2.1 Clinical Significance – Hypoglycemia in type 1 diabetes mellitus
Hypoglycemia is rare in people without diabetes (11;63;131-133). However, hypoglycemia
is one of the most serious acute complications of well-controlled type 1 diabetic patients and
often represents the limiting factor to insulin therapy (134-140). Based on conservative
estimates, 10% of type 1 diabetic individuals using conventional insulin therapy and 25% of
diabetic individuals using intensive insulin therapy experience at least one bout of severe,
debilitating hypoglycemia, often with seizure or coma, in a given year (138;139;141).
Furthermore, patients practicing conventional insulin therapy undergo an average of one
bout of mild to moderate symptomatic hypoglycemia per week while those being intensively
treated suffer from two such episodes weekly (142). It can thus be projected that over 40
years of type 1 diabetes, an average patient may experience 2000-4000 bouts of
symptomatic hypoglycemia (143). Hence, iatrogenic hypoglycemia is evidently problematic
for type 1 diabetic patients attempting to manage their plasma glucose levels in a range
commonly recommended by practitioners to curtail diabetic complications resulting from
poor glycemic control. To further complicate matters, the strongest predictor of severe
hypoglycemia was a history of severe hypoglycemia (144). This suggests any bout of
hypoglycemia can predispose an individual to suffer subsequent bouts of hypoglycemia.
The topic of recurrent hypoglycemia will be discussed below.
12
1.2.2 Clinical Significance – Hypoglycemia in type 2 diabetes mellitus
Individuals with type 2 diabetes generally experience less frequent severe hypoglycemia
than those with type 1 diabetes as has been reported by two separate clinical trials (143).
Individuals with type 2 diabetes are at a two- to four-fold greater risk of serious
cardiovascular outcomes compared with those without diabetes (145). As with type 1
diabetes, the ultimate goal of well-controlled glycemia to reduce the risk of diabetic
complications is still elusive due to an increased threat of hypoglycemia that accompanies
intensive treatment (146). Treatment-induced hypoglycemia is a limiting factor of glycemic
management not only in individuals with type 1 diabetes, but also in many with advanced
type 2 diabetic individuals in which there is an absolute endogenous insulin deficiency
(63;147-149). Overall, hypoglycemia is less frequent in type 2 diabetes than in type 1
diabetes, but hypoglycemia becomes progressively more frequent and limiting to glycemic
control in advanced type 2 diabetes (4). Patients with type 2 diabetes recently started on
insulin had rates of hypoglycemia which were similar to those patients who were taking
sulphonylureas (150). However, individuals with type 2 diabetes treated with insulin for
over 5 years and whose endogenous insulin production as measured by stimulated C-
peptide was low had significantly higher rates of hypoglycaemia than individuals with
shorter duration of insulin treatment or individuals treated with sulphonylureas, including
severe episodes (150;151). Strict glycemic control remains the most effective strategy to
reduce the development and/or progression of microvascular disease. Interestingly,
however, recent clinical trials in type 2 diabetic patients – Action to Control Cardiovascular
Risk in Diabetes Study Group (ACCORD) (152), Action in Diabetes and Vascular Disease
(ADVANCE) (153), and Veterans Affairs Diabetes Trial (VADT) (154) – reported that
reducing HbA1C to below 7% did not significantly reduce cardiovascular mortality.
However, it has been suggested that the study duration of these aforementioned trials may
13
have been too short to show a significant effect of intensive glycemic control on
macrovascular complications (146). The UKPDS study, on the other hand, showed
significantly lower relative risk reduction for myocardial infarctions and overall mortality in
patients that receive intensive treatment compared with those who received conventional
treatment in the 10-year follow-up study (155). Thus, the effect of intensive control of
glycemia to reduce cardiovascular morbidity has been demonstrated, but it may be limited
to younger patients with shorter duration of diabetes and no prior cardiovascular disease
(156).
Despite the benefits of well-controlled glycemia on cardiovascular morbidity, intensive
treatment to control glucose is associated with a significantly greater incidence of severe
hypoglycemic events (152-154). Mild hypoglycemia events were also more frequent in the
intensive control arm as compared to conventional control arm in the ADVANCE trial (153).
In the ACCORD trial, there was a 3-fold greater incidence of severe hypoglycemia in the
intensive treatment group as compared with conventional treatment group (152). The
VADT study reported 3-fold greater incidence of hypoglycemia with symptoms, and a 5-fold
greater incidence of hypoglycemia without symptoms, in the intensive versus standard
therapy arms (154). This is problematic since in the VADT, severe hypoglycemia was the
most powerful predictor of cardiovascular death. Likewise in ACCORD, patients with severe
hypoglycemia had higher mortality than those without in both the intensive and
conventional treatment study arms. Hypoglycemia is associated with activation of
adrenergic responses and prolonged QTc intervals and cardiac arrhythmias (157), which can
contribute to increased cardiovascular mortality. In addition, diabetic autonomic
neuropathy may also render patients more vulnerable to adverse cardiovascular outcomes
(158). Thus, intensive treatment to keep HbA1C below 7% reduces the risk of
14
macrovascular complications in individuals with type 2 diabetes, but the corollary is that
intensive glucose control is associated with frequent episodes of severe hypoglycemia and
consequent cardiovascular events leading to mortality.
1.3 Defective counterregulation in diabetes
Normal counterregulatory responses to hypoglycemia have been described above as it
applies to healthy individuals. However, hypoglycemia in type 1 diabetic patients is the
consequence of an interplay between insulin excess as well as compromised glucose
counterregulation (159). In type 2 diabetes, both a history of previous hypoglycemia and
duration of insulin treatment are significant predictors of hypoglycemia (148;160). As
patients progress with type 2 diabetes, they approach the insulin-deficient end of this
disease until they reach the stage of being absolutely endogenous insulin deficient. Then
patients are thus similar to individuals with type 1 diabetes in that compromised glucose
counterregulation may include defective hormone responses to restore euglycemia,
hypoglycemia unawareness, and elevated glycemic thresholds (i.e. lower glycemia required)
for responses to hypoglycemia (161).
1.4 Mechanisms of defective counterregulation in diabetes
Fundamental alterations in glucose counterregulation occur in individuals with established
type 1 and type 2 diabetes (159;162). When diabetes is fully developed, endogenous
insulin secretion in completely absent (163;164), and plasma insulin concentrations reflect
that those which are provided by exogenously administered insulin and do not diminish
when blood glucose levels fall. Thus the first defense against hypoglycemia, the decrement
15
of endogenous insulin secretion, is non-existent (159;162). As patients with type 2
diabetes approach the insulin-deficient end of this disease, they become similar to
individuals with type 1 diabetes in that both have absolute -cell failure, which causes the
loss of the insulin decrement in response to hypoglycemia (4).
1.4.1 Glucagon counterregulation in impaired in diabetes
The glucagon response, the second defense to combat hypoglycemia, is also lost in
established type 1 diabetes (165;166) and in advanced type 2 diabetes (167;168). In type
1 diabetes, this usually occurs within the first few years of onset of the disease (165;166).
This defect may be specific to insulin-induced hypoglycemia as a stressor since glucagon
counterregulation to other stressors, such as arginine infusion or intracerebroventricular
carbachol infusion, in diabetic subjects or animals are still intact (166;169;170). Although it
has been shown that the impairment is linked to a loss of residual -cell function (171), the
exact mechanisms underlying the defect in glucagon response still remain unclear.
Hypotheses related to impaired glucagon counterregulation as a result of loss of -cell
function include a requirement of a decrement of intraislet insulin release (172;173) as well
as a -cell insulin “switch-off” hypothesis (82;97) to trigger glucagon secretion in response
to hypoglycemia. Other hypotheses include chronic hyperglycemia since it was
demonstrated that restoration of normal glycemia independent of insulin can improve
glucagon counterregulation (174), increased -cell sensitivity to exogenous insulin as a
result of the absence of -cell function (175), and a defect in autonomic response to
hypoglycemia (175), and in particular defective sympathetic innervation of the islet to
release glucagon in response to hypoglycemia (176). Reduced autonomic responses to
hypoglycemia may be the result of up-regulated brain glucose transport since it has been
demonstrated that this is a prominent mechanism after long repeated exposure to
16
hypoglycemia (177;178). In -cell-deficient STZ-diabetic rats treated with insulin, it was
demonstrated that the glucagon response to insulin-induced hypoglycemia can be enhanced
by pancreatic infusion and subsequent switch-off of somatostatin (at hypoglycemia),
thereby supporting the notion that glucagon counterregulation is a general disinhibition
phenomenon and can be enhanced by switch-off of -cell-suppressing intrapancreatic
signals other than insulin or its co-secretory products (179).
In type 2 diabetes, which tends to be a more heterogeneous disease than type 1 diabetes,
investigations of how hypoglycemic counterregulation is altered in this disease must also
consider factors such as age, duration of diabetes, -cell reserve, type of therapy (i.e. diet,
exercise, oral medications, insulin, etc.), body fat composition, co-morbidities, and
metabolic control (180;181). The glucagon response to hypoglycemia in type 2 diabetes has
been shown to be preserved in some studies (182-185), but defective in other reports
(167;168;186-188). An absolute insulin deficiency associated with advanced type 2
diabetes is suggested to underlie the glucagon impairment in advanced type 2 diabetes
(4;161). A study by Segel et al. separated the glucagon responses of type 2 diabetic
subjects on insulin therapy, who represent an insulin-deficient group, from type 2 diabetic
subjects on oral medications, who represent the insulin-sufficient group, and demonstrates
that insulin-deficient individuals, but not those with endogenous insulin, have diminished
glucagon counterregulation to hypoglycemia (168).
Besides these hypotheses of local factors responsible for impaired glucagon
counterregulation, several mechanisms related to the central nervous system have also
been posited. Local glucopenia in the absence of peripheral hypoglycemia induced by 2-
deoxyglucose injection into the VMH stimulates glucagon and epinephrine responses in non-
diabetic rats, but these responses were markedly suppressed in diabetic rats (189). It is
17
speculated that the impairment of the glucagon response to hypoglycemia in diabetes in
which there is an absolute insulin deficiency might result in part from the simultaneous
increase in insulin at the levels of the VMH and in the pancreatic islet as a result of
exogenous insulin administration (190). Recently, it was demonstrated that insulin
microinjected into the VMH can suppress the glucagon response to hypoglycemia induced by
phloridzin (i.e. hypoglycemia not induced by insulin) by approximately 40% and that VMH
blockade of insulin via insulin immunoneutralization can amplify the glucagon response by
more than 2-fold (190). However, this has yet to be demonstrated in a diabetic model. The
role of glucose in the VMH has also been implicated as mechanism of influencing
hypoglycemic counterregulation. Local delivery of glucose into the VMH suppresses
glucagon and epinephrine responses to hypoglycemia (36;191). When glucose levels
increase in the VMH, an increased in the ATP:ADP ratio in local glucose-excited neurons
leads to closure of KATP channels, membrane depolarization, Ca2+ influx via voltage-
dependent calcium channels, and release of neurotransmitters such as GABA (39;192;193).
GABA acting in the VMH blunts glucagon and epinephrine counterregulation to
hypoglycemia, whereas inhibiting GABA actions can stimulate these counterregulatory
responses (39). A recent study provided the link between the effects of VMH glucose and
GABA by demonstrating the glucose administrated in the VMH dose-dependently activates
local GABA release, which consequently dose-dependently suppresses glucagon and
epinephrine responses to hypoglycemia (191). Studies have also demonstrated a role for a
different population of glucose-sensing neurons of the VMH, the glucose-inhibited (GI)
neurons, in glucagon counterregulation. GI neurons increase their activity in response to
low glucose levels (194). AMP-activated protein kinase (AMPK) acts as an intracellular fuel
gauge which responds to a rise in the intracellular AMP:ATP ratio and is thus implicated in
the glucose sensing pathway used by GI neurons (195). Activation of AMPK in the VMH with
18
locally administered 5-aminoimidazole-4-carboxamide (AICAR) lowered the exogenous
glucose infusion rate and increased glucose production in response to hypoglycemia in non-
diabetic rats (196) and amplified the glucagon responses to hypoglycemia in diabetic rats
(197).
1.4.2 Epinephrine counterregulation in diabetes
The epinephrine response to hypoglycemia is critical in a setting of deficient glucagon
counterregulation to hypoglycemia (4). Individuals lacking both glucagon and epinephrine
counterregulation are at a 25-fold or greater risk of severe hypoglycemia compared to
individuals lacking glucagon but have an intact epinephrine response (198;199). A
combined defect in both glucagon and epinephrine responses is associated with impaired
glucose production in the liver and kidney (143;200). Epinephrine counterregulation to
hypoglycemia has been shown to be both impaired (165;201-205) or not impaired (206-
208) in type 1 diabetes. In non-diabetic humans in which two different doses of insulin
were used to induce hypoglycemia of equivalent depth, it was shown that the higher insulin
dose resulted in a markedly greater increase in epinephrine release than the lower dose
(209). However, this stimulatory effect of high insulin dose did not amplify epinephrine
counterregulation in type 1 diabetic humans, suggesting some adrenomedullary deficit with
insulin-deficient diabetes (210). It has been shown that the glycemic threshold for
epinephrine release is altered such that lower glycemia is needed to elicit a response
(203;211). In type 2 diabetic subjects, the epinephrine response has mostly been reported
to be normal (185;188;212). Interestingly, some have also reported an increased in
epinephrine counterregulation to hypoglycemia in type 2 diabetic subjects (186;213). This
enhanced epinephrine response to hypoglycemia in type 2 diabetes may partially offset
impaired glucagon secretion and counteract the effects of hyperinsulinemia on liver, fat, and
19
skeletal muscle (186) and/or contribute to the promotion of hypoglycemic recovery since an
increase in renal glucose release was also observed in this group (213). The factor of age
should also be considered since it has been reported in non-diabetic individuals that the
glucose threshold for epinephrine and glucagon responses in older patients (2.8 mM) was
significantly lower than in younger patients where the threshold was 3.3 mM (214). Indeed,
although epinephrine and cortisol responses to hypoglycemia in older type 2 diabetic adults
were increased, glucagon and growth hormone responses were reduced when compared to
age-matched non-diabetic controls (215). Furthermore, epinephrine defect in diabetes may
be stressor-specific: although epinephrine was reduced in response to hypoglycemia and
cold stress (216), it was not impaired in response to exercise (204;217). It has also been
shown that poorly controlled diabetic individuals may not suffer from impaired epinephrine
to the same extent of intensively treated diabetic patients (206;207;211;218), suggesting
that prior glycemic control of diabetes may also affect epinephrine counterregulation. In
type 2 diabetic patients, for example, intensive treatment to better control glycemia in has
been shown to blunt epinephrine counterregulation to hypoglycemia (212;219). However,
since tight control of blood glucose levels is also associated with increased frequency of
hypoglycemic episodes, it is also possible that recurrent hypoglycemia leads to the impaired
epinephrine response observed in diabetes, as has been previously observed (220).
Mechanisms related to the regulation of epinephrine counterregulation by the brain, in
particular by the VMH, have been discussed above as it pertains to glucagon. Many of these
studies demonstrate simultaneous influences on both glucagon and epinephrine release in
both non-diabetic (36;39) and diabetic rats (189), suggesting that the counterregulatory
release of both these glucoregulatory hormones are regulated by similar neural pathways
integrated by the VMH. Interestingly, VMH administration of insulin did not affect
20
epinephrine counterregulation (190), suggesting that different neural pathways involving
the VMH also exist. Furthermore, it was demonstrated that inhibition of VMH nitric oxide
(NO) signalling impairs epinephrine, but not glucagon, counterregulation and results in a
greater exogenous glucose infusion rate to prevent hypoglycemia (221). VMH GI neurons
respond to decreased glucose by activating AMPK and stimulating the production of NO
(195;222), and it has been hypothesized that VMH NO production is necessary for
generation of hypoglycemic counterregulation (221).
1.4.3 Norepinephrine, growth hormone, and glucocorticoid counterregulation in diabetes
With respect to the other counterregulatory hormones, it is controversial as to
whether or not neuroendocrine responses are impaired in type 1 diabetes. Studies
examining norepinephrine counterregulation are varied as some studies find decreased
responses (205;223;224) while others do not (202-204;206;225-227). Growth hormone
responses to hypoglycemia have also been reported to be decreased (204;224;228;229) or
unchanged (203;225-227) in type 1 diabetes. Growth hormone responses to hypoglycemia
in type 1 (230) and type 2 (215) diabetic individuals were reduced when compared to age-
matched non-diabetic controls. Lastly, glucocorticoid counterregulation has also been
reported to be decreased (202;205;206;224;226;228) or unchanged (203;204;225;227).
Interestingly, it has been reported that scrupulous avoidance of hypoglycemia could reverse
the impairments of some counterregulatory hormone responses (224). Similar to
epinephrine, prior strict glycemic control, and consequently repeated hypoglycemia, may
also affect the impairment of these responses (206;207;231).
21
1.4.4 Hypoglycemia unawareness in diabetes
Part of the defect in glucose counterregulation to hypoglycemia in diabetes is the clinical
syndrome of hypoglycemia unawareness, which is the impaired awareness of hypoglycemia
(4). More specifically, it is the inability to recognize the neurogenic warning symptoms of
hypoglycemia or the failure for symptoms to occur before the start of neuroglycopenia
(232). With this absence of awareness, a subject developing hypoglycemia is averted from
undertaking protective action to prevent or correct impending hypoglycemia, such as
nutrient ingestion. Hypoglycemia unawareness is associated with a 6-fold increased risk of
severe hypoglycemia (233). It is suggested that the pathophysiology of glucose
counterregulation is similar in type 1 and advanced type 2 diabetes although the timeframe
of these impairments may be different (4). The failure of -cell function is more rapid in
type 1 diabetes but occurs more slowly in type 2 diabetes, and thus the syndromes of
defective glucose counterregulation occur earlier in the former and later in the latter (4).
The attenuation of the sympathoadrenal (mainly sympathetic neural) response causes
hypoglycemia unawareness (233), but several factors are believed to contribute to this
impairment (234). Hypoglycemia unawareness can result from diminished autonomic
responsiveness to hypoglycemia since patients with type 1 diabetes were reported to have
reduced -adrenergic sensitivity, which may play a role to their inability to recognize
adrenergic warning signs to hypoglycemia (235). The lack of the catecholamine response to
hypoglycemia has been attributed to hypoglycemia unawareness since subjects with this
hormone impairment also were asymptomatic for hypoglycemia (236). Elderly patients are
more susceptible to hypoglycemia unawareness than middle-aged patients with type 2
diabetes, and this was found to be independent of differences in hormone counterregulation
between both groups (237). However, the younger cohort had better autonomic and
22
neuroglycopenic symptom scores and were better able to estimate their glycemia to be low
during hypoglycemia. Prior and repeated hypoglycemia also leads to hypoglycemia
unawareness, and it was demonstrated that careful avoidance of hypoglycemia can reverse
hypoglycemia unawareness and improve the epinephrine response (238-240). This may be
associated with improved -adrenergic activity as a result of strict avoidance of
hypoglycemia as has been observed in type 1 diabetic subjects (241).
Hypoglycemia, even if asymptomatic, causes a vicious cycle of recurrent hypoglycemia by
causing hypoglycemia-associated autonomic failure, the clinical syndromes of defective
glucose counterregulation and hypoglycemia unawareness (4), as described below.
1.4.5 Hypoglycemia-associated autonomic failure (HAAF) in diabetes
Hypoglycemia-associated autonomic failure, or HAAF, in diabetes is a concept developed by
Cryer based on the well-established theories that recent antecedent hypoglycemia
(150;153;242), as well as sleep (56) and antecedent exercise (243), cause reduced
sympathoadrenal responses to hypoglycemia, which in turn leads to reduced sympathetic
neural responses and hypoglycemia unawareness as well as defective glucose
counterregulation. Taken together, these impairments lead to a vicious cycle of recurrent
hypoglycemia (63). This concept was originally developed to explain the increased
susceptibility of hypoglycemia in patients with type 1 diabetes (244) and has since also
been applied to explain the increased development of hypoglycemia in advanced type 2
diabetic individuals (168). In type 2 diabetic subjects, recent and repeated hypoglycemia
shifts the glycemic thresholds for autonomic (including adrenomedullary epinephrine) and
symptomatic responses to subsequent hypoglycemia to lower plasma glucose
concentrations, thus contributing to HAAF in type 2 diabetes (168). The concept of HAAF is
23
widely accepted and quoted by many others with respect to both type 1 and type 2 diabetes
(181;219;245-247).
1.5 Recurrent hypoglycemia in non-diabetic subjects
Recurrent hypoglycemia has been shown to blunt subsequent counterregulation to
hypoglycemia in healthy, non-diabetic subjects (248-251). For example, it has been
consistently demonstrated that glucagon and epinephrine responses to hypoglycemia are
diminished after recurrent hypoglycemia in non-diabetic humans (248;250-254) and rats
(255). Prior bouts of hypoglycemia blunted epinephrine, but not norepinephrine, responses
(111;256). Prior bouts also impaired cognitive function during subsequent hypoglycemia in
non-diabetic rats (254;257). Whether impairments exist in the other neuroendocrine
counterregulation, however, is debatable. Norepinephrine (248;251) and cortisol (248;250)
responses have been reported to be reduced in some studies, but these findings have been
inconsistent.
1.6 Recurrent hypoglycemia in diabetes
Recurrent hypoglycemia increases the susceptibility of individuals to subsequent bouts of
hypoglycemia since it contributes to both defective hormone counterregulation and reduced
symptom recognition (hypoglycemia unawareness) (4). HAAF, as explained above, is
relevant in both type 1 diabetes (203) and type 2 diabetes of long duration in which there is
an absolute endogenous insulin deficiency (168). In addition to these physiological
consequences, hypoglycemia can also have a profound impact on the lives of individuals
with diabetes, and it has been noted that this population may fear hypoglycemia more than
24
the long-term diabetic complications (1;258). As such, the management of glycemia in
diabetes is impeded by the threat of iatrogenic hypoglycemia (161).
Physiological modifications occur following recurrent hypoglycemia. In animal models,
moderate recurrent hypoglycemia has been shown to have a protective role in preventing
age-related decline of hippocampal cognitive function (259) and decreasing brain damage
after severe hypoglycemia (260). However, these beneficial effects do not negate the fact
that compromised counterregulatory hormone defenses against low blood glucose levels
caused by recurrent hypoglycemia persist, which result in psychological and physical
morbidities (162). In diabetes, recurrent hypoglycemia decreases glycemic thresholds for
counterregulatory responses (203) and decreases neuroendocrine and autonomic responses
to subsequent hypoglycemia. In type 1 diabetes, prior, repeated bouts of hypoglycemia
cause further suppression of the already impaired counterregulatory hormone responses
that are observed with the disease (203;205;220;227;261-263). Following recurrent
hypoglycemia, diabetic subjects show markedly diminished epinephrine counterregulation
compared with acutely hypoglycemic controls (203;205;223;226;261;263;264).
Interestingly, this epinephrine defect was not observed in a study that tested recurrent
hypoglycemia with episodes 2 days apart, and the authors suggested that the
pathophysiological effect of recurrent hypoglycemia may be of short duration in patients
with type 1 diabetes (262) as compared to non-diabetic subjects (265). Since glucagon
response is already absent in most diabetic subjects, it has not been shown to be further
worsened by recurrent hypoglycemia (203;264). Similar to that in non-diabetic subjects,
norepinephrine (205;262;264) and glucocorticoid (205;227;264) responses are not as
conclusive since studies have shown either decreased or unchanged counterregulation of
these hormones. Recurrent hypoglycemia in type 2 diabetic individuals with moderate
25
glycemic control has been shown to blunt counterregulation to subsequent hypoglycemia
compared non-diabetic controls, and counterregulatory defenses were further impaired in
intensively treated type 2 diabetes (219). Glucagon and epinephrine hormone
counterregulation, and neurogenic and neuroglycopenic symptom scores to hypoglycemia
were reduced following repeated hypoglycemia in type 2 diabetic subjects, and glycemic
thresholds were also shifted to a lower glycemic level (168).
Ultimately, hypoglycemia remains a serious complication and limiting factor to glycemic
management in both type 1 and type 2 diabetes. Without adequate counterregulation,
recovery of blood glucose levels to euglycemia cannot be achieved, and the result is a
prolonged state of hypoglycemia with the increased potential for morbidity and mortality.
1.7 Somatostatin
In 1968, rat hypothalamic extracts were demonstrated to inhibit growth hormone secretion
from the pituitary gland (266). However, it was not until 1972 that somatostatin, a cyclic
tetradecapeptide that inhibited the release of pituitary growth hormone, was first identified
and sequenced by the laboratory of Guillemin from sheep hypothalami (267). Guillemin was
awarded the Nobel Prize in 1977 for his research on hypothalamic hormones (268). A
second form of the peptide with an extension of 14 additional amino acids at the N-
terminus, somatostatin-28, was subsequently identified (269). The amino-acid sequences
of somatostatin and somatostatin-28 are shown in Figure 1-1. Since its discovery,
somatostatin has been found to be widely distributed throughout the body with a broad
spectrum of biological effects mediated via a family of five receptors. As such, various
analogues for somatostatin designed for therapeutic use began to be synthesized as early
26
as 1974 (270). Several somatostatin-like peptides have also be identified and reviewed and
will be described in brief below.
1.7.1 Functions
The best known physiological role of somatostatin is its regulation of hormone secretion, but
its other diverse effects include regulation of cell growth, nutrient absorption, smooth
muscle contractility, and neuromodulation (271;272). Somatostatin regulates hormone
secretion from the pituitary gland and pancreatic islets, gastrointestinal cell function, and
immune cell function (271).
1.7.1.1 General somatostatin effects in pancreatic islets.
Pancreatic islets have a rich vascular supply and receive up to 10% of the total blood flow to
the pancreas despite the fact that they comprise only about 1% of pancreatic tissue (273).
Somatostatin’s main effect on pancreatic hormones is inhibition of both insulin and glucagon
release (274;275). It also has an autocrine function whereby somatostatin inhibits its own
release (272). Pancreatic -cells are juxtaposed to insulin- and glucagon- containing -cells
and -cells, respectively, within islets (276). There is also evidence of paracrine intraislet
control exerted by somatostatin since -cells are in close proximity to both - and -cells in
rat and human islets and -cell processes were observed to extend into -cell clusters in rat
islets (277;278). Isolated pancreatic islets incubated in a medium containing anti-
somatostatin antibodies to bind endogenously secreted somatostatin have significantly
increased release of insulin and glucagon (279;280), and isolated pancreata perfused with
somatostatin antibody to immnoneutralize islet somatostatin similarly demonstrate
increased stimulation of pancreatic glucagon and insulin release (281;282). Furthermore, in
vivo microscopy experiments of rat and mouse pancreas microcirculation demonstrate a
plausible mechanism in which cell-to-cell communication between -cells and -cells can
27
exist within the islet (283). Taken together, its anatomical juxtaposition to - and -cells,
findings from in vitro and ex vivo somatostatin immunoneutralization studies, and intra-islet
microcirculation experiments all support the concept that somatostatin is a local regulator of
pancreatic islet -and -cell function.
1.7.1.2 Arguments against local somatostatin effects on pancreatic islets.
Some studies suggest that somatostatin-secreting -cells are downstream of glucagon-
secreting -cells and insulin-secreting -cells in the islet microcirculation of non-diabetic
rats, and thus have argued against the regulation of glucagon and insulin by local
somatostatin (79;284;285). This hypothesis of islet blood flow implies that pancreatic
somatostatin must pass through the systemic circulation before acting on cells of the
pancreatic islet. Furthermore, early work with intravenously administered antisomatostatin
serum, which has the effect of neutralizing somatostatin’s actions, demonstrated no
inhibitory effect on plasma insulin and glucagon levels (286), which contrasts the in vitro
and ex vivo effects of antisomatostatin administration and the local role of regulating
pancreatic hormone release. However, it should be noted that antisomatostatin antibodies
are very large in structure, and if given via an intravenous route, may not be accessible to
the interstitium of pancreatic islets for regulation of pancreatic hormone release (88;287).
1.7.1.3 General somatostatin effects in the brain and pituitary gland.
The physiological roles of somatostatin include inhibition of hormone secretion as well as
neurotransmission. Somatostatin inhibits GHRH (288) and TRH (289) secretion from the
hypothalamus. Within the brain, somatostatin can act as a neurotransmitter with effects on
cognition, locomotor, sensory, and autonomic functions (reviewed in: (290-292)). The
localization and release of somatostatin from nerve endings supports the transmitter and
modulator role of somatostatin (293). Notably, somatostatin also modulates the release of
28
other brain neurotransmitters: it inhibits the release of norepinephrine, corticotrophin
releasing hormone (CRH), and endogenous somatostatin from the hypothalamus – all of
which may play a role in the counterregulatory hormone response. Somatostatin inhibits
growth hormone release from the anterior pituitary (267;272). Release of thyrotropic
hormone, also known as thyroid stimulating hormone (TSH), from the anterior pituitary is
inhibited by somatostatin (272). Somatostatin also inhibits the secretion of
adrenocorticotrophic hormone from the anterior pituitary (ACTH) (271;294), but it has not
been shown to affect the reproductive hormones luteinizing hormone (LH), follicle-
stimulating hormone (FSH), or prolactin in normal subjects (271).
1.7.1.4 General somatostatin effects in the gastrointestinal tract.
In the gastrointestinal tract, somatostatin acts as a neurotransmitter in the myenteric
plexus and as a paracrine regulator in epithelial cells where it influences the function of
adjacent cells (272). By and large, somatostatin inhibits gut exocrine secretions of gastric
acid, pepsin, bile, and colonic fluid. Somatostatin also suppresses motor activity of the gut
by inhibiting gastric emptying, gall bladder contraction, and small intestine segmentation
and decreases splanchnic blood flow and glucose absorption from the gut. In general,
somatostatin appears to inhibit the majority of gut hormones, such as vasoactive intestinal
polypeptide, gastrin, gastric inhibitory peptide, secretin and cholecystokinin (271;295).
Somatostatin also inhibits stimulated glucagon-like peptide-1 release from the gut
(296;297).
1.7.1.5 Other effects of somatostatin relating to glucose homeostasis.
Somatostatin has well-established effects on regulating the secretion of hormones
responsible for maintaining glucose homeostasis. But the question arises whether
somatostatin has other direct effects. Somatostatin decreases hepatic glucose output, and
29
this effect is thought to be secondary to the inhibition of pancreatic hormone secretion
(295). In a hyperinsulinemic-euglycemic clamp in non-diabetic humans, somatostatin
infusion at a dose commonly used in human investigation (600 g/h) did not increase
insulin-stimulated glucose uptake in humans (298).
1.7.2 Localization of somatostatin-producing cells
Two main types of somatostatin-producing cells exist and have different morphologies: 1)
secretory cells, which have short cytoplasmic extensions; and 2) nerve cells, with multiple
branches. In the rat, approximately 65% of total body somatostatin-immunoreactivity is
from the gastrointestinal tract, 25% from the brain, 5% in the pancreas, and 5% from other
tissues (271).
1.7.2.1 Pancreatic somatostatin-producing cells.
In the pancreas, somatostatin-producing cells are found in -cells of the islet. Somatostatin
was identified in a population of islet cells that differed from glucagon- and insulin-secreting
cells in 1974 (299). In rodent islets, the proportion of -cells relative to total cells of the
islet (5-10%) is normally far less than that of -cells (60-80%) and -cells (15-20%) but
greater than that of pancreatic polypeptide (PP)-cells and ghrelin-secreting -cells (<3%)
(300-303). The lower proportion of -cells is the same for human islets, in which islet cell
composition differs from rodent islets. Numerous recent reports have indicated that
compared with rodent islets, the percentage of -cells (~50%) and -cells (~40%) is less in
humans, but the percentage of -cells is similar (~10%) (301;304). Some have suggested
that the human islets have as much as twice the proportion of -cells as mouse islets (305).
This proportion of -cells is altered in many models of diabetes, which will be discussed
below. Pancreatic -cells secrete somatostatin into capillaries or perivascular spaces within
islets and normally contribute to approximately 5% of circulating somatostatin (271;306).
30
Approximately 15% of -cells lack cytoplasmic processes, which implicates a paracrine role
for -cells. In the adult, somatostatin-14 is the primary secretory product of pancreatic -
cells (307;308). Individual islet cells bind somatostatin-14 differently from somatostatin-
28. Although somatostatin-14 binds with - and -cells, and somatostatin-28 binds with -,
-, and -cells, there appears to be a preferential binding association of somatostatin-14
with -cells and somatostatin-28 with -cells (309). The differential binding is likely due to
the differential distribution of somatostatin receptors on each islet cell type (310), as will be
discussed below.
1.7.2.2 Brain somatostatin-producing cells.
The brain is rich with somatostatin-positive neurons and fibers (292;311;312).
Somatostatin-cells are abundant in the hypothalamus, brainstem, the deeper layers of the
cerebral cortex, and limbic structures. Hypothalamic somatostatin is most well known for
its role in inhibiting growth hormone and thyroid-stimulating hormone release from the
anterior pituitary (271). Approximately 80% of hypothalamic somatostatin is located in
cells of the periventricular nucleus which project their axons to the median eminence, and
this comprises the main somatostatinergic tract (271;313). Somatostatin-producing
neurons are also located in the paraventricular nucleus (122) which also project to the
median eminence (292); arcuate nucleus; supraoptic nucleus; suprachiasmatic nucleus; and
ventromedial nucleus of the hypothalamus (293;311;312). In the brainstem region,
somatostatin is also localized in the dorsal vagal complex (311;314). Somatostatinergic
neurons of the nucleus of the solitary tract project to the hypothalamic paraventricular
nucleus (292). As discussed in earlier sections, these hypothalamic nuclei and the dorsal
vagal complex are well-known for their role in regulating glucose homeostasis (13;14).
31
Thus, colocalization of somatostatin in these glucose sensing and regulatory brain regions
could implicate a putative role for somatostatin in regulating glucose homeostasis.
1.7.2.3 Gastrointestinal somatostatin-producing cells.
Within the gastrointestinal tract, there are two main types of somatostatin-producing cells:
D-cells in the mucosa of the pyloric antrum and in the intestine and neurons that are part of
submucosa and myenteric plexuses (313;315-317). In the myenteric plexus, somatostatin
inhibits the induced release the neurotransmitter acetylcholine (315).
1.7.2.4 Other somatostatin-producing cells.
In addition to these main organs that secrete most of the body’s somatostatin, there are
other tissue and cell types that also produce somatostatin. Within the thyroid, somatostatin
is produced with calcitonin in a subpopulation of C-cells (313;318). Immune and
inflammatory cells of the spleen and thymus (e.g. lymphocytes, macrophages) also secrete
somatostatin in small amounts when activated (319;320). Somatostatin inhibits the release
of growth factors and cytokines and inhibits the proliferation and adhesion of lymphocytes
(271;321), presumably as a way of regulating the secretions and functions of these cells.
Whereas somatostatin was detected at high levels from extracts of the posterior pituitary,
the anterior pituitary had no detectable levels of somatostatin (313;322). There are also
small numbers of somatostatin-producing cells in the kidneys and in the adrenal glands
(271).
1.7.3 Synthesis and structure
Somatostatin is synthesized from the preprosomatostatin gene (323). The rat somatostatin
gene encodes preprosomatostatin, a precursor of 116 amino acids that is processed within
the endoplasmic reticulum to yield prosomatostatin, a peptide of 92 amino acids (323).
32
Prosomatostatin is subsequently cleaved posttranslationally to produce somatostatin-28 and
somatostatin-14 by prohormone convertases 1 and 2 (PC1/PC2) and carboxypeptidase E
(CPE) (272). The two forms of the peptide are found in varying amounts in somatostatin-
producing cells due to the differential processing by PC1, PC2, and CPE (271).
Somatostatin-14 can also be derived from alternate processing of somatostatin-28.
Somatostatin-14 is the predominant form in the brain, pancreatic islets, retina, peripheral
nerves, and enteric neurons. Somatostatin-28 is predominant form in the gastrointestinal
tract, especially the duodenum and jejunum, where the prosomatostatin gene is processed
in the intestinal muscosal cells. Somatostatin-28 accounts for approximately 20-30% of
total immunoreactive somatostatin in the brain (271).
The preprosomatostatin gene in humans has striking homology with other vertebrates. The
sequence of somatostatin-14 is completely conserved between fish and mammals, but
mammalian somatostatin-28 shares only 40-60% homology with fish somatostatin-28
(324). Two other somatostatin-like peptides have also been identified: cortistatin and
neuronostatin.
1.7.3.1 Cortistatin.
A somatostatin-like gene called cortistatin gives rise to two cleavage products which are
comparable to somatostatin-14 and somatostatin-28: cortistatin-17 (human) or cortistatin-
14 (rat) and cortistatin-29 (human and rat) (325). Cortistatin shares high structural
homology with somatostatin and binds to somatostatin receptor subtypes with similar
affinity, but its actions, tissue expression patterns, and regulation are not completely the
same as that of somatostatin. Cortistatin gene expression was originally thought to be
restricted to the cerebral cortex and hippocampus, but its mRNA expression has since been
detected in peripheral tissues also known to express somatostatin including the pancreas,
33
adrenal, liver, and small and large intestine (326). Its presence in the brain is only at a
small fraction of the brain with far less distribution (272). Cortistatin has been
demonstrated to have some similar hormone regulatory effects as somatostatin (namely,
inhibition of growth hormone and insulin release), but it also has additional distinct
functions on sleep modulation (327), brain function (325), and effects on immune cells
(328).
1.7.3.2 Neuronostatin.
Neuronostatin is a 13-amino acid peptide encoded by the preprosomatostatin gene (329).
Its amino acid sequence shares very little similarity to somatostatin (329). It is highly
produced in the hypothalamus, and neuronostatin-immunoreactive cells were found to be
comparable in number and intensity to somatostatin immunoreactive cells in the
hypothalamic periventricular nucleus. However, these peptides differ in their calcium
mobilizing effects in cultured rat hypothalamic neurons, which results in diverse cellular
activities (somatostatin reduces, while neuronostatin increases, calcium mobilization) (330).
For example, intracerebroventricular treatment with neuronostatin increased blood pressure
but suppressed food intake and water drinking (329). Furthermore, neuronostatin has no
effect on stimulated GH secretion from pituitary. Neuronostatin can also be found in the
pancreas where it is thought to be colocalized with somatostatin in islet -cells.
Importantly, whereas somatostatin activated the Gi-protein signalling pathway mediated via
the five different somatostatin receptors, neuronostatin had no such effect, which likely
indicates that neuronostatin does not bind to native receptors for somatostatin (329).
1.7.3.3 Apelin
Apelin is a circulating and paracrine peptide hormone which also acts as a neuromodulator.
It has various isoforms: apelin-36, apelin-17, and apelin-13 (331). It is secreted by adipose
34
tissue and is also found in the gastric mucosa and hypothalamus. Specifically in the
hypothalamus, apelin is detected in the SON, PVN, and SCN (331). Known for its
hypotensive effects (332) and also as an adipokine (333), apelin has more recently
garnered attention for its pancreatic effects on insulin inhibition (334;335) and for its
localization within the pancreatic islet. Apelin is found in cells and -cells of human, rat,
and mouse islets but not -cells or PP-cells (335). Apelin itself is upregulated directly by
insulin in both human and rodents (336), and islet apelin mRNA expression is suppressed by
glucocorticoids (335). Apelin has been shown to lower plasma glucose via increased glucose
utilization in fat and muscle (337;338). Similar to somatostatin, the receptor for apelin –
the APJ receptor – is a G-protein-coupled receptor which is expressed in various parts of the
brain: hippocampus, striatum, thalamus, cortex, cerebellum, and hypothalamus (332;339).
The APJ receptor is upregulated in the hypothalamic PVN by acute and repeated stress
(340). More recently, APJ expression was found in human and mouse islets (335).
Recently, it was reported that children with type 1 diabetes have increased circulating apelin
levels compared to non-diabetic controls. However, no correlations were found between
elevated apelin levels and body mass index, glycemia, lipids, and insulin sensitivity in these
type 1 diabetic children (341).
1.7.4 Regulation of somatostatin synthesis
The regulatory domains that are located upstream of the 5’ transcriptional unit of the rat
somatostatin gene contain: a TATA box, a cAMP response element (CRE), two nonconsensus
glucocorticoid response elements (GREs), and a consensus insulin response element CGGA
activated by an ETS-related transcription factor (271). Pancreatic duodenal homeobox 1
(PDX-1) is a transcriptional factor required for activating somatostatin gene transcription
and maintains pancreatic islet functions along with activating gene transcription of insulin,
35
islet amyloid polypeptide, glucose transporter type 2, and glucokinase (342). Transcription
of the somatostatin gene can be repressed by two silencer elements located in the promoter
region (343).
Somatostatin mRNA levels are regulated by many of the factors that also influence
somatostatin secretion. Somatostatin gene transcription is stimulated by glucocorticoids,
growth hormone, testosterone, estradiol, NMDA receptor agonists, growth factors (IGF-I,
IGF-II) and cytokines (IL-1, IL-10, TNF-, and IFN-). Conversely, somatostatin gene
transcription is also inhibited by glucocorticoids, insulin, leptin, and TGF-. Glucocorticoids
have a dual effect on the somatostatin gene by enhancing its synthesis via its interaction
with the glucocorticoid receptor and GRE and inhibiting its synthesis via accelerated
somatostatin transcript degradation. Insulin is also known to accelerate somatostatin mRNA
degradation. Among the intracellular mediators known to modulate somatostatin mRNA,
Ca2+, cGMP, nitric oxide, and cAMP, cAMP most potently activates somatostatin gene
transcription. cAMP induces PKA phosphorylation of nuclear cAMP response element binding
protein (CREB), which binds to CRE (271).
In neurons, somatostatin gene transcription is strongly activated by binding of the
phosphorylated transcription factor cAMP response element-binding protein (CREBP) to the
cAMP response element in the promoter sequence of its gene (344;345) and the
homeodomain transcription factor PDX-1 to the promoter element TSEI. In pancreatic
islets, somatostatin gene is also upregulated by cAMP and PDX-1. Interestingly, enhancer
elements in the promoter region of the somatostatin gene that upregulate its expression in
pancreatic islets may actually have the opposite function and act as gene silencer elements
in neurons. This includes complexes that bind transcription factors PAX6, PBX, and PREP1
to TSEII and UE-A elements in the promoter region of the somatostatin gene (272).
36
Somatostatin has a short half-life (approximately 1.1 to 3 minutes in humans) since it is
rapidly metabolized by peptidase enzymes in the blood and tissues. The kidney and liver
are the main sites of somatostatin clearance (271).
1.7.5 Regulation of somatostatin secretion
Some agents exert common secretory effects on somatostatin-producing cells throughout
the body while others have differing effects depending on the type of tissue. Typically, the
divergent effects of these agents occur because of tissue-specific expression of certain
receptors for the agent or because of indirect effects through the release of other
transmitters or peptides (271). Generally, membrane depolarization of somatostatin-
containing nerve cells or peripheral somatostatin secretory cells is a common mechanism
that elicits somatostatin release (291).
1.7.5.1 Regulation of pancreatic somatostatin.
Somatostatin release from pancreatic islets -cells is normally increased in response to
glucose stimulation (305;346) and other nutrients such as amino acids and lipids (271).
Glucose stimulation leads to closure of KATP-channels (presumably via an increase in the
cytoplasmic ATP/ADP ratio), and membrane depolarization. Sulfonylureas also stimulate
somatostatin release by closing KATP channels (347). Glucagon stimulates the release of
somatostatin (348). Insulin inhibits pancreatic somatostatin release (271) as does
activation of gamma-aminobutyric acid (GABA) receptors on -cells (295). Somatostatin
secretion by pancreatic -cells is stimulated by activation of both -adrenergic and
cholinergic receptors (295). In isolated perfused human pancreas, stimulation of the celiac
neural bundle has the predominant effect of inhibiting glucose-stimulated somatostatin
secretion via an -adrenergic mechanism (349). -adrenergic fibers stimulate somatostatin
secretion, whereas cholinergic fibers had a weaker effect (349). Similarly in perfused dog
37
pancreas, somatostatin secretion was increased by -adrenergic activation and suppressed
by -adrenergic activation (72). Interestingly, destruction of the VMH increased pancreatic
somatostatin release to nutrient stimulation (350). CCKB receptors found on pancreatic -
cells (351), and more recently, occupation of CCK-1 and CCK-2 receptors was shown to
initiate somatostatin secretion in rat pancreatic islet cell line RIN-14B cells (352).
1.7.5.2 Regulation of brain somatostatin.
Unlike its action in the pancreas, glucose inhibits hypothalamic somatostatin secretion, and
amino acids do not appear to have a role. Likewise, insulin stimulates hypothalamic
somatostatin, which is opposite to its effect in the pancreatic islet. Somatostatin also has
an autoregulatory effect whereby it inhibits its own release in the hypothalamus (271).
Growth hormone and thyroid hormones enhance somatostatin release, suggesting that
somatostatin plays a negative feedback role on regulating these hormones (353;354).
Secretion of somatostatin from the hypothalamus is promoted by dopamine, substance P,
glucagon, acetylcholine, norepinephrine, vasoactive intestinal polypeptide, and
cholecystokinin (318;355). Various cytokines, such as IL-1, IL-6, and TNF-, also stimulate
somatostatin secretion from the rat brain (356). In contrast, leptin and TGF- have been
shown to inhibit somatostatin secretion from rat hypothalamic cells (357;358). Opiates and
GABA likewise inhibit somatostatin release.
1.7.5.3 Regulation of gastrointestinal somatostatin.
Although the focus of this thesis is not on gastrointestinal somatostatin regulation, it is
important to briefly mention stimulators and inhibitors of somatostatin from the gut since it
represents the main source of circulating somatostatin (271). Gut secretion of somatostatin
is triggered by luminal, but not circulating somatostatin (291;359). Stimulation of the
vagus nerve induced secretion of somatostatin into the antral lumen (360). Somatostatin
38
release is also stimulated by insulin (271) as well as GLP-1, but not GLP-2 (361). Gastrin-
releasing peptide stimulates somatostatin secretion from the intestine, but galanin,
vasoactive intestinal peptide, and epinephrine had no effect (361). Bombesin, a
neuropeptide and hormone that stimulates gastric release and aids in negative feedback
signals to suppress eating, also stimulates somatostatin (362). In the fasting state, plasma
concentration of somatostatin is low (30–100 pg/mL) and increases by approximately 2-fold
in the postprandial state (363). This postprandial increase in plasma somatostatin is mostly
due to somatostatin derived from the intestinal epithelium (364;365).
1.8 Somatostatin receptors (SSTRs)
Somatostatin receptors (SSTRs) were first described in 1978 in pituitary cell lines (366), but
it was not until 20 years after the discovery of somatostatin that structure of one of its
receptors was characterized by molecular cloning (367). It is now known that SSTRs are
found in various densities in the brain, pituitary gland, gastrointestinal tract, endocrine and
exocrine pancreas, adrenal glands, thyroid, kidneys, and immune cells (271). Tumour cell
lines are also rich in SSTRs, but a review of this literature is beyond the scope of the
present thesis. For the purposes of this thesis, the general localization and function of the
family of receptors for somatostatin, SSTR1 to SSTR5, inclusive, will be briefly examined,
and more emphasis will be taken to examine our SSTR of interest, SSTR2.
Somatostatin binds to each of the SSTRs with very high affinity; that is, in the nanomolar
range (368). Somatostatin-14 binds to all the SSTRs with greater affinity with the
exception of SSTR5, in which somatostatin-28 is the ligand with greater selectivity (369).
The receptors can also be grouped into two subfamilies in which SSTR2, 3, and 5 bind well
39
to short somatostatin analogues (i.e. hexapeptide and octapeptides) and SSTR1 and 4
which have poor binding with these short peptide analogues (369). In general, the SSTR
subtypes are of a similar size (356-391 amino acids in length), and each has seven -helical
transmembrane segments typical of G-protein coupled receptors with an extracellular N-
terminus and an intracellular C-terminus. In the seventh transmembrane segment, there is
a signature sequence for this family of receptors that is highly conserved in all SSTR
isoforms from humans and other species. The five SSTR subtypes display a high level of
structural conservation across species (369;370). The nearest related family of receptors to
SSTRs are the opiod receptors (371).
1.8.1 General localization of SSTRs
The central nervous system, pituitary, and gastrointestinal tract ubiquitously express all
members of the SSTR family, SSTR1-5. In the central nervous system, SSTR1 is most
highly expressed in the neuraxis (the axis of the central nervous system) and throughout
the entire brain. SSTR2 has a high level of expression in the cerebral cortex. SSTR3 has
preferential expression in the cerebellum, SSTR4 is less well expressed as compared to the
other types and in early studies was referred to as the “brain-specific” SSTR (372), and
SSTR5 is moderately well expressed throughout the brain (373-377). Interestingly, brain
SSTR5 in humans is less well expressed than in rats (376). Specifically in the
hypothalamus, SSTR1 has the highest overall expression, followed by SSTR2, 4, 3 and 5.
SSTR1 seems to be highest expressed in neurons of all major hypothalamic nuclei, in nerve
fibers along the median eminence, and along the third ventricle. SSTR2 is likewise
expressed in these areas but at a lower density than SSTR1. SSTR3 is localized in the
paraventricular nucleus, dorsomedial nucleus, arcuate nucleus, and median eminence.
SSTR4 is localized to the arcuate nucleus, ventromedial nucleus, and median eminence.
40
SSTR5 is the least expressed subtype and appears in the median eminence (374;375;378).
In the pituitary, all five subtypes of SSTR are expressed in rats, but human pituitaries lack
SSTR4. SSTR5 is the most predominant subtype expressed in the pituitary, followed by
SSTR2 (373;379-382). In the gastrointestinal tract, all five SSTRs have been identified in
the stomach and small and large intestine, and the enteric plexus expresses SSTR1-3
(383;384).
Rat and human pancreatic islets also express all five SSTR subtypes, but the species differ
in their level of SSTR expression on the different islet cell types. In human pancreatic islets,
insulin-secreting -cells highly express SSTR1 and SSTR5, glucagon-secreting -cells
predominantly express SSTR2, and somatostatin-secreting -cells predominantly express
SSTR5 (385). In human isolated islets, it was demonstrated that SSTR2 was the
predominant subtype that mediates the suppression of glucagon release by somatostatin
(386). In rodent islets, the main difference is that -cells more exclusively express SSTR5
(387). Rat -cells and -cells show the same selective predominant expression of SSTR2
and SSTR5, respectively (388-391). Functional studies in rodents are consistent with the
above findings of receptor localization showing that SSTR2 mediates the inhibitory effect of
somatostatin on glucagon secretion while SSTR5 inhibits insulin release (388;389;392-394).
Notably, one group has reported slightly different findings in which rat and mouse -cells
showed high expression of SSTR2 and SSTR5 and - and -cells showed high levels of
SSTR1, 2 and 5, suggesting that more than one SSTR needs to be activated to suppress
islet glucagon and insulin release (395;396).
In the adrenal gland, there is a high concentration of SSTR2 (390;397-399) and also
moderate levels of SSTR1 and SSTR3 (373;400). In the liver and kidney, SSTR3 is
expressed. The lung, heart, and placenta express SSTR4. Immune cells preferentially
41
express SSTR2 (319;401;402), but recent studies report that SSTR1 and SSTR2 colocalized
on human macrophages are responsible for the immunosuppressive effect of somatostatin
(403). The retina expresses all SSTRs, with highest levels of SSTR1 and SSTR2 (404).
Interestingly, the majority of human tumour cells are usually positive for SSTRs (271) with
predominant highest frequencies reported for SSTR2 (405) or SSTR3 mRNA expression
(406-408). More specifically in human neuroendocrine tumours, a recent study
demonstrated that SSTR1 and SSTR5 were the most highly detected forms of receptors,
followed by SSTR3 and SSTR2 (409).
1.8.2 General functions of SSTRs
SSTRs mediate the functions of somatostatin. As previously mentioned, one of the main
functions of somatostatin is to inhibit exocytosis in target cells. This action is mediated
predominantly via SSTR2, SSTR3, and SSTR5 and involves i) decreased intracellular cAMP
due to inhibition of adenylyl cyclase, ii) decreased Ca2+ influx due to action on K+ and Ca2+
ion channels, and iii) stimulation of phosphatases such as calcineurin (which inhibits
exocytosis) and serine threonine phosphatases (which dephosphorylate and activate K+ and
inhibit Ca2+ ion channels) (369). In addition to its anti-secretory effects, somatostatin also
has: 1) anti-proliferative, 2) anti-growth, and 3) apoptotic functions (271). The anti-
proliferative effects of somatostatin are mediated primarily via SSTR1, 2, 4, and 5 by which
it induces cell cycle arrest at the G1 phase. Anti-proliferative effects of somatostatin have
been demonstrated in normally dividing cell types such as activated lymphocytes and
inflammatory cells (410;411), intestinal muscosal cells (318), bone and cartilage cells
(412), as well as tumour cells (271). SSTRs activate phosphotyrosine phosphatases (PTPs)
to transduce anti-growth signals via modulation of a mitogen-activated protein kinase
(MAPK) pathway. SHP-1 and SHP-2 belong to the family of PTPs which are implicated in
42
SSTR-mediated anti-growth signaling (413). Somatostatin induces growth arrest by
indirectly activating nitric oxide synthase via SSTR2 and via a negative coupling with
guanylate cyclase via SSTR5. Somatostatin’s anti-growth effects are mediated via SSTR2
(in various tumour cells) and SSTR4 (in human B lymphocytes) through a mechanism
involving MAPK-ERK1/2 (extracellular regulated kinase) upregulation of cyclin-dependent
kinase inhibitors (414). Via SSTR3, somatostatin activates apoptosis by inducing p53 and
Bax expression (415).
1.8.3 Specific localization, ligand binding, and signalling of SSTR2
The rat SSTR2 gene was identified in 1992 (416). Two spliced variants of the SSTR2 gene
exist: a long form (SSTR2A), and a short form (SSTR2B). These two variants are generated
through alternate mRNA splicing and differ only in the length of their cytoplasmic tail, with
the SSTR2B form differing in 15 amino acids at the C-terminus (400;417). The C-terminal
tail is not essential for coupling to G-proteins or adenylyl cyclase. There is a 93-96%
conservation of the sequence identity of SSTR2 isoforms among human, rat, mouse,
porcine, and bovine species.
SSTR2 is highly prevalent in the kidney, and pancreas and along with SSTR1 is prevalent in
the stomach, pituitary, small intestine (particularly the duodenum), and spleen
(271;367;385). It is the main subtype expressed in lymphocytes and inflammatory cells
(319;401;402). There are also low levels of SSTR2 detected in the liver (367) although in
healthy liver, SSTR2 may be localized on other cell types such as cholangiocytes rather than
hepatocytes (418). SSTR2 is the main subtype responsible for the suppression of gastric
acid (388).
43
In human pancreatic islets, SSTR2 is predominantly expressed on glucagon-secreting -cells
(385). In human isolated islets, it was demonstrated that SSTR2 was the predominant
subtype that mediates the suppression of glucagon release by somatostatin (386). Rat -
cells show the same selective predominant expression of SSTR2 (388-391). Functional
studies in rodents are consistent with the above findings of receptor localization showing
that SSTR2 mediates the inhibitory effect of somatostatin on glucagon secretion
(388;389;392-394).
In the brain, moderate to high levels of SSTR2 expression include the basolateral amygdala
(BLA) (419-421); in neurons of all major hypothalamic nuclei (378;422), including
mediobasal hypothalamus (312;423) and specific nuclei regulating endocrine and fluid
homeostasis such as the supraoptic nucleus (SON) and PVN and feeding centers such as the
ARC and dorsomedial nucleus (420;424-428); cerebral cortex (419;420); parabrachial
nucleus, locus coeruleus, and NTS of the brainstem (419;420), and in the nerve fibers along
the median eminence (378). Intracerebroventricular administration of a selective SSTR2
agonist elicited neuronal activation (as measured by an increase in Fos expression) in brain
regions such as the BLA, SON, PVN, ARC, parasubthalamic nucleus, lateral parabrachial
nucleus (429). A recent study reports that selective activation of brain SSTR2 induces a
feeding response while blocking brain SSTR2 reduced food intake (430). Interestingly, the
effect of this antagonist was specific to central administration and not reproducible by
intraperitoneal administration. Drinking, grooming, and locomotor activity were also
increased by selective activation of brain SSTR2 (430).
With SSTR5, SSTR2 inhibits growth hormone and thyroid stimulating hormone from human
and rat pituitary cells (431;432). However, there is also evidence demonstrating the
importance of SSTR1 in regulating GHRH and growth hormone release (423;428;433;434).
44
SSTR2 is not internalized as readily as the other SSTRs (435-437). From studies that
demonstrated that SSTR2 is sensitive to GTP analogues and pertussis toxin, it is now known
that SSTR2 is associated with inhibitory G-proteins Gi and Go, which are the G-proteins that
involved with the inhibition of adenylyl cyclase (438).
1.9 Somatostatin in type 1 diabetic humans and animal models
Somatostatin levels are increased in many diabetic subjects studied. The most notable
change is the increase in pancreatic somatostatin content which is has been observed in
type 1 diabetic humans (439) in which an increased number and volume of -cells has been
observed (440). Pancreatic somatostatin release was elevated in type 1 diabetic subjects
(363;441), particularly in those with poor glycemic control (441). Increased basal plasma
somatostatin has also been reported in type 1 diabetic individuals (442;443). Experimental
diabetes induced in monkeys (444) showed increased -cell volume and hyperplasia.
Alloxan-diabetic dogs also demonstrated elevations in islet somatostatin content and -cell
area (90;445) as well as increased basal and nutrient-induced circulating somatostatin
levels (446) as compared to non-diabetic dogs.
There is an abundance of literature demonstrating increased somatostatin levels in
streptozotocin- (STZ-) diabetic rats. STZ-diabetes is an experimental model of diabetes
(discussed in section 3.1.2). STZ-diabetic rats have increased pancreatic somatostatin
(174;439;447-452) and secrete more pancreatic somatostatin than non-diabetic controls
(451). It was demonstrated that pancreata from STZ-diabetic rats had more pancreatic
somatostatin content which increased in proportion to the dose of STZ used to induce
diabetes while graded reductions of insulin content were observed (453). In addition, these
45
pancreata had increased arginine-stimulated secretion of somatostatin, which also
negatively correlated with insulin release. This suggests that pancreatic somatostatin
content and secretion are proportional to the state of insulin deficiency (453). Pancreatic
prosomatostatin mRNA was increased in STZ-diabetic rats compared to non-diabetic rats
(205;454). Plasma somatostatin levels were also elevated in STZ-diabetic rats
(174;205;455). Fasting reduced basal plasma somatostatin in both STZ-diabetic and non-
diabetic rats (455). The stomach of STZ-diabetic rats was also shown to have elevated
levels of somatostatin as compared to non-diabetic rats (452;456;457). These D-cells of
STZ-diabetic rats also secreted more somatostatin when stimulated than those of non-
diabetic counterparts (456). Small intestine somatostatin content was also increased in
STZ-diabetic rats compared with control animals (457). Intravenous arginine increased
plasma somatostatin levels to a greater extent in STZ-diabetic rats as compared to non-
diabetic rats (455).
Alloxan-diabetes is another form of induced, experimental diabetes. In alloxan-diabetic
rats, pancreatic -cell mass was increased (458;459), as was arginine-stimulated
somatostatin release (459). In one study, hyperplasia of -cells was observed after 14
months of alloxan diabetes (458).
Increased pancreatic somatostatin has also been reported in NOD mice (460). In NOD mice
15 days after onset of diabetes, pancreatic islets were characterized by infiltration of
lymphocytes, and somatostatin-containing cells occupied the majority of endocrine cells of
the islets while insulin-containing cells decreased as expected and glucagon-containing cells
remained similar (460).
46
There is evidence in animal models of diabetes that insulin treatment can reduce and/or
partially normalize pancreatic somatostatin levels (90;351;452), arginine-induced elevations
of plasma somatostatin (455), and high basal somatostatin secretion rates in islets from
untreated diabetic rats (461). This suggests that that increased somatostatin during
diabetes may be due, at least in part, to a lack of endogenous insulin action or its metabolic
consequences. However, it should be noted that insulin treatment of type 1 diabetic
humans did not prevent the abundance of -cells found in human diabetic pancreata (439)
nor the elevation in plasma immunoreactive somatostatin levels (363). In addition, mRNA
expression of pancreatic prohormone convertases PC1 and PC2 were found to be >2-fold
and >4-fold increased, respectively, in STZ-diabetic rats, which may also be in part
responsible for increased pancreatic somatostatin in diabetes (462). It has also been
postulated that increased glucagon, representing an absolute or relative glucagon excess,
within the pancreatic islet might lead to a compensatory response of the -cell to secrete
more somatostatin. This postulate was supported by observations that glucagon-secreting
-cell tumours also showed hyperplasia of -cells (439).
Whereas glucose stimulates somatostatin-secretion from healthy -cells, somatostatin-
secreting -cells from islets from STZ-diabetic rats were unresponsive to changes in glucose
concentrations but still responded to increased cAMP levels (461). This suggests that the
hyperglycemia associated with diabetes may not be responsible for the increased pancreatic
somatostatin release observed in diabetes. In vivo insulin treatment of STZ-diabetic rats
restored the glucose sensitivity of -cells (461). Literature also widely supports the concept
that somatostatin release is stimulated by glucose and tolbutamide in healthy individuals,
but that these effects are lost in type 1 and type 2 diabetes, which has been proposed to
47
contribute to the impaired prandial suppression of glucagon secretion in diabetes (305;463-
468).
1.9.1 Brain somatostatin in experimental diabetes
The literature regarding brain somatostatin levels is less consistent than that of the
pancreas and gastrointestinal tract. In untreated STZ-diabetic rats, somatostatin mRNA
expression was reduced in the central portion of the periventricular nucleus with no changes
observed in the other somatostatin-rich hypothalamic areas: the periventricular nucleus or
the arcuate, suprachiasmatic or paraventricular nuclei (469). Interestingly, this anatomical
area of somatostatin reduction is involved with regulation of the anterior pituitary hormone
release. These changes in hypothalamic somatostatin expression were restored with insulin
treatment that normalized blood glucose levels (469). Older studies, however, did not
observe changes in hypothalamic somatostatin content or mRNA expression in STZ-diabetic
as compared to non-diabetic rats (448;449;452;470). Similarly, there was no change in
hypothalamic somatostatin content of db/db and ob/ob mice (471). It is possible that no
changes were observed if total hypothalamic content were measured as opposed to specific
anatomical areas. Interestingly, others have observed increased hypothalamic secretion of
somatostatin into the hypophyseal portal blood in vivo in STZ-diabetic rats (472). In other
areas of the brain, decreased somatostatin mRNA expression in the hippocampus and
frontal cortex of STZ-diabetic rats has also been reported (473), but how and whether these
anatomical changes affect glucose homeostasis in diabetes has yet to be determined.
48
1.10 Somatostatin in type 2 diabetic humans and animal models
Reports of somatostatin levels and -cell function in type 2 diabetes are not as consistent as
that described in type 1 diabetes. Pancreatic somatostatin secretion was shown to be
greater in type 2 diabetic humans, to a similar extent as type 1 diabetic subjects, as
compared to non-diabetic individuals (441). The number of somatostatin-expressing -cell
was increased by 58% in type 2 diabetic human pancreases as compared with non-diabetic
human pancreases and represented an absolute increase in number (474). However, other
studies showed no difference in percentage volume (475) or number (440) of -cells in type
2 diabetic human pancreatic islets or in basal plasma somatostatin levels (476).
In db/db mice, increased pancreatic somatostatin content and -cell hyperplasia were
observed. In ob/ob mice, pancreatic somatostatin content was also increased, but no
increase was noted in the number -cells (471). However, other studies in db/db and ob/ob
mice demonstrated that there were no differences in hypothalamic, gastric, or pancreatic
somatostatin levels in these genetically diabetic and/or obese mice until their serum insulin
levels decreased (477). Based on the temporal relationships of pancreatic somatostatin to
the disturbances in carbohydrate metabolism, the authors suggest the concept that changes
in pancreatic somatostatin represent a response to, rather than a cause of, hypoinsulinemia
(477).
1.11 Diabetes-induced changes in SSTR expression
Some of the studies that investigated changes in SSTR levels in diabetic animal models had
the purpose of examining growth hormone regulation and thus focused their investigations
on the brain and pituitary gland. Some older studies did not discern between which subtype
49
of SSTR was detected. In STZ-diabetes of short duration (5 and 9 days of diabetes),
concentrations of SSTRs in the hypothalamus and anterior pituitary were greatly reduced
and were not corrected by insulin treatment (478). More specifically, one group showed
that hypothalamic mRNA expression of SSTR5, but not SSTR1-4, and pituitary mRNA
expression of SSTR1, 2, 3, and 5, but not SSTR4, was reduced in STZ-diabetic rats (479).
In these animals, insulin treatment restored hypothalamic SSTR5 levels and partially
restored pituitary SSTR1 and SSTR5 levels. It was suggested that chronic exposure to high
somatostatin levels in diabetes may account for reduced SSTR mRNA expression due to
receptor desensitization, and insulin, high blood glucose levels, or glucocorticoids may also
in part regulate the expression of hypothalamic and pituitary SSTR mRNA expression (479).
However, the explanation behind the subtype-specific reduction is not yet apparent. SSTRs
in the cerebral cortex were not affected by STZ-diabetes of short duration (478).
1.12 Somatostatin: hypoglycemia-induced changes
Circulating somatostatin levels increase in response to insulin-induced hypoglycemia. This
has been observed both in non-diabetic and type 1 diabetic patients without diabetic
autonomic neuropathy (236;480). However, plasma somatostatin levels are not elevated in
response to hypoglycemia in subjects with diabetic autonomic neuropathy, thus
underscoring the importance of autonomic nervous system activity in pancreatic hormone
regulation during hypoglycemia (480). The increase in circulating somatostatin to insulin
hypoglycemia is mediated via activation of the vagus nerve and is in part regulated by the
associated increase in gastric acid (481;482). Truncal vagotomy also abolished the rise in
somatostatin to insulin-induced hypoglycemia in humans. It was concluded that the
somatostatin response is dependent upon vagal integrity and that section of the vagus
50
nerve unmasks a suppressive effect of insulin action or its metabolic or hormonal
consequences on circulating somatostatin levels (483). There is also evidence that
activation of the -adrenergic system by hypoglycemia may stimulate increased secretion of
somatostatin (451;484). Under low glucose conditions, locally secreted glucagon was
shown to increase somatostatin secretion in isolated islets via L-glutamate, a co-secretory
product from -cells that acts on a glutamate receptor on -cells, at least in islets on non-
diabetic rats (485). This response of somatostatin to hypoglycemia is not dependent on
residual -cell function since this rise in somatostatin was demonstrated in both type 1
diabetic patients with and with residual -cell function (486). This rise in plasma
somatostatin was similar in magnitude in both non-diabetic and diabetic individuals (486).
Although insulin-induced hypoglycemia elicited an increase in plasma somatostatin, there
was no rise of somatostatin to surgical stress, thus it has been suggested that this elevation
of somatostatin is likely specific to metabolic stress in non-diabetic humans (487).
Circulating somatostatin levels increase with insulin-induced hypoglycemia but not with
insulin infusion with dextrose to maintain euglycemia, thus this rise in plasma somatostatin
is not due to the effect of insulin but is stimulated indirectly via hypoglycemia (488). In
type 2 diabetic individuals, no rise in plasma somatostatin was observed in response to
insulin-induced hypoglycemia although an increase was observed in non-diabetic individuals
with equivalent hypoglycemia (476).
It is important to note that one of the problems in interpreting plasma somatostatin
responses is the origin of the circulating somatostatin since it can originate from various
tissues (318;489), especially since stimuli such as insulin, glucose, and hypoglycemia can
have divergent effects on hypothalamic and pancreatic somatostatin release, as mentioned
in an earlier section.
51
1.12.1 Hypoglycemia-induced somatostatin and SSTR changes in the brain
Interestingly, hypothalamic somatostatin mRNA expression levels were reported to be
dramatically increased by insulin-induced hypoglycemia in vivo (490). In numerous in vitro
studies, both low glucose concentrations and intracellular glycopenia induced with 2-deoxy-
D-glucose markedly stimulated somatostatin release from rat hypothalamic fragments (491-
494). Glucopenia induced by 2-deoxy-D-glucose, however, did not alter hypothalamic
somatostatin gene expression (494).
In contrast, it has been demonstrated that severe hypoglycemia of a longer duration than
the studies described above produces a disappearance of somatostatin-like
immunoreactivity in the dorsal hippocampus and frontal cortex (495). Furthermore, other
earlier studies demonstrated that hypoglycemia did not affect somatostatin levels in the
hypothalamus, cerebral cortex, hippocampus, and striatum (496-498). However, the total
number of SSTRs (subtype not specified) decreased in the hippocampus and striatum in
response to insulin-induced hypoglycemia as compared to controls but was unchanged in
the hypothalamus and cerebral cortex (496;497).
1.13 Somatostatin and its analogues in diabetic therapy
Type 1 and type 2 diabetic individuals have a decreased secretory response of somatostatin
to glucose stimulation, which has been postulated to contribute to impaired prandial
glucagon inhibition (305;463-468), and hyperglucagonemia can stimulate hepatic glucose
output, thus worsening diabetic hyperglycemia (463;464;467). Thus, somatostatin has also
been considered as an adjunct therapy with insulin for the treatment of diabetes
(489;499;500). The mechanism for improved glycemic control with somatostatin was
52
based on the somatostatin’s action to suppress glucagon and growth hormone secretion and
delay carbohydrate absorption (489). Due to the short half-life of the somatostatin peptide,
synthetic analogs, such as octreotide, were synthesized (501-503). However, somatostatin
analogues have not consistently been shown to be a beneficial adjunct therapy for diabetes
(504;505).
1.14 Somatostatin antagonist – PRL-2903
Functional biochemistry studies have shown that four amino acids (Phe-Trp-Lys-Thr) in the
native somatostatin peptide form a -turn that is essential for the biological activity of
somatostatin (506;507). With this knowledge, various agonists and antagonists with
greater metabolic stability and/or greater binding affinities have been synthesized with
pharmacological selectivity for particular SSTRs.
The SSTR2 peptide antagonist used in the present thesis is PRL-2903 and has the chemical
structure H-Fpa-cyclo[DCys-Pal-DTrp-Lys-Tle-Cys]-Nal-NH2 (Figure 1-1, Figure 1-2). This
peptide was synthesized by Dr. David Coy at Tulane University, Head of Peptide Research
Labs (New Orleans, LA, USA) (508;509). It is also referred to as DC-41-33 and BIM-23458.
This octapeptide has a molecular weight of 1160 da. The peptide has an IC50 of 2.5 nM in a
rat pituitary growth hormone in vitro antagonist assay versus somatostatin (1 nM) and it
binds to cloned human SSTR2 with a Ki of 26 nM. This peptide was also selective for SSTR2
over SSTR3 and SSTR5 by ~10- and 20-fold, respectively, and had negligible binding
affinity to SSTR1 and SSTR4 (509).
53
Figure 1-1. Linear structures of somatostatin, somatostatin-28, and SSTR2 antagonist PRL-2903.
H2N
NH
HN
NH
HN
NH
NH
O
O
O
O O
HN
NH2
O
O
NH2
NF
S S
HN
O
Figure 1-2. Structure of SSTR2 antagonist PRL-2903.
54
54
Chapter 2 Objectives
2 General Objectives
Hypoglycemia can have a profound impact on the lives of individuals with diabetes, and it
this population may fear hypoglycemia more than the long-term diabetic complications
(1;258). Thus, minimizing the incidence of hypoglycemia will improve the quality of life of
people with diabetes until a cure or prevention of diabetes is found.
The main objective of this thesis was to determine a means to improve the
counterregulatory response to hypoglycemia – in particular the glucagon response, which
plays a key role in promoting glycemic recovery (510), and which has consistently been
reported to be impaired in diabetes (167;168;511-513).
2.1 Specific Aim: Study 1
As described in the Introduction and will be further discussed in the chapters ahead, it is
recognized that the impairment in the glucagon response to hypoglycemia in diabetes can
be due to several factors. In brief, these mechanisms are related to local effects in the
pancreatic islet (76), or to central effects in brain regions known to detect glucose levels
and activate glucoregulatory responses (13;193). In addition to these reported factors, we
hypothesized that in diabetes during hypoglycemia, glucagon is suppressed by the
prevailing inhibitory effect of excessive somatostatin acting via SSTR2. Somatostatin has
55
inhibitory effects on the stimulated release of glucagon in the pancreas via SSTR2.
Furthermore, somatostatin and SSTR2 are found in brain regions that regulate glucose-
sensing and glucoregulatory response, and somatostatin is also known to have inhibitory
actions on the secretion of neuropeptides that are involved with the activation of
counterregulatory hormone responses to hypoglycemia. Thus, the first objective of this
thesis was to determine whether defective glucagon, and other hormone,
counterregulation can be restored in diabetic rats if somatostatin actions are
inhibited by using a selective SSTR2 antagonist.
2.2 Specific Aim: Study 2
In light of the fact that we were able to demonstrate a restoration of the glucagon response,
and markedly improved corticosterone response, to hypoglycemia in diabetic rats, we then
endeavoured to determine whether such hormone improvements could translate to
enhanced recovery of hypoglycemia, or prevention of hypoglycemia. From our first study,
we demonstrated deficient glucagon and corticosterone counterregulation to hypoglycemia
in diabetic rats. However, in this model of diabetes, the epinephrine response was not
impaired. Thus, we wanted to test our hypothesis of counterregulatory improvement in a
model with a well-known epinephrine counterregulation defect in addition to impairments of
glucagon and corticosterone – recurrent hypoglycemia (203;205;223;226;261;263;264).
We hypothesized that blocking the actions of somatostatin via SSTR2 would promote
glycemic recovery. Thus, the second objective of this thesis was to determine whether
counterregulatory responses can also be restored by SSTR2 antagonist in diabetic
rats exposed to recurrent hypoglycemia and if such improvements can lessen the
severity of subsequent hypoglycemia.
56
56
Chapter 3 General Materials and Methods
3 General Materials and Methods
3.1 Experimental animals
3.1.1 Care and maintenance
Male Sprague-Dawley rats (Charles River Laboratories, Saint-Constant, QC, Canada) with an
initial body weight of 275-300 g were used. Rats were individually housed in opaque cages
in temperature (22-23°C) and light-controlled (12-h light:12-h dark cycle; lights on
between 0700 and 1900) rooms. Rats had free access to drinking water and fed ad libitum
with rat chow (Teklad Global 18% protein, Harlan Laboratories, Madison, WI, USA). The
rats were allowed 1 week to acclimatize to experimenter handling and their environment
before experimental manipulation. Blood glucose, body weight, and food intake were
monitored for a minimum of 5 days per week for the duration of the experiment. Morning
(fed state) blood glucose was measured using a handheld glucometer (Ascencia Elite
handheld glucometer, Bayer Canada Ltd., Etobicoke, ON, Canada) via a tail-nick blood
sample. All procedures were in accordance with Canadian Council on Animal Care
Standards and were approved by the Animal Care Committee of the University of Toronto.
3.1.2 Streptozotocin-diabetic rat model of diabetes mellitus
Streptozotocin (STZ) consists of a 2-deoxy-D-glucose molecule substituted at C2 with a N-
methyl-N-nitrosourea group (514). The structure of STZ is shown in Figure 3-1 (514). STZ
is a diabetogenic agent used to induce experimental diabetes in animals via its cytotoxic
57
effects on pancreatic -cells (515). The deoxyglucose moiety of STZ directs it to the
pancreatic -cell where it is taken up via glucose transporter GLUT2 (516). The expression
of GLUT2 on -cells is needed for the diabetogenic action of STZ (517). The nitrosurea
moiety of STZ confers its cytotoxic effect.
It is suggested that -cell death is the result of one or more of the following mechanisms: 1)
DNA alkylation; 2) nitric oxide (NO formation); 3) free radical formation. It is proposed that
the primary mechanism for STZ-induced -cell death is DNA fragmentation resulting from
DNA alkylation, which related to the nitrosurea moiety of STZ (518). DNA is alkylated by
highly reactive carbonium ions (CH3+) are formed by the decomposition of nitrosurea (519).
NO is liberated when STZ is metabolized and is known to have cytotoxic effects on -cells
(520). NO also partially mediates a restriction of mitochondrial ATP generation (516). The
reduction of ATP generation results in high intracellular levels of ADP which causes
mitochondrial damage and the generation of hypoxanthine. Xanthine oxidase (XOD), the
activity of which is high in -cells, catalyzes the oxidation of hypoxanthine to xanthine and
xanthine to uric acid, both steps yield hydrogen peroxide and free oxygen radicals as
byproducts. Since -cells are deficient in superoxide dismutase, they are rendered
inefficient at scavenging free radicals and are thus more susceptible to the effects of STZ
(519). Along with DNA alkylation, the production of NO and reactive oxygen species further
contribute to DNA damage, which ultimately leads to an excision and repair process by poly
Figure 3-1. Structure of streptozotocin; see text for reference.
58
(ADP-ribose) synthase. This leads to the depletion of cellular nicotinamide adenine
dinucleotide (NAD+), a substrate for poly (ADP-ribosylation) and further reduction of cellular
ATP, which results in the subsequent inhibition of insulin synthesis and secretion (521).
To summarize, the toxicity of STZ is especially relevant to -cells due to several intrinsic
properties of -cells: 1) intrinsically low levels of protective superoxide dismutase; 2)
intrinsically low content of the substrate NAD+, which is needed for DNA repair; 3)
intrinsically high activity of XOD, which forms free radicals; and 4) intrinsic expression of
GLUT2, which is the transporter by which STZ enters the -cell. Thus, -cells are extremely
vulnerable to STZ-toxicity. STZ-induced experimental diabetes is sometimes criticized for
its non--cell effects. Some have argued that other GLUT2-expressing tissues, such as
hypothalamic astrocytes (522), may be compromised by STZ. Nevertheless, the
administration of STZ in rats generates metabolic and endocrine changes that are relevant
for the present study and remains a good a model for diabetes. Approximately 70% of -
cells are destroyed with a single, moderate dose of STZ (65 mg/kg) (470), and thus in
contrast to fully developed type 1 diabetes in which endogenous insulin secretion is
completely absent (523), this form of diabetes is less severe. STZ at 65 mg/kg yields a
diabetic model characterized by fasting and fed hyperglycemia, normal fasting plasma
insulin levels, but reduced fed-state plasma insulin levels (524).
3.1.3 Induction of diabetes using streptozotocin
Streptozotocin (STZ, 65 mg/kg, Sigma Chemical Co., St. Louis, MO, USA) was dissolved in
0.9% saline and immediately injected intraperitoneally to induce diabetes in the rats.
Within 24 h of STZ injection, post-prandial plasma glucose levels were elevated, food intake
was increased, and body weight was less than that of saline-injected controls. Rats that did
59
not exhibit hyperglycemia (i.e. > 10 mM) 48 h following injection of STZ were excluded
from the study.
3.1.4 Chronic vessel catheterization
Chronic, indwelling catheters were implanted in the left carotid artery and right jugular bein
to allow for undisturbed blood sampling and re-infusion of red blood cells. Surgery was
performed in designated operating rooms at the University of Toronto’s Department of
Comparative Medicine animal facility under aseptic conditions. All procedures were in
accordance with Canadian Council on Animal Care Standards and were approved by the
Animal Care Committee of the University of Toronto.
3.1.4.1 Pre-operative preparation.
Surgical instruments, gauze, cloths, and gloves were autoclaved prior to use. Sterile, new
syringes, needles, and sutures were used. Catheters were made from polyethylene tubing
(PE-50, length: 80 cm, ID: 0.58 mm, OD: 0.965 mm, Becton Dickinson, Sparks, MD, USA)
with a 3.0 cm- overlap of silastic tubing (ID: 0.76 mm, OD: 1.65, Dow Corning Corporation,
Midland, MI, USA). The silastic overlap was dipped in diethylether to expand the tubing
prior to being slipped over the end of the polyethylene catheter, forming an overlap of 1.5
cm. The silastic end of the catheter was then bevelled at 45° to facilitate insertion into the
vessel. Catheters were soaked in 70% ethanol to disinfect for at least 1 hour, flushed with
saline, and primed with 10 USP/mL heparinized saline (Heparin LEO; 1000 USP units/mL;
LEO Pharma Inc., Thornhill, ON, Canada) prior to vascular insertion.
3.1.4.2 Surgical procedure.
Rats were anesthetized using a ketamine cocktail, which consisted of ketamine (100 mg/kg,
ip; MTC Pharmaceuticals, Cambridge, ON, Canada), acepromazine (1 mg/kg, ip; Wyeth-
60
Ayerst Canada Inc., Montreal, QC, Canada), and xylazine (1 mg/kg, ip; Bayer Inc.,
Etobicoke, ON, Canada). Once rats were anesthetized, the ventral side of the neck and the
dorsal side of the neck between the scapulae were shaved and cleaned with 70% ethanol
and 10% povidone-iodine (Betadine solution, Purdue Pharma, Pickering, ON, Canada). The
rat was placed in the dorsal recumbent position on an operating tray, and its chin and limbs
were fastened to the tray with masking tape. The rat was covered with sterile surgical
cloths exposing only the incision area. The ventral skin just anterior to the collarbone was
cut with a 2-cm transverse incision. Using blunt dissection through muscle layers, the left
carotid artery was isolated from the vagus nerve and connective tissue. The exposed vessel
was ligated at the cranial end using sterile 3-0 silk thread. Another ligature was loosely
tied at the caudal end of the exposed carotid. To temporarily stop blood flow to this
segment of the vessel, the exposed carotid artery was pulled taut at the 2 ligatures.
Scissors were used to make a small incision in the vessel wall. The primed, bevelled silastic
end of the catheter was inserted through the opening in the carotid, past the loose caudal-
end ligature, until the silastic-polyethylene overlap of the catheter was also inside the
vessel. The catheter was then secured by tightening the loose ligature at the caudal end.
Two additional sutures were tied to anchor the catheter to the vessel. The catheter was
then tested to ensure blood withdrawal and infusion were possible and that air emboli were
absent. Cannulation of the right jugular vein was carried out using the same procedure.
A 2-cm transverse incision was made through the shaved dorsal surface between the
scapulae. A small subcutaneous pocket anterior to the incision was formed by using forceps
to loosen the skin from the underlying connection tissue. Using a 16G needle and scalpel, a
small opening was made in the skin 1.5 cm anterior to the dorsal incision. A metal coil
tether (rodent tether, 18”; Lomir Biomedical Inc., Notre-Dame-de-I'Île Perrot, QC, Canada)
61
with a plastic button base was tunneled through the incision, into the pocket, and out the
small opening, leaving the button under the skin. The button was sutured to the skin using
3-0 silk sutures (SofSilk, Tyco Healthcare Group Canada Inc., Ville St. Laurent, QC,
Canada), securing the externalized tether. To feed the catheter through the tether, the
catheter was first tunneled subcutaneously on the right side of the neck, from the ventral to
the dorsal incision areas using a 16G needle as a guide. The catheter was fed through the
underside of the plastic button and into the tether such that the end of the catheter
extended out of the tether. The tether and catheter were then secured to the tether-swivel
connector, which was fastened to a clamp on a retort stand. The catheter was tested again
to ensure for proper blood sampling and re-infusion. This rodent tethering system allowed
for manual, undisturbed blood sampling and for unrestricted movement of the rat. The
dorsal incision was closed with discontinuous 3-0 silk sutures. On the ventral side, the
catheter was anchored to the underside of the skin just cranial to the incision line, and the
incision was closed with continuous 3-0 silk sutures.
3.1.4.3 Post-operative care.
Following surgery, incision sites and the dorsal button area were cleaned with 10%
povidone-iodine. Rats were injected subcutaneously with 3.0 mL of saline to prevent
dehydration during recovery from anesthetization. Rats were then allowed to recover in
clean cages lined with paper towel overtop bedding material. The tether extended from the
back of the neck of the rat, through the cage lid, and connected to the swivel apparatus
external to the cage. Rats were allowed at least 3 full days to recover from surgery prior to
experimentation.
62
3.1.4.4 Catheter patency and blood sampling.
To ensure that catheters remained free from clots, the lines were flushed daily with
heparinized (10 USP U/mL) saline. Carotid catheters were then filled with 100 USP U/mL
heparinized saline, plugged with a saline-filled syringe with a 23-gauge blunted needle, and
clamped with hemostats with silastic cuffs. Jugular catheters were filled with 100 USP
U/mL heparinized saline, plugged with blunted pins, and secured against the metal tether
with masking tape to avoid being caught or pulled.
3.2 General laboratory methods
3.2.1 Blood Glucose Determination
Whole blood glucose concentrations were measured immediately after obtaining blood
samples during experiments by the glucose oxidase method using a glucose analyzer
(Analox glucose analyzer, GMD-9D, Analox Instruments USA Inc., Lunenburg, MA). This
method was suitable for use with whole blood collected with heparin and/or EDTA. A 10 L
blood sample was pipetted into the reaction well, which contained the glucose oxidase
reagent (Glucose oxidase reagent kit, GMRD-020, Analox Instruments USA Inc., Lunenburg,
MA). In the presence of oxygen, glucose from the blood sample is oxidized by glucose
oxidase to gluconic acid and hydrogen peroxide as follows:
-D-glucose + O2 glucose oxidase
D-gluconic acid + H2O2
Oxygen consumption is directly proportional to glucose concentration, and the analyzer
measures the rate of oxygen uptake in the reaction well using a Clark-type amperometric
oxygen electrode at 30C. The analyzer is calibrated before the start of, and intermittently
63
throughout, each experiment using glucose standards of 8.0 (Glucose standard 8.0 mM,
GMRD-011) and 2.5 mM (Glucose standard 2.5 mM, RMRD-009), respectively. Results were
obtained within 35 sec of sample addition, and blood samples were analyzed in duplicate,
ensuring that the measurements obtained were ± 0.2 mM. The analyzer has a linearity of
30 mM and 50 mM using 10 L and 5 L samples, respectively.
For blood glucose measurements taken daily to monitor fed morning glycemia, a handheld
glucometer (Ascencia Elite, Bayer Canada Ltd., Etobicoke, ON, Canada) was used with blood
glucose test strips (Elite, Bayer Bayer Canada Ltd., Etobicoke, ON, Canada). Test strips
have been calibrated to give plasma equivalent glucose results. Test strips also use the
glucose oxidase method for determinations of glucose concentrations. The range of glucose
concentration measurable using test strips was 1.1 to 33.3 mM.
3.2.2 Preparation of blood sample collection tubes
1.5 mL microtubes (Eppendorf; Diamed Lab Supplies Inc., Mississuaga, ON, Canada) were
used to collect blood samples for various assays. Tubes chilled on ice containing 25 U of
dried heparin were used for collection of 0.1 mL of blood for corticosterone assays. For
glucagon, catecholamine, insulin, and growth hormone assays, 0.5 mL of blood was
collected in chilled tubes containing 50 L of a 1:1 solution of ethylenediamine tetraacetic
acid (EDTA; 0.24 g/mL in distilled water; Sangon Ltd. Canada, Scarborough, ON, Canada)
and Trasylol (2000 kallikrein IU; Bayer Canada Ltd., Etobicoke, ON, Canada). For
somatostatin assay, two tubes of 1.0 mL blood each were collected in chilled tubes each
containing 100 L of the 1:1 EDTA:Trasylol solution (i.e. 2.0 mL of blood collected in total at
euthanasia for somatostatin assay). EDTA is an anticoagulant, and Trasylol is a broad
spectrum proteolytic inhibitor that protected the plasma against loss of hormone reactivity.
These tubes were kept chilled (4C) prior to collection of blood.
64
After blood was collected in the respective tubes, tubes were shaken to ensure adequate
mixing of their contents. Blood was then centrifuged (30-60 sec at 9000 rpm) to separate
plasma from packed red blood cells. Plasma was then immediately frozen and kept at -
80C.
3.2.3 Radioimmunoassays (RIA) for plasma hormone levels
Plasma corticosterone, glucagon, and catecholamine levels were measured using
radioimmunoassay (RIA). This procedure involves a competitive reaction between an
unknown amount of antigen (i.e. hormone) present in a plasma sample and a known
amount radiolabeled antigen for limited binding sites on an antibody (525). In our RIAs, the
radioactive label used was 125I. After an incubation period between these reagents during
which unlabeled and labeled hormones vie for a binding site on the antibody, an equilibrium
is reached. This equilibrium is dependent on the relative amounts of unlabeled and labeled
hormones and reflects the nature of competitive reactions. The bound hormone-antibody
complexes, which are in the form of a precipitant, are then separated from the free
hormones, which are in the liquid phase. This separation involves centrifuging the mixtures
and removing the liquid phase by decanting or aspirating. The amount of bound
radiolabeled hormone is then measured in a gamma scintillation counter. The assay is
calibrated by measuring standards of known concentrations and cross-plotting the counts
emitted by the radioactive label versus the concentration of the standards to generate a
dose-response curve. As the concentration increases, the number of counts decreases
exponentially. This is true also for the sample in question; the precipitated complex of a
sample carrying a high concentration of unlabeled hormone will have lower radioactivity
since there would be less radiolabeled hormone bound to the limited amount of antibody.
The reverse is also true in that a sample with a low concentration of unlabeled hormone will
65
yield a precipitated pellet of lower radioactive signal. Non-specific binding is a control
parameter that represents the minimal binding (525). Percent bound values are calculated
for both standards and samples in the equation:
Percent bound = [ sample counts ‐ non-specific binding counts ]
(zero calibrator counts ‐ (non-specific binding counts)] × 100%
3.2.3.1 Plasma corticosterone assay.
ImmunoChem™ Double Antibody Corticosterone 125I RIA kits (MP Biomedicals, Solon, OH,
USA) were used to measure total corticosterone levels in rat plasma. Assay controls were
reconstituted with 2 mL of distilled water and allowed to sit at room temperature for at least
30 min before use. Other reagents from the kit and frozen plasma samples were also
brought to room temperature. Thawed samples were then centrifuged at 4C to remove
fibrin or other particulate matter. Plasma was diluted at a ratio of 1:200 by adding 2 mL of
steroid diluent to 10 L of plasma. The steroid diluent provided with the kit consisted of
phosphosaline gelatin buffer at pH 7.0 ± 0.1 with rabbit gamma globulins.
Six corticosterone standards in concentrations ranging from 0 to 1000 ng/mL were used to
produce a standard curve for the assay. 100 L of each of the standards, controls, and
diluted plasma samples were pipetted into polystyrene tubes. Standards were assayed in
triplicate while controls and samples were assayed in duplicate. To each of these tubes,
200 L of 125I-corticosterone followed by 200 L of anti-corticosterone antibody was added,
vortexed, and incubated at room temperature for 2 h. Corticosterone-3-
carboxymethyloxime:BSA was used as the antigen to generate antiserum in rabbits.
Following the incubation, 500 L of precipitating solution, a mixture of goat anti-rabbit
gamma globulin and polyethylene glycol in TRIS buffer, was added to the tubes. Tubes
66
were then vortexed and centrifuged at 2500 rpm for 20 min. This allowed for the
separation of bound antibody-antigen complexes (pellet) from the free fraction
(supernatant). A triplicate of tubes containing only 125I-corticosterone (to measure total
counts) and another triplicate of tubes containing only 125I-corticosterone and precipitating
solution (to measure non-specific binding) also underwent the same incubation and
vortexing procedures. The supernatant was then aspirated from all tubes, except for the
tube only containing 125I-corticosterone, and the precipitate was counted in a gamma-
scintillation counter to measure their reactivity. A standard curve was produced by plotting
percent bound against concentration of corticosterone for the standards. Plasma
concentrations of the samples were automatically calculated by computer software linked to
the gamma counter. The manufacturer’s assay precision was reported as intra-assay
coefficient of variation between 4.4-10.3% and inter-assay coefficient of variation between
6.5-7.1%.
3.2.3.2 Plasma glucagon assay.
Plasma glucagon levels were measured using LINCO/Millipore’s Glucagon RIA Kit (GL-32K,
LINCO Research Inc., St. Charles, MO, USA/Millipore Corporation, Billerica, MA, USA). This
assay uses 125-glucagon and glucagon antibody to determine the level of glucagon in plasma
by using the double antibody technique.
Samples were thawed just prior to the assay and centrifuged to separate plasma from fibrin
or other particulate matter. All reagents, besides the 125I-glucagon tracer, were provided
ready to use. 100 L of plasma was added with 100 L of assay buffer, which contained
0.2M glycine, 0.03M EDTA, 0.08% sodium azide, and 1% RIA-grade BSA at a pH 8.8 into
polystyrene tubes. When 100 L of plasma was not available, smaller volumes of sample
were used and additional assay buffer was added to compensate for the difference so that
67
the total sample volume was equivalent to 100 L, as directed by the kit. Five standards
ranging from glucagon concentrations of 20 to 400 pg/mL were included in the kit. A zero
standard was produced using 200 L of assay buffer as instructed by the kit, and a 10
pg/mL standard was made by diluting the 20 pg/mL standard in a 1:1 ratio with assay
buffer. 100 L of each standard and control was pipetted into tubes along with 100 L of
assay buffer. To sample, standard, and control tubes, 100 L of guinea pig glucagon
antibody was added. All tubes were assayed in duplicate. Tubes containing 300 L of assay
buffer and no antibody were included in the assay to measure non-specific binding. Tubes
were vortexed, covered, and incubated at 4C for 20 hours.
Following the incubation period, lyophilized 125I-glucagon tracer was mixed with label
hydrating buffer, which had the same composition as assay buffer, and allowed to sit at
room temperature for 30 min. All tubes were then pipetted with 100 L of 125I-glucagon.
100 L of 125I-glucagon was added to two more tubes to measure total radioactivity (i.e.
total count tubes). All tubes were then vortexed, covered, and allowed to incubate at 4C
for an additional 20 hours.
After the second incubation period, 1.0 mL of cold (i.e. 4C) precipitating solution was added
to all tubes except for total count tubes. Tubes were then vortexed and incubated for 20
min at 4C after which they were centrifuged for 20 min at 4C. Supernatant was then
immediately aspirated from the tubes, except for total count tubes, and pellets containing
the antibody-antigen complexes were counted in a gamma-scintillation counter to measure
their radioactivity. A standard curve was plotted from the assay standards. Plasma
concentrations of the samples were automatically calculated by computer software linked to
the gamma counter. Samples which contained less than 100 L plasma were multiplied by
the appropriate factor. The intra-assay coefficient of variation was reported as 4.0-6.8%.
68
The inter-assay coefficient of variation was reported as 7.3-13.5%. The specificity of the
test was reported as 100% for glucagon and <0.1% for oxyntomodulin, which contains the
glucagon sequence.
3.2.3.3 Plasma catecholamine assay.
A two-catecholamine RIA kit from Labor Diagnostika Nord (LDN) was used for the
quantitative determination of plasma epinephrine and norepinephrine (BA 1500, LDN GmbH
& Co. KG; Nordhorn, Germany). In this test, epinephrine and norepinephrine are first
extracted by using a cis-diol-specific affinity gel, acylated to N-acylepienphrine and N-
acylnorepienphrine, and then enzymatically converted during the detection procedure to N-
acylmetanephrine and N-acylnormetanephrine. The subsequent assay procedure follows the
basic RIA principle.
All reagents are brought to room temperature before use, except for the precipitating
solution which is kept chilled (~ 4C). Standards, controls, and plasma samples are first
extracted. Six standards ranging for each of epinephrine and norepinephrine are provided
with the kit in the concentration range of 0 to 90 ng/mL and 0 to 450 ng/mL, respectively.
20 L of each standard and controls and 80 L of distilled water are pipetted into wells of
the extraction plate, which is coated with boronate affinity gel. 100 L of sample plasma is
also pipetted into separate wells of the extraction plate. 50 L of each of assay buffer
(containing 1 M hydrochloric acid) and extraction buffer are added to all wells, and the plate
is covered and incubated at room temperature on an orbital shaker (600-900 rpm) for 30
min. Following the incubation period, standards, controls, and samples are acylated to N-
acylepinephrine and N-acylnorepinephrine. The plate is decanted, and 150 L of acylation
buffer followed by 25 L of acylation reagent are added to all wells. The plate is then
incubated under the same conditions as before for 15 min, decanted, pipetted with 1 mL of
69
distilled water per well, incubated again for 5 min, and decanted again. 200 L of 0.025 M
hydrochloric acid is then added to each well, and the plate is covered and incubated as
before for 10 min. This eluate is then ready for RIA.
Epinephrine and norepinephrine RIAs are performed in separate tubes but from the same
extracted samples. Thus, the appropriate radioactively labeled antigen and antibody must
be used for each assay. 90 L of the extracted standards, controls, and samples are
pipetted into polystyrene tubes for each of the epinephrine and norepinephrine assays. To
measure non-specific binding, 90 L of hydrochloric acid is pipetted into separate tubes. An
enzyme provided with the kit containing catechol-O-methyltransferase is reconstituted in 1
mL of distilled water mixed thoroughly. To this solution, 0.3 mL of the coenzyme S-
adenosyl-L-methionine is then added, followed by 0.7 mL of the enzyme buffer. This
solution must be prepared no longer than 10 min prior to use. 25 L of enzyme solution is
added to all tubes. Tubes are then mixed and incubated at 37C for 30 min.
After the incubation, 50 L of 125I-epinephrine (or 125I-norepinephrine) is added to the
tubes. Tubes for measuring total radioactivity (i.e. total counts) are also included in the
assay and contain only the radioactive label. 50 L of epinephrine antibody (or
norepinephrine antibody) is then added to all tubes except tubes for non-specific binding or
total counts. After tubes are mixed and centrifuged at 500 xg and incubated at 4C
overnight. Cold precipitating reagent is mixed and 1 mL is then added to all tubes (except
total counts). Tubes are vortexed and centrifuged for 15 min at 3000 xg at 4C.
Supernatant is then aspirated, leaving behind a pellet containing antibody-antigen
complexes. Tubes for each assay were counted separately in a gamma-scintillation counter
to measure their radioactivity. A standard curve was plotted from the assay standards.
Plasma concentrations of the samples were automatically calculated by computer software
70
linked to the gamma counter. The intra-assay coefficient of variation was reported as 4.6-
14% and 4.0-4.6% for epinephrine and norepinephrine, respectively. The inter-assay
coefficient of variation was reported as 5.6-6.1% and 6.1-10% for epinephrine and
norepinephrine, respectively.
3.2.3.4 Plasma somatostatin assay.
The EURIA somatostatin RIA kit was used for the quantitative determination of plasma
somatostatin concentrations (RB-306, Euro-Diagnostica AB, Malmo, Sweden). Due to the
large volume of plasma needed for this assay, plasma was obtained from trunk blood at
euthanasia. Somatostatin from the plasma is first extracted with Sep-Pak C18 cartridges
(WAT023635, Waters Ltd., Milford, MA). The extracts are then assayed using 125-Tyr1-
somatostatin and an antibody to synthetic somatostatin-14 to determine the level of
somatostatin in the sample using the double antibody technique.
Plasma samples were thawed just prior to the assay and centrifuged to separate plasma
from fibrin or other particulate matter, and 0.5 mL of plasma was aliquoted into eppendorf
tubes. 50 L of 1M hydrochloric acid was added to each sample and vortexed. The Sep-Pak
cartridge was wetted with 5 mL of methanol and washed with 20 mL of distilled water.
Separate cartridges were used for each sample. At a flow rate no greater than 1 mL/10 sec,
the plasma-acid solution was applied to the Sep-Pak cartridge and then washed with 20 mL
of 4% acetic acid in distilled water. Somatostatin was subsequently eluted from the
cartridge with 2 mL of methanol also at a flow rate less than 1 mL/10 sec and collected in a
10 mL glass tube. The eluate was then dried in an evaporator. Extracted somatostatin
dissolved in 0.5 mL of assay diluents, which contained 0.05 M phosphate buffer at pH 7.4,
0.25% human serum albumin, 0.25% EDTA, 0.05% sodium azide, 0.1% Tween 80, and 500
71
KIU/mL Trasylol. Reconstituted samples were vortexed thoroughly and rested for 30
minutes prior to the RIA procedure.
For determination of the recovery in the extraction procedure, two recovery controls were
prepared. Control A consisted of 0.8 mL of rat plasma combined with 80 L of 1M
hydrochloric acid, to which 200 L of the 250 pmol/L somatostatin standard was added to
yield a final concentration of 50 pmol/L. Control B consisted of 0.8 mL of the same rat
plasma combined with 80 L of 1M hydrochloric acid, to which 200 L of assay diluents was
added. Both controls were extracted using the same procedure described above for the
samples. Control B was used for the correction for endogenous somatostatin in the
calculation of the recovery of added somatostatin.
A 250 pmol/L synthetic cyclic somatostatin (MW = 1638.1) standard was prepared in a
solution with same composition as the assay diluent and lyophilized. This lyophilized
standard was reconstituted in 5 mL distilled water and serially diluted with assay diluent to
yield 7 standard solutions ranging from 0 to 125 pmol/L. Rabbit somatostatin antibody was
raised against cyclic somatostatin conjugated to bovine thyroglobulin. The antibody and 125-
somatostatin were prepared in a solution with same composition as the assay diluent and
lyophilized, and both were reconstituted in 22 mL and 25 mL of distilled water, respectively,
prior to the RIA procedure. 100 L of standards, controls, and reconstituted samples were
pipetted into polystyrene tubes in duplicate. An additional pair of tubes with 300 L of
assay diluent was included to measure non-specific binding. 200 L of somatostatin
antibody was added to tubes containing standards, controls, and reconstituted samples and
vortexed. After a 20-h incubation at 4C, 200 L of 125- somatostatin was added to all tubes
and vortexed. Two additional tubes of 200 L of 125- somatostatin were included to measure
total count of radioactivity. After a second 20-h incubation at 4C, 100 L of precipitating
72
reagent was added to all tubes except for total counts. This reagent consisted of rabbit
immunoglobulins coupled to cellulose particles and since it was a suspension, it required
continuous stirring during pipetting. Tubes were vortexed thoroughly, incubated for 45
minutes at 4C, and centrifuged at 2500 rpm at 4C for 20 min. Supernatant was then
immediately aspirated from the tubes, except for total count tubes, and pellets containing
the antibody-antigen complexes were counted in a gamma-scintillation counter to measure
their radioactivity. A standard curve was plotted from the assay standards. Plasma
concentrations of the samples were automatically calculated by computer software linked to
the gamma counter.
Somatostatin recovery was calculated as follows:
% recovered somatostatin = [ concentration Control A – concentration Control B ]
50 × 100%
The recovery should be at least 60% for a valid assay. Sample concentrations were then
corrected for the percent recovery and also multiplied by a factor of 1.1 to correct for the
increased sample volume by adding 1M hydrochloric acid. The intra-assay coefficient of
variation was reported as 2.8-8.3%. The inter-assay coefficient of variation was reported as
3.3-6.4%.
3.2.3.5 Plasma insulin assay
Plasma insulin levels were measured using LINCO/Millipore’s Rat Insulin RIA Kit (RI-13K,
LINCO Research Inc., St. Charles, MO, USA/Millipore Corporation, Billerica, MA, USA). This
assay uses 125-insulin and a rat insulin antibody to determine the level of rat insulin in
plasma by using the double antibody technique.
73
Samples were thawed just prior to the assay and centrifuged to separate plasma from fibrin
or other particulate matter. Since high doses of insulin were administered in the
hypoglycemia experiments, plasma samples obtained after insulin administration had to be
diluted with assay buffer before assay. For Study 1, when 10 U of insulin was injected,
plasma samples at time 60 and 180 min were diluted 100 and 20 times, respectively. For
Study 2, plasma samples at time 60 were diluted 100 times.
All reagents, besides the 125I-rat insulin tracer, were provided ready to use. One-half of the
volumes of all reagents suggested in the manufacturer’s protocol were used in this assay.
50 L of plasma (or diluted plasma) was pipetted into glass sample tubes. 100 L and 50 L
of assay buffer, which contained 0.05 M phosphosaline at pH 7.4, 0.025M EDTA, 0.08%
sodium azide, and 1% RIA-grade BSA, was added to the non-specific binding tubes and
reference tubes, respectively. Seven standards ranging from rat insulin concentrations of
0.1 to 10.0 ng/mL were included in the kit. 50 L of each standard and control was pipetted
into tubes. All tubes were assayed in duplicate. Lyophilized 125I-insulin tracer was hydrated
with 27 mL of hydrating buffer and rested at room temperature for 30 min with occasional
gentle mixing. The hydration buffer contained normal guinea pig immunoglobulin G. 50 L
of hydrated 125I-insulin was added to all tubes. 50 L of 125I-insulin was added to two more
tubes to measure total radioactivity (i.e. total count tubes). To sample, standard, and
control tubes, 50 L of guinea pig rat insulin antibody was added. The rat insulin antibody
was raised in guinea pigs against highly purified rat insulin. All tubes were assayed in
duplicate. Tubes were vortexed, covered, and incubated at 4C for 20 hours.
After the incubation period, 0.5 mL of cold (i.e. 4C) precipitating solution was added to all
tubes except for total count tubes. The precipitating solution contained goat anti-guinea pig
immunoglobulin G serum, 3% polyethylene glycol, 0.05% TritonX-100 in 0.05 M
74
phosphosaline, 0.025 M EDTA, and 0.08% sodium azide. Tubes were then vortexed and
incubated for 20 min at 4C after which they were centrifuged for 20 min at 4C.
Supernatant was then immediately aspirated from the tubes, except for total count tubes,
and pellets containing the antibody-antigen complexes were counted in a gamma-
scintillation counter to measure their radioactivity. A standard curve was plotted from the
assay standards. Plasma concentrations of the samples were automatically calculated by
computer software linked to the gamma counter. Samples which were diluted were
multiplied by the appropriate factor. The intra-assay coefficient of variation was reported as
1.4-1.6%. The inter-assay coefficient of variation was reported as 8.5-9.4%. The
specificity of the test was reported as 100% for rat, human, and porcine insulin and not
detectable for IGF-I or rat C-peptide.
3.2.3.6 Plasma growth hormone assay
Plasma growth hormone levels were measured using LINCO’s Rat Growth Hormone RIA Kit
(RGH-45HK, LINCO Research Inc., St. Charles, MO, USA). This assay uses 125-rat growth
hormone and a rat growth hormone antibody to determine the level of rat growth hormone
in plasma by using the double antibody technique.
Samples were thawed just prior to the assay and centrifuged to separate plasma from fibrin
or other particulate matter. All reagents, besides the 125I-growth hormone tracer, were
provided ready to use. 100 L of plasma was pipetted into sample tubes containing 100 L
assay buffer. The assay buffer contained 0.05 M phosphosaline at pH 7.4, 0.025M EDTA,
0.08% sodium azide, and 1% RIA-grade BSA. 300 L and 200 L of assay buffer was added
to the non-specific binding tubes and reference tubes, respectively. Seven standards
ranging from rat growth hormone concentrations of 0.5 to 50.0 ng/mL were included in the
kit. 100 L of each standard and control was pipetted into tubes. All tubes were assayed in
75
duplicate. Lyophilized 125I-growth hormone tracer was hydrated with 13.5 mL of hydrating
buffer and rested at room temperature for 30 min with occasional gentle mixing. The
hydration buffer contained normal guinea pig serum. 100 L of hydrated 125I-growth
hormone was added to all tubes. 100 L of 125I-growth hormone was added to two more
tubes to measure total radioactivity (i.e. total count tubes). Both the 125I tracer and
standards were prepared with recombinant rat growth hormone. To sample, standard, and
control tubes, 100 L of guinea pig rat growth hormone antibody was added. The rat
growth hormone antibody was raised in guinea pigs against recombinant rat growth
hormone. All tubes were assayed in duplicate. Tubes were vortexed, covered, and
incubated at 4C for 20 hours.
After the incubation period, 1.0 mL of cold (i.e. 4C) precipitating solution was added to all
tubes except for total count tubes. The precipitating solution contained goat anti-guinea pig
immunoglobulin G serum, 3% polyethylene glycol, 0.05% TritonX-100 in 0.05 M
phosphosaline, 0.025 M EDTA, and 0.08% sodium azide. Tubes were then vortexed and
incubated for 20 min at 4C after which they were centrifuged for 20 min at 4C.
Supernatant was then immediately aspirated from the tubes, except for total count tubes,
and pellets containing the antibody-antigen complexes were counted in a gamma-
scintillation counter to measure their radioactivity. A standard curve was plotted from the
assay standards. Plasma concentrations of the samples were automatically calculated by
computer software linked to the gamma counter. The specificity of the test was reported as
100% for rat growth hormone and <0.1% for rat prolactin and human and porcine growth
hormone.
76
3.2.4 Pancreatic protein determination
Pancreatic glucagon and somatostatin protein content was measured from pancreata
collected from animals in Study 1. Pancreata were quickly removed at euthanasia, frozen in
sterile tubes on dry ice, and stored at -80°C.
3.2.4.1 Pancreas homogenization for protein isolation
Frozen pancreata were individually homogenized in 3 10-second intervals on medium-high
speed in 50-mL falcon tubes kept on ice in 10 mL of extraction medium containing 9.2%
hydrochloric acid, 5% formic acid, 1% trifluoroacetic acid (TFA), and 1% sodium chloride.
Homogenates were centrifuged at 2300 rpm at 4C for 15 minutes. The supernatant was
collected in a separate falcon tube. An additional 10 mL of extraction medium was added to
the remaining pellet, re-homogenized as before, and centrifuged again at 2300 rpm at 4C
for 15 minutes. The second supernatant was collected in the same tube as the first (total
final volume of 20 mL), and the pellet was discarded.
3.2.4.2 Sep-Pak protein extraction
Pancreatic protein was isolated by eluting the supernatant of pancreatic homogenates using
Sep-Pak C18 cartridges (WAT023635 Waters Ltd., Milford, MA). Separate cartridges were
used for each sample. Using a 20 mL syringe, each Sep-Pak cartridge was first wetted with
15 mL of a solution containing 80% isopropanol and 0.1% TFA, followed by 15 mL of 0.1%
TFA. The 20 mL of supernatant from the homogenized pancreata were then slowly passed
through the Sep-Pak twice. Each Sep-Pak cartridge is subsequently washed using 15 mL of
0.1% TFA to remove any unbound sample. At the end of this stage only is air allowed to
pass through the column to remove all liquid (approximately 2 mL of air from a syringe).
The protein is then eluted from the column using 10 mL of solution containing 80%
isopropanol and 0.1% TFA into a 15 mL falcon tube. Pancreatic protein eluates were frozen
77
at -80°C until used. For glucagon and somatostatin determinations using commercially
available radioimmunoassay kits, 1-mL aliquots of these eluates were evaporated, and
isolated protein was re-dissolved in 3 mL of double-distilled water. Glucagon and
somatostatin measurements were normalized for total protein content as determined by
spectrophotometer analysis.
3.2.5 Liver mRNA expression quantification
Livers were quickly removed at euthanasia, frozen in sterile tubes on dry ice, and stored at -
80°C.
3.2.5.1 Total RNA preparation.
Total RNA was extracted from frozen liver using a modified phenol-chloroform method with
TRI Reagent® (TR-118, Sigma-Aldrich, St. Louis, MO, USA). TRI Reagent® combines phenol
and guanidine thiocyanate to facilitate inhibition of RNAse activity. A small sample of liver
(approximately 2 x 2 x 2 mm3) was homogenized in a 15 mL snap cap tube for 20-30 on
medium-high speed in a fume hood. The homogenate was then incubated at room
temperature for at least 5 min. 800 L of chloroform was then added to the homogenate
and shaken vigorously before incubating for an additional 5 min at room temperature.
Using a 1 mL pipette, the upper phase (approximately 2 mL of clear fluid) of the mixture
was carefully collected in a new 15 mL snap cap tube with care being taken to avoid the
buffy white layer to avoid DNA contamination. At this stage, RNA remains exclusively in the
aqueous phase (supernatant), DNA in the interphase (buffy white layer), and proteins in the
organic phase (pellet). 2 mL of isopropanol was then added to the supernatant collected,
and the tube was mixed by inversion and incubated at room temperature for 15 min. Tubes
containing the samples were centrifuged at 12 000 g at 4C for 10 min. The orientation of
the tubes was noted prior to centrifugation so that the small RNA pellet could be easily
78
identified following centrifugation. The supernatant was then removed by aspiration, and 4
mL of ice-cold 75% ethanol was added to the remaining pellet. Tubes were then vortexed
thoroughly and centrifuged at 10 000 g at 4C for 5 min. The supernatant was then
carefully removed by aspiration. Tubes were then allowed to vent at room temperature for
30 min to evaporate off any remaining ethanol. Pellets were resuspended in 100 L
diethylpyrocarbonate (DEPC) water (i.e. RNAse free water) by repeated drawing and
expelling the pellet with a pipette tip.
Quantification of RNA content was performed by measuring the optical density (OD) at 260
and 280 nm using 2 L of sample with a NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientific, Mississauga, ON, Canada). For RNA, the ratio of 260/280 should be between 1.8
and 2. OD measurements below this ratio are indicative of contamination with protein or
solvents. RNA concentration (in g/mL) was then calculated as:
RNA concentration = OD260 × dilution factor × 40
The resuspended RNA sample was transferred to eppendorf tubes and stored at -80C until
use.
3.2.5.2 cDNA synthesis.
Frozen RNA dissolved in DEPC water was heated in a water bath at 65C for 5 min. Using
concentrations obtained from spectrophotometer determinations, 10 g of RNA was very
gently combined with 5 L DEPC water, 2 L DNAse buffer (10x), and 3 L DNAse in sterile
microtubes. After a 5-min incubation at room temperature, the DNAse reaction was
stopped with incubation with 2 L 25mM EDTA at 70C for 12 min.
79
Following treatment with DNase I, purified RNA was reverse transcribed to synthesize first-
strand cDNA using SuperScript™III (Invitrogen Corporation, Carlsbad, CA, USA). 2 L of
random primers (12-times dilution in DEPC water; 48190-011, Invitrogen Corporation) 2 L
10 mM dNTP (Fermentas, Thermo Fisher Scientific, Mississauga, ON, Canada) were added to
the DNAse-treated RNA and heated at 65C for 5 min and cooled on ice for 1 min. 8 L
First-Strand buffer (5x, Invitrogen Corporation) and 2 L 0.1 M DTT (Invitrogen
Corporation) were added to the tubes. The contents of each tube (total volume = 36 L)
was then equally divided into 2 sets of tubes (18 L per tube): RT+ tubes to which 1 L of
SuperScript™III Reverse Transcriptase (Invitrogen Corporation) was added and RT- tubes
(a negative control for reverse transcription), to which 1 L DEPC water was added. The
tubes were then incubated at 25C for 10 min (reaction for random primers), 50C for 60
min (reverse transcription reaction), and 70C for 15 min (inactivation of reaction) in a
thermal cycler (Vapo Protect Mastercycler® pro, Eppendorf Canada, Mississauga, ON,
Canada). RNA complementary to the cDNA was then removed by adding 1L RNAse H (2.5-
times dilution in RNAse buffer; Fermentas) and incubating at 37C for 20 min. The cDNA
can then be used as a template for amplification.
3.2.5.3 Polymerase chain reaction (PCR) of -actin.
This PCR was used to determine the integrity of the RT+ and RT- sets of synthesized cDNA.
Samples from RT+ tubes should demonstrate amplification of the DNA of interest (-actin),
whereas RT- tubes which lacked reverse transcriptase enzyme should not amplify DNA.
Signals that appear in the RT- tubes are indicative of DNA contamination. A PCR mixture is
first made for all samples to be run by combining the following reagents using the following
ratio per 1 L cDNA sample: 11 L double-distilled water, 0.25 L 5’ (forward) primer for -
actin (ACGT Corp, Toronto, ON, Canada), 0.25 L 3’ (reverse) primer for -actin (ACGT
80
Corp), and 12.5 L REDTaq® (Sigma-Aldrich, St. Louis, MO, USA). Care should be taken to
gently combine the REDTaq® solution, which contains the enzyme Taq DNA polymerase. In
96-welled plates, 1 L of cDNA from each of RT+ and RT- sets of tubes was first pipetted
before 24 L of the PCR mixture was then added to each well. Plates were then spun at
1000 rpm at 4C for 30 sec. After thermal cycler PCR machine was warmed up, plates were
sealed with a film to prevent evaporation and placed in the thermal cycler at 94C for 5 min
(initial denaturation) and cycled 40 times at 94C for 30 sec, 45C for 30 sec, and 72C for
30 sec (amplification) prior to incubation at 72C for 4 min (final elongation), and then 4C
for storage.
A 1% agarose running gel for -actin was prepared by combining 200 mL 1x TBE (Tris, boric
acid, and EDTA), 2 g agarose powder, and 20 L SYBR® Safe (10 000x, Invitrogen
Corporation) DNA gel stain, heating until completely dissolved, and setting into a 20-comb
cast. The first well of each row was reserved for 10 L of DNA ladder (GeneRuler™, 1 kb,
Fermentas), and 10 L of sample was loaded into the wells. Charge was applied to the gel
at approximately 90 V, and samples travelled through the gel from the negative to positive
electrode. Blots on finished gels were visualized under ultra violet light in a UVP BioDoc-It
System (UVP, Upland, CA, USA). Real-time quantitative PCR was run only for samples that
showed no contamination.
3.2.5.4 Real-time quantitative PCR.
Real-time quantitative PCR was run only for samples that showed no contamination.
Several RT- samples and a DEPC-water sample were included in the run to serve as
controls. All samples were run in duplicate. 1 L of cDNA and 4 L of yellow-coloured DEPC
water was pipette into wells of MicroAmp® Optical 384-Well Reaction Plates (Applied
Biosystems, Foster City, CA, USA). The yellow colouring allowed for easier detection when
81
working with such small volumes. For cyclophilin, cDNA was first diluted 50 times prior to
adding 1 L of the diluted cDNA to the wells. Real-time quantitative PCR was performed for
using primers for 2 genes of interest (PEPCK1 (Pck1), Mm01247058_m1; G6Pase (G6pc),
Mm00839363_m1) and 1 housekeeping gene (cyclophilin (Ppia), Mm02342430_g1) using
TaqMan Gene Expression Assays (Applied Biosystems). A reaction mixture of TaqMan®
Universal PCR Master Mix (Applied Biosystems), primer of the gene, and blue-coloured DEPC
water was combined together in a ratio of 10:1:4 prior to pipetting 15 L of this mixture
into each well. Plates were sealed with MicroAmp® Optical Adehesive Film (Applied
Biosystems) and spun at 1000 for 1 min at 4C.
Real-time quantitative PCR was performed with ABI Prism 7900 Sequence Detection System
with Sequence Detection System v2.1 software (Applied Biosystems). The thermal cycling
conditions for the reaction consisted of 2 min at 50C, 10 min at 95C, and 40 cycles of 15
sec at 95C and 1 min at 60C. After plates were run, threshold cycle (Ct) values were
analyzed. Ct values should be between 20-25; cDNA needs to be diluted if Ct values are
below this range. If Ct values fall above this range, cDNA needs to be more concentrated,
or optimization of the primer is necessary. Ct values for the samples run were within the
optimal range. The expression values of each gene of interest were normalized to the
internal control gene, cyclophilin, for the efficiency of amplification and quantified by the 2-
Ct method (526). Cyclophilin expression values did not vary between experimental groups,
deeming it a suitable control gene.
82
3.3 Preparation of SSTR2 antagonist and saline infusates
This peptide (referred to in literature by the names PRL-2903, DC-41-33, and BIM-23458)
was synthesized and provided by Dr. David Coy (Tulane University, New Orleans, LA, USA)
in lyophilized form. The peptide was stored at -20C in a jar of desiccant. To prepare
stock-solutions for long-term storage, the peptide was carefully weighed and aliquoted into
eppendorf tubes, and dissolved in a calculated volume of 1% acetic acid to a concentration
of approximately 25 000 nmol/mL. Each vial of aliquot was carefully labeled for its
concentration, sealed with parafilm, and stored also at -20C. Repeated thawing and
refreezing was avoided. On the morning of the experiment, a vial of aliquoted peptide stock
solution was thawed on ice and diluted with 0.9% saline (NaCl solution)specific to the dose
used for each experiment (1500 nmol/kg/h in Study 1 or 3000 nmol/kg/h in Study 1 and
Study 2). In Study 1, 5 mL of infusate was prepared per animal, and in Study 2, 6 mL of
infusate was prepared per animal. This volume was used to allow for enough infusate for
the 4 or 5 h infusion period for each of Study 1 and Study 2, respectively, at an infusion
rate of 1 mL/h in addition to the volume needed to prime the infusion lines. Infusates were
neutral in pH. Rats that did not receive SSTR2 antagonist were given infusions of vehicle
solution (i.e. 1% acetic acid in 0.9% saline at a ratio of approximately 250 L : 5 mL).
3.4 Statistical analysis
Statistical analysis was performed using Statistica software (Statsoft Inc., Tulsa, OK, USA).
In all tests, significance was deemed when P < 0.05. Unless otherwise stated, all data are
expressed as mean ± standard error of the mean (SEM). Outlying data points were
removed when they occurred greater than two standard deviations from the mean.
83
One-Way Analysis of Variance (ANOVA) was used to compare metabolic parameters, basal
hormone values, hormone responses, areas under the curve (AUC), and tissue mRNA and
protein levels between groups, unless otherwise stated. AUC was calculated using Prism
software (GraphPad Software, San Diego, CA, USA). Measurements that were taken
repeatedly over time were compared using Repeated Measures ANOVA. If differences
between groups were significant using ANOVA, Duncan’s post-hoc test was used to
determine which groups differed from each other. In Study 2, comparisons within the same
group on Experimental Day 1 and Experimental Day 2 were assessed using a paired T-test.
84
84
Chapter 4 Study 1: Effect of SSTR2 antagonism on
counterregulation to hypoglycemia
4 Study 1
4.1 Aims
The objective of this study was to determine whether the glucagon response to
hypoglycemia can be improved or normalized in diabetic rats by removing the suppressive
effect of somatostatin on glucagon secretion. Different subtypes of the somatostatin
receptor within the pancreatic islet mediate the inhibitory effects of somatostatin on islet
hormone secretion. In rodent and human islets, somatostatin receptor type 2 (SSTR2) are
found nearly exclusively on glucagon-secreting alpha-cells while SSTR1 and SSTR5 are
abundant on human and human and rodent beta-cells, respectively (385;389). In this
study, we use an antagonist to SSTR2, via which somatostatin exerts its inhibitory effect on
stimulated glucagon secretion. Using this selective antagonist to SSTR2, Efendic and
colleagues demonstrated that stimulated-secretion of glucagon is dose-dependently
enhanced in perifused islets and perfused pancreata of non-diabetic rats. Increasing
somatostatin concentrations dose-dependently reverses the effectiveness of the SSTR2
antagonist, which demonstrates a competitive nature for the SSTR2 (392). We hypothesize
that in diabetes during hypoglycemia, glucagon release is, at least in part, suppressed by
the prevailing inhibitory effect of excessive somatostatin acting via SSTR2. Thus, we
hypothesize that selective SSTR2 antagonism will normalize the glucagon response to
hypoglycemia.
85
Somatostatin also inhibits the release of other counterregulatory hormones: the
hypothalamic-pituitary-adrenal (HPA) axis (corticotrophin-releasing hormone (CRH) and
adrenocorticotrophic hormone (ACTH)) and the sympathoadrenal system (epinephrine and
norepinephrine) (271). Intracerebroventricular administration of somatostatin or its
analogues decreases stress-induced glucocorticoid and catecholamine responsiveness
(169;527;528). Thus, we also evaluated the effect of SSTR2 antagonism on other
counterregulatory hormone responses during hypoglycemia. Presently, we demonstrate
that SSTR2 antagonism restores glucagon and corticosterone counterregulation to
hypoglycemia in diabetic rats. In the absence of hypoglycemia, this SSTR2 antagonist
neither elicits hyperglycemia nor markedly elevates counterregulatory hormone levels.
Finally, we wished to determine whether improved glucagon and corticosterone
counterregulation could: 1) reduce the potential risk of hypoglycemia in an unclamped
condition as would be indicated by a decrease in the exogenous glucose requirement during
our conditions of hypoglycemic clamp; and 2) increase the mRNA expression of
gluconeogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase), despite the large dose of insulin necessary to induce hypoglycemia
in our diabetic rats.
4.2 Experimental methods
4.2.1 Study design
The experimental protocol of Study 1 is shown in Figure 4-1. Three main groups of rats –
non-diabetic controls (N), diabetic controls (D), and diabetic rats given somatostatin
receptor type 2 antagonist (D+SSTR2a) – were used in hypoglycemia clamp experiments
and in control experiments during basal conditions (i.e. in the absence of exogenously
86
administered insulin). An additional group to assess the effects of SSTR2a during
hypoglycemia in non-diabetic rats (N+SSTR2a) was also included. Schematics to illustrate
the procedures for hypoglycemia clamp and control experiments are shown in Figure 4-2A
and Figure 4-2B, respectively.
4.2.2 Hypoglycemia experiments
After basal samples were obtained at t=-60 min, infusions of saline or SSTR2 antagonist
(3000 nmol/kg/h) at 1 mL/h were started for controls and D+SSTR2a rats, respectively.
Infusions were delivered via digital pumps (Harvard Apparatus PHD 22/2000 syringe pumps,
Holliston, MA). A SSTR2 antagonist dose of 1500 nmol/kg/h was initially tested in our pilot
studies based on unrelated in vivo studies in non-diabetic rats using the same antagonist
(508). However, since the effect of the SSTR2 antagonist at 1500 nmol/kg/h to enhance
glucagon release during hypoglycemia was only moderate in diabetic rats, we rationalized
that a larger dose of the antagonist may be necessitated since diabetic rats have increased
somatostatin. Blood glucose was measured a glucose analyzer in duplicate at the time
points -60, -40, -20, 0, 5, 10, 15, 20, and every 10 min thereafter until 180 min. Blood
samples were obtained from the carotid catheter at regular time intervals throughout the
glucose clamp and from trunk blood at euthanasia for measurement of plasma hormone
levels. After plasma was removed, packed red blood cells were re-suspended in heparinized
saline (10 USP U/mL) containing 1% bovine serum albumin and re-infused into the rat.
After blood samples were obtained at t=0, regular insulin (10 U/kg; Humulin R, Eli Lilly,
Indianapolis, IN) was injected subcutaneously in all rats (N, n=14; D, n=14, D+SSTR2a,
n=18). In this study, we chose to give a subcutaneous injection of insulin rather than
insulin infusion to induce hypoglycemia. This method of insulin administration is more
similar to the clinical insulin regime where hypoglycemia is more relevant. Also, we have
87
noticed a more marked impairment of the glucagon response to hypoglycemia using insulin
injection (174) than insulin infusion (529), despite a similar amount of insulin administered,
and we wished to test the efficacy of our SSTR2 antagonist in a setting of greater glucagon
unresponsiveness. However, this method of insulin bolus rather than infusion does not
result in a steady state of insulin action, and therefore it makes it difficult to measure
glucose turnover precisely, which is why we did not use glucose tracer techniques. To
evaluate the effect of a lower insulin dose with the same SSTR2 antagonist dose (3000
nmol/kg/h) on glucose infusion rates, hypoglycemia was also induced using 5 U/kg (N, n=5;
D, n=4, D+SSTR2a, n=4). Glucose infusions (50% dextrose) were given at a variable rate
to clamp glycemia at a target hypoglycemia of 2.5±0.5 mM. After t=180 min, rats were
quickly euthanized by decapitation. Plasma from trunk blood and organs were collected,
frozen immediately, and stored at -80°C until assayed.
4.2.3 Control experiments: SSTR2 antagonist in the absence of hypoglycemia
To evaluate the effect of SSTR2 antagonist infusion per se, glycemia and plasma glucagon,
corticosterone, and catecholamines were measured in the absence of hypoglycemia in a
separate set of non-diabetic (Ctrl:N, n=7), diabetic (Ctrl:D, n=7), and diabetic rats given
somatostatin receptor type 2 antagonist (Ctrl:D+SSTR2a, n=7) under basal conditions for
240 min. The same methodology and sampling procedure was used during these control
experiments with the following exceptions: saline rather than insulin was injected at t=0,
and glucose infusions were not used. SSTR2 antagonist was infused at 3000 nmol/kg/h in
these control experiments (Ctrl:D+SSTR2a).
4.2.4 Effect of SSTR2 antagonist in non-diabetic rats during hypoglycemia
The effect of SSTR2 antagonism in non-diabetic rats was also assessed during
hypoglycemia. This control group allows (N+SSTR2a) for an assessment of the diabetic
88
impairment that might be attributable to elevated somatostatin. Using the same protocol as
the hypoglycemia experiments described above, glucagon and corticosterone responses to
hypoglycemia in non-diabetic rats under conditions of high insulin dose (10 U/kg) and 1500
(n=3) and 3000 (n=4) nmol/kg/h SSTR2 antagonist and at low insulin dose (5 U/kg) and
3000 nmol/kg/h (n=10) were assessed and compared to the corresponding non-diabetic
controls (N) described above.
4.3 Results
4.3.1 Daily blood glucose, body weight, and food intake
Metabolic parameters such as fed morning blood glucose, body weight, and food intake
were measured daily to monitor the health of all rats and to ensure that diabetic rats were
of a similar diabetic state leading up to the experimental day before being randomly
assigned into control or SSTR2 antagonist treatment groups. Fed morning glycemia
significantly increased 4-fold in D compared with N in all three hypoglycemia (including the
pilot study) (P<0.0002) and control (P<0.0002) studies (Table 4-1). Diabetic groups within
each study had similar hyperglycemia leading up to the clamps. Similarly, D had
significantly decreased body weight as compared to N in all three hypoglycemia (P<0.03)
and control (P<0.03) studies and similar body weight to D+SSTR2a (Table 4-1). Average
daily food intake also significantly increased in D compared with N in all hypoglycemia
(P<0.0002) and control (P<0.0001) studies (Table 4-1). D+SSTR2a rats in the
hypoglycemia study group with the dosing combination of 10 U/kg insulin and 3000
nmol/kg/h had a slightly lower food intake (P<0.04) as compared to D, despite having
similar basal glycemia and body weight. The metabolic changes associated with 3-weeks of
diabetes (i.e. severe postprandial hyperglycemia and decreased body weight compared to
89
non-diabetic controls despite hyperphagia) have been well-documented and represent a
slew of physiologic processes which, taken together, can be summarized as accelerated
catabolism. Simply stated, the metabolic derangements observed in diabetic subjects result
in large from a state of relative insulin deficiency, which leads to catabolic processes
including gluconeogenesis, lipolysis, ketogenesis, and proteolysis (530).
4.3.2 Hypoglycemia clamp experiments
4.3.2.1 Pilot study: using 10 U/kg insulin and 1500 nmol/kg/h SSTR2 antagonist.
In our pilot studies, we initially used SSTR2 antagonist at a dose of 1500 nmol/kg/h, a dose
based on previous in vivo studies in non-diabetic rats (508). SSTR2 antagonist at a dose of
1500 nmol/kg/h in our initial pilot studies yielded significant but very modest improvements
of the glucagon response (Figure 4-3A) and modest and insignificant increases of
corticosterone (Figure 4-3B). We speculated that a larger dose of SSTR2 antagonist would
be required to overcome the increased amounts of pancreatic and circulating somatostatin
observed in STZ-diabetic rats and doubled the dose of SSTR2 antagonist in subsequent
experiments.
4.3.2.2 Using 10 U/kg insulin and 3000 nmol/kg/h SSTR2 antagonist.
D had elevated basal plasma glucagon (P<0.004), corticosterone (P<0.006), and
epinephrine (P<0.04) levels as compared with N, and both groups of diabetic rats had
similar basal plasma hormone levels before administration of SSTR2 antagonist (Table 4-2).
Basal plasma insulin in D was reduced to one-half of the levels in N (P<0.05) and similar in
both diabetic groups (Table 4-3).
In the hypoglycemia studies, all groups reached target hypoglycemia (2.5 ± 0.5 mM) by 70
min after insulin injection and remained there until the end of experiment at 180 min
90
(Figure 4-4). N rats reached target hypoglycemia at time 50 min slightly before the diabetic
groups.
As expected, N exhibited a robust, 11-fold increase in plasma glucagon whereas D had a
markedly attenuated glucagon response (P<0.0002 vs N). The glucagon response in
D+SSTR2a was fully normalized (P<0.0001 vs D; Figure 4-5A). Similarly, the
corticosterone response was significantly blunted in D as compared to the 10-fold increase
observed in N (P<0.002) but was greatly improved in D+SSTR2a (P<0.05 vs D; Figure
4-5B).
In the high-dose insulin hypoglycemia clamps, glucose infusion rates (mean infusion rates
N: 8.1±1.0; D: 8.9±1.2; D+SSTR2a: 9.2±1.2 mg/kg/min) nor the total amount of glucose
infused to maintain target hypoglycemia (Figure 4-5C) differed amongst groups.
N rats exhibited a 69-fold increase in plasma epinephrine, and interestingly, D rats attained
a similar plasma epinephrine level to N rats, suggesting that in this model of hypoglycemia,
diabetic rats do not exhibit a defect of epinephrine counterregulation (Figure 4-6A). SSTR2
antagonist administration did not alter the epinephrine response to hypoglycemia (Figure
4-6A), presumably because the maximal epinephrine response was already achieved.
Norepinephrine levels were likewise similar in all groups, achieving 3- to 5-fold increases in
responses to hypoglycemia (Figure 4-6B).
Plasma insulin levels after high-dose (10 U/kg) insulin injection increased approximately
144- to 200-fold in all three groups due to the large amount of insulin required to induce
hypoglycemia in diabetic rats which are otherwise quite insulin resistant (Table 4-3). The
same dose was used in non-diabetic rats to allow for more relevant comparisons with
diabetic groups.
91
4.3.2.3 Using 5 U/kg insulin and 3000 nmol/kg/h SSTR2 antagonist.
An overnight fast lowered initial starting blood glucose levels in both diabetic groups to
similar euglycemic levels as non-diabetic rats, despite marked fed glycemia (Table 4-1) and
basal plasma insulin at half the concentration of non-diabetic rats (Table 4-3). In the low
dose insulin hypoglycemia studies, all groups reached target hypoglycemia (2.5 ± 0.5 mM)
30 min after insulin injection and remained there until the end of experiment at 180 min
(Figure 4-7).
Basal plasma glucagon levels were increased in both diabetic groups as compared with non-
diabetic rats (Table 4-3). However, basal plasma corticosterone, epinephrine, and
norepinephrine were similar in all groups (Table 4-3). D rats also demonstrated markedly
attenuated glucagon (P<0.04; Figure 4-8A) and corticosterone (P<0.04; Figure 4-8B)
responses to hypoglycemia induced with a lower dose (5 U/kg) of insulin. D+SSTR2
exhibited fully restored glucagon (P<0.005; Figure 4-8A) and corticosterone (P<0.04;
Figure 4-8B) responses. Thus, the SSTR2 antagonist was effective in improving glucagon
and corticosterone counterregulation to hypoglycemia induced by both the high and low
doses of insulin tested.
In the low-dose insulin hypoglycemia clamps, D+SSTR2a required lower glucose infusion
rates (mean infusion rates: N: 14.1±1.4; D: 15.5±1.5; D+SSTR2a: 6.2±1.2 mg/kg/min;
P<0.001, D vs D+SSTR2a) and had a lower total glucose requirement than D (P<0.008;
Figure 4-8C).
N exhibited an 87-fold increase in plasma epinephrine, and interestingly, D attained
epinephrine levels similar to N, suggesting that 3-week STZ-diabetic rats do not exhibit a
defect of epinephrine counterregulation (Figure 4-9A). Norepinephrine levels were likewise
92
similar in all groups, achieving 2- to 3-fold increases in response to hypoglycemia (Figure
4-9B).
Plasma insulin levels after low-dose (5 U/kg) insulin injection increased to approximately 60
ng/mL in N, D, and D+SSTR2a (Table 4-3).
Basal plasma growth hormone levels were significantly lower in D as compared to N
(P<0.01), and both diabetic groups had similar basal plasma growth hormone levels (Figure
4-10). Plasma growth hormone levels were similar in all groups during hypoglycemia.
Notably, administration of SSTR2 antagonist in diabetic rats did not affect growth hormone
concentrations.
4.3.3 Effect of SSTR2 antagonist in the absence of hypoglycemia
All groups that underwent control experiments had similar basal hormone levels (Table
4-4). The lack of difference in glucagon and corticosterone between Ctrl:N and Ctrl:D may
be attributed to elevated levels of these basal hormones in Ctrl:N, which suggests that
Ctrl:N rats may have been a mildly stressed despite the extreme care taken to avoid stress
during handling.
Glycemia remained steady throughout the 4-h experiment (Figure 4-11). Notably, glycemia
in D+SSTR2a was unaltered, which demonstrates that SSTR2 antagonist administration did
not affect glycemia during basal conditions.
Plasma glucagon levels remained unaltered at all time points in N and D groups during the
control experiments. However, Ctrl:D+SSTR2a demonstrated very modest, transient
increases in plasma glucagon at 40, 60, and 90 min (Table 4-4). AUC calculations revealed
no significant difference in overall glucagon in Ctrl:D and Ctrl:D+SSTR2a in the absence of
93
hypoglycemia (P=0.12). Plasma corticosterone, epinephrine, and norepinephrine levels also
remained similar in all groups (Table 4-4). These controls demonstrate that SSTR2
antagonist, per se, did not elicit hyperglycemia or marked, sustained elevations of stress
hormones.
4.3.4 Pancreatic glucagon and pancreatic and plasma somatostatin measurements
Pancreatic glucagon protein content increased 50% in D compared to N in both
hypoglycemia and control studies (P<0.02) and was similar in both D and D+SSTR2a
(Figure 4-12A). Similarly, pancreatic somatostatin protein content following hypoglycemia
was increased by 65% in D rats as compared to N rats (P<0.02) and was not affected by
SSTR2 antagonist (Figure 4-12B). All three control groups showed no statistical difference
in pancreatic somatostatin content (Ctrl:N vs Ctrl:D: P=0.09; Ctrl:D vs Ctrl:D+SSTR2a:
P=0.07). Plasma somatostatin concentrations taken at euthanasia showed a similar trend
to pancreatic somatostatin: following hypoglycemia, plasma somatostatin increased 60%
increase in D, but this failed to reach statistical significance (P=0.08, Figure 4-12C).
4.3.5 Liver PEPCK1 and G6Pase mRNA expression
To determine whether the normalization of glucagon and corticosterone responses to
hypoglycemia in SSTR2 antagonist-treated diabetic rats also affected the expression of
these gluconeogenic enzymes, despite the lack of change in glucose infusion rates, real-time
PCR was used to quantitatively measure the levels of mRNA expression in the livers of the
high dose insulin group (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). There was no
statistical difference in PEPCK1 expression between all groups, regardless of diabetes,
hypoglycemia, and SSTR2 antagonist administration (Table 4-5). In control groups, G6Pase
expression was 6-fold lower in Ctrl:D as compared to Ctrl:N (P<0.0001). Ctrl:D+SSTR2a
showed increased G6Pase expression as compared to Ctrl:D (P<0.05) during basal
94
conditions. Insulin-induced hypoglycemia significantly suppressed G6Pase expression in N
(P<0.0001) and D+SST2Ra (P<0.007).
4.3.6 Effect of SSTR2 antagonist in non-diabetic rats during hypoglycemia
We assessed the effect of SSTR2 antagonist during hypoglycemia in non-diabetic rats.
Basal metabolic parameters of these rats (Table 4-6) were similar to non-diabetic controls.
Blood glucose levels during hypoglycemia clamp experiments were the same in N and
N+SSTR2a at each of the dosing combinations of insulin to induce hypoglycemia and SSTR2
antagonist tested (Figure 4-13A-C). At 1500 nmol/kg/h, SSTR2 antagonist had no effect on
glucagon responses to hypoglycemia in non-diabetic rats (Figure 4-14A). At 3000
nmol/kg/h, SSTR2 antagonist had an opposite effect and strikingly decreased plasma
glucagon levels in response to hypoglycemia at the 40, 60, 90, and 120 min time points
(Figure 4-14B, C). This suppressive effect of 3000 nmol/kg/h SSTR2 antagonist in non-
diabetic rats was more marked at the higher dose of insulin (10 U/kg, Figure 4-14B) than at
the lower dose of insulin (5 U/kg, Figure 4-14C). SSTR2 antagonism had no effect on
corticosterone responses to hypoglycemia in both of the doses tested (Figure 4-14D-F).
N+SSTR2a rats had similar pancreatic and plasma somatostatin levels as N following
hypoglycemia (Table 4-7).
4.4 Discussion
4.4.1 Role for SSTR2 in the enhancement of glucagon counterregulation
The attenuation or absence of the glucagon response to hypoglycemia in diabetes is well
established (165;166). We demonstrate for the first time that antagonism of SSTR2
enhances hypoglycemia-stimulated, but not basal, glucagon and corticosterone release in
95
diabetic rats. In the present study, administration of SSTR2 antagonist (3000 nmol/kg/h)
fully restored glucagon counterregulation to hypoglycemia in diabetic rats induced with
either high (10 U/kg) or low (5 U/kg) dose insulin.
The inhibitory effect of somatostatin on -cell glucagon release via SSTR2 is well-
established in both rodents (389;531;532) and humans (385;533). In very early studies,
anti-somatostatin antibodies were shown to increase stimulated glucagon release from
isolated, non-diabetic islets (279), thus demonstrating that blocking the actions of
somatostatin could enhance glucagon secretion. A recent study demonstrated that global
somatostatin knockout increased nutrient-stimulated, but not basal, glucagon secretion
compared with wild-type mice in vivo and in isolated islets, the latter implicating the
profound role of locally released somatostatin on stimulated glucagon secretion (534). In
addition, in STZ-treated rats treated with insulin, it was demonstrated that the glucagon
response to insulin-induced hypoglycemia can be enhanced by pancreatic infusion and
subsequent switch-off (at hypoglycemia) of somatostatin, thereby supporting the notion
that glucagon counterregulation can be enhanced by deactivating intrapancreatic signals
suppressing -cells (179). The localization of particular receptor subtypes on different islet
cell types allows for specific receptor agonists/antagonist to exert specific effects on the
cells. In rodent islets, SSTR2 are found nearly exclusively on glucagon-secreting -cells
while SSTR5 are found on -cells (388;389). Studies in whole-body somatostatin receptor-
type-2 knockout (SSTR2 KO) mice showed that stimulated glucagon secretion was
approximately 2-fold greater in islets isolated from SSTR2KO mice than wild-type (389). In
humans, somatostatin also exerts its inhibitory effects on glucagon secretion via SSTR2 on
-cells (385;535). An in vitro study in human islets demonstrated that an agonist to the
SSTR2 was more potent than other receptor subtype agonists at inhibiting arginine-
96
stimulated glucagon secretion and that a dose-dependent reversal of SSTR2-agonist-
induced glucagon suppression was achieved by using the same SSTR2 antagonist as the
present study (386). The findings from this study in human islets suggest that our present
work using this SSTR2 antagonist may also be relevant to human studies. Taken together,
these studies support the role of somatostatin acting via the SSTR2 in inhibiting stimulated
glucagon secretion.
We demonstrate that pancreatic content of glucagon remains elevated in diabetic rats even
subsequent to hypoglycemia. This supports our idea that during hypoglycemia, there is a
defect in the secretory mechanism of the diabetic -cell where glucagon remains present,
which contributes to impaired glucagon counterregulation. We speculate that this defect is
due, at least in part, to increased pancreatic somatostatin and increased insulin sensitivity
of diabetic -cells. In addition, we observe that pancreatic glucagon content is unchanged
with SSTR2 antagonist treatment, yet diabetic rats which received SSTR2 antagonist had
markedly enhanced glucagon release in response to hypoglycemia. This may suggest that
that the amount of glucagon secreted in response to hypoglycemia represents only a small
amount of glucagon stored in the pancreas or that glucagon is quickly re-synthesized after
its secretion in diabetic rats that received SSTR2 antagonist.
Presently, we observe that pancreatic somatostatin remains elevated in diabetic rats
following hypoglycemia as previously reported (174). It is because diabetic rats have
elevated somatostatin that we decided to double our initial dose of SSTR2 antagonist from
our pilot studies. Elevated pancreatic and circulating somatostatin has been reported in
various diabetic species, including type 1 diabetic humans, STZ-diabetic and alloxan-
diabetic animals, and NOD mice, but BB rats are one diabetic model in which pancreatic
somatostatin is not increased (536-539). Untreated diabetic BB rats demonstrated reduced
97
concentration of pancreatic somatostatin (540). However, circulating somatostatin remains
elevated in BB rats (537;541). BB rats also have impaired glucagon and catecholamine
responses to hypoglycemia (263;542;543). Thus, increased pancreatic somatostatin is not
the only factor for impaired counterregulation. In the present study, there was a trend for
increased plasma somatostatin in diabetic groups, although this did not reach statistical
significance (Figure 4-12). Interestingly, however, diabetic rats in the control group under
basal conditions did not exhibit elevated somatostatin. It has been reported that fasting for
15-h (544) and 48-h (545) decreased pancreatic somatostatin levels in rats. This effect of
fasting may be biphasic since with prolonged fasting of 72 h in rats, pancreatic somatostatin
levels eventually become elevated (544). At the time of euthanasia when pancreata were
harvested, these rats would have been fasted for 24 h. Thus, the reduction in pancreatic
somatostatin under basal conditions could be due to a more profound effect of fasting on
diabetic groups. When we combined the data within each treatment group for all rats that
were subjected to hypoglycemia Table 4-7, we can observe a significant effect of diabetes in
elevating both pancreatic (P<0.0004) and plasma somatostatin (P<0.004) levels. Even if
somatostatin is not excessive, suppression of somatostatin may be useful to alleviate
further inhibition on diabetic -cells, which are already more sensitive to inhibition by
exogenous insulin during hypoglycemia.
Some may not have considered increased somatostatin to be a strong candidate for
impaired glucagon responsiveness because somatostatin-secreting -cells have been
reported to be downstream of glucagon-secreting -cells in the islet microcirculation of non-
diabetic rats (79;284). This differed from earlier views that suggested a parallel distribution
of -cells and -cells in all species and in which -- represented the core-to-periphery
arrangement of islet cells (276). Since pancreata from non-diabetic rats perfused with
98
SSTR2 antagonist indeed show increased stimulated glucagon secretion (392), this supports
the role of somatostatin in the local regulation of glucagon release via the microcirculation
or interstitial interactions. In STZ-diabetic rats, however, this architecture of islet cell type
is altered such that -cells are also distributed in central portions of islet cells (546). The
arrangement of human endocrine islet cells is likewise more disperse throughout the islet
(304;547). Furthermore, immunofluorescent methods in pancreata of STZ-diabetic rats, as
well type 1 diabetic humans, revealed hyperplasia and hypertrophy of pancreatic -cells
(439). These findings suggest that paracrine actions of islet hormones may be altered in
diabetes such that -cell release of somatostatin may very well regulate glucagon secretion.
4.4.2 Potential role for SSTR2 in insulin secretion?
In some studies in human perfused pancreas (548) and of incubations of cloned hamster -
cell lines (549), it was demonstrated that activation of SSTR2 could inhibit insulin secretion,
which may lead to speculation that SSTR2 antagonism may promote insulin release. The
laboratory of Efendic also demonstrated a moderate (~30%) increase in arginine-stimulated
insulin secretion with the same SSTR2 antagonist (PRL-2903) in batch incubated islets of
non-diabetic rats (392). It should be noted, however, that the increase in glucagon
secretion (5-fold) under the same conditions was much greater thus demonstrating a much
larger effect of the SSTR2 antagonist on stimulated glucagon, rather than insulin, secretion.
There was no effect of the SSTR2 antagonist in insulin secretion in perifused isolated islets
or perfused pancreas. Although this SSTR2 antagonist has a 20-fold greater binding affinity
for SSTR2 than SSTR5 (expressed on rodent -cells), high concentrations of SSTR2
antagonist may exert a non-specific effect if sufficient amounts of a native competitor (i.e.
endogenous somatostatin) are not present. This concept of non-specific role of SSTR2 in
promoting insulin secretion will be discussed further in section 4.4.9 in the interpretation of
99
our data for SSTR2 antagonism in non-diabetic rats during hypoglycemia. In contrast, our
experiments conducted under basal conditions do not demonstrate an effect on insulin
release with SSTR2 antagonism, presumably primarily because of STZ-diabetic rats have
markedly less pancreatic insulin due to -cell destruction, and also because SSTR5 rather
than SSTR2 is the predominant isoform of SSTR on rodent -cells (387). It is possible that
SSTR2 antagonism may have some effect on insulin secretion in humans since some SSTR2
are detected human, but not rodent, -cells, (385). This expression is relatively low as it
was reported in pancreatic islets of non-diabetic humans that approximately 45% of -cells
expressed SSTR2 whereas approximately 100% and 90% expressed SSTR1 and SSTR5,
respectively. Furthermore, SSTR2 antagonism is unlikely to exacerbate hypoglycemia if
used clinically in diabetic humans since individuals with type 1 diabetes will not have
functioning insulin-secreting -cells.
4.4.3 Role for SSTR2 in the enhancement of corticosterone counterregulation
Whereas glucagon is important during the early fall in plasma glucose, catecholamines and
glucocorticoids become increasingly important at lower glucose levels and during prolonged
hypoglycemia (3;232). Dysregulation of the hypothalamo-pituitary-adrenal (HPA) axis can
contribute to defective counterregulation, since it not only regulates glucocorticoid secretion
but also affects epinephrine secretion (202;220;550-554). Glucocorticoids increase liver
sensitivity to glucagon and epinephrine as well as decrease hepatic and peripheral insulin
sensitivity (555;556). Presently, we demonstrate that peripheral administration of SSTR2
antagonist normalizes the attenuated corticosterone response to hypoglycemia in diabetic
rats, which may be due to a central effect of somatostatin antagonism or to a peripheral
effect of SSTR2 antagonism at the level of the pituitary or adrenal glands. The attenuated
corticosterone response in diabetic rats occurred in both high (10 U/kg) and low (5 U/kg)
100
dose insulin-induced hypoglycemia experiments in which basal corticosterone was either
elevated or similar to non-diabetic rats. The markedly blunted corticosterone responses of
diabetic rats as compared with non-diabetic supports previous findings (202;205). In our
low-dose insulin-induced hypoglycemia experiments, plasma insulin levels were similar at all
time after insulin administration. Despite the fact that all rats in the high dose insulin
experiments received 10 U/kg, plasma insulin levels at t=60 and 180 min were
approximately 50% elevated in non-diabetic as compared to diabetic controls. This may be
due to enhanced clearance of exogenous insulin by diabetic rats. It has been reported that
insulin dose and consequent plasma levels, per se, affect hormonal responses to
hypoglycemia. In non-diabetic humans, a 6-fold higher insulin level significantly increased
cortisol and catecholamine, but not glucagon, responses by 58% and 33%, respectively, to
hypoglycemia despite an equivalent level of hypoglycemia, but this amplifying effect of
insulin was lost in subjects with type 1 diabetes (209;210). Thus, the higher plasma insulin
levels in our non-diabetic rats of the high-dose insulin-induced hypoglycemia study may be
of concern. In our studies, high-dose insulin yielded a 2-fold greater peak plasma insulin
level as compared to low-dose insulin experiments in our non-diabetic rats; however, peak
cortisol, epinephrine, and norepinephrine levels were similar. Glucagon responses were
slightly, but not significantly, greater in high-dose insulin as compared with low-dose insulin
regimes. Thus, in our studies, it is unlikely that insulin, per se, caused an amplifying effect
of counterregulatory hormones to hypoglycemia, and thus the difference in peak plasma
insulin levels between non-diabetic and diabetic controls in the high-dose insulin
experiments would not account for the observation of attenuated corticosterone (or
glucagon) counterregulation in diabetic rats.
101
Basal corticosterone levels are often reported to be elevated in diabetic rats, an effect which
is attributed to increased HPA activity due to molecular HPA dysregulation (202;205;557).
Increased basal corticosterone in diabetes was observed in our high dose insulin
hypoglycemia experiments, but not in our low dose insulin hypoglycemia or control
experiments. We attribute the lack of elevated corticosterone to increased basal
corticosterone levels of our non-diabetic controls since these values were augmented
approximately 4-fold relative to our non-diabetic rats in the high dose insulin group, which
had a comparatively larger sample size. This increase in basal corticosterone in non-
diabetic rats may have been due to unwanted stress effects, but since basal epinephrine
levels remained low, any unwanted stress was likely very mild. A circadian effect is also
possible if basal hormone samples of thee non-diabetics were obtained slightly later in the
day. It is known that in the non-diabetic rat, a nocturnal animal, the corticosterone nadir
occurs in the morning and peaks in the evening (558). However, diabetic rats (559), as
well as humans (560), disrupted circadian patterns of corticosterone/cortisol secretion, with
elevated levels during the trough and normal or slightly elevated values during peak
secretion. However, this is unlikely to have affected our results since the patterns of
corticosterone responses to hypoglycemia were similar in both sets of hypoglycemia
experiments.
The role of somatostatin on the regulation of corticosterone is less well-documented than its
role on suppressing glucagon release. However, somatostatin also inhibits the secretion of
both CRH and ACTH (271;294), which regulate corticosterone secretion; thus, somatostatin
inhibits the function of the HPA axis. SSTR2 have been localized in several brain regions
and specifically in areas pertaining to HPA activity – the hypothalamic paraventricular
nucleus (420) and ACTH cells in the anterior pituitary (561). It is unknown whether this
102
antagonist crosses the blood-brain-barrier. However, a cyclic octapeptide with a similar
chemical structure, CTAP, is known to enter the brain when administered peripherally (562).
The corticosterone response to hypoglycemia is often impaired in diabetes
(202;205;206;225;563). Our laboratory has previously shown that carbachol injected
intracerebroventricularly into the third ventricle (a model of stress) increases the release of
cortisol in non-diabetic and diabetic dogs (169). However, when somatostatin was given
acutely with carbachol, cortisol responses were abolished in both normal and diabetic dogs
(528). Furthermore, somatostatin has been demonstrated to inhibit arginine vasopressin
release in response to hypoglycemia (564). Arginine vasopressin is one of the
neuropeptides involved in the activation of the HPA axis during stress. This supports the
idea that the SSTR2 antagonist could improve counterregulation through a central pathway
and could be a mechanism whereby the SSTR2 antagonist also markedly increases the
corticosterone response to hypoglycemia in diabetic rats. Along with other subtypes, SSTR2
are normally expressed in the pituitary (561). Pituitaries of SSTR2 knockout mice release
more ACTH in vitro (565), and corticosterone levels are elevated in SST knockout mice
(566), which supports the role of endogenous somatostatin on regulating corticosterone
release. An alternative possibility is an enhancement of corticosterone through
somatostatin receptors in the adrenal cortex. In the normal adrenal gland, all five subtypes
of SSTR are identified although SSTR2 and SSTR4 are most highly expressed (567;568).
However, despite consistent detection of SSTR2 in the zona glomerulosa (390;397-399), its
detection is not as consistent in the corticosterone-synthesizing fasciculata and reticularis
zonae of the adrenal cortex (390;569).
103
4.4.4 Epinephrine responses to hypoglycemia were unaffected
In the present study, we observed no difference in the epinephrine response to
hypoglycemia in non-diabetic and three-week STZ-diabetic rats. Although this lack of an
epinephrine defect contrasted with our prior experiments in which intravenous insulin
infusion was used to induce hypoglycemia (202;205), it is consistent with other
observations in which hypoglycemia was induced with a subcutaneous insulin injection
(174), suggesting that the route of insulin administration may also play a role in the
epinephrine response. An effect of the SSTR2 antagonist on epinephrine levels in diabetic
rats was not observed, either because somatostatin has no role in epinephrine
counterregulation to hypoglycemia or because the maximal physiological epinephrine
response was already achieved. It would be of future interest to evaluate the effect of
SSTR2 antagonism in a diabetic model in which a defect of epinephrine is observable (e.g.
diabetes of longer duration (570)) to determine whether somatostatin may also play a role
in hypoglycemia-stimulated epinephrine release.
Somatostatin inhibits glucagon secretion in response to various stimuli, and it also blocks
the effect of epinephrine to stimulate glucagon release as was demonstrated by the
exogenous administration of somatostatin to isolated perfused rat pancreas (571).
Somatostatin and epinephrine share common mechanistic pathways by which they regulate
glucagon release from the -cell. Somatostatin activation of SSTR2 inhibits adenylate
cyclase activity, thus reducing cAMP levels and subsequently inhibits protein kinase A (PKA)-
stimulated glucagon release (572-574). PKA is a serine/threonine kinase that
phosphorylates substrate proteins at serine or threonine sites (575). In contrast,
epinephrine activation of 1- and -adrenergic receptors on -cells stimulates adenylate
cyclase activity, in turn increasing cAMP levels and promoting PKA-stimulated glucagon
104
release (576-578). Somatostatin abolishes L-type Ca2+ channel-dependent release of
glucagon (579), whereas epinephrine enhances Ca2+ influx through L-type Ca2+ channels
which increased intracellular Ca2+ levels to promote glucagon release (577). Somatostatin
activates calcineurin, a serine/threonine phosphatase that “deprimes” glucagon-containing
granules and thus inhibits glucagon release (579), whereas epinephrine accelerates the
mobilization of glucagon-containing granules, increasing the number of readily releasable
granules by 5-fold (577). Thus, epinephrine can help to enhance glucagon secretion during
hypoglycemia, but excessive somatostatin may hinder this enhancement. In our present
studies, a robust glucagon response to hypoglycemia in our non-diabetic rats was
accompanied with a robust epinephrine response. In our diabetic rats, however, the
glucagon response to hypoglycemia was markedly abolished despite epinephrine responses
of the same magnitude as non-diabetic rats. When diabetic rats were treated with SSTR2
antagonist, glucagon responses to hypoglycemia were normalized. Thus, we presently
hypothesize that SSTR2 antagonism may also alleviate the suppressive effects of
somatostatin on the potentiating effects of epinephrine on glucagon release in response to
hypoglycemia.
4.4.5 SSTR2 antagonist demonstrated no effect on growth hormone
Presently, we see no effect of SSTR2 antagonism on growth hormone release during the 1-h
basal period or during 3-h hypoglycemia when SSTR2 antagonist was given at high dose.
Furthermore, no increase of growth hormone is observed in response to hypoglycemia.
Since growth hormone is known to play a role in prolonged hypoglycemia (143;580), the
present hypoglycemia experiments may not have been of sufficient duration to stimulate a
growth hormone response. Another possibility for the lack growth hormone increase is that
plasma epinephrine levels were markedly increased during hypoglycemia. This elevation of
105
epinephrine could have suppressed growth hormone, as could an epinephrine-induced
increase in free fatty acid levels, both of which are known to suppress growth hormone
secretion (581). Also, it should be noted that samples were obtained at very few time
points (four time points over a four hour experiment). Since growth hormone release is
pulsatile (581), frequent blood sampling is required to accurately measure growth hormone
response. Thus, the growth hormone data obtained in the present study may not truly be
indicative of the pattern anticipated in response to hypoglycemia. In response to prolonged
hypoglycemia, growth hormone counterregulation can contribute to the promotion of
glycemic recovery by suppressing insulin-mediated glucose utilization and increasing
glucose release into the circulation (582;583). When growth hormone secretion is inhibited,
liver and peripheral insulin sensitivity decreases (500;584), and nonesterified fatty acid
levels increase (500). SSTR5 is the predominant isoform of SSTR expressed in rat pituitary,
followed by the expression of SSTR2. Immunohistochemical colocalization studies
demonstrated that SSTR5 is expressed in 86% of rat GH-positive cells as compared to
SSTR2 in 42% of rat somatotrophes (379). Furthermore, it has demonstrated that for
somatostatin to effectively inhibit growth hormone secretion, the SSTR5 must also be
involved (431), and heterodimerization and activation of both SSTR2 and SSTR5 results in
synergistic GH suppression (432;585). Thus, it is not surprising that our selective SSTR2
antagonist, which does not have a high affinity for SSTR5, does not affect growth hormone
release in our experiments. However, it should be noted that growth hormone is very
pulsatile in its release and that we took measurements at relatively few time points and
may have missed periods of plasma differences in growth hormone secretion.
106
4.4.6 SSTR2 antagonism does not cause hyperglycemia or undesired stress
We also demonstrate that SSTR2 antagonist does not affect glycemia or markedly alter
counterregulatory hormones in the absence of hypoglycemia. The control experiments in
the absence of insulin were performed to examine the effects of SSTR2 antagonist, per se,
during basal conditions.
Somatostatin analogues were clinically used to help lower blood glucose levels in diabetic
patients (586;587). Also, the anti-diabetic activity of a SSTR2 agonist was demonstrated in
rodent models of type 2 diabetes in which the agonist lowered plasma glucagon and glucose
levels (588). Thus, it was important to evaluate the effect of the SSTR2 antagonist when
administered during the basal state if SSTR2 antagonism could have any putative clinical
role as a therapy for hypoglycemia in the diabetic population. Since basal
hyperglucagonemia can persist despite elevated plasma somatostatin levels in diabetes, the
role of somatostatin-induced glucagon inhibition has been questioned (489). Presumably,
some could speculate that the SSTR2 antagonist may promote basal hyperglycemia, which
is undesired in diabetic patients. However, this can be reconciled with understanding an
action of somatostatin receptor-coupled signalling in the -cell: somatostatin via SSTR2
inhibits Ca2+-induced glucagon exocytosis via Gi2-dependent activation of calcineurin, a
serine/threonine protein phosphatase which “deprimes” glucagon-containing granules
associated with L-type Ca2+ channels but does not affect the granules associated with N-
type Ca2+ channels, which mediate basal glucagon secretion (577;579;589). In addition to
this mechanism, somatostatin can also inhibit adenylate cyclase activity, consequently
reducing cAMP levels and protein kinase A (PKA)-stimulated glucagon secretion, as well as
activate G-protein-coupled K+ channels on -cells, which causes hyperpolarization of the
107
plasma membrane and subsequent inhibition of -cell electrical activity and glucagon
release (589).
Presently, we demonstrate that antagonism of SSTR2 enhances hypoglycemia-stimulated,
but not basal, glucagon release in diabetic rats. In vitro experiments in pancreatic islets of
non-diabetic mice demonstrate that blocking somatostatin receptor type 2 using SSTR2
antagonist stimulated glucagon secretion in low glucose conditions but did not affect
glucagon secretion at “normal” glucose conditions of 7 mM (590). Administration of SSTR2
antagonist in perfused non-diabetic rat pancreas did not affect the inhibitory effect of
hyperglycemia on glucagon secretion (591), thus confirming that SSTR2 did not elicit
hyperglucagonemia when glucose concentrations were already high. Presently, we
demonstrate that SSTR2 antagonism during basal conditions in vivo yielded very small
transient increases of glucagon which did not cause hyperglycemia and did not alter
corticosterone or catecholamine levels, suggesting that this antagonist does not elicit
marked, non-stimulated secretion of counterregulatory hormones. However, it remains to
be investigated whether prolonged administration of SSTR2 antagonists will lead to
hyperglycemia. Studies in SSTR2 knockout mice showed no differences in fasting and fed
blood glucose levels, fasting and fed plasma glucagon levels, or responses to glucose
tolerance tests compared wild-type controls, but diet-induced obesity in these knockouts
caused fasting and fed hyperglycemia, fed hyperglucagonemia, and impaired glucose
tolerance compared to wild-types given the same high-fat diet (592). It remains to be seen
if a prolonged administration of SSTR2 antagonist in diabetic animals would exacerbate
diabetes.
108
4.4.7 Glucose requirement during hypoglycemia
Glucose infusion rates and total glucose infused were decreased with SSTR2 antagonism
during low-dose insulin-induced hypoglycemia in the present study. A lower glucose
requirement during hypoglycemia is consistent with normalized glucagon and corticosterone
responses in the SSTR2 antagonist-treated diabetic group.
At the high insulin dose, there were no differences in glucose infusions rates between non-
diabetic and diabetic rats. With three weeks of chronic hyperglycemia in our STZ-diabetic
rats, it would be anticipated that some insulin resistance would develop, as has been
previously reported (205). However, glucose infusion rates were not lower in untreated
diabetic rats during hypoglycemia presumably because the expected insulin resistance of
diabetic rats was offset by the generally lower counterregulatory response. Furthermore,
the hypothesized reduction in glucose requirement in SSTR2 antagonist treated animals
may have been masked by the overwhelming maximal inhibitory effect of insulin to
suppress endogenous glucose production and increase glucose utilization. Our method of
inducing hypoglycemia with insulin injection creates a major perturbation of steady state
which renders classic glucose turnover techniques to measure glucose production and
utilization less reliable, especially during the rapid change of glycemia at the onset of insulin
injection in the present experiments, thus we used the exogenous glucose requirement and
expression of gluconeogenic enzymes as indicators of effects of improved counterregulation
on glucose homeostasis.
Despite using half the dose of insulin in our low-dose versus high-dose insulin experiments,
glucose infusion rates seemingly appear greater in groups induced with 5 U/kg insulin. We
attribute this to the fact that hypoglycemia was reached at an earlier time point in the low-
dose study (i.e. non-diabetic rats: at t=20 min for low-dose as compared to t=50 min for
109
high dose insulin-induced hypoglycemia experiments; both diabetic groups: at t=25 min for
low-dose as compared to t=70 min for high-dose insulin-induced hypoglycemia
experiments), and thus the glucose requirement would be greater to maintain clamped
hypoglycemia for a longer duration. Alternatively, diabetic rats in the low-dose insulin
experiments may have had a greater exogenous glucose requirement since they had a lower
initial basal glycemia and may have been less insulin resistant than diabetic rats in the high-
dose group. Regardless, diabetic groups within each experiment were similar, and thus the
effects of SSTR2 antagonist treatment could be accurately compared.
4.4.8 Expression of gluconeogenic enzymes
Gluconeogenesis plays a role in restoring blood glucose levels in response to hypoglycemia
and is particularly relevant after an overnight fast in which glycogen stores are depleted in
rodents, resulting in gluconeogenesis rather than glycogenolysis as the main contributor to
glucose synthesis (593-595). Glucagon (596-598) and corticosterone (599-601) are well
known to induce the expression of PEPCK and G6Pase. Glucagon activates protein kinase A,
increasing cAMP levels, which induces gluconeogenic enzymes (596-598). Corticosterone
induces PEPCK (599) and G6Pase (600;601) expression by binding with glucocorticoid
receptors and activating glucocorticoid-responsive elements on the promoter regions of
these genes. Furthermore, the nuclear coactivator protein peroxisome proliferator activated
receptor- coactivator 1 (PGC-1) is induced by glucagon and corticosterone and promotes
increased transcription of both PEPCK and G6Pase by its interaction with HNF-4, thus
contributing as a key mechanism for controlling glucose production in hepatocytes (602).
Since glucagon and corticosterone responses to hypoglycemia were normalized in diabetic
rats with SSTR2 antagonism without an effect on glucose infusion rates at the high insulin
dose, we wished to determine if gene expression of these gluconeogenic enzymes was
110
increased and this would have served as better markers than glucose infusion rates of
counterregulatory hormone actions.
Hypoglycemia markedly decreased G6Pase mRNA expression in both non-diabetic and
diabetic rats, which is attributed to the large amount of insulin administered (up 200-fold
increase in plasma levels), which has a large suppressive effect on gluconeogenic enzyme
synthesis (596;603) and can override the stimulatory effect of increased counterregulatory
hormones (604). PEPCK1, the cytosolic form, is the predominant form in rodent liver (605).
Unlike G6Pase, expression of PEPCK1 was not decreased by hypoglycemia in the present
study. This is in accordance with another study in which epinephrine could overcome the
inhibitory effect of insulin on stimulating PEPCK1 expression in rat hepatocytes (606). Thus,
despite robust increases of glucagon and corticosterone during hypoglycemia, the
expression of PEPCK1 and G6Pase was not affected, perhaps masked by the stimulatory
effect of epinephrine or overwhelming inhibitory effect of insulin, respectively.
In the absence of hypoglycemia, G6Pase in diabetic rats was actually decreased compared
with non-diabetic rats, and SSTR2 antagonist treatment in diabetic rats partially increased
this expression. The modest, transient increase of plasma glucagon levels in the SSTR2
antagonist-treated group may be responsible for the moderate increase in G6Pase
expression in the present study. Modest increases in circulating glucagon are sufficient in
increasing glucose production in the short-term (i.e. 2 h) in partially insulin-deprived
humans (607), although in our study, hyperglycemia was not observed during the 4-h time-
frame of our experiments. Our basal gluconeogenic enzyme results are in contrast to the
popular view that expression of gluconeogenic enzymes PEPCK (608-610) and G6Pase
(601;611-614) are elevated with diabetic rodents, but are in line with a recent finding in
mildly hyperglycemic, overnight fasted, STZ-diabetic rats, (615). A shorter duration of
111
fasting (i.e. 6-h) in STZ-diabetic rats likewise yielded no differences in PEPCK1 and GP6Pase
expression despite elevated fasting plasma glucose levels and rates of endogenous glucose
production (615). In addition to suggesting the role of other key enzymes which may be
responsible for regulating gluconeogenesis, the authors suggest that increased PEPCK and
G6Pase expression are often associated with diabetic models with increased corticosterone
levels and demonstrate that expression does not increase from controls in STZ-diabetic rats
without hypercorticosteronemia. In our non-diabetic and diabetic rats which had similar
plasma corticosterone levels for the duration of the control experiments, we likewise do not
observe increased expression of gluconeogenic enzymes. Another possibility is that basal
gluconeogenic enzyme transcription is not increased in our diabetic rats despite lower
endogenous insulin because of hyperglycemia. At present, there is no known direct effect of
SSTR2 antagonism on hepatic gluconeogenesis. SSTR1 (271) and SSTR3 (373), but not
SSTR2, have been detected on hepatocytes, and the SSTR2 antagonist has no reactivity
with SSTR1 and 10-fold less binding affinity with SSTR3 (509). In isolated rat hepatocytes,
somatostatin has been reported to have no direct effects on basal glucose production
(616;617) on glucagon-stimulated glucose production, or on PEPCK and G6Pase activity
(617). Similarly, studies in conscious dogs have demonstrated that somatostatin does not
alter basal glucose production rates when the levels of insulin and glucagon are maintained
(618). Besides its use in pancreatic clamp studies to measure glucose turnover, the direct
effects of somatostatin effect on the liver are not well-documented aside from its use in liver
tumour cells or cirrhotic liver (418). Somatostatin bound to its receptors elicit their cellular
responses through G-protein coupling, including inhibition of adenylyl cyclase via inhibitory
G proteins (271), thus it is possible that somatostatin can lower cAMP levels directly within
hepatocytes, consequently blunting expression of gluconeogenic enzymes such as PEPCK
and G6Pase and thus affecting gluconeogenesis and subsequent hepatic glucose production.
112
However, there is no evidence that such a mechanism exists at the present time. However,
the modest, transient increase of plasma glucagon levels in the SSTR2 antagonist-treated
group may be responsible for the moderate increase in G6Pase expression observed in the
present study.
4.4.9 Effect of SSTR2 antagonism during hypoglycemia in non-diabetic rats
The main objective of this study was to evaluate the effect of SSTR2 blockade on hormone
counterregulation to hypoglycemia in diabetic rats. We postulated that elevated
somatostatin in diabetes contributes to this impairment, and SSTR2 antagonism in non-
diabetic rats provides a control during hypoglycemia so that the magnitude of the
impairment in diabetes that might be attributable to elevated somatostatin may be
assessed. Both groups of non-diabetic rats in this study have similar pancreatic and plasma
somatostatin levels (Table 4-7). We presently provide evidence that SSTR2 antagonist
treatment in non-diabetic rats does not increase glucagon or corticosterone responses to
hypoglycemia. This is in contrast to diabetic rats with elevated somatostatin in which
disinhibition of somatostatin acting via SSTR2 normalized the defects of both glucagon and
corticosterone counterregulation. We assessed the effects of diabetes and administration of
SSTR2 antagonist on pancreatic and plasma somatostatin levels by combining available data
of the groups form the hypoglycemia experiments (Table 4-7). Using Two-Way ANOVA
statistical analysis, it can be shown that there is an effect of diabetes, but not SSTR2
antagonist (P=0.51 for both), on both pancreatic somatostatin (P<0.0004) and plasma
somatostatin (P<0.004) values. Thus, data from the non-diabetic control for SSTR2
antagonism during hypoglycemia provides support for a role of elevated somatostatin in
diminishing glucagon and corticosterone responses to hypoglycemia in diabetic rats, but not
non-diabetic rats.
113
At 1500 nmol/kg/h, SSTR2 antagonist had no effect on glucagon responses to hypoglycemia
in non-diabetic rats. This supports the hypothesis that somatostatin does not play a role in
suppressing glucagon release in non-diabetic rats, but taken together with the data in
diabetic rats in which somatostatin is elevated, it demonstrates that disinhibition of the -
cell (which is has increased sensitivity to the suppressive effects of exogenous insulin)
during hypoglycemia enhances glucagon release in diabetes. However, it was very
surprising to observe that when a two-fold larger dose of SSTR2 antagonist was used in
non-diabetic rats, an effect opposite to that which would be expected of somatostatin
blockade ensued: glucagon responses were markedly attenuated rather than enhanced.
This effect could have been mediated by a stimulated release of insulin resulting from a
non-specific effect of a high dose SSTR2 antagonist on -cells (which express SSTR5 and
not SSTR2 in rats), which could locally act to suppress glucagon release. It is possible that
when high doses of this antagonist are used in the absence of a sufficient amount of a
competitor (i.e. non-diabetic rats have significantly less somatostatin than diabetic rats),
binding to the SSTR5 on -cells may occur, which could disinhibit the -cell from the
suppressive effects of somatostatin and promote insulin secretion. Cejvan et al. reported
that this SSTR2 antagonist under certain conditions at high dose modestly increased insulin
secretion in non-diabetic rat islets when it should have had no effect (392). A similar
concept has previously been suggested by Gromada et al. (589) who used a high dose of
SSTR2 antagonist in studies of isolated rat -cells. In this in vitro setting in which the
purified -cell fraction did not contain any detectable amounts of endogenous somatostatin,
the SSTR2 antagonist applied at a comparatively high dose (2 M) increased insulin
secretion, which led to the authors cautioning against the use of these compounds in the
absence of native competitive receptor agonists (589). Thus, despite the fact that our
SSTR2 antagonist binds with 20-fold lower affinity to SSTR5 than SSTR2, thus suppressing
114
glucagon release, it is possible that -cell release of insulin may have been stimulated by
high dose SSTR2 antagonist in non-diabetic rats of our study. Non-diabetic rats did not
have augmented pancreatic somatostatin as diabetic rats, and the excessive amount of the
peptide may have suppressed the -cell rather than disinhibiting it. Future analysis using a
C-peptide assay could determine whether SSTR2 antagonist stimulates insulin release in
non-diabetic rats. This would not occur in diabetic rats, which have both elevated
somatostatin and markedly reduced -cell function. Alternatively, it is also possible that at
high doses, our peptide antagonist could have partial agonist activity. One group has
cautioned that certain competitive peptide analogues could exert opposite effects when used
at higher concentrations (619).
4.5 Study 1 Conclusions
In conclusion, we demonstrate that glucagon and corticosterone counterregulatory hormone
responses to hypoglycemia can be normalized in diabetic rats with specific antagonism of
the SSTR2, which does not elicit hyperglycemia or substantial elevations in
counterregulatory hormones during basal conditions. Our results therefore suggest an
important role for increased pancreatic, and possibly circulating, somatostatin in defective
glucagon and corticosterone counterregulation in diabetes but do not rule out other
mechanisms of impairment. Under conditions of lower dose insulin injection, SSTR2
antagonism reduced the glucose requirement during hypoglycemic clamp, which is
indicative of a lower risk of hypoglycemia. In this model of diabetes, epinephrine and
norepinephrine counterregulation to hypoglycemia induced with both high and low doses of
insulin were similar in both non-diabetic and diabetic rats. Growth hormone levels were not
affected by SSTR2 administration.
115
Figure 4-1. Study 1 protocol design.
116
Figure 4-2. Schematic representation of A) hypoglycemia clamp experiments (solid lines) and B) control experiments during basal conditions in the absence of exogenously administered insulin (dashed lines). In (A), “x” represents dose of insulin (high dose = 10 U/kg, low dose = 5 U/kg) and “y” represents dose of SSTR2 antagonist (pilot study = 1500 nmol/kg/h, else = 3000 nmol/kg/h). In (B), no insulin or glucose infusions are administered in these experiments under basal conditions. White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a.
117
Figure 4-3. Pilot study: Plasma hormone levels during hypoglycemia clamp (10 U/kg insulin, 1500 nmol/kg/h SSTR2 antagonist). A) Glucagon. B) Corticosterone. White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. White bars: N; black bars: D, grey bars: D+SSTR2a. Data are represented as means ± SEM. *P<0.05 D vs N. †P<0.05 D vs D+SSTR2a.
A.
B.
-10000
-5000
0
5000
10000
15000
20000
25000 AUC
†
0
50
100
150
200
250
300
350
400
-60 0 20 40 60 80 100 120 140 160 180
Pla
sma
glu
cag
on
(p
g/m
L)
Time (min)
\\
-100
-50
0
50
100
150
200
250
300
350
400
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
∆ P
lasm
a co
rtic
ost
ero
ne
(ng
/ml)
\\
-20000
-10000
0
10000
20000
30000
40000
50000
60000 AUC
118
Figure 4-4. Blood glucose levels during hypoglycemia clamp (10 U/kg insulin, 3000 nmol/kg SSTR2 antagonist). White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. Data are represented as means ± SEM.
0
1
2
3
4
5
6
7
8
9
10
11
12
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
Time (min)
Blo
od
glu
cose
(m
mo
l/l)
119
Figure 4-5. Plasma hormone levels during hypoglycemia clamp (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). A) Glucagon. B) Corticosterone. C) Glucose infusion. White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. White bars: N; black bars: D, grey bars: D+SSTR2a. Data are represented as means ± SEM. *P<0.002 D vs N. †P<0.05 D vs D+SSTR2a.
A.
B.
C.
0
50
100
150
200
250
300
350
400
-60 0 20 40 60 80 100 120 140 160 180
Pla
sma
glu
cag
on
(p
g/m
l)
Time (min)
\\
††
† ††
†
†0
5000
10000
15000
20000
25000
30000 AUC
†
0
50
100
150
200
250
300
350
400
450
-60 0 20 40 60 80 100 120 140 160 180Time (min)
\\
†
∆ P
lasm
a co
rtic
ost
ero
ne
(ng
/ml)
0
10000
20000
30000
40000
50000
60000
70000 AUC
†
0
2
4
6
8
10
12
14
16
18
20
22
-60 0 20 40 60 80 100 120 140 160 180Time (min)
\\
Glu
cose
infu
sio
n r
ate
(mg
/kg
/min
)
0
500
1000
1500
2000
To
tal g
luco
se in
fuse
d(m
g/k
g)
120
Figure 4-6. Plasma A) epinephrine and B) norepinephrine levels during hypoglycemia clamp (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. Data are represented as means ± SEM.
A. B.
0
1000
2000
3000
4000
5000
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
\\
Pla
sma
epin
eph
rin
e (p
g/m
l)
0
200
400
600
800
1000
1200
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
\\
Pla
sma
no
rep
inep
hri
ne
(pg
/ml)
121
Figure 4-7. Blood glucose levels during hypoglycemia clamp using low insulin dose (5 U/kg insulin, 3000 nmol/kg SSTR2 antagonist). White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. Data are represented as means ± SEM.
0
1
2
3
4
5
6
7
8
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
Blo
od
glu
cose
(m
mo
l/l)
Time (min)
122
Figure 4-8. Plasma hormone levels during hypoglycemia clamp (5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). A) Glucagon. B) Corticosterone. C) Glucose infusion. White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. White bars: N; black bars: D, grey bars: D+SSTR2a. Data are represented as means ± SEM. *P<0.05 D vs N. †P<0.05 D vs D+SSTR2a. A. B.
C.
0
100
200
300
400
500
600
700
-60 0 20 40 60 80 100 120 140 160 180
Pla
sma
glu
cag
on
(p
g/m
l)
Time (min)
\\
†† † 0
10000
20000
30000
40000
50000
60000 AUC
†
-50
0
50
100
150
200
250
300
350
400
450
-60 0 20 40 60 80 100 120 140 160 180Time (min)
∆ P
lasm
a co
rtic
ost
ero
ne
(ng
/ml)
\\ 0
10000
20000
30000
40000
50000
60000
70000 AUC
†
02468
10121416182022242628
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
Glu
cose
infu
sio
n r
ate
(mg
/kg
/min
)
\\ 0
500
1000
1500
2000
2500
3000
3500
To
tal g
luco
se in
fuse
d(m
g/k
g)
†
123
Figure 4-9. Plasma A) epinephrine and B) norepinephrine levels during hypoglycemia clamp (5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. Data are represented as means ± SEM. A. B.
0
1000
2000
3000
4000
5000
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
\\
Pla
sma
epin
eph
rin
e (p
g/m
l)
0
200
400
600
800
1000
1200
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
\\
Pla
sma
no
rep
inep
hri
ne
(pg
/ml)
124
Figure 4-10. Plasma growth hormone levels during hypoglycemia clamp (5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. Data are represented as means ± SEM.
0
5
10
15
20
25
30
-60 0 60 120 180
Pla
sma
gro
wth
ho
rmo
ne
(ng
/mL
)
Time (min)
125
Figure 4-11. Blood glucose levels during control experiments in the absence of insulin (0 U/kg, 3000 nmol/kg/h). White diamonds (◊): N; black squares (): D; grey circles (): D+SSTR2a. Data are represented as means ± SEM.
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100110120130140150160170180
Time (min)
Blo
od
glu
cose
(m
mo
l/l)
126
Figure 4-12. Pancreatic protein content of A) glucagon and B) somatostatin, and C) plasma somatostatin, following hypoglycemia clamp (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist) and control experiments in the absence of insulin (0 U/kg, 3000 nmol/kg/h). Solid bars represent hypoglycemia experiments. Hashed bars represent control experiments. White bars: N; black bars: D, grey bars: D+SSTR2a. Data are represented as means ± SEM. *P<0.02 D vs N. A. B. C.
0
100
200
300
400
500
600
700
0
100
200
300
400
500
600
700
Pan
crea
tic
glu
cag
on
(n
g/m
g p
rote
in)
0
20
40
60
80
100
120
140
160
P=0.09 n.s. P=0.07 n.s.
0
10
20
30
40
50
0
20
40
60
80
100
120
140
160
Pan
crea
tic
som
ato
stat
in
(pm
ol/m
g p
rote
in)
0
10
20
30
40
50
P=0.08 n.s.
Pla
sma
som
ato
stat
in (
pg
/ml)
127
Figure 4-13. Blood glucose levels during hypoglycemia clamp in non-diabetic rats at the various dosing combinations of insulin and SSTR2 antagonist. A) 10 U/kg insulin, 1500 nmol/kg/h SSTR2 antagonist; B) 10 U/kg insulin 3000 nmol/kg/h SSTR2 antagonist; (C) 5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist. White diamonds (◊): N; grey triangles (): N+SSTR2a. Data are represented as means ± SEM.
A.
B.
C.
0
1
2
3
4
5
6
7
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100110120130140150160170180
Time (min)
Blo
od
glu
cose
(m
M)
0
1
2
3
4
5
6
7
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100110120130140150160170180
Time (min)
Blo
od
glu
cose
(m
M)
0
1
2
3
4
5
6
7
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100110120130140150160170180
Time (min)
Blo
od
glu
cose
(m
M)
128
Figure 4-14. Effect of SSTR2 antagonist on plasma glucagon A-C) and corticosterone D-F) at the various dosing combinations of insulin and SSTR2 antagonist in non-diabetic rats. TOP (A, D): 10 U/kg insulin, 1500 nmol/kg/h SSTR2 antagonist; MIDDLE (B, E): 10 U/kg insulin 3000 nmol/kg/h SSTR2 antagonist; BOTTOM (C, F): 5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist. White diamonds (◊): N; grey triangles (): N+SSTR2a. Data are represented as means ± SEM. *P<0.05 N vs N+SSTR2a. †P<0.005 N vs. N+SSTR2a.
A.
B.
C.
0
100
200
300
400
500
600
700
-60 0 20 40 60 80 100 120 140 160 180
Tme (min)
Pla
sma
cort
ico
ster
on
e(n
g/m
L)
\\0
50
100
150
200
250
300
350
400
450
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
Pla
sma
glu
cag
on
(p
g/m
L)
†
†
\\
0
100
200
300
400
500
600
700
-60 0 20 40 60 80 100 120 140 160 180Time (min)
Pla
sma
cort
ico
ster
on
e(n
g/m
L)
\\0
50
100
150
200
250
300
350
400
450
-60 0 20 40 60 80 100 120 140 160 180Time (min)
Pla
sma
glu
cag
on
(p
g/m
L)
\\
0
100
200
300
400
500
600
700
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
Pla
sma
cort
ico
ster
on
e(n
g/m
L)
\\0
50
100
150
200
250
300
350
400
450
-60 0 20 40 60 80 100 120 140 160 180
Time (min)
Pla
sma
glu
cag
on
(p
g/m
L)
\\
D.
E.
F.
129
Table 4-1. Metabolic parameters of rats that underwent hypoglycemia clamps or control experiments in the absence of insulin. Fed blood glucose, body weight, and food intake were measured daily, and the table below shows the mean of values averaged over the last week before the experimental day. Daily blood glucose measurements were obtained using a glucometer. Data are represented as means ± SEM. *P<0.0002 D vs N in the respective experiment. **P<0.03 D vs N in the respective experiment. †P<0.04 D vs D+SSTR2a in the respective experiment.
fed blood glucose (mM)
body weight (g)
food intake (g)
(pilot study) hypoglycemia clamps (10 U/kg; 1500 nmol/kg/h)
N (n=5)
5.3 ± 0.2 408 ± 5 18 ± 2
D (n=3)
28.1 ± 1.8 * 340 ± 7 * 42 ± 3 *
D+SSTR2a (n=3)
26.3 ± 2.7 351 ± 9 36 ± 3
hypoglycemia clamps (10 U/kg; 3000 nmol/kg/h)
N (n=14)
5.2 ± 0.1 435 ± 7 23 ± 1
D (n=14)
22.4 ± 1.2 * 365 ± 5 * 37 ± 2 *
D+SSTR2a (n=18)
22.8 ± 1.1 355 ± 6 30 ± 1 †
hypoglycemia clamps (5 U/kg; 3000 nmol/kg/h)
N (n=5)
5.6 ± 0.3 400 ± 15 19 ± 3
D (n=4)
24.8 ± 3.5 * 323 ± 20 ** 32 ± 4 **
D+SSTR2a (n=4)
25.6 ± 1.0 331 ± 25 35 ± 3
controls in absence of insulin (0 U/kg; 3000 nmol/kg/h)
Ctrl:N (n=7)
5.8 ± 0.1 419 ± 6 18 ± 1
Ctrl:D (n=7)
24.7 ± 1.3 * 378 ± 9 ** 36 ± 3 **
Ctrl:D+SSTR2a (n=7)
26.4 ± 1.9 368 ± 15 38 ± 3
130
Table 4-2. Basal plasma counterregulatory hormone levels for rats that underwent hypoglycemia clamp (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist) and control experiments in the absence of insulin (0 U/kg, 3000 nmol/kg/h) at time = -60 min. “N/A” denotes time points at which samples for the particular hormone were not obtained. Data are represented as means ± SEM. *P<0.01 D vs N.
Basal plasma hormone concentration
glucagon (pg/mL)
corticosterone (ng/mL)
epinephrine (pg/mL)
norepinephrine (pg/mL)
(pilot study) hypoglycemia clamps (10 U/kg insulin, 1500 nmol/kg/h SSTR2 antagonist)
N 31 ± 9 134 ± 34 N/A N/A
D 71 ± 14 311 ± 32 N/A N/A
D+SSTR2a 46 ± 2 309 ± 133 N/A N/A
hypoglycemia clamps (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist)
N 32 ± 4 42 ± 9 55 ± 11 162 ± 26
D 51 ± 5 * 156 ± 26 * 148 ± 28 * 211 ± 35
D+SSTR2a 65 ± 5 148 ± 33 134 ± 57 334 ± 60
hypoglycemia clamps (5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist)
N 13 ± 6 174 ± 38 40 ± 12 323 ± 50
D 52 ± 8 * 220 ± 19 93 ± 33 324 ± 29
D+SSTR2a 37 ± 6 226 ± 45 147 ± 40 282 ± 64
control experiments (no exogenous insulin administered)
Ctrl:N 50 ± 6 165 ± 34 31 ± 15 318 ± 11
Ctrl:D 45 ± 3 189 ± 54 110 ± 46 310 ± 82
Ctrl:D+SSTR2a 50 ± 4 245 ± 42 217 ± 65 290 ± 38
131
Table 4-3. Plasma insulin levels (ng/mL) during hypoglycemia clamps (10 U/kg or 5 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). Data are represented as means ± SEM. *P<0.05 D vs N.
Time (min)
-60 0 60 180
Hypoglycemia clamps using 10 U/kg insulin and 3000 nmol/kg/h SSTR2 antagonist
N 1.0 ± 0.07 0.9 ± 0.07 141.5 ± 8.0 59.6 ± 7.4
D 0.5 ± 0.04 * 0.5 ± 0.07 * 93.2 ± 7.2 * 24.1 ± 2.9 *
D+SSTR2a 0.5 ± 0.1 0.7 ± 0.2 107.9 ± 14.1 26.3 ± 4.4
Hypoglycemia clamps using 5 U/kg insulin and 3000 nmol/kg/h SSTR2 antagonist
N 0.6 ± 0.4 0.6 ± 0.2 62.4 ± 13.2 5.2 ± 0.9
D 0.3 ± 0.2 0.2 ± 0.5 59.4 ± 17.8 1.5 ± 0.5
D+SSTR2a 0.3 ± 0.07 0.5 ± 0.2 58.6 ± 18.0 3.0 ± 1.5
132
Table 4-4. Plasma counterregulatory hormone and insulin levels during control experiments in the absence of insulin (0 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist). “N/A” denotes time points at which samples for the particular hormone were not obtained. Data are represented as means ± SEM. *P<0.05 D vs N. †P<0.03 D vs D+SSTR2a.
Time (min)
-60 0 20 40 60 90 120 180
Plasma glucagon (pg/mL)
Ctrl:N 50 ± 6 70 ± 15 79 ± 24 64 ± 14 42 ± 12 47 ± 9 33 ± 9 39 ± 8
Ctrl:D 45 ± 3 50 ± 12 41 ± 13 43 ± 8 50 ± 10 51 ± 18 55 ± 10 59 ± 17
Ctrl:D+SSTR2a 50 ± 4 88 ± 18 101 ± 24 100 ± 22 † 97 ± 15 † 95 ± 11 † 80 ± 13 73 ± 13
Plasma corticosterone (ng/mL)
Ctrl:N 165 ± 31 210 ± 47 313 ± 36 294 ± 60 233 ± 56 195 ± 38 N/A 208 ± 29
Ctrl:D 205 ± 49 248 ± 75 351 ± 93 349 ± 84 335 ± 86 254 ± 74 180 ± 43
Ctrl:D+SSTR2a 273 ± 46 261 ± 53 316 ± 49 322 ± 55 331 ± 58 293 ± 50 225 ± 40
Plasma epinephrine (pg/mL)
Ctrl:N 31 ± 15 94 ± 19 89 ± 16 112 ± 19 85 ± 14 82 ± 25 N/A 45 ± 12
Ctrl:D 110 ± 46 85 ± 31 157 ± 43 116 ± 29 264 ± 112 382 ± 272 123 ± 49
Ctrl:D+SSTR2a 217 ± 65 180 ± 85 243 ± 156 385 ± 191 345 ± 149 371 ± 163 235 ± 111
Plasma norepinephrine (pg/mL)
Ctrl:N 356 ± 39 393 ± 45 428 ± 46 435 ± 88 353 ± 79 392 ± 78 N/A 293 ± 41
Ctrl:D 310 ± 82 292 ± 59 272 ± 31 310 ± 48 376 ± 96 301 ± 80 246 ± 108
Ctrl:D+SSTR2a 290 ± 38 238 ± 58 242 ± 100 381 ± 125 351 ± 76 315 ± 96 330 ± 105
Plasma insulin (ng/mL)
Ctrl:N 1.1 ± 0.2* 1.1 ± 0.1* N/A N/A 0.8 ± 0.1 N/A N/A 0.8 ± 0.1
Ctrl:D 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1
Ctrl:D+SSTR2a 0.5 ± 0.1 0.7 ± 0.2 0.6 ± 0.2 0.6 ± 0.1
133
Table 4-5. Quantitative mRNA expression of liver PEPCK1 and G6Pase following hypoglycemia clamp (10 U/kg insulin, 3000 nmol/kg/h SSTR2 antagonist) and control experiments in the absence of insulin (0 U/kg, 3000 nmol/kg/h). As per the 2-∆∆Ct method (526), gene expression was normalized to the control group, Ctrl:N. Data are represented as means ± SEM. *P<0.0001 Ctrl:N vs Ctrl:D. †P<0.05 Ctrl:D vs Ctrl:D+SSTR2a. ‡P<0.0001 Ctrl:N vs N. §P<0.01 Ctrl:D+SSTR2a vs D+SSTR2a.
mRNA expression
(fold-change relative to Ctrl:N group)
PEPCK1 G6Pase
Controls
Ctrl:N 1.000 ± 0.233 1.000 ± 0.301
Ctrl:D 0.395 ± 0.111 0.160 ± 0.041 *
Ctrl:D+SSTR2a 1.177 ± 0.280 0.499 ± 0.169 †
Hypoglycemia
N 1.039 ± 0.256 0.171 ± 0.049 ‡
D 1.293 ± 0.444 0.031 ± 0.008
D+SSTR2a 0.509 ± 0.183 0.033 ± 0.011 §
134
Table 4-6. Metabolic parameters of non-diabetic rats treated with SSTR2 antagonist (N+SSTR2a) that underwent hypoglycemia clamp experiments using the different insulin (U/kg) and SSTR2 antagonist (nmol/kg/h) dosing combinations. Fed blood glucose, body weight, and food intake were measured daily, and the table below shows the mean of values averaged over the last week before the experimental day. Daily blood glucose measurements were obtained using a glucometer. Data are represented as means ± SEM.
fed blood glucose (mM)
body weight (g)
food intake (g)
N+SSTR2a
10 U/kg, 1500 nmol/kg/h (n=3)
5.7 ± 0.2 419 ± 9 19 ± 1
10 U/kg, 3000 nmol/kg/h (n=4)
5.2 ± 0.1 405 ± 22 19 ± 1
5 U/kg, 3000 nmol/kg/h (n=10)
5.3 ± 0.2 396 ± 21 16 ± 1
135
Table 4-7. Pancreatic somatostatin protein levels (pmol/mg protein) and plasma somatostatin levels (pmol/mL) in all hypoglycemic rats. To assess the effects of diabetes and administration of SSTR2 antagonist on somatostatin, available data was combined for each treatment group, irrespective of doses of insulin or SSTR2 antagonist administered. Data are represented as means ± SEM. *P<0.04 D vs N. †P<0.005 D+SSTR2a vs N+SSTR2a. ‡P<0.03 D+SSTR2a vs N+SSTR2a. aP=0.08 D vs N. Additionally, statistical analysis using Two-Way ANOVA shows that there is an effect of diabetes, but not SSTR2 antagonist (P=0.51), on both pancreatic somatostatin (P<0.0004) and plasma somatostatin (P<0.004) values.
Pancreatic somatostatin
(pmol/mg protein)
Plasma somatostatin
(pg/mL)
N 85.3 ± 5.1 11.3 ± 2.4
D 121.1 ± 12.9 * 18.4 ± 2.3 a
N+SSTR2a 78.9 ± 7.8 12.0 ± 2.7
D+SSTR2a 130.4 ± 10.6 † 21.2 ± 2.2 ‡
136
136
Chapter 5 Study 2: Amelioration of hypoglycemia
using SSTR2 antagonism
5 Study 2
5.1 Aims
Based on our prior observation that SSTR2 antagonism restored glucagon and
corticosterone counterregulation in acutely hypoglycemic diabetic rats, we wished to test
whether SSTR2 antagonism could ameliorate subsequent hypoglycemia by restoring blood
glucose levels to euglycemia, and whether this glycemic rescue could be attributed to
improved hormone counterregulation, despite exposure to recurrent hypoglycemia. Thus
the aim of the present study was to determine whether counterregulatory hormone
responses can be restored by SSTR2 antagonism in diabetic rats exposed to recurrent
hypoglycemia and if such improvements can lessen the severity of subsequent
hypoglycemia. Recurrent hypoglycemia is associated with marked impairments of
counterregulatory hormone responses. Glucagon counterregulation in diabetes is often
absent (165;166), thus it has not been shown to be further worsened by recurrent
hypoglycemia (203;227;264). However, there is evidence demonstrating markedly
diminished epinephrine counterregulation following recurrent hypoglycemia in diabetic
subjects (203;205;220;227;261;263;264). Cortisol responses following recurrent
hypoglycemia are less consistent, having been found unaltered (203;264) or decreased
(205;227) in diabetes. In the present study, diabetic rats were subjected to 5 prior
episodes of hypoglycemia (i.e. recurrent hypoglycemia treatment) in an attempt to create a
137
model of markedly defective counterregulation. Our present results demonstrate that
SSTR2 antagonism promotes the recovery of hypoglycemia in recurrently hypoglycemic
diabetic rats and that improved glucagon counterregulation may be responsible, at least in
part, for this amelioration.
5.2 Experimental methods
5.2.1 Study design
Figure 5-1 illustrates the study design for the main protocol. As will be described in detail
below, two groups of STZ-diabetic rats were used in this study. Initial pilot studies
examined the effect of only 2 consecutive days of hypoglycemia (i.e. without prior recurrent
hypoglycemia treatment) and is presented in Figure 5-2 and Figure 5-3.
5.2.2 Recurrent hypoglycemia treatment
Rats were subjected to 5 episodes of recurrent hypoglycemia over 3 consecutive days (i.e. 2
episodes per day on the first two days and 1 episode on the third day). Rats were partially
fasted overnight prior to each day of recurrent hypoglycemia treatment. Partial fasting
consisted of 10-15 g of rat chow (i.e. approximately 25-40% of ad libitum consumption)
and free access to 5% sucrose water. Basal blood glucose was measured at the 0 min time
point, and regular insulin (20 U/kg; Humulin R, Eli Lilly, Indianapolis, IN) was injected
subcutaneously to induce each episode of hypoglycemia. Glucose infusions (50% dextrose)
were given at a variable rate to clamp glycemia at a target hypoglycemia of 3.0±0.5 mM.
Blood glucose was measured (Analox glucose analyzer, GMD-9D, Analox Instruments USA
Inc., Lunenburg, MA) in duplicate every 15 min for 180 min. During a rest period between
180 and 240 min, rats were given access to 5% sucrose water and intravenous glucose
138
infusion to recover from hypoglycemia. One blood glucose sample was obtained during the
break to monitor glycemia. At 240 min, rats were given a second insulin injection as above
and remained at hypoglycemic until 420 min. Food and sucrose water were fed to aid
recovery after hypoglycemia treatment.
5.2.3 Partial overnight fasting prior to hypoglycemia experiments
Rats were partially fasted overnight prior to each experimental day. This food restriction
consisted of 10-15 g of rat chow (i.e. approximately 25-40% of ad libitum consumption)
given overnight when rats are awake. Fasting rats in this manner was necessary for three
purposes: (i) it allowed target hypoglycemia to be achieved more easily during recurrent
hypoglycemia treatment as compared to non-fasted conditions; (ii) it allowed rats to
preserve some glycogen stores to facilitate recovery from hypoglycemia during
Experimental Days 1 and 2; (iii) and it allowed for better control of body weight and initial
glycemia, which was important since insulin dosing was dependent on these variables and
we wished to keep the amount of insulin administered consistent between the 2
experimental days. Limitations to this fasting method included an inability to precisely
determine the time at which rats ate their rationed chow; we narrowed the window of
rationed chow availability to between 22:00 (when chow was weighed and rationed) and
09:00 (when rat cages where changed, any uneaten food removed, and 5% sucrose water
replaced with regular water).
5.2.4 Hypoglycemia on Experimental Days 1 and 2
Following recurrent hypoglycemia treatment, each rat subsequently underwent 2 days of
experimentation. The protocol for experimental day 1 (ExptD1) and experimental day 2
(Expt2) is summarized in Figure 5-1. On the morning of the experiments, rats were
weighed and had their cages changed, connected to infusion lines, and acclimatized for a
139
minimum of 2 h prior to the start of experimentation. Basal blood samples for glucose and
hormones were taken at the start of the experiment (i.e. t=-60 min) from freely moving,
conscious rats. Extreme care was taken to avoid stresses to the rats during the
experiments since it is well known that even minimal disturbances caused by sounds,
scents, and vibrations can increase the release of the stress hormones measured. On
ExptD1, 0.9% saline infusion (1 mL/h) was started after basal samples were obtained at the
-60 min time point. Blood glucose was measured using a glucose analyzer in duplicate at
times -60, -40, -20, 0, and every 10 min thereafter until 240 min. Blood samples were
obtained from the carotid catheter at regular time intervals throughout the experiment for
measurement of plasma hormone levels. After plasma was removed, packed red blood cells
were re-suspended in heparinized saline (10 USP U/mL) containing 1% bovine serum
albumin and re-infused into the rat. After blood samples were obtained at t=0, an
intravenous insulin bolus (10 U/kg) was administered, and a primed intravenous insulin
infusion (50 mU/kg/min) was commenced and terminated specifically for each rat at the
experimenter’s discretion when target hypoglycemia (<4.0 mM) was approached. Infusions
were delivered via digital pumps (Harvard Apparatus PHD 22/2000 syringe pumps,
Holliston, MA), and both the volume of insulin infused and the time at which the infusion
was stopped were recorded. The purpose of Experimental Day 1 was to precisely determine
the minimal amount of insulin necessary to induce hypoglycemia in a particular rat.
Determining the insulin dosage specifically for each rat was necessary since the insulin
sensitivities of these diabetic rats varied. No glucose infusions or SSTR2 antagonist were
given on the experimental days.
On ExptD2, rats were divided into the SSTR2 antagonist treatment group (saline-SSTR2a,
n=13) or control group (saline-saline, n=7). In each rat, the same insulin administration
140
regime was used as ExptD1. It is important to emphasize that: (i) the same rat was used in
both ExptD1 and ExptD2 for comparisons; (ii) the SSTR2 antagonist treatment group and
the control group represent two different groups of rats. In the treatment group, SSTR2
antagonist infusion (3000 nmol/kg/min at 1 mL/h) was commenced at t=-60 min and
continued for 5-h duration of the experiment to determine the effect of SSTR2 antagonism
on the extent (i.e. depth and duration) of hypoglycemia. This dose of SSTR2 antagonist
was chosen because it normalized glucose and corticosterone responses to acute
hypoglycemia in diabetic rats and did not elicit hyperglycemia or marked elevations in
counterregulatory during an absence of hypoglycemia (Study 1). In the control group,
saline was infused without SSTR2 antagonist to control for the repeated bout of
hypoglycemia (i.e. saline infusions on both ExptD1 and ExptD2). Body weight, initial
glycemia, and overnight food intake were controlled for both days in all rats. At the end of
240 min on ExptD2, rats were quickly euthanized by decapitation. Rats that required
glucose infusion due to severe hypoglycemia (i.e. < 1.6 mM) were excluded from the data
presented.
5.3 Results
5.3.1 Pilot Studies: How the present method was established
Initial pilot studies examined the effect of only 2 consecutive days of hypoglycemia (i.e.
without prior recurrent hypoglycemia treatment) in STZ-diabetic rats in which insulin was
administered subcutaneously with repeated staggered injections (Figure 5-2; n=4; average
of 4.8 U insulin injected) or intravenously via bolus and infusion (Figure 5-3; n=3; average
of 4.9 U insulin administered). Repeated, staggered subcutaneous injections proved to be
problematic since: i) unwanted stress was caused, and ii) precise dosing was difficult to
141
administer. In both studies, as in the data presented below, a minimal amount of insulin to
induce hypoglycemia was administered on the first day, the same amount of insulin was
given on the second day to the same rat, and no glucose infusion was given so that
recovery could be assessed. In these pilot studies, rats were overnight fasted. In both
studies, one prior bout of hypoglycemia the day before greatly worsened hypoglycemia
induced with the same amount of insulin on the next consecutive day as was apparent both
by the measurement of blood glucose levels (Figure 5-2A, Figure 5-3A) as well as the
observable behavioural condition of the rats (i.e. immobilization, and in many rats, severe
twitches, which may have been seizures). One antecedent bout of hypoglycemia was
sufficient to markedly diminish glucagon responses to subsequent hypoglycemia (Figure
5-2B, Figure 5-3B). We reasoned that a protocol that involved recurrent hypoglycemia
treatment in a clamped setting prior to experimentation would be useful for the following
reasons: i) from a practical standpoint, several prior repeated episodes of hypoglycemia
would help to minimize the glycemic variation between subsequent bouts of hypoglycemia
(i.e. we hypothesized a habituation effect); ii) it would allow us to evaluate the effect of
SSTR2 antagonist in a established model of severe counterregulatory impairment; and iii) as
we hypothesized that epinephrine counterregulation would be diminished in recurrently
hypoglycemic diabetic rats (unlike in our acute hypoglycemia setting in Study 1), it would
allow us to evaluate the effect of SSTR2 antagonist on epinephrine counterregulation. Due
to the marked effect of one antecedent bout of hypoglycemia on impairing hypoglycemic
recovery, we also decided to partially fast, instead of fully fast, rats overnight.
5.3.2 Daily blood glucose, body weight, and food intake
Metabolic parameters such as fed morning blood glucose, body weight, and food intake
were measured daily to monitor the health of the rats and to ensure that diabetic rats were
142
of a similar diabetic state leading up to recurrent hypoglycemia treatment. In the week
prior to recurrent hypoglycemia, fed morning hyperglycemia, body weight, and daily food
intake were the same in rats that would later be divided into SSTR2 antagonist treatment
and controls groups for hypoglycemia experiments (Table 5-1).
5.3.3 Glycemia during recurrent hypoglycemia treatment
Both groups achieved 5 similar episodes of recurrent hypoglycemia over 3 days (3.0±0.5
mM for an average of 90 min per episode; Figure 5-4).
5.3.4 Basal blood glucose and plasma hormone levels after recurrent hypoglycemia treatment
On the morning of Experimental Days 1 and 2, body weight and initial glycemia did not
differ between rats (Table 5-2). Thus, all rats had similar metabolic starting points following
recurrent hypoglycemia, which allowed for baseline control conditions. Basal plasma
glucagon, epinephrine, norepinephrine, and insulin were also similar in all rats (Table 5-3).
Oddly, basal corticosterone of ExptD2-SSTR2a was lower compared with its respective
ExptD1 (P<0.03), whereas basal corticosterone was unchanged in controls (Table 5-3).
This is unusual because this change cannot be attributed to any changes in the metabolic
parameters measured, to the levels of basal hormones measured, to recurrent
hypoglycemia, or to SSTR2 antagonist since this was before the antagonist was
administered.
5.3.5 Blood glucose and plasma insulin levels during Experimental Days 1 and 2
On ExptD1, insulin induced a similar rate of decline in blood glucose levels to <4.0 mM by
90 min in both treatment (Figure 5-5) and control (Figure 5-6) groups. The hypoglycemic
nadirs were likewise the same in both treatment (Figure 5-7A) and control groups (Figure
5-7B) on ExptD1. The control group had a longer duration of hypoglycemia compared to
143
the treatment group. When SSTR2 antagonist was administered on ExptD2 with the same
insulin administration regime (i.e. same bolus dose and same infusion dose, rate, and
timing of administration) as ExptD1, a similar glycemic decline from hyperglycemia ensued,
but the depth and duration of hypoglycemia was significantly less when SSTR2 antagonist
was given (Figure 5-7A). This demonstrates that SSTR2 antagonism does not affect insulin
sensitivity or its glycemia lowering effect. SSTR2a rats recovered from hypoglycemia more
quickly, and the hypoglycemic nadir was less severe in ExptD2-SSTR2a (3.7±0.3 mM) than
on the preceding day (2.9±0.1 mM; P<0.01). The extent of hypoglycemia, calculated as
the area under the curve below 4.0 mM, was significantly reduced in the SSTR2 antagonist
treatment group (P<0.001; Figure 5-7A). Analysis of time points after glycemia in both
groups fell below 7.0 mM (i.e. t=50-240min) or 4.0 mM (i.e. t=110-240 min) with Repeated
Measures ANOVA revealed a significant effect of SSTR2 antagonist (P<0.02 and P<0.005,
respectively). Without the SSTR2 antagonist, there was no improvement in hypoglycemic
recovery (Figure 5-7B). Controls had similar hypoglycemia on both days (nadirs: 2.8±0.4
mM).
As we carefully endeavoured, similar amounts of insulin (via bolus, infusion, and total
amount given) were administered to both groups on both days (Table 5-2). Giving the
same amount of insulin on both experimental days within a group was important so that any
changes observed with glycemia would not be attributed to the amount of insulin
administered. This resulted in similar plasma insulin profiles for both groups (Table 5-4).
5.3.6 Counterregulatory hormones levels during Experimental Days 1 and 2
Following recurrent hypoglycemia, glucagon responses on Experimental Day 1 in both
groups (Figure 5-8) were modest. Figure 5-8A shows all rats that received SSTR2
antagonist on ExptD2 and their respective glucagon responses on ExptD1. Figure 5-8B
144
omits six rats that did not experience hypoglycemia as a result of their SSTR2 antagonist
treatment on ExptD2 and their respective glucagon responses on ExptD1 (i.e. Figure 5-8B
shows data for both experimental days of rats whose blood glucose levels dipped below the
normal physiological threshold of 4.0 mM in response to insulin administration despite
SSTR2 antagonist treatment on ExptD2). Figure 5-8C shows the glucagon responses of
control rats (i.e. no SSTR2 antagonist administered on ExptD2). It should be noted that
none of the ExptD2-control rats had hypoglycemia prevented. SSTR2 antagonist
significantly increased plasma glucagon on ExptD2 by 3-fold as compared to ExptD1
(P<0.04, Figure 5-8A) and had a strong tendency to improve plasma glucagon by 2.2-fold in
rats that still experienced hypoglycemia (P=0.05, Figure 5-8B), whereas the glucagon
response in controls remained markedly attenuated and exhibited a trend to be decreased,
although this was not statistically significant (Figure 5-8C).
Epinephrine responses were significantly lower in ExptD2-SSTR2a rats than on their
respective ExptD1 (Figure 5-9A). We attribute this attenuated epinephrine response to the
improvement in hypoglycemic recovery on ExptD2 due to SSTR2 antagonism; since many of
these rats did not experience marked hypoglycemia, there was no need for them to respond
with robust epinephrine counterregulation. When epinephrine responses were analyzed
having omitted the six rats in which hypoglycemia was prevented on ExptD2 due to
administration of SSTR2 antagonist, it is observed that SSTR2 antagonist preserves
epinephrine counterregulation to recurrent hypoglycemia (Figure 5-9B). In contrast,
ExptD2-controls had a significantly blunted epinephrine counterregulation (38% reduction)
compared to their respective responses on ExptD1 (P<0.02; Figure 5-9C). As mentioned
above, none of the ExptD2-control rats had hypoglycemia prevented. This suggests that
145
SSTR2 antagonism can help preserve the epinephrine response in recurrently hypoglycemic
rats when exposed to subsequent hypoglycemia.
Corticosterone responses likewise were decreased in ExptD2-controls by 46% compared to
their responses on ExptD1 (P<0.04, Figure 5-10C). However, treatment in ExptD2-SSTR2a
preserved the corticosterone response to hypoglycemia following recurrent hypoglycemia
(Figure 5-10A). Omission of the six rats in which hypoglycemia was prevented did not
significantly alter the corticosterone profile of the ExptD2-SSTR2a group, although these
rats demonstrated a strong tendency for increased corticosterone counterregulation
(P=0.05; Figure 5-10B).
Despite similar metabolic profiles (i.e. body weight, severity of diabetic hyperglycemia at
baseline), similar recurrent hypoglycemia treatment, and similar insulin administration and
plasma levels, ExptD1 epinephrine and corticosterone responses to hypoglycemia were
greater in controls than in the treatment group. Similar counterregulatory hormone
responses following recurrent hypoglycemia were expected on ExptD1, which occurred
before SSTR2 antagonist treatment, since rats had similar metabolic profiles and were
treated in the same way up until this point. We attribute the larger epinephrine and
corticosterone responses of the ExptD1 control group to a greater extent of hypoglycemia
(Figure 5-7B) as compared with ExptD1 in the treatment group (Figure 5-7A). This
supports the idea that different rats have different insulin sensitivities; given the same
amount of insulin, some rats may be more susceptible to hypoglycemia than others. Thus,
it was important that we used the method of comparing the same rat to the effects of
recurrent hypoglycemia on ExptD1 and ExptD2, with (i.e. treatment group) and without (i.e.
control group) SSTR2 antagonist.
146
Norepinephrine levels were similar on both experimental days in each of the groups (Figure
5-11).
Figure 5-12 compares the peak incremental hormone responses to acute hypoglycemia from
Study 1 and recurrent hypoglycemia from Study 2 in diabetic control rats and diabetic rats
treated with SSTR2 antagonist and will be discussed below.
5.4 Discussion
5.4.1 Amelioration of hypoglycemia with SSTR2 antagonism
We demonstrate that SSTR2 antagonism promotes the recovery of hypoglycemia by
reducing both the depth and duration of hypoglycemia in recurrently hypoglycemic diabetic
rats. Whereas control animals subjected to recurrent hypoglycemia had glycemic nadirs of
2.8±0.4 mM on both experimental days, rats given SSTR2 antagonist had a significantly
improved glycemic profile as demonstrated by a shorter duration of hypoglycemia and an
elevated glycemic nadir of 3.7±0.3 mM. Lessening the hypoglycemic nadir is important to
preserve brain function. An early study demonstrated that hypoglycemia at 3.3 mM
reduced cognitive function as compared with euglycemia in diabetic subjects (620). Blood-
to-brain glucose transport is a direct function of the arterial plasma glucose concentration,
and during hypoglycemia blood-to-brain glucose transport becomes limiting to brain glucose
metabolism and, therefore, function (4). The American Diabetes Association Workgroup on
Hypoglycemia has emphasized not only the inherent danger of the nadir glucose
concentration and the duration of hypoglycemia but also of the frequency of hypoglycemic
events (1). Some (151;621;622) have challenged the substantiality of defining
hypoglycemia as 3.9 mM, as published by the American Diabetes Association Workgroup
147
on Hypoglycemia (1). Amiel et al. suggest that glycemic excursions in the range of 3.5–4.0
mM, provided that further glycemic decline is prevented, is of little clinical significance
(151). Swinnen et al. report that defining hypoglycemia at a higher glucose level of 3.9
mM overestimates the prevalence of asymptomatic episodes of hypoglycemia and suggest a
lower glycemic cut-off (622). Frier suggests that a cut-off level of 3.5 mM or lower to
define the onset of hypoglycemia would be clinically appropriate since cognitive function is
not impaired, and symptoms are often not generated, until glycemia approaches 3.2 mM
(621). If this were indeed the case, then our present data would illustrate that SSTR2
antagonist treatment could not only facilitate recovery from low blood glucose levels but
also prevent the onset of hypoglycemia. However, it should be noted that a more
conservative definition of hypoglycemia (i.e. at the biochemical level of 3.9 mM) has its
merits as rebutted by Cryer (623). Hypoglycemia, even when unaccompanied by
symptoms, leads to defective glucose counterregulation and eventually hypoglycemia
unawareness (63;168). Since these episodes substantially increase the risk of subsequent
hypoglycemia, all hypoglycemic events can harm the individual with diabetes in the short or
long term (1). It has been suggested that delayed recovery of hypoglycemia may
frequently occur in type 1 diabetic individuals in which deficient epinephrine and glucagon
counterregulation results in impaired hepatic glucose release (225). Thus, developing a
means to promote hypoglycemic recovery is of vital importance.
Hypoglycemia unawareness is the development of neuroglycopenia without appropriate prior
autonomic warning symptoms (232;624) and contributes to the increased risk of recurrent
hypoglycemia (63). In type 1 diabetic patients, avoidance of hypoglycemia could restore
hypoglycemia awareness. Improved symptom scores, increased glycemic thresholds for
responses, and/or improved epinephrine counterregulation were observed after 2 weeks
148
(625), 3 months (625;626), or 4 months (238;241). However, the restoration of awareness
would often come at the cost of less strict glycemic control as measured by increased
hemoglobin A1C levels (241;625;626). Thus, our findings suggest a means by which
hypoglycemia can be ameliorated without compromising glycemic management.
So how might SSTR2 antagonism facilitate the recovery of hypoglycemia? We demonstrate
that facilitated recovery from hypoglycemia using SSTR2 antagonist is associated with an
improvements in glucagon, epinephrine, and corticosterone responses to recurrent
hypoglycemia. As will be discussed in section 5.4.2, improvements of hormone
counterregulation could increase glucose production during hypoglycemia to help restore
euglycemia, thus ameliorating hypoglycemia via SSTR2 antagonism.
It has been demonstrated that central administration of somatostatin has no effect on
plasma glucose levels under basal conditions. However, when somatostatin was
administered into the central nervous system in conjunction with -endorphin or bombesin,
the hyperglycemia that would typically ensue from each of these substances was abolished
(627;628). An elevation of blood glucose levels is achieved by increasing glucose
production and decreasing glucose clearance. From Study 1, 4-h infusion of SSTR2
antagonist in diabetic rats during hypoglycemia yielded no changes in growth hormone
levels as compared with saline infused controls, thus it is unlikely that growth hormone-
induced hepatic glucose output contributed to improved hypoglycemic recovery. The
inability of somatostatin to directly affect glucose turnover both in vivo in dogs (629) and in
vitro in rat hepatocytes (616) has been reported by much earlier studies by Cherrington et
al. In dogs, infusion of somatostatin with intraportal replacement co-infusions insulin and
glucagon did not affect glucose production, which suggests that somatostatin may affect
glucose production indirectly via its effects on insulin and glucagon, but not directly (629).
149
However, the lack of effect of somatostatin reported in these studies was during the basal,
non-stimulated state and is does not necessarily represent conditions of hepatic stimulation.
In perfused rat liver, somatostatin inhibited glucagon-stimulated, but not basal, hepatic
glucose output (630). Since somatostatin also blunted cAMP-induced glucose output, the
authors suggest the effect of somatostatin to suppress stimulated hepatic glucose release is
mediated via cAMP (630), which is consistent with a known mechanism of action of
somatostatin. Furthermore, in isolated hepatocytes, somatostatin inhibited both glucagon-
stimulated glycogenolysis and gluconeogenesis by 40-50%, but somatostatin had no effect
on epinephrine-stimulated glycogenolysis (631). At present, however, there is no known
direct effect of SSTR2 antagonism on hepatic glucose production. SSTR1 (271) and SSTR3
(373), but not SSTR2 (418;632), have been detected on hepatocytes, and the SSTR2
antagonist has no reactivity with SSTR1 and 10-fold less binding affinity with SSTR3 (509).
We demonstrate that SSTR2 antagonism did not affect the mRNA expression of
gluconeogenic enzyme PEPCK in diabetic rats during basal conditions or in response to
hypoglycemia (Study 1). Similarly, SSTR2 antagonist did not affect expression of G6Pase
following hypoglycemia but increased G6Pase expression during basal conditions (Study 1).
In another study, however, SSTR2-deficient mice were shown to have increased mRNA
expression of PEPCK, but not G6Pase (592).
It has been postulated that an increase in glucose clearance may be attributed to some
extrapancreatic effect of somatostatin (633). In one study, somatostatin infusion did not
increase whole-body glucose disposal in non-diabetic humans during a hyperinsulinemic-
euglycemic clamp (298). In contrast, a direct effect of somatostatin to enhance insulin-
stimulated muscle glucose uptake, but not basal muscle glucose uptake, was demonstrated
in non-diabetic humans (634). During a hyperinsulinemic-euglycemic clamp, local forearm
150
perfusion (via the brachial artery) with somatostatin elicited a significant 55% increase in
insulin-stimulated forearm glucose uptake as compared with systemic venous somatostatin
infusion without affecting the exogenous glucose requirement or plasma insulin, glucagon,
or growth hormone levels. The authors concluded that somatostatin may increase insulin-
stimulated glucose uptake in muscle via local mechanisms (634). Thus, it is plausible that
inhibition of somatostatin in the present study could contribute to reduced muscle glucose
uptake during hypoglycemia, thus increasing blood glucose levels. Evidence of SSTR
subtypes on skeletal muscle is scarce, but one group has reported detection of SSTR2,
SSTR3, and SSTR4 mRNA in rat skeletal muscle (635) while another group has evidence of
SSTR5 mRNA in skeletal muscle (636).
5.4.2 SSTR2 antagonism improves counterregulation following recurrent hypoglycemia
Recurrent hypoglycemia is well known to impair counterregulatory hormone responses in
both non-diabetic (227;265;637-640) and diabetic (203;205;220;227;261;263;264)
subjects. We also demonstrate that the peak incremental glucagon (P<0.005) and
epinephrine (P<0.001) responses to subsequent hypoglycemia are blunted in recurrently
hypoglycemic rats as compared to rats subject to acute hypoglycemia (Figure 5-12).
5.4.2.1 SSTR2 antagonism increases glucagon counterregulation.
Presently, we provide evidence that SSTR2 antagonism increases plasma glucagon levels in
recurrently hypoglycemic diabetic rats. In contrast, the glucagon response to recurrent
hypoglycemia was absent in control rats without SSTR2 antagonist. In the present study,
we were unable to collect and analyze pancreata from our experimental animals. However,
we previously observed increased pancreatic prosomatostatin mRNA expression in diabetic
rats as compared to non-diabetic rats (205). After 7 episodes of recurrent hypoglycemia in
diabetic rats, the expression of somatostatin was slightly but not significantly decreased
151
compared to diabetic controls without recurrent hypoglycemia but remained partially
elevated in as compared with non-diabetic controls, which indicates partial normalization of
pancreatic somatostatin expression following recurrent hypoglycemia (205). In contrast, 7
recurrent episodes of recurrent hyperinsulinemia, per se, decreased but did not fully
normalize pancreatic somatostatin mRNA, which demonstrates that repeated insulin
administration, and not repeated hypoglycemia, may help to partially normalize pancreatic
somatostatin expression. In these diabetic rats that received recurrent hyperinsulinemic
treatment, with or without recurrent hypoglycemia, and had partially normalized pancreatic
somatostatin expression, glucagon responses to subsequent hypoglycemia was improved as
compared with acutely hypoglycemic diabetic controls but still impaired compared to non-
diabetic controls (205). Thus, as with acute hypoglycemia, increased pancreatic
somatostatin may play a role in impairing glucagon release in response to repeated
hypoglycemia.
It should be noted that although SSTR2 antagonism improved glucagon responsiveness in
recurrently hypoglycemic rats by 3-fold, this peak incremental response was much less than
the glucagon response in SSTR2 antagonist-treated diabetic rats during acute hypoglycemia
from Study 1 (30±10 vs. 228±57 pg/mL; Figure 5-12A). In a separate study we previously
demonstrated that chronic, modest insulin treatment in STZ-diabetic rats does not
normalize glucagon counterregulation following recurrent hypoglycemia (641). Thus,
recurrent hypoglycemia still overwhelmingly attenuates glucagon counterregulation,
irrespective of insulin treatment, and we suggest that SSTR2 antagonism may offer
significant improvement.
152
5.4.2.2 SSTR2 antagonism preserves epinephrine counterregulation.
A very important defect of counterregulation in many diabetic individuals is the poor
response of epinephrine, especially in conjunction with an absent glucagon response and
hypoglycemia unawareness (3). Previously, we observed a deficiency of the epinephrine
response to recurrent hypoglycemia in STZ-diabetic rats (205), and this defect was
attributed, in part, to deficiencies in the mRNA expression of two key catecholamine-
synthesizing enzymes (220). Furthermore, it has also been shown that although BB
diabetic rats had normal total catecholamine content in the adrenal medulla, they showed a
hypofunctional adrenomedullary chromaffin cell release of epinephrine (642). A central
effect of somatostatin on regulating epinephrine cannot be ruled out. Prior studies have
demonstrated that analogues of somatostatin inhibit the plasma catecholamine response to
central glucopenia and to central administration of carbachol and bombesin (528;643).
We presently hypothesized that antagonizing somatostatin may play a role in increasing
secretion of adrenomedullary epinephrine in response to recurrent hypoglycemia. In our
prior acute hypoglycemia study (Study 1), we observed no effect of the SSTR2 antagonist
on epinephrine levels in diabetic rats, which had the same epinephrine response as non-
diabetic controls. We postulated that no further enhancement by SSTR2 antagonist could
be observed in those rats because the maximal physiological epinephrine response was
already achieved. As compared to our acute hypoglycemia study, peak increments in
plasma epinephrine levels following recurrent hypoglycemia were markedly reduced (acute
diabetic control: 3845±358 vs. recurrently hypoglycemic diabetic control: 1013±270
pg/mL), demonstrating that our recurrent hypoglycemia treatment generated a model of
defective counterregulation. The findings from the present study suggest that: (i) recurrent
hypoglycemia further decreased epinephrine levels in controls; (ii) when hypoglycemia is
153
prevented, administration of SSTR2 antagonist does not increase plasma epinephrine levels;
but that (iii) SSTR2 antagonism helps to preserve the epinephrine response from further
decrement in rats whose glycemia dips below the normal physiological range, which may aid
in the promoted recovery from hypoglycemia.
SSTR2 has been widely identified in the adrenal medulla (390;397-399). It has been shown
that somatostatin inhibits acetylcholine-stimulated release of epinephrine from the adrenal
medulla (644;645). This is the mechanism whereby epinephrine is released during
hypoglycemia and other stressors (646). Somatostatin is postulated to inhibit receptor-
coupled signalling initiated by acetylcholine-nicotinic receptor binding, subsequent
membrane depolarization, and intracellular calcium increase (647-649), resulting in the
consequent inhibition of adrenomedullary epinephrine secretion from the adrenal medulla.
Furthermore it has been shown that although diabetic rats had normal catecholamine
content in the adrenal medulla, a defect in the secretory mechanism of epinephrine from
adrenomedullary chromaffin cells was observed (642). Therefore, we hypothesize that
administration of the SSTR2 antagonist may improve or normalize the epinephrine response
to hypoglycemia in diabetic rats. Co-storage and co-secretion of somatostatin with
catecholamines in chromaffin cells of the adrenal medulla granules have been demonstrated
(650). Thus, somatostatin may have the physiologic role of a negative feedback mechanism
for catecholamine release in the adrenal medulla (647). In addition, it is well known that
somatostatin administered directly in the brain reduces stimulated epinephrine responses.
Intracerebroventricular administration of somatostatin or its analogs reduces stress-induced
plasma epinephrine levels in non-diabetic rats and non-diabetic and diabetic dogs
(169;528;643;651;652). Thus, in addition to the direct effect of SSTR2 blockade at the
154
adrenal medulla, it is also possible that inhibition of SSTR2 in the brain may indirectly
increase plasma epinephrine responses to hypoglycemia.
An improvement in the epinephrine response might also contribute to the amelioration of
hypoglycemia as observed in this study. It has been reported that in many type 2 diabetic
individuals with insulin resistance, the lipolytic effects of epinephrine outweigh the effects of
insulin on adipose tissue (186). Plasma free fatty acids increase in response to
hypoglycemia in type 2 diabetes (167;183;186) but not in type 1 diabetes (653).
Epinephrine secretion during hypoglycemia may therefore have a greater protective effect in
insulin-resistant subjects by promoting metabolic substrate release rather than storage.
Epinephrine also stimulates release of glucose from the kidney, and, in subjects who have a
deficient glucagon response to hypoglycemia, this has been suggested to compensate for
their impaired hepatic glucose output (213).
Norepinephrine counterregulation was not affected by recurrent hypoglycemia; peak
incremental norepinephrine responses were similar in diabetic control rats following acute
and recurrent hypoglycemia (565±43 vs. 604±129 pg/mL, respectively). SSTR2
antagonism had no effect on plasma norepinephrine levels in recurrently hypoglycemic rats.
This finding is consistent with the report that intracerebroventricular administration of
somatostatin or its analogs does not reduce stress-induced plasma elevations of plasma
norepinephrine (654).
5.4.2.3 SSTR2 antagonism preserves corticosterone counterregulation.
The glucocorticoid response to hypoglycemia plays a role in reinstating euglycemia, is
important during prolonged hypoglycemia, but may not play a critical role in rapid
counterregulation if other responses are intact (3). We have demonstrated that SSTR2
155
antagonism can improve the corticosterone response to acute hypoglycemia in diabetic rats
(Study 1). In this study, we report that SSTR2 antagonist preserves the corticosterone
response to recurrent hypoglycemia whereas rats exposed to recurrent hypoglycemia
without SSTR2 antagonism display attenuated corticosterone counterregulation. Previously,
we demonstrated that insulin-treated STZ-diabetic rats had an absent corticosterone
response following recurrent hypoglycemia (641). We attributed this defect mainly to a lack
of suppression of hippocampal mineralocorticoid receptor mRNA expression and a
consequent lack of increase of hypothalamic CRH mRNA expression in response to
hypoglycemia (655). Intracerebroventricular administration of somatostatin blunts stress-
induced plasma cortisol levels in non-diabetic and diabetic dogs (169;528). Furthermore,
central administration of somatostatin inhibits pituitary release of ACTH (656), which
stimulates adrenocortical release of corticosterone. SSTR2 have been localized in several
brain regions and specifically in areas pertaining to HPA activity – the hypothalamic
paraventricular nucleus (420) and ACTH cells in the anterior pituitary (561). Interestingly,
somatostatin inhibits CRH and ACTH release (271;294;657;658), which regulate
corticosterone secretion. At present, the precise mechanism of somatostatin on its
regulation of the HPA axis in unknown, but we postulate that somatostatin may play a role
in regulating the stress response to hypoglycemia.
5.4.3 Discussion of other mechanisms for reduced counterregulation following recurrent hypoglycemia
Hypoglycemia diminishes hormone, symptom, and cognitive responses to subsequent
hypoglycemia in type 1 diabetic (203;223;226), type 2 diabetic (168), and non-diabetic
individuals. Recurrent hypoglycemia alters the thresholds for these responses such that
lower blood glucose levels must be reached before counterregulation is initiated (4).
Notably, the epinephrine response to hypoglycemia is diminished by recurrent
156
hypoglycemia, which plays a role both in defective glucose counterregulation due to absent
glucagon counterregulation and hypoglycemia unawareness. Taken together, recurrent
hypoglycemia and the associated impairment of epinephrine counterregulation substantially
contribute to hypoglycemia-associated autonomic failure (HAAF) (63). Several different
mechanisms have been hypothesized to contribute to these impairments associated with
recurrent hypoglycemia.
Several studies have demonstrated that recurrent hypoglycemia alters glucose sensing in
the brain (193). The VMH contains glucose-sensing neurons (24;40;659) and also is a
critical region for the initiation of hypoglycemic counterregulation (34-36). Glucose-
inhibited (GI) neurons in the VMH increase their firing rate when extracellular glucose levels
decrease (40). Recurrent hypoglycemia impairs the response of VMH GI neurons to low
glucose conditions and lowers the glucose threshold at which neurons are activated
(263;660). Chan et al. have demonstrated that increased VMH GABAergic tone suppresses
counterregulation following recurrent hypoglycemia (661). This effect of increased GABA
inhibitory tone resulting from recurrent hypoglycemia is believed to be mediated via
glucose-excitatory (GE) neurons in the VMH. A recent hypothesis by McCrimmon posits that
recurrent hypoglycemia alters the balance between the 2 subpopulations of glucose sensing
neurons: the GI neurons and GE neurons. It is hypothesized that GI neurons, which act to
amplify counterregulation, are less likely to be active and/or GE neurons, which act to
suppress counterregulation, are more likely to be active following recurrent hypoglycemia
(193). This hypothesis is consistent with the studies mentioned above which demonstrate
that in the VMH, recurrent hypoglycemia increased GABAergic inhibitory tone (which is
postulated to be GE neuron-mediated) and decreased AMPK activity (which is postulated to
be GI neuron-mediated) (193). Thus, the decreased counterregulatory hormone responses
157
observed in the recurrently hypoglycemic rats of the present study may be due to
recurrent-hypoglycemia induced alterations in brain glucose sensing.
In addition to the VMH, other brain areas have also been implicated in regulating
counterregulation to hypoglycemia. Integration of behavioural responses to hypoglycemia
is associated with brain networks that include the amygdala, brain stem, orbitofrontal cortex
(cognitive decision-making), and ventral striatum (reward centre) (662). Hypoglycemia
unaware subjects, who also had decreased epinephrine counterregulation, demonstrated
reduced responses in these networks, and it is hypothesized that habituation of these
behavioural responses may contribute to hypoglycemia unawareness (662). Furthermore,
the dorsal midline thalamus has been demonstrated to play an inhibitory role following
recurrent hypoglycemia and contribute to HAAF by reducing both symptom and epinephrine
responses to subsequent hypoglycemia (663). Thus, the counterregulatory defects
observed following recurrent hypoglycemia are regulated by complex neural integration of
both glucose sensing and afferent neural pathways that initiate counterregulatory
responses.
Another hypothesized mechanism relates to increased transport of glucose or other fuels to
the brain following recurrent hypoglycemia. When the brain fails to sense a local decrease
in glucose concentrations as a result of increased blood-to-brain transport of glucose or
alternate fuels, the brain reduces its initiation of counterregulatory hormone responses
(664;665). Boyle et al. have demonstrated adaptations that maintain brain glucose uptake
at normal levels following recurrent hypoglycemia and in type 1 diabetic individuals, thereby
reducing neuroendocrine counterregulatory responses (178;666). Prolonged, chronic
hypoglycemia of at least 3 days increases glucose transporter (GLUT)-1 mRNA and protein
at the blood-brain-barrier and glucose uptake in rats (177;667;668). However, this
158
hypothesis has been challenged in light of evidence that demonstrated that 24 h of
hypoglycemia in humans blunted counterregulation to subsequent hypoglycemia but did not
affect glucose transport, glucose metabolism, or blood flow in the brain (669).
Furthermore, recurrent hypoglycemia of a shorter duration blunts hormone
counterregulation, but increases of local glucose concentrations in various brain regions
during subsequent hypoglycemia have not been observed. Thus, recurrent intermittent
hypoglycemia may not be a potent enough stimulus to cause alterations in brain glucose
transport that could be responsible for the defects of hormone counterregulation to
subsequent hypoglycemia presently observed.
5.4.4 Why might SSTR2 antagonism not have as great of an effect on recurrent hypoglycemia as acute hypoglycemia?
In Study 1, we consistently observed robust restoration of glucagon and corticosterone
counterregulation to acute hypoglycemia in diabetic rats with SSTR2 antagonism. Although
glucagon, corticosterone, and epinephrine responses in Study 2 are shown to be
significantly increased or preserved, the magnitudes of these improvements with SSTR2
antagonist treatment are not as profound following recurrent hypoglycemia. One possibility
to explain this difference of the glucagon response is that STZ-diabetic rats are more insulin
resistant than human type 1 diabetes, and thus much greater doses of insulin must be used
to induce hypoglycemia in these animal experiments than is usually used in insulin-
treatment of human diabetes. Thus following recurrent hypoglycemia, the sensitivity of
diabetic pancreatic -cells to the suppressive effects of exogenously administered insulin
becomes so overwhelming that disinhibition of somatostatin’s effect on the -cell is
ineffective at stimulating glucagon release to hypoglycemia. Peak absolute plasma levels of
insulin were similar in both Study 1 (D: 93.2 ± 7.2 ng/mL, D+SSTR2a: 107.9 ± 14.1
ng/mL; Table 4-3) and Study 2 (ExptD2-Ctrl: 71.9±18.7 ng/mL, ExptD2-SSTR2a:
159
75.7±12.3ng/mL; Table 5-4), and even exhibited a tendency to be greater in the acute
hypoglycemia experiment of Study 1; thus it is likely that the sensitivity to insulin, rather
than the absolute amount of circulating insulin, is the more important factor for suppressing
glucagon release. We have previously demonstrated that chronic, moderate insulin
treatment administered for the purpose of lessening insulin resistance in STZ-diabetic rats
helps to improve sensitivity to insulin in part, but that these rats still necessitated more
insulin to induce hypoglycemia than non-diabetic rats, despite co-administration of
phloridzin (641).
Another explanation for the diminished capacity of SSTR2 antagonist to fully enhance
hormone responses following recurrent hypoglycemia is that different mechanisms regulate
the defects of counterregulatory hormone responses to acute versus recurrent
hypoglycemia. Thus, while SSTR2 blockade can acutely augment glucagon and
corticosterone in diabetic rats, presumably because elevated pancreatic and/or circulating
somatostatin, it is possible that elevated somatostatin does not contribute to the changes in
neurocircuitry and central mechanisms that are altered with recurrent hypoglycemia. As
discussed in part above, some of these mechanisms include, but are not limited to: (i)
alterations of key brain regions responsible for glucose-sensing (245;660;670); (ii)
alterations of mechanisms responsible for relaying counterregulatory responses
(197;220;641;661;671); and/or (iii) a compensatory increase in glucose and/or other fuel
uptake by the brain (38;178;672). Despite the very modest improvements in hormone
counterregulation attributable to SSTR2 antagonist administration, it is noteworthy to
emphasize that alleviation of the effect somatostatin via SSTR2 resulted in a remarkable
amelioration of hypoglycemia in recurrently hypoglycemic diabetic rats.
160
5.5 Study 2 Conclusions
We provide support that recurrent hypoglycemia in diabetic rats markedly attenuates
glucagon and epinephrine responses, as compared to the acute responses in Study 1, to
subsequent hypoglycemia. We demonstrate that hypoglycemia can be ameliorated by
SSTR2 antagonism following recurrent hypoglycemia in diabetic rats by lessening the depth
and duration of hypoglycemia, and this glycemic rescue may be attributable in part to
enhanced glucagon, epinephrine, and/or corticosterone release. We hypothesize that
somatostatin may act via SSTR2 at various sites – pancreas, adrenal, brain, and/or
pituitary, to regulate counterregulation in diabetes but do not exclude other mechanisms of
impairment. Further investigation is necessary to further elucidate the mechanisms by
which euglycemia is restored by inhibiting the action of somatostatin. By minimizing the
risk of hypoglycemia, intensive insulin treatment would be more effective, leading to a lower
incidence of diabetic complications and decreasing the stress associated with the anxiety of
becoming hypoglycemic, consequently improving the quality of life for diabetic patients.
161
Figure 5-1. Study 2 protocol design.
n=13 n=7
162
Figure 5-2. Pilot study: A) Glycemia during 2 consecutive days of hypoglycemia (i.e. without prior recurrent hypoglycemia). B) Plasma glucagon levels during 2 consecutive days of hypoglycemia. Total average insulin administered = 4.8 U s.c. Data are represented as mean ± SEM.
A.
B.
0
50
100
150
200
250
-60 0 20 40 60 80 100 120 140 160 180
Pla
sma
glu
cag
on
(p
g/m
L)
Time (min)
0123456789
10111213141516171819202122232425
-60 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
Pla
sma
Glu
cose
(m
M)
Time (min)
1st day 2nd day
163
Figure 5-3. Pilot study: A) Glycemia during 2 consecutive days of hypoglycemia (i.e. without prior recurrent hypoglycemia). B) Plasma glucagon levels during 2 consecutive days of hypoglycemia. Insulin administered via i.v. bolus + infusion. Data are represented as mean ± SEM.
A.
B.
0
1
2
3
4
5
6
7
8
9
10
-60 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
Blo
od
glu
cose
(m
M)
Time (min)
0
50
100
150
200
250
-60 0 20 40 60 80 100 120 140 160 180
Pla
sma
glu
cag
on
(p
g/m
L)
Time (min)
1st day 2nd day
164
Figure 5-4. Blood glucose levels during recurrent hypoglycemia treatment (5 episodes over 3 days) in rats that will later be divided into SSTR2 antagonist-treatment (saline-SSTR2a; dark grey squares ()) and control (saline-saline; light grey circles ()) groups for hypoglycemia experiments. Data are represented as mean ± SEM.
0123456789
10111213141516171819202122232425
0 30 60 90 120150180 240270300330360390420 0 30 60 90 120150180 240270300330360390420 0 30 60 90 120150180
Blo
od
Glu
cose
(m
M)
Time (min)
Day -3 Day -2 Day -1
165
Figure 5-5. Blood glucose levels during hypoglycemia experiments in saline-SSTR2a treatment group. ExptD1: black squares (), and ExptD2: white squares (). Data are represented as means ± SEM. An enlarged scale of the period of interest (i.e. euglycemia and hypoglycemia) is presented in Figure 5-7A. †P<0.02 vs. ExptD1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240
Blo
od
Glu
cose
(m
M)
Time (min)
ExptD1 ExptD2: SSTR2a
† P<0.02
166
Figure 5-6. Blood glucose levels during hypoglycemia experiments in saline-saline control group. ExptD1: black circles (), and ExptD2: white circles (). Data are represented as means ± SEM. An enlarged scale of the period of interest (i.e. euglycemia and hypoglycemia) is presented in Figure 5-7B.
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240
Blo
od
Glu
cose
(m
M)
Time (min)
ExptD1 ExptD2: Ctrl
167
Figure 5-7. Enlarged scale showing blood glucose levels during hypoglycemia experiments in the A) saline-SSTR2a treatment group (solid bars) and B) saline-control group (hashed bars) on ExptD1 (black) and ExptD2 (white). Inset graphs represent extent of hypoglycemia and are calculated as area under the curve of glycemia <4.0 mM. Data are represented as means ± SEM. *P<0.001 vs. ExptD1. †P<0.02 vs. ExptD1
A.
B.
0
1
2
3
4
5
6
7
8
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240
Blo
od
Glu
cose
(m
M)
Time (min)
0
1
2
3
4
5
6
7
8
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240
Blo
od
Glu
cose
(m
M)
Time (min)
0
20
40
60
80
100
120
140
160
180Extent of hypoglycemia
(AUC <4.0 mM)
*
0
50
100
150
200
250
300Extent of hypoglycemia
(AUC <4.0 mM)
ExptD1 ExptD2: Ctrl
ExptD1 ExptD2: SSTR2a
† P<0.02
168
Figure 5-8. Plasma glucagon during ExptD1 (black) and ExptD2 (white) in A) saline-SSTR2a treatment (solid bars); B) saline-SSTR2a treatment with rats that did not experience hypoglycemia omitted; and C) saline-saline control groups (hashed bars). Data are represented as mean ± SEM. *P<0.04 vs. ExptD1.
A.
B.
C.
-5
0
5
10
15
20
25
30
35
40
-60 0 20 40 60 80 100 120 140 160 180 200 220 240
Time (min)
∆ P
lasm
a g
luca
go
n (
pg
/mL
)
0
1000
2000
3000
4000
5000
6000 Glucagon AUC
*
-5
0
5
10
15
20
25
30
35
40
45
-60 0 20 40 60 80 100 120 140 160 180 200 220 240
Time (min)
∆ P
lasm
a g
luca
go
n (
pg
/mL
)
0
1000
2000
3000
4000
5000
6000
7000 Glucagon AUCP=0.05
-10
-5
0
5
10
15
20
25
30
35
40
-60 0 20 40 60 80 100 120 140 160 180 200 220 240
Time (min)
∆ P
lasm
a g
luca
go
n (
pg
/mL
)
0
1000
2000
3000
4000
5000Glucagon AUC
ExptD1 ExptD2: SSTR2a
ExptD1 ExptD2: Ctrl
169
Figure 5-9. Plasma epinephrine during ExptD1 (black) and ExptD2 (white) in A) saline-SSTR2a treatment (solid bars); B) saline-SSTR2a treatment with rats that did not experience hypoglycemia omitted; and C) saline-saline control groups (hashed bars). Data are represented as mean ± SEM. * P<0.03 vs. ExptD1.
A.
B.
C.
0
100
200
300
400
500
600
700
800
900
-60 0 20 40 60 80 100 120 140 160 180 200 220 240Time (min)
∆ P
lasm
a ep
inep
hri
ne
(pg
/mL
)
0
50000
100000
150000Epinephrine AUC
*
0
100
200
300
400
500
600
700
800
900
-60 0 20 40 60 80 100 120 140 160 180 200 220 240Time (min)
∆ P
lasm
a ep
inep
hri
ne
(pg
/mL
)
0
50000
100000
150000Epinephrine AUC
0
200
400
600
800
1000
1200
1400
1600
1800
2000
-60 0 20 40 60 80 100 120 140 160 180 200 220 240Time (min)
∆ P
lasm
a ep
inep
hri
ne
(pg
/mL
)
0
50000
100000
150000
200000
250000
300000Epinephrine AUC
*
ExptD1 ExptD2: Ctrl
ExptD1 ExptD2: SSTR2a
170
Figure 5-10. Plasma corticosterone during ExptD1 (black) and ExptD2 (white) in A) saline-SSTR2a treatment (solid bars); B) saline-SSTR2a treatment with rats that did not experience hypoglycemia omitted; and C) saline-saline control groups (hashed bars). Data are represented as mean ± SEM. * P<0.04 vs. ExptD1
A.
B.
C.
0
50
100
150
200
250
300
350
400
-60 0 20 40 60 80 100 120 140 160 180 200 220 240
Time (min)
∆ P
lasm
a C
ort
ico
ster
on
e (n
g/m
L)
0
10000
20000
30000
40000
50000
60000
Corticosterone AUC
0
50
100
150
200
250
300
350
400
-60 0 20 40 60 80 100 120 140 160 180 200 220 240Time (min)
∆ P
lasm
a C
ort
ico
ster
on
e (n
g/m
L)
0
10000
20000
30000
40000
50000
60000
70000Corticosterone AUC
P=0.05
-100
0
100
200
300
400
500
-60 0 20 40 60 80 100 120 140 160 180 200 220 240
Time (min)
∆ P
lasm
a C
ort
ico
ster
on
e (n
g/m
L)
0
10000
20000
30000
40000
50000
60000
70000
80000Corticosterone AUC
*
ExptD1 ExptD2: Ctrl
ExptD1 ExptD2: SSTR2a
171
Figure 5-11. Plasma norepinephrine during ExptD1 (black) and ExptD2 (white) in A) saline-SSTR2a treatment (solid bars); B) saline-SSTR2a treatment with rats that did not experience hypoglycemia omitted; and C) saline-saline control groups (hashed bars). Data are represented as mean ± SEM.
A.
B.
C.
0
100
200
300
400
500
600
-60 0 20 40 60 80 100 120 140 160 180 200 220 240
Time (min)∆ P
lasm
a n
ore
pin
eph
rin
e(p
g/m
L)
0
10000
20000
30000
40000
50000
60000
70000
80000
Norepinephrine AUC
0
100
200
300
400
500
600
700
800
-60 0 20 40 60 80 100 120 140 160 180 200 220 240
Time (min)∆ P
lasm
a n
ore
pin
eph
rin
e(p
g/m
L)
0
20000
40000
60000
80000
100000
120000
Norepinephrine AUC
-200
0
200
400
600
800
1000
1200
-60 0 20 40 60 80 100 120 140 160 180 200 220 240
Time (min)∆ P
lasm
a n
ore
pin
eph
rin
e(p
g/m
L)
0
20000
40000
60000
80000
100000
120000
140000
160000
180000Norepinephrine AUC ExptD1 ExptD2: Ctrl
ExptD1 ExptD2: SSTR2a
172
Figure 5-12. Comparison of peak incremental hormone responses to acute hypoglycemia (Study 1; solid bars) and recurrent hypoglycemia (RH) (Study 2; speckled bars) in control (Ctrl; black) and SSTR2 antagonist-treatment (SSTR2a; white) groups. A) Plasma glucagon; B) plasma epinephrine; C) plasma corticosterone. Data are represented as mean ± SEM. *P<0.003 vs. Acute-Ctrl. †P<0.05 vs. RH-Ctrl. ‡P<0.03 vs. Acute-Ctrl.
A.
B.
C.
Acute-Ctrl Acute-SSTR2a RH-Ctrl RH-SSTR2a
0
50
100
150
200
250
300
Pea
k in
crem
enta
l g
luca
go
n (
pg
/mL
)
*
†
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
Pea
k in
crem
enta
l ep
inep
hri
ne
(pg
/mL
)
0
50
100
150
200
250
300
350
400
450
500
Pea
k in
crem
enta
l co
rtic
ost
ero
ne
(ng
/mL
)
‡
173
Table 5-1. Metabolic parameters for rats that underwent recurrent hypoglycemia treatment. Fed blood glucose, body weight, and food intake were measured daily, and the table shows the mean ± SEM of values averaged over the last week before commencement of recurrent hypoglycemia treatment in rats that would later be divided into SSTR2a-treatment and control groups for hypoglycemia experiments. Daily blood glucose measurements were obtained using a glucometer.
Treatment group
(saline-SSTR2a)
Control group
(saline-saline)
fed blood glucose (mM) 25.3 ± 0.9 23.6 ± 2.1
body weight (g) 365 ± 6 372 ± 11
food intake (g) 39 ± 1 37 ± 2
174
Table 5-2. Body weight and amount of insulin administered via iv bolus and iv infusion, and total insulin administered in both groups on both days. Rats received a 10 U/kg iv bolus of insulin after basal samples were obtained at time = 0 min. Subsequently, insulin infusion (50 mU/kg/min) was started and stopped at the experimenter's discretion when hypoglycemia was neared. This volume of insulin infusion was recorded on ExptD1 and repeated on ExptD2. Data are represented as mean ± SEM.
Treatment group
(saline-SSTR2a)
Control group
(saline-saline)
ExptD1 ExptD2 ExptD1 ExptD2
body weight (g) 341 ± 11 340 ± 10 340 ± 11 338 ± 10
initial glycemia (mM) 25.5 ± 1.7 24.1 ± 1.9 20.9 ± 4.0 21.5 ± 4.4
insulin via iv bolus (U) 3.24 ± 0.27 3.26 ± 0.29 3.12 ± 0.63 3.09 ± 0.64
insulin via iv infusion (U) 0.88 ± 0.11 0.90 ± 0.11 0.89 ± 0.30 0.89 ± 0.30
total insulin administered (U) 4.12 ± 0.31 4.16 ± 0.34 4.01 ± 0.86 3.98 ± 0.85
175
Table 5-3. Basal plasma hormone levels on Experimental Day 1 (ExptD1) and Experimental Day 2 (ExptD2) in rats that underwent SSTR2a-treated and control hypoglycemia experiments. These represent basal hormone levels after 5 episodes of recurrent hypoglycemia and a partial overnight-fast. Data are represented as mean ± SEM. * P<0.05 vs. ExptD1
Treatment group (saline-SSTR2a) Control group (saline-saline)
ExptD1 ExptD2 ExptD1 ExptD2
glucagon (pg/mL) 58 ± 5 60 ± 6 55 ± 5 53 ± 5
epinephrine (pg/mL) 106 ± 17 102 ± 21 126 ± 33 129 ± 29
corticosterone (ng/mL) 110 ± 20 54 ± 12 * 110 ± 37 132 ± 28
norepinephrine (pg/mL) 326 ± 77 300 ± 77 401 ± 52 378 ± 72
insulin (ng/mL) 0.98 ± 0.2 0.98 ± 0.1 1.00 ± 0.2 0.97 ± 0.2
176
Table 5-4. Plasma insulin levels (ng/mL) during ExptD1 and ExptD2 in saline-SSTR2a treatment and saline-saline control groups. Insulin was administered as an i.v. bolus followed by i.v. infusion after samples were obtained at the 0 time point. Infusions were stopped at the experimenter’s discretion (usually between 30-120 min) but kept consistent for the same rat on both experimental days. Data are represented as mean ± SEM.
Plasma insulin (ng/mL)
-60 0 60 180 240
saline-SSTR2a
ExptD1 0.98 ± 0.15 0.90 ± 0.17 96.71 ± 15.94 1.13 ± 0.09 0.70 ± 0.05
ExptD2 0.98 ± 0.15 1.03 ± 0.17 75.71 ± 12.34 1.03 ± 0.07 0.75 ± 0.08
saline-saline
ExptD1 1.00 ± 0.22 1.02 ± 0.22 89.27 ± 32.92 1.43 ± 0.55 0.63 ± 0.14
ExptD2 0.97 ± 0.17 0.93 ± 0.21 71.93 ± 18.73 1.32 ± 0.46 0.60 ± 0.09
177
177
Chapter 6 Study Summaries and General Discussion
6 Study Summaries and Limitations
Hypoglycemia remains an obstacle and limitation to stringent glycemic control in diabetes
(4;161). The result of -cell failure in type 1 diabetes and advanced type 2 diabetes causes
the loss of the first two key defenses against a fall in blood glucose levels: the decrement of
insulin and the corresponding -cell response to release glucagon (172). Since glucagon
counterregulation normally plays the primary role in promoting glycemic recovery from
hypoglycemia (510), such that even increases of epinephrine cannot fully compensate for
the absence of glucagon on hepatic glucose production during hypoglycemia (62), it is of
great clinical relevance to discover methods to improve and restore glucagon
counterregulation to hypoglycemia in diabetes. Two main theories underlay the glucagon
deficiency in the present thesis: that in diabetes, the -cell becomes more sensitive to the
inhibitory effects of exogenous insulin, and that excessive somatostatin further inhibits the
ability of the diabetic -cell to release glucagon via SSTR2 agonism during hypoglycemia.
Because somatostatin also has been shown to suppress stress-induced epinephrine and
cortisol/corticosterone release (169;528;628;652;654;656), and because SSTR2 are
present in tissues that store or regulate epinephrine and cortisol/corticosterone secretion
(373;378;379;390;397-400), we also hypothesized that SSTR2 blockade would enhance the
release of these counterregulatory hormones to hypoglycemia. The main objectives of this
thesis were: 1) to evaluate a means to improve the counterregulatory response to
hypoglycemia in a diabetic animal model by use of a SSTR2 antagonist, and 2) to assess if
178
counterregulatory hormone improvements could be extended and have a biological effect to
ameliorate hypoglycemia after exposure to recurrent hypoglycemia.
6.1 Summary of Study 1
Data from the present study demonstrate that diabetic rats had markedly attenuated
glucagon and corticosterone responses to hypoglycemia as compared to non-diabetic rats,
which is in agreement with our previous studies (205). We demonstrate that glucagon and
corticosterone counterregulatory hormone responses to hypoglycemia can be restored in
diabetic rats with specific antagonism of the SSTR2 using both high (10 U/kg) and low (5
U/kg) doses of insulin to induce hypoglycemia. We attribute these defects in part to
elevated pancreatic and circulating somatostatin levels which were increased in diabetic rats
following hypoglycemia. SSTR2 antagonist given to non-diabetic rats, in which somatostatin
levels were the same as non-diabetic controls, did not increase glucagon or corticosterone
responses, which further provides support for the contribution of augmented somatostatin.
During basal conditions in the absence of insulin, this SSTR2 antagonist does not elicit
hyperglycemia or substantial elevations in counterregulatory hormones, which is important
if this antagonist is potentially considered for therapeutic use in humans. Under conditions
of lower dose insulin injection, SSTR2 antagonism reduced the glucose requirement during
hypoglycemic clamp, which is consistent with improved glucagon and corticosterone
counterregulation and is indicative of a lower risk of hypoglycemia. In these 3-week STZ-
diabetic rats, epinephrine and norepinephrine counterregulation to hypoglycemia induced
with both high and low doses of insulin were similar in both non-diabetic and diabetic rats;
thus, these rats did not demonstrate a defect in catecholamine responses to hypoglycemia.
Epinephrine, norepinephrine, and growth hormone levels were not affected by SSTR2
179
administration. Despite improvements of glucagon and corticosterone to hypoglycemia,
expression of gluconeogenic enzymes PEPCK1 and G6Pase were unaltered.
6.2 Summary of Study 2
In light of the evidence from Study 1 that SSTR2 antagonism could normalize glucagon and
corticosterone response to hypoglycemia, we designed a set of experiments to determine
whether such improvements in hormone responses could have a biological effect and
improve recovery from hypoglycemia in a model with established counterregulatory defects:
recurrent hypoglycemia. In these experiments, we first subjected diabetic rats to 5
episodes of hypoglycemia. Subsequently, we compared the responses of each rat over two
experimental days. Much care was taken to control for similar baseline metabolic
parameters, such as initial glycemia, body weight, and overnight food intake, so that
meaningful and relevant comparisons between the two experimental days could be made.
On the first experimental day (ExptD1), we determined the minimum amount of insulin
necessary to induce hypoglycemia at 3.0 mM in a given rat, which was necessary since
diabetic rats have varying insulin sensitivities. On the second experimental day (ExptD2),
we used to the same dose of insulin in the same rat and compared its glycemic and
hormone responses to ExptD1. We included two groups in this study: a treatment group
which received SSTR2 antagonist on ExptD2, and a control group which did not receive
SSTR2 antagonist on ExptD2. By comparison with Study 1, we demonstrated that recurrent
hypoglycemia further reduced the attenuated glucagon response, and markedly reduced the
epinephrine response, to subsequent hypoglycemia in diabetic rats. Our most striking
finding was that hypoglycemia can be ameliorated by SSTR2 antagonism in diabetic rats,
despite the marked attenuation of glucagon and epinephrine caused by recurrent
180
hypoglycemia. By blocking the actions of somatostatin on SSTR2, the depth and duration of
hypoglycemia were significantly lessened, and a quicker recovery to euglycemia ensued in
animals, despite prior exposure to repeated hypoglycemia. This amelioration of
hypoglycemia may be due, at least in part, to enhanced glucagon release and to
improvements in epinephrine and corticosterone counterregulation which are observed in
the SSTR2 antagonist treatment group. Norepinephrine levels were not affected by
recurrent hypoglycemia or by SSTR2 antagonist treatment.
6.3 General discussion
Our results suggest an important role for increased pancreatic, and possibly circulating,
somatostatin in defective glucagon, corticosterone, and/or epinephrine counterregulation in
diabetes but do not exclude other mechanisms of impairment. From our present findings, it
is hypothesized that selective SSTR2 blockade at the levels of the brain, pituitary, pancreas,
and adrenal gland during hypoglycemia may help to reduce the severity, duration, or onset
of hypoglycemia by enhancing the release of counterregulatory hormones such as glucagon,
corticosterone, and epinephrine.
6.3.1 Limitations of the present study
The main limitation is that a precise mechanism of action of the SSTR2 antagonist could not
be delineated from the work of this thesis. From the data presented in this thesis, we can
suggest that SSTR2 antagonism plays a role in restoring glucagon and corticosterone
counterregulation to acute hypoglycemia, and has some effect to improve glucagon,
epinephrine, and corticosterone responses following recurrent hypoglycemia, but we have
yet to delineate the precise mechanism by which this occurs. These impairments in
181
hormone responses can occur at the tissue level (pancreatic islets for glucagon, adrenal
cortex for corticosterone, or adrenal medulla for epinephrine), via the peripheral nerves, or
at the level of the brain or pituitary. We suggest that increased pancreatic somatostatin,
and potentially increased circulating somatostatin, can affect local and central control of
counterregulatory hormone release. With respect to deficient glucagon counterregulation,
we hypothesize that despite the fact that somatostatin may not be excessive in certain
models of diabetes, antagonism of somatostatin’s suppressive actions may still be beneficial
since diabetic -cells are already more sensitive to the inhibition of insulin. With respect to
impaired corticosterone counterregulation, we hypothesize that an additional alleviation of
suppression of corticosterone release may improve this response to hypoglycemia. Our
laboratory has previously demonstrated that in diabetes, corticosterone release to
hypoglycemia is attenuated by suppression on the HPA axis (202;220;641;673). Although
we did not delineate a role for somatostatin on this inhibition, we presently hypothesize that
somatostatin may inhibit activation of the HPA axis since somatostatin is known to inhibit
release of neurotransmitters and hormones involved in the HPA response, namely
norepinephrine, CRH, and ACTH. However, the limitation remains that studies to assess the
direct effect of SSTR2 blockade in the hypothalamic PVN (which could be achieved by
stereotaxic microinjection of the SSTR2 antagonist) or in corticotropes of the anterior
pituitary were not performed. Measurement of plasma ACTH could also provide an
indication as to whether inhibition of somatostatin involved an effect at the level of the
anterior pituitary. The anterior pituitary is not protected by the blood-brain-barrier, and
peripheral administration of the SSTR2 antagonist could theoretically bind with SSTR2 in the
anterior pituitary. Thus, if the SSTR2-mediated improvements in corticosterone
counterregulation are accompanied by increased ACTH levels, this would indicate a direct
182
effect of disinhibition at the level of the corticotrope or suggest an involvement of a central
mechanism.
In addition, another limitation is that we did not measure glucose turnover in these studies.
Precise and accurate measurements of glucose turnover could have helped us to determine
whether the enhancement of counterregulatory hormones and improvement in
hypoglycemic recovery associated with SSTR2 blockade had an effect on glucose
production, glucose utilization, or both. Further investigation is therefore necessary to
elucidate the mechanism by which hormone counterregulation is improved and euglycemia
is restored via inhibiting the action of somatostatin via SSTR2.
6.3.2 Hypothesizing a mechanism of action: CNS effects?
Our initial hypothesis was that the concomitant elevation of pancreatic somatostatin and
heightened sensitivity of diabetic -cells to exogenous insulin contributed to the impairment
of the glucagon response to hypoglycemia in diabetes. This, of course, cannot explain the
improvements of corticosterone and epinephrine counterregulation with SSTR2 disinhibition.
In the Discussions of Study 1 and Study 2, several potential mechanisms were addressed
that may underlie SSTR2-mediated improvements to glucose counterregulation. In addition
to these, this section will briefly propose possible roles of SSTR2 antagonism within the
brain that could regulate counterregulatory hormone responses.
There is vast, compelling evidence dating back to early studies of Claude Bernard in the
19th century in which he demonstrated that punctures of the fourth cerebral ventricle
rendered dogs glycosuric (674). Recent reviews (13;14;193) on brain glucosensing and
glucose counterregulation also irrevocably demonstrate the importance of the central
183
nervous system on regulating glucose homeostasis. Initiation of counterregulatory hormone
responses in the central nervous system involves: (i) afferents that detect changes in
glucose levels in the brain and/or periphery; (ii) integration and relay of signals within
specific brain regions; and (iii) efferent pathways from integration centres in the brain that
project as autonomic signals to the body to maintain glucose homeostasis (13;14;193).
Interestingly, many of these brain regions that comprise the neural networks that regulate
hypoglycemic counterregulation also are rich in somatostatin and its receptors. This is not
surprising since within the brain, somatostatin serves as a neurotransmitter. Yet it allows
us to speculate: could alterations in brain somatostatin action as a result of diabetes and/or
recurrent hypoglycemia contribute to the impairments of hypoglycemic counterregulation?
In addition to mechanisms within the pancreas responsible for glucagon release in response
to hypoglycemia (76), glucagon counterregulation is also regulated centrally. Buijs et al.
used a pseudorabies virus as a retrograde transsynaptic tracer to elucidate the neuronal
parasympathetic and sympathetic efferent pathways that control pancreatic hormone
secretion (99). Buijs et al. identified a sympathetic pathways involving (i) neurons of the
ventromedial hypothalamus (VMH), arcuate nucleus (ARC), central amygdala, bed nucleus
of the stria terminalis (BNST), suprachiasmatic nucleus (SCN), and medial preoptic area
(MPO) projecting to the paraventricular nucleus (PVN) and hypothalamic zona incerta (ZI),
which in conjunction with a projection from the lateral hypothalamus (LHA) project to the
intermediolateral column (IML) of the spinal cord; and (ii) neurons of the nucleus of the
solitary tract (NTS) projecting to the locus coeruleus (LC) of the brain stem, which
subsequently joins a projection from the prefrontal cortex, or from the NTS to the
rostroventrolateral medulla (RVLM) to project to the IML. Both of these neuronal pathways
subsequently projecting from the IML of the spinal cord provides the sympathetic efferent to
184
the pancreas to stimulate glucagon release (99). In addition, in a recent review, Watts and
Donovan summarized the interactions between networks involving the periphery, hindbrain,
and hypothalamic components involved with hypoglycemic counterregulation (14). In brief,
glucose sensors are located in the portal/mesenteric vein (PMV), hindbrain, and
hypothalamic nuclei (LHA, ARC, and VMH). These signals are then integrated in networks
involving the hindbrain and hypothalamus. The hindbrain and hypothalamic integrators
then activate autonomic efferent neurons to stimulate glucagon and catecholamine release,
or via a neuroendocrine route the PVN stimulates glucocorticoid release (14). In his review,
Cryer has also indicated key brain regions that participate in the mechanisms of
hypoglycemia-associated autonomic failure, which include the prefrontal cortex, the dorsal
midline thalamus, hypothalamus, hippocampus, brain stem, and amygdala (4).
These recent reviews identify key brain areas involved with hypoglycemic counterregulation.
Within the brain, somatostatin-immunoreactivity is found in many neurons. As reviewed by
Viollet et al., somatostatinergic neurons are highly detected in the mediobasal
hypothalamus, median eminence, amygdala, hippocampus, cerebral cortex, and brainstem
(292). In addition to short projections that act within a local area, somatostatinergic
neurons can also project to other target areas, and several examples include: amygdala
parabrachial nucleus (PBN), NTS, and dorsal motor nucleus of the vagus (DMNV);
periventricular nucleus median eminence, ARC, habenula, and LC; PBN thalamus; and
NTS PVN, PBN. SSTR2 expression has been reported in hypothalamic ARC, PVN, and
VMH (420;424;426), medial habenular nucleus of the thalamus (420), cerebral cortex,
hippocampus, LC, basolateral amygdala (BLA), NTS, PBN, and spinal cord (419;420;425).
In light of the fact that several SSTR2-expressing brain regions endogenously are targeted
by somatostatinergic neurons, and that these regions also play a role in glucose-detection
185
and/or regulation of the counterregulatory responses, it would be of interest to evaluate the
effect of specific SSTR2 antagonism on glucose-regulatory neuronal populations. This could
be achieved by inhibiting these receptors during hypoglycemia by directly administering the
SSTR2 antagonist to specific brain regions or by silencing the SSTR2 gene at specific brain
nuclei via viral gene delivery. Also, it would be interesting to determine whether these
glucose-regulatory neurons are affected by diabetes and/or hypoglycemia. This could
provide new insights for the role of somatostatin in diabetic hypoglycemic counterregulation.
6.3.2.1 Does peripherally administered SSTR2 antagonist enter the brain?
We are not aware at the present time of any reports whether our SSTR2 antagonist can
enter the brain when administered peripherally via an intravenous route. CTAP, a cyclic
octapeptide with the structure D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 is a -opiod
receptor antagonist that has been reported to cross the blood-brain-barrier (562).
However, the majority of literature, however, suggests that a compound like our cyclized
octapeptide antagonist (see Figure 1-2 for structure) would likely not cross the blood-brain-
barrier (675). Octreotide, an octapeptide somatostatin analogue, is unlikely to cross the
blood-brain-barrier in any significant amounts when peripherally administered (676).
Furthermore, SSTR3 octapeptide antagonists cyclized via a disulfide bridge have been
reported to be very poor at crossing the blood-brain-barrier (677). In view of these reports,
our peripherally infused SSTR2 antagonist may not have entered the brain to have any
central effects. Further investigation is needed to more precisely determine whether this
compound could enter the brain. The MDCK-MDR1 cell line is an established in vitro model
of the blood-brain-barrier and can be used to test the permeation properties of peptides
(678).
186
6.3.3 Brief evaluation of tachyphylactic effects of SSTR2 antagonism
It is known that G-protein coupled receptors (GPCRs), including SSTRs, share a common
property whereby they regulate their own responsiveness to continued agonist exposure
(679). For example, GPCRs become desensitized after acute treatment to agonists. Three
main steps are responsible for this: 1) uncoupling of the GPCR from G proteins; 2) receptor
internalization via the phosphorylation of the C-terminal tail and intracellular loops by
second-messenger-activation or GPCR-kinases, which has been demonstrated in rat
pituitary and islet tumour cells; and 3) receptor downregulation. SSTR2, for example
couples with adenylyl cyclase via inhibitory G proteins when activated by somatostatin and
undergoes endocytosis via clathrin-coated pits (680). However, GPCRs also become
upregulated after prolonged agonist exposure (679). This is associated with: 1) the active
process of ligand-induced receptor recruitment from a preexisting cytoplasmic pool; 2) does
not require new protein synthesis; and 3) depends on molecular signals on the C-terminal
tail. This has also been observed in receptors for somatostatin (681). These findings are
relevant for agonist exposure. However, it remains to be seen if the same applies for
antagonist exposure. For our SSTR2 antagonist used in this study, in which the peptide
ligand binds to the SSTR2 without inducing the same intracellular responses as somatostatin
would, it is not known how prolonged exposure would affect receptor expression on target
tissues, such as pancreatic -cells, the brain, or adrenal glands. There is no consensus in
literature as to whether antagonists initiate internalization of GPCRs. Peptide receptor
antagonists for cholecystokinin (682) and neuropeptide Y (683), for example, have been
reported to stimulate receptor internalization. One study demonstrated that SSTR agonists,
but not antagonists internalized SSTR2 (680). Another study likewise demonstrated that
antagonists for SSTR2 or SSTR3 did not affect internalization in human embryonic kidney
187
cells (684), but studies for our specific antagonist and its result in -cells are still required
to elucidate the long-term efficacy of this peptide.
6.3.4 Potential side effects of SSTR2 antagonism
Since receptors for somatostatin are expressed ubiquitously throughout the body, it is
important to target the particular tissue – and specifically the cell type – in which a
pharmacological compound is to take effect. In particular, we initially sought to target
SSTR2 because of its mediation of somatostatin’s inhibitory effect on -cell glucagon
release. Using an antagonist with high selectivity, binding affinity, and biological activity is
of key importance, and the peptide antagonist that was used in this study offered these
characteristics (509). However, although most tissues tend to show preferential expression
for particular SSTR subtypes, SSTR2 is still expressed in high levels in several areas. These
areas include the stomach, the cerebral cortex, pancreatic -cell, and adrenal medulla. In
the pituitary, SSTR5 has the highest level of expression, followed by SSTR2. The high
expression of SSTR2 on -cells and the adrenal medulla is of course favourable for our
studies in glucagon and epinephrine counterregulation. These other tissues/cell types are
mentioned here to assess potential side effects of SSTR2 antagonist administration during
our experiments.
Although pancreatic -cells in rodents exclusively express SSTR5 and not SSTR2 (387), high
levels of SSTR2 antagonist without sufficient competition by native somatostatin or with
saturation of SSTR2 on -cells may lead to non-specific binding with SSTR5. This would
lead to enhanced insulin secretion from functional -cells, including those in non-diabetic
subjects or possibly in non-advanced type 2 diabetes. This may explain why diminished
glucagon responses to hypoglycemia were observed in our studies of SSTR2 antagonist in
non-diabetic rats. This would not be a concern, however, in type 1 diabetes or likely not in
188
STZ-diabetes where the majority of -cells are destroyed. Furthermore, although human -
cells predominantly express SSTR1 and SSTR5, SSTR2 is expressed in up to 25% of human
-cells, which may suggest a greater potential side effect of SSTR2 antagonist in promoting
insulin release. Thus, patients with type 2 diabetes who still have insulin secretory capacity
should avoid SSTR2 antagonist as a therapy to prevent hypoglycemia.
In the stomach, SSTR2 has been reported as the main subtype through which somatostatin
inhibits gastrin-stimulated gastric acid secretion both through studies using SSTR2 peptide
analogs (685) and SSTR2 knockout mice (686). A study using the same SSTR2 antagonist
in this present work demonstrated in non-diabetic rats that SSTR2 antagonism blocked the
inhibitory effect of somatostatin on gastrin-stimulated release. At a dose which we used in
our pilot studies (1500 nmol/kg/h), the SSTR2 antagonist likewise inhibited the suppressive
effect of GLP-1 on gastrin-stimulated gastric acid output (508). However, a recent study
reported normal circulating levels of gastric and unaltered gastric acid output in SSTR2
knockout mice (687), which suggests that blocking the effects mediated via SSTR2 may not
necessarily affect gastric function. However, it remains possible that in our studies,
stimulated-gastric acid output could have been increased in our rats. Other gut effects
mediated by somatostatin action via SSTR2, such as suppression of intestinal muscosal cell
proliferation and colonic motility, may also be inhibited by SSTR2 antagonism. Although
glucose absorption was shown to be inhibited by somatostatin (688), the receptor subtype
by which this action is mediated was not determined.
In the brain, somatostatin functions as a neurotransmitter contributing to cognitive,
locomotor, sensory, and autonomic activities (271). SSTR1 is considered by many reviews
to be more vastly distributed and highly expressed than other receptor subtypes, and is
often found in higher levels than SSTR2 in areas such as the cerebral cortex and
189
hippocampus where SSTR2 is considered to be highly expressed (271;378;420).
Somatostatin was initially known for its effect to suppress growth hormone secretion (267).
Somatostatin produced in the periventricular nucleus (where hypothalamic somatostatin is
greatest (271)) and released from the median eminence directly inhibits growth hormone
release from somatotrophes of the anterior pituitary via SSTR2 and SSTR5 (292;431).
SSTR5 is the main subtype expressed throughout the pituitary, followed by SSTR2 (380).
There is also evidence that SSTR1 is also implicated in the control of growth hormone
release (433). Whereas SSTR2 antagonist disinhibition to stimulate growth hormone
secretion would be favourable during hypoglycemia, this was not observed in our present
findings. However, it remains to be determined whether prolonged treatment with SSTR2
antagonist, or blood sampling at more frequent intervals, could stimulate growth hormone
release. Presently, we have no direct data to report whether SSTR2 antagonist stimulated
anterior pituitary secretion of adrenocorticotrophic hormone (ACTH), but our improved
corticosterone data with SSTR2 antagonist treatment could support this. Other studies have
demonstrated an inhibitory effect of somatostatin on ACTH release (294) and the presence
of SSTR2 on ACTH cells in the anterior pituitary (561). Other pituitary hormones, such as
thyroid stimulating hormone and adrenocorticotrophic hormone, may also be altered by
SSTR2 antagonism (290).
190
190
Chapter 7 Future Directions
7 Future Directions
7.1 Delineating a mechanism of action for SSTR2 antagonism
To address the main shortcoming of this project, which is a lack of mechanistic explanation
for the SSTR2-antagonism mediated improvements in glucose counterregulation, an
important future study would be to delineate a mechanism by which SSTR2 blockade acts
to: (i) improve hormone counterregulation to acute hypoglycemia; (ii) more effectively
restore low blood glucose back to euglycemia. For the latter, tracer experiments using
traditional hyperinsulinemic-hypoglycemic clamp techniques can provide glucose turnover
data which may provide insights as to whether somatostatin affects glucose production or
uptake during hypoglycemia. This is important since we have previously shown that peak
glucose production was decreased during hypoglycemia in diabetic rats (205). An
improvement in net glucose production is essential since the overall purpose in improving
counterregulation is to restore plasma glucose levels in diabetic patients suffering from
hypoglycemia. However, despite the unspecified etiology of the effect, a significant
improvement in glycemic recovery was demonstrated by SSTR2 inhibition, and it is often
the overall effect of a pharmacological compound that garners the interest and attention of
patients.
To determine whether normalized glucagon and corticosterone counterregulation was
mediated via a central nervous system effect, SSTR2 antagonist can be
191
intracerebroventricularly administrated during hypoglycemia in diabetic rats. Finally,
evaluating the counterregulatory hormone responses to hypoglycemia in genetic animal
models with tissue-specific SSTR2 knockout can also help to elucidate mechanisms of
somatostatin action.
7.2 Testing the efficacy of SSTR2 antagonism in other diabetic models
In light of the fact that certain diabetic rodent models, such as the BB rat, which do not
have increased pancreatic somatostatin, but do have elevated circulating somatostatin
(537;689) do show impairments in the counterregulatory hormone responses to insulin-
induced hypoglycemia (263;542;543), it is worthwhile to investigate the efficacy of SSTR2
antagonism in this model of experimental diabetes to determine the contribution of
excessive pancreatic somatostatin on glucagon counterregulation in diabetes. It is unknown
why BB rats do not have increased pancreatic somatostatin, unlike other experimental rat
models of diabetes. An earlier hypothesis suggested that BB rats had “more severe islet
destruction” than STZ-diabetic rats (537). In addition, it has been demonstrated that
insulin treatment of STZ-diabetic rats can normalize, at least in part, pancreatic and
circulating somatostatin levels, yet insulin-treated diabetic animals do not have fully
normalized hormone counterregulation to hypoglycemia (174;202;641). Thus, performing
similar hypoglycemia studies with and without SSTR2 antagonist in insulin-treated rats will
allow us to determine whether improvements in diabetic hyperglycemia and -cell
sensitivity may alter the effectiveness of SSTR2 antagonism during hypoglycemia. Insulin-
treated diabetic subjects may also be less insulin resistant, which would allow us to use less
insulin to induce hypoglycemia. This is important since excessively high insulin levels alter
192
counterregulation and glucose production. Insulin-treated diabetes is more clinically
relevant since type 1 diabetic humans are insulin treated.
7.3 Effect of SSTR2 antagonism to non-hypoglycemia stimuli
It is presently unknown whether SSTR2 antagonism will enhance glucagon release in
response to other stimuli known to trigger glucagon release, such as an amino acid-rich
meal or exercise. Hypoglycemia and amino acids stimulate glucagon secretion by two
different processes, the latter of which only can be counteracted by amylin (690). Exercise
and hypoglycemia similarly stimulate glucagon via activation of the autonomic nervous
system and neuroendocrine response (149). Unlike hypoglycemia, the glucagon response
to amino-acid rich meals (691-694) and exercise (149;695-697) are preserved, or even
exaggerated, in diabetes. Thus, studies designed to evaluate the effects of SSTR2
antagonist on other glucagon secretagogues will be of interest, and it may help to
determine if this effect to enhance counterregulatory hormones is hypoglycemia-specific.
Plasma glucagon could be measured in response to: i) a high protein meal, and ii) exercise
with and without administration of the antagonist, in the presence or absence of elevated
somatostatin, and in non-diabetic or diabetic subjects, to determine the stimulus-specificity
of SSTR2 inhibition and the condition(s) in which it applies.
7.4 Interaction between glycemia, insulin, and somatostatin antagonism on glucagon release
Using perfused pancreata or isolated islets, the direct effect of the SSTR2 antagonist on
glucagon release can be assessed with carefully controlled interactions between glycemia,
193
insulin, and somatostatin antagonism on glucagon release. These ex vivo or in vitro
experiments have the benefit of clarifying the role of somatostatin antagonism in the
pancreas more directly since in vivo experiments also involve many other hormonal and
metabolic changes. Efendic et al. has shown previously that this SSTR2 antagonist can
increase arginine-induced glucagon release in perfused pancreata at both 5.5 and 3.3 mM
glucose concentrations in non-diabetic rats (392). However, those experiments did not
answer the main question of whether SSTR2 antagonist can, in presence of insulin which
inhibits -cells, increase glucagon release in diabetic islets, which are often deprived of the
tonic effect of insulin. These experiments can also assess the contribution of increased -
cell sensitivity to insulin as a result of a chronic lack of the presence of insulin on glucagon
secretion to insulin-induced hypoglycemia. These experiments could also show whether the
local effect on glucagon release is as marked as when SSTR2 antagonist is given
peripherally.
194
194
Chapter 8 Conclusions
8 Conclusions
8.1 Importance of contributions to current body of knowledge
Our laboratory first suggested 20 years ago that increased somatostatin in diabetes may
contribute to the impaired glucagon response to hypoglycemia in diabetes (90). We
hypothesized that the combined suppressive effects of excessive pancreatic somatostatin
and increased sensitivity of diabetic -cells to exogenously administered insulin contributes
to defective glucagon counterregulation. The work in this thesis demonstrates for the first
time that antagonizing the actions of somatostatin acting on SSTR2 can fully abolish this
glucagon defect in diabetes during acute hypoglycemia. Thus, disinhibition of the diabetic
-cell from somatostatin, one of its key suppressing influences, can improve its secretory
capacity in response to hypoglycemic stimulation. We also demonstrate that the attenuated
corticosterone response in diabetic rats was significantly improved with SSTR2 blockade, an
effect which at the present time can only be speculated to due to alleviation of
somatostatin’s inhibitory release of corticosterone, or other regulators of its release directly
at the adrenal cortex or indirectly mediated in the brain or pituitary in diabetes. These
improvements of glucagon and corticosterone were observed to be diabetes-specific since
SSTR2 antagonism in non-diabetic rats during hypoglycemia did not increase these hormone
responses. Importantly, we also demonstrate that during basal conditions in the absence of
insulin that SSTR2 antagonist treatment neither causes marked sustained elevations of
counterregulatory hormones nor elicits undesired hyperglycemia in diabetic rats. In
195
addition, we provide novel evidence that SSTR2 antagonism can promote the recovery of
hypoglycemia, presumably in part by improving glucagon, and preserving epinephrine and
corticosterone, hormone responses in diabetic rats exposed to repeated episodes of
hypoglycemia. This exciting and novel finding reveals that the depth and duration of
hypoglycemia can be significantly be reduced and even prevented, even in diabetic subjects
with marked counterregulatory defects. Taken together, these findings implicate an
important role for increased pancreatic, and possibly circulating, somatostatin in defective
hypoglycemic counterregulation in diabetes and do not discount other mechanisms of
impairment, which have been discussed in this thesis.
8.2 Potential clinical contributions
The goal of this work was to develop a means to ameliorate hypoglycemia. This objective
differs from the current hypoglycemia therapies, such as injectable glucagon and dextrose,
which are reactionary measures as opposed to preventive therapies. Hypoglycemia that is
particularly dangerous includes that which occurs undetected, such as during sleep and in
diabetic children and adolescents. Reactionary therapies necessitate the recognition of
hypoglycemia by the individual or the care giver, which would be difficult with hypoglycemic
unawareness or during nocturnal hypoglycemia. A prophylactic solution involves
administration of a therapeutic prior to hypoglycemia onset so that the duration/severity of
hypoglycemia is lessened or prevented entirely so that the patient does not become
debilitated. This could involve administration of the SSTR2 antagonist with one’s insulin,
particularly when the risk of hypoglycemia may be greater (i.e. at bedtime and/or after
exercise). By minimizing the risk of hypoglycemia, intensive insulin treatment would be
more effective, leading to a lower incidence of diabetic complications and decreasing the
196
stress associated with the anxiety of becoming hypoglycemic, consequently improving the
quality of life for diabetic patients.
197
197
Chapter 9 References
1. American Diabetes Association Workgroup on Hypoglycemia: Defining and reporting hypoglyecemia in diabetes. Diabetes Care 28:1245-1249, 2005
2. McCall A: Effects of glucose deprivation on glucose metabolism in the central nervous system. In Hypoglycemia and Diabetes. Frier B, Fisher B, Eds. London, Edward Arnold, 1993, p. 56-71
3. Cryer P, Gerich J: Hypoglycemia in type 1 diabetes mellitus: Interplay of insulin excess and compromised glucose counterregulation. In Ellenberg & Rifkin's Diabetes Mellitus. Sixth ed. Porte JrD, Sherwin R, Baron A, Eds. New York, McGraw-Hill, 2003, p. 523-530
4. Cryer,P: The barrier of hypoglycemia in diabetes. Diabetes 57:3169-3176, 2008
5. American Diabetes Association Workgroup on Hypoglycemia: Defining and reporting hypoglycemia in diabetes. A report from the American Diabetes Association workgroup on hypoglycemia. Diabetes Care 28:1245-1249, 2005
6. The DCCT Research Group: Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Annals of Internal Medicine 124:379-388, 1996
7. Cryer,P: Hypoglycemia, functional brain failure, and brain death. J Clin Invest 117:868-870, 2007
8. Towler,D, Havlin,C, Craft,S, Cryer,P: Mechanisms of awareness of hypoglycemia: Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 42:1791-1798, 1993
9. Schwartz,N, Clutter,W, Shah,S, Cryer,P: Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 79:777-781, 1987
10. Mitrakou,A, Ryan,C, Veneman,T, Mokan,M, Jenssen,T, Kiss,I, Durrant,J, Cryer,P, Gerich,J: Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. American Journal of Physiology Endocrinology and Metabolism 260:E67-E74, 1991
198
11. Cryer,P, Axelrod,L, Grossman,A, Heller,S, Montori,V, Seaquist,E, Service,F: Evaluation and management of adult hypoglycemic disorders: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94:709-728, 2009
12. Mitrakou,A, Ryan,C, Veneman,T, Mokan,M, Jenssen,T, Kiss,I, Durrant,J, Cryer,P, Gerich,J: Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. American Journal of Physiology Endocrinology and Metabolism 260:E67-E74, 1991
13. Marty,N, Dallaporta,M, Thorens,B: Brain glucose sensing, counterregulation, and energy homeostasis. Physiology 22:241-251, 2007
14. Watts,A, Donovan,C: Sweet talk in the brain: glucosensing, neural networks, and hypoglycemic counterregulation. Frontiers in Neuroendocrinology 31:32-43, 2010
15. Adachi,A, Shimizu,N, Oomura,Y, Kobashi,M: Convergence of hepatoportal glucose-sensitive afferent signals to glucose-sensitive units within the nucleus of the solitary tract. Neuroscience Letters 46:215-218, 1984
16. Shimizu,N, Oomura,Y, Novin,D, Grijalva,C, Cooper,P: Functional correlations between lateral hypothalamic glucose-sensitive neurons and hepatic portal glucose-sensitive units in rat. Brain Research 265:49-54, 1983
17. Hevener,A, Bergman,R, Donovan,C: Portal vein afferents are critical for the sympathoadrenal response to hypoglycemia. Diabetes 49:8-12, 2000
18. Burcelin,R, Dolci,W, Thorens,B: Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization. Diabetes 49:1635-1642, 2000
19. Russek,M: Participation of hepatic glucoreceptors in the control of intake of food. Nature 197:79-80, 1963
20. Donovan,C, Hamilton-Wessler,M, Halter,J, Bergman,R: Primacy of liver glucosensors in the sympathetic response to progressive hypoglycemia. Proceedings of the National Academy of Sciences U S A 91:2863-2867, 1994
21. Hevener,A, Bergman,R, Donovan,C: Novel glucosensor for hypoglycemic detection localized to the portal vein. Diabetes 46:1521-1525, 1997
22. Thorens B: The hepatoportal glucose sensor: Mechanisms of glucose sensing and signal transduction. In Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Matschinski F, Magnuson M, Eds. Basel, Karger, 2004, p. 327-338
23. Dunn-Meynell,A, Rawson,N, Levin,B: Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Research 814:41-54, 1998
199
24. Kang,L, Routh,V, Kuzhikandathil,E, Gaspers,L, Levin,B: Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons. Diabetes 53:549-559, 2004
25. Yang,X, Kow,L, Pfaff,D, Mobbs,C: Metabolic pathways that mediate inhibition of hypothalamic neurons by glucose. Diabetes 53:67-73, 2004
26. Wang,R, Liu,X, Hentges,S, Dunn-Meynell,A, Levin,B, Wang,W, Routh,V: The regulation of glucose-excited neurons in the hypothalamic arcuate nucleus by glucose and feeding-relevant peptides. Diabetes 53:1959-1965, 2004
27. Oomura,Y, Kimura,K, Ooyama,H, Maeno,T, Iki,M, Kuniyoshi,M: Reciprocal activities of the ventromedial and lateral hypothalamic areas of cats. Science 143:484-485, 1964
28. Oomura,Y, Ooyama,H, Sugimori,M, Nakamura,T, Yamada,Y: Glucose inhibition of the glucose-sensitive neurone in the rat lateral hypothalamus. Nature 247:284-286, 1974
29. Silver,A, Erecinska,M: Glucose-induced intracellular ion changes in sugar-sensitive hypothalamic neurons. Journal of Neurophysiology 79:1733-1745, 1998
30. Leibowitz,S, Sladek,C, Spencer,L, Tempel,D: Neuropeptide Y, epinephrine and norepinephrine in the paraventricular nucleus: stimulation of feeding and the release of corticosterone, vasopressin and glucose. Brain Research Bulletin 21:905-912, 1988
31. Guillod-Maximin,E, Lorsignol,A, Alquier,T, Penicaud,L: Acute intracarotid glucose injection towards the brain induces specific c-fos activation in hypothalamic nuclei: involvement of astrocytes in cerebral glucose-sensing in rats. Journal of Neuroendocrinolgy 16:464-471, 2004
32. Briski,K: Intraventricular 2-deoxy-D-glucose induces Fos expression by hypothalamic vasopressin, but not oxytocin neurons. Brain Research Bulletin 51:275-280, 2000
33. Swanson L: The hypothalamus. In Handbook of Chemical Neuroanatomy. Bjorklund A, Hokfelt T, Swanson L, Eds. Amsterdam, Elsevier, 1987, p. 1-124
34. Borg,W, During,M, Sherwin,R, Borg,M, Brines,M, Shulman,G: Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia. J Clin Invest 93:1677-1682, 1994
35. Borg,W, Sherwin,R, During,M, Borg,M, Shulman,G: Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes 44:180-184, 1995
36. Borg,M, Sherwin,R, Borg,W, Tamborlane,W, Shulman,G: Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Clin Invest 99:361-365, 1997
200
37. Beverly,J, de Vries,M, Bouman,S, Arseneau,L: Noradrenergic and GABAergic systems in the medial hypothalamus are activated during hypoglycemia. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 280:R563-R569, 2001
38. Borg,M, Tamborlane,W, Shulman,G, Sherwin,R: Local lactate perfusion of the ventromedial hypothalamus suppresses hypoglycemic counterregulation. Diabetes 52:663-666, 2003
39. Chan,O, Zhu,W, Ding,Y, McCrimmon,R, Sherwin,R: Blockade of GABA(A) receptors in the ventromedial hypothalamus further stimulates glucagon and sympathoadrenal but not the hypothalamo-pituitary-adrenal response to hypoglycemia. Diabetes 55:1080-1087, 2006
40. Song,Z, Levin,B, McArdle,J, Bakhos,N, Routh,V: Convergence of pre- and postsynaptic influences on glucosensing neurons in the ventromedial hypothalamic nucleus. Diabetes 50:2673-2681, 2001
41. Mizuno,Y, Oomura,Y: Glucose responding neurons in the nucleus tractus solitarius of the rat: in vitro study. Brain Research 307:109-116, 1984
42. Yettefti,K, Orsini,J, Perrin,J: Characteristics of glycemia-sensitive neurons in the nucleus tractus solitarii: possible involvement in nutritional regulation. Physiology and Behavior 61:93-100, 1997
43. Dallaporta,M, Himmi,T, Perrin,J, Orsini,J: Solitary tract nucleus sensitivity to moderate changes in glucose level. Neuroreport 10:2657-2660, 1999
44. Funahashi,M, Adachi,A: Glucose-responsive neurons exist within the area postrema of the rat: in vitro study on the isolated slice preparation. Brain Research Bulletin 32:531-535, 1993
45. Balfour,R, Hansen,A, Trapp,S: Neuronal responses to transient hypoglycaemia in the dorsal vagal complex of the rat brainstem. Journal of Physiology 570:469-484, 2006
46. Andrew,S, Dinh,T, Ritter,S: Localized glucoprivation of hindbrain sites elicits corticosterone and glucagon secretion. american 292:R1792-R1798, 2007
47. Ritter,S, Dinh,T, Li,A: Hindbrain catecholamine neurons control multiple glucoregulatory responses. Physiology and Behavior 89:490-500, 2006
48. Ritter,S, Dinh,T, Zhang,Y: Localization of hindbrain glucoreceptive sites controlling food intake and blood glucose. Brain Research 856:37-47, 2000
49. Zhou,L, Podolsky,N, Sang,Z, Ding,Y, Fan,X, Tong,Q, Levin,B, McCrimmon,R: The medial amygdalar nucleus: A novel glucose-sensing region that modulates the counterregulatory response to hypoglycemia. Diabetes 2010
201
50. Cryer,P, Davis,S, Shamoon,H: Hypoglycemia in diabetes. Diabetes Care 26:1912, 2003
51. Cryer,P: Glucose counterregulation: The prevention and correction of hypoglycemia in humans. American Journal of Physiology Endocrinology and Metabolism 264:E149-E155, 1993
52. Heller,S, Cryer,P: Hypoinsulinemia is not critical to glucose recovery from hypoglycemia in humans. American Journal of Physiology Endocrinology and Metabolism 261:E41-E48, 1991
53. Butler,P, Rizza,R: Regulation of carbohydrate metabolism and response to hypoglycemia. Endocrinol Metab Clin North Am 18:1-25, 1989
54. Shulman G, Barrett E, Sherwin R: Integrated fuel metabolism. In Ellenberg & Rifkin's Diabetes Mellitus. Sixth ed. Porte JrD, Sherwin R, Baron A, Eds. New York, McGraw-Hill, 2003, p. 1-13
55. Sherck,S, Shiota,M, Saccomando,J, Cardin,S, Allen,E, Hastings,J, Neal,D, Williams,P, Cherrington,A: Pancreatic response to mild non-insulin-induced hypoglycemia does not involve extrinsic neural input. Diabetes 50:2487-2496, 2001
56. Banarer,S, Cryer,P: Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: Reduced awakening from sleep during hypoglycemia. Diabetes 52:1195-1203, 2003
57. Lacey,R, Cable,H, James,R, London,N, Scarpello,J, Morgan,N: Concentration-dependent effects of adrenaline on the profile of insulin secretion from isolated human islets of Langerhans. Journal of Endocrinology 138:555-563, 1993
58. Cryer,P: Glucose counterregulation in man. Diabetes 30:261-264, 1981
59. Gerich,J, Davis,J, Lorenzi,M, Rizza,R, Bohannon,N, Karam,J, Lewis,S, Kaplan,R, Shultz,T, Cryer,P: Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. American Journal of Physiology Endocrinology and Metabolism 236:E380-E385, 1979
60. Rizza,R, Cryer,P, Gerich,J: Role of glucagon, catecholamines and growth hormone in human glucose counterregulation: Effect of somatostatin and combined alpha- and beta-adrenergic bloackade on plasma glucose recovery. J Clin Invest 64:62-71, 1979
61. Lins,P, Adamson,U, Clausen,N, Hamberger,B, Efendic,S: The role of glucagon, catecholamines and cortisol in counterregulation of insulin-induced hypoglycemia in normal man. Acta Medica Scandinavica 200:39-46, 1986
62. De Feo,P, Perriello,G, Torlone,E, Fanelli,C, Ventura,M, Santeusanio,F, Brunetti,P, Gerich,J, Bolli,G: Evidence against important catecholamine compensation for absent glucagon counterregulation. Am J Physiol 260:E203-E212, 1991
202
63. Cryer,P: Diverse causes of hypolgycemia-associated autonomic failure in diabetes. New England Journal of Medicine 350:2272-2279, 2004
64. Boyle,P, Cryer,P: Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemia. American Journal of Physiology Endocrinology and Metabolism 260:E395-E402, 1991
65. Dunning,B, Scott,M, Neal,D, Cherrington,A: Direct quantification of norepinephrine spillover and hormone output from the pancreas of the conscious dog. American Journal of Physiology Endocrinology and Metabolism 272:E746-E755, 1997
66. Havel,P, Mundinger,T, Veith,R, Dunning,B, Taborsky,GJ: Corelease of galanin and NE from pancreatic sympathetic nerves during severe hypoglycemia in dogs. American Journal of Physiology Endocrinology and Metabolism 263:E8-16, 1992
67. Havel,P, Taborsky,GJ: The contribution of the autonomic nervous system to changes of glucagon and insulin secretion during hypoglycemic stress. Endocr Rev 10:332-350, 1989
68. Schwartz,T: Pancreatic polypeptide: a hormone under vagal control. Gastroenterology 85:1411-1425, 1983
69. Hisatomi,A, Maruyama,H, Orci,L, Vasko,M, Unger,R: Adrenergically mediated intrapancreatic control of the glucagon response to glucopenia in the isolated rat pancreas. J Clin Invest 75:420-426, 1985
70. Ahren,B, Veith,R, Taborsky,GJ: Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 1). Effects on basal release of insulin and glucagon. Endocrinology 121:323-331, 1987
71. Kaneto,A, Kajinuma,H, Kosaka,K, Nakao,K: Stimulation of insulin secretion by parasympathomimetic agents. Endocrinology 83:651-658, 1968
72. Samols,E, Weir,G: Adrenergic modulation of pancreatic A, B, and D cells: alpha-Adrenergic suppression and beta-adrenergic stimulation of somatostatin secretion, alpha-adrenergic stimulation of glucagon secretion in the perfused dog pancreas. J Clin Invest 63:230-238, 1979
73. Gerich,J, Karam,JH, Forsham,P: Stimulation of glucagon secretion by epinephrine in man. J Clin Endocrinol Metab 37:479-481, 1973
74. Hirose,H, Maruyama,M, Itoh,K, Koyama,K, Kido,K, Saruta,T: Alpha-2 adrenergic agonism stimulates islet glucagon release from perfused rat pancreas: possible involvement of alpha-2A adrenergic receptor subtype. Acta Endocrinologica 127:279-283, 1992
75. Lacey,R, Berrow,N, Scarpello,J, Morgan,N: Selective stimulation of glucagon secretion by beta 2-adrenoceptors in isolated islets of Langerhans of the rat. British Journal of Pharamcology 103:1824-1828, 1991
203
76. Taborsky,GJ, Ahren,B, Havel,P: Autonomic mediation of glucagon secretion during hypoglycemia: Implications for impaired -cell responses in Type 1 Diabetes. Diabetes 47:995-1005, 1998
77. Iismaa,T, Kerr,E, Wilson,J, Carpenter,L, Sims,N, Biden,T: Quantitative and functional characterization of muscarinic receptor subtypes in insulin-secreting cell lines and rat pancreatic islets. Diabetes 49:392-398, 2000
78. Maruyama,H, Hisatomi,A, Orci,L, Grodsky,G, Unger,R: Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74:2296-2299, 1984
79. Samols,E, Stagner,J, Ewart,R, Marks,V: The order of islet microvascular cellular perfusion is B --> A --> D in the perfused rat pancreas. J Clin Invest 82:350-353, 1988
80. Banarer,S, McGregor,V, Cryer,P: Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51:958-965, 2002
81. Slucca,M, Harmon,J, Oseid,E, Bryan,J, Robertson,R: ATP-sensitive K+ channel mediates the zinc switch-off signal for glucagon response during glucose deprivation. Diabetes 59:128-134, 2010
82. Zhou,H, Zhang,T, Harmon,J, Bryan,J, Robertson,R: Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo. Diabetes 56:1107-1112, 2007
83. Ravier,M, Rutter,G: Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 54:1789-1797, 2005
84. Bansal,P, Wang,Q: Insulin as a physiological modulator of glucagon secretion. American Journal of Physiology Endocrinology and Metabolism 295:E751-E761, 2008
85. Rorsman,P, Berggren,P, Bokvist,K, Ericson,K, Mohler,H, Ostenson,C, Smith,P: Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. Nature 34:233-236, 1989
86. Hales,T, Tyndale,R: Few cell lines with GABAA mRNAs have functional receptors. Journal of Neuroscience 14:5429-5436, 1994
87. Xu,E, Kumar,M, Ju,W, Obata,T, Zhang,N, Deng,S, Ebina,Y, Braun,M, Wang,Q: Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metabolism 3:47-58, 2006
88. Taborsky Jr,G: Evidence of a paracrine role of pancreatic somatostatin in vivo. American Journal of Physiology Endocrinology and Metabolism 245:E598-E603, 1983
89. Brunicardi,F, Wen,D, Bradley,J, Elahi,D, Miller,C, Hanks,J: The effect of intraislet somatostatin immunoneutralization on insulin secretion in the isolated perfused rat pancreas. International Journal of Surgical Investigation 1:381-388, 2000
204
90. Rastogi,K, Lickley,L, Jokay,M, Efendic,S, Vranic,M: Paradoxical reduction in pancreatic glucagon with normalization of somatostatin and decrease in insulin in normoglycemic alloxan diabetic dogs: A putative mechanism of glucagon irresponsiveness to hypoglycemia. Endocrinology 126:1096-1104, 1990
91. Wierup,N, Yang,S, McEvilly,R, Mulder,H, Sundler,F: Ghrelin is expressed in a novel endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832/13) cells. J Histochem Cytochem 52:301-310, 2004
92. Egido,E, Rodriguez-Gallardo,J, Silvestre,R, Marco,J: Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur J Endocrinol 146:241-244, 2002
93. Gerich,J, Charles,M, Grodsky,G: Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. J Clin Invest 54:833-841, 1974
94. Pipeleers,D, Schuit,F, Van Schravendijk,C, Van de Winkel,M: Interplay of nutrients and hormones in the regulation of glucagon release. Endocrinology 117:817-823, 1985
95. Franklin,I, Gromada,J, Gjinovci,A, Theander,S, Wollheim,C: Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54:1808-1815, 2005
96. Olsen,H, Theander,S, Bokvist,K, Bushchard,K, Wollheim,C, Gromada,J: Glucose stimulates glucagon release in single rat -cells by mechanisms that mirror the stimulus-secretion coupling in -cells. Endocrinology 146:4861-4870, 2005
97. Zhou,H, Tran,P, Yang,S, Zhang,T, Leroy,E, Oseid,E, Robertson,R: Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the "switch-off" hypothesis. Diabetes 53:1482-1487, 2004
98. Tong,Q, Ye,C, McCrimmon,R, Dhillon,H, Choi,B, Kramer,M, Yu,J, Yang,Z, Christiansen,L, Lee,C, Choi,C, Zigman,J, Shulman,G, Sherwin,R, Elmquist,J, Lowell,B: Synaptic glutamate release by ventromedial hypothalamic neurons is part of the neurocircuitry that prevents hypoglycemia. Cell Metabolism 5:383-393, 2007
99. Buijs,R, Chun,S, Niijima,A, Romijn,H, Nagai,K: Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. Journal of Comparative Neurology 431:405-423, 2001
100. Clarke,W, Santiago,J, Thomas,L, Ben-Galim,E, Haymond,M, Cryer,P: Adrenergic mechanisms in recovery from hypoglycemia in man: adrenergic blockade. American Journal of Physiology Endocrinology and Metabolism 236:E147-E152, 1979
101. Rizza,R, Cryer,P, Gerich,J: Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and
205
beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest 64:62-71, 1979
102. Davis,S, Fowler,S, Costa,F: Hypoglycemic counterregulatory responses differ between men and women with type 1 diabetes. Diabetes 49:65-72, 2000
103. Kvetnansky,R, Pacak,K, Sabban,E, Kopin,I, Goldstein,D: Stressor specificity of peripheral catecholaminergic activation. Advances in Pharmacology 42:556-560, 1998
104. Shum,K, Inouye,K, Chan,O, Mathoo,J, Bilinski,D, Matthews,S, Vranic,M: Effects of antecedent hypoglycemia, hyperinsulinemia, and excess corticosterone on hypoglycemic counterregulation. American Journal of Physiology Endocrinology and Metabolism 281:E455-E465, 2001
105. Hoffman,R, Sinkey,C, Anderson,E: Muscle sympathetic nerve activity is higher in intensively versus conventionally treated IDDM subjects. Diabetes Care 18:287-291, 1995
106. Hoffman,R, Sinkey,C, Dopp,J, Phillips,B: Systemic and local adrenergic regulation of muscle glucose utilization during hypoglycemia in healthy subjects. Diabetes 51:734-742, 2002
107. Porte,D: A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest 45:86-94, 1967
108. Young J, Landsberg L: Catecholamines and the adrenal medulla. In Williams Textbook of Endocrinology. 9th ed. Wilson J, Foster D, Kronenberg H, Larsen P, Eds. Philadelphia, W.B. Saunders Company, 1998, p. 665-728
109. Guse-Behling,H, Ehrhart-Bornstein,M, Bornstein,S, Waterman,M, Scherbaum,WA, Adler,G: Regulation of adrenal steroidogenesis by adrenaline: expression of cytochrome P450 genes. Journal of Endocrinology 135:229-237, 1992
110. Hansen,I, Firth,R, Haymond,M, Cryer,P, Rizza,R: The role of autoregulation of hepatic glucose production in man: Response to a physiologic decrement in plasma glucose. Diabetes 35:186-191, 1986
111. Shum,K, Inouye,K, Chan,O, Mathoo,J, Bilinski,D, Matthews,S, Vranic,M: Effects of antecedent hypoglycemia, hyperinsulinemia, and excess corticosterone on hypoglycemic counterregulation. American Journal of Physiology Endocrinology and Metabolism 281:E455-E465, 2001
112. Altorfer,R, Ziegler,W, Froesch,E: Insulin hypoglycaemia in normal and adrenalectomized subjects: comparison of metabolic parameters and endocrine counter regulation. Acta Endocrinologica 98:413-419, 1981
113. Yamaguchi,N, Briand,R, Brassard,M: Direct evidence that an increase in aortic norepinephrine level in response to insulin-induced hypoglycemia is due to increased
206
adrenal norepinephrine output. Canadian Journal of Physiology and Pharamcology 67:499-505, 1989
114. Khalil,Z, Marley,P, Livett,B: Elevation in plasma catechoamines in response to insulin stress is under both neuronal and nonneuronal control. Endocrinology 119:159-167, 1986
115. Fanelli,C, De,FP, Porcellati,F, Perriello,G, Torlone,E, Santeusanio,F, Brunetti,P, Bolli,G: Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. J Clin Invest 89:2005-2013, 1992
116. Lafontan,M, Berlan,M: Fat cell adrenergic receptors and the control of white and brown fat cell function. Journal of Lipid Research 34:1057-1091, 1993
117. De Feo,P, Perriello,G, Torlone,E, Ventura,M, Santeusanio,F, Brunetti,P, Gerich,J, Bolli,G: Demonstration of a role of growth hormone in glucose counterregulation. American Journal of Physiology Endocrinology and Metabolism 256:E835-E843, 1989
118. De Feo,P, Perriello,G, Torlone,E, Ventura,M, Fanelli,C, Santeusanio,F, Brunetti,P, Gerich,J, Bolli,G: Contribution of cortisol to glucose counterregulation in humans. American Journal of Physiology Endocrinology and Metabolism 257:E35-E42, 1989
119. Masuda,A, Shibasaki,T, Hotta,M, Yamauchi,T, Ling,N, Demura,H, Shizume,K: Insulin-induced hypoglycemia, L-dopa and arginine stimulate GH secretion through different mechanisms in man. Regulatory Peptides 31:53-64, 1990
120. Pacak,K, Palkovits,M: Stressor specificity of central neuroendocrine responses: implication for stress-related disorders. Endocrine Reviews 22:502-548, 2001
121. Sawchenko,P, Li,H, Ericsson,A: Circuits and mechanisms governing hypothalamic responses to stress: a tale of two paradigms. Progress in Brain Research 122:61-80, 2000
122. Swanson,L, Sawchenko,P: Paraventricular nucleus: a site for the intergration of neuroendocrine and autonomic mechansims. Neuroendocrinology 31:410-417, 1980
123. De Kloet,E, Vreugdenhil,E, Oitzl,M, Joels,M: Brain corticosteroid receptor balance in health and disease. Endocr Rev 19:269-301, 1998
124. Opherk,C, Tronche,F, Kellendonk,C, Kohlmuller,D, Schulze,A, Schmid,W, Schutz,G: Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Molecular Endocrinology 18:1346-1353, 2004
125. McMahon,M, Gerich,J, Rizza,R: Effects of glucocorticoids on carbohydrate metabolism. Diabetes/Metabolism Reviews 4:17-30, 1988
207
126. Dinneen S: The effects of glucocorticoid hormones on substrate metabolism. In Clinical Research in Diabetes and Obesity. Draznin B, Rizza R, Eds. Tototwa, Humana Press, 1997, p. 243-258
127. Lecavalier,L, Bolli,G, Gerich,J: Glucagon-cortisol interactions on glucose turnover and lactate gluconeogenesis in normal humans. American Journal of Physiology Endocrinology and Metabolism 258:E569-E575, 1990
128. Dirlewanger,M, Schneiter,P, Paquot,N, Jequier,E, Rey,V, Tappy,L: Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clinical Nutrition 19:29-34, 2000
129. Bolli,G, De Feo,P, Perriello,G, De Cosmo,S, Ventura,M, Campbell,P, Brunetti,P, Gerich,J: Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest 75:1623-1631, 1985
130. Connolly,C, Myers,S, Neal,D, Hastings,J, Cherrington,A: In the absence of counterregulatory hormones, the increase in hepatic glucose production during insulin-induced hypoglycemia in the dog is initiated in the liver rather than the brain. Diabetes 45:1805-1813, 1996
131. Service,F: Classification of hypoglycemic disorders. Endocrinol Metab Clin North Am 28:501-17, vi, 1999
132. Service,F: Hypoglycemic disorders. New England Journal of Medicine 332:1144-1152, 1995
133. Guettier,J, Gorden,P: Hypoglycemia. Endocrinol Metab Clin North Am 35:753-7ix, 2006
134. Muhlhauser,I, Berger,M, Sonnenberg,G, Koch,J, Jorgens,V, Schernthaner,G, Scholz,V, Padagogin,D: Incidence and management of severe hypoglycemia in 434 adults with insulin-dependent diabetes mellitus. Diabetes Care 8:268-273, 1985
135. Goldstein,D, England,J, Hess,R, Rawlings,S, Walker,B: A prospective study of symptomatic hypoglycemia in young diabetic patients. Diabetes Care 4:601-604, 1981
136. Mecklenbeurg,R, Benson,E, Benson,J, Blumenstein,B, Fredlund,P, Guinn,T, Metz,R, Nielson,R: Acute complications associated with insulin infusion pump therapy: report of experience with 161 patients. Journal of the American Medical Association 252:3265-3269, 1984
137. Goldgewicht,C, Slama,G, Papoz,L, Tchobroutsky,G: Hypoglycemic reactions in 172 type 1 (insulin-dependent) diabetic patients. Diabetologia 24:95-99, 1983
138. The DCCT Research Group: Diabetes Control and Complications Trial (DCCT): Results of feasibility study. Diabetes Care 10:1-19, 1987
208
139. The DCCT Research Group: Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. American Journal of Medicine 90:450-459, 1991
140. Reichard,P, Nilsson,B-Y, Rosenquist,U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine 329:304-309, 1993
141. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329:977-986, 1993
142. Cryer,P: Hypoglycemia: The limiting factor in the management of IDDM. Diabetes 43:1378-1389, 1994
143. Alsahli M, Gerich J: Hypoglycemia in Diabetes Mellitus. In Principles of Diabetes Mellitus. Second ed. Poretsky L, Ed. Boston, Springer US, 2010, p. 297-312
144. The DCCT Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
145. Schernthaner,G: Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Research and Clinical Practice 31 Suppl:S3-13, 1996
146. Del Prato,S, LaSalle,J, Matthaei,S, Bailey,C, on behalf of the Global Partnership for Effective Diabetes Management: Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. International Journal of Clinical Practice 64:295-304, 2010
147. Cryer,P: Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45:937-948, 2002
148. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 35:837-853, 1998
149. Davis,S: Diabetes: Hypoglycemia - a new approach to an old problem. Nature Reviews Endocrinology 5:243-245, 2009
150. UK Hypoglycaemia Study Group: Risk of hypoglycaemia in type 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50:1140-1147, 2007
151. Amiel,S, Dixon,T, Mann,R, Jameson,K: Hypoglycaemia in Type 2 diabetes. Diabetic Medicine 25:245-254, 2008
152. Gerstein,H, Miller,M, Byington,R, Goff,DJ, Bigger,J, Buse,J, Cushman,W, Genuth,S, Ismail-Beigi,F, Grimm,RJ, Probstfield,J, Simons-Morton,D, Friedewald,W: Effects of
209
intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 358:2545-2559, 2008
153. Patel,A, MacMahon,S, Chalmers,J, Neal,B, Billot,L, Woodward,M, Marre,M, Cooper,M, Glasziou,P, Grobbee,D, Hamet,P, Harrap,S, Heller,S, Liu,L, Mancia,G, Mogensen,C, Pan,C, Poulter,N, Rodgers,A, Williams,B, Bompoint,S, de Galan,B, Joshi,R, Travert,F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 358:2560-2572, 2008
154. Duckworth,W, Abraira,C, Moritz,T, Reda,D, Emanuele,N, Reaven,P, Zieve,F, Marks,J, Davis,S, Hayward,R, Warren,S, Goldman,S, McCarren,M, Vitek,M, Henderson,W, Huang,G: Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 360:129-139, 2009
155. Holman,R, Paul,S, Bethel,M, Matthews,D, Neil,H: 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 359:1577-1589, 2008
156. Schernthaner,G: Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wiener Medizinische Wochenschrift 160:8-19, 2010
157. Landstedt-Hallin,L, Englund,A, Adamson,U, Lins,P: Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. Journal of Internal Medicine 246:299-307, 1999
158. Vinik,A, Ziegler,D: Diabetic cardiovascular autonomic neuropathy. Circulation 115:387-397, 2007
159. Cryer P, Gerich J: Hypoglycemia in type 1 diabetes mellitus: Interplay of insulin excess and compromised glucose counterregulation. In Ellenberg & Rifkin's Diabetes Mellitus. Sixth ed. Porte JrD, Sherwin R, Baron A, Eds. New York, McGraw-Hill, 2003, p. 523-530
160. Donnelly,L, Morris,A, Frier,B, Ellis,J, Donnan,P, Durrant,R, Band,M, Reekie,G, Leese,G, DARTS/MEMO Collaboration: Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabetic Medicine 22:749-755, 2005
161. Cryer,P: Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocrine Practice 14:750-756, 2008
162. Cryer P: Hypoglycemia in diabetes. Pathophysiology, prevalence, and prevention. Alexandria, VA, American Diabetes Association, 2009,
163. The DCCT Research Group: Effects of age, durage and treatment of insulin-dependent diabetes mellitus on residual -cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 65:30-36, 1986
210
164. Madsbad,S: Prevalence of residual cell function and its metabolic consequences in type 1 (insulin-dependent) diabetes. Diabetologia 24:141-147, 1983
165. Bolli,G, De Feo,P, Compagnucci,P, Cartechini,M, Angeletti,F, Santeusanio,F, Brunetti,P, Gerich,J: Abnormal glucose counterregulation in insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32:134-141, 1983
166. Gerich,J, Langlois,M, Noacco,C, Karam,J, Forsham,P: Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 182:171-173, 1973
167. Bolli,G, Tsalikian,E, Haymond,M, Cryer,P, Gerich,J: Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest 73:1532-1541, 1984
168. Segel,S, Paramore,S, Cryer,P: Hypoglycemia-associated autonomic failture in advanced type 2 diabetes. Diabetes 51:724-733, 2002
169. Miles,P, Yamatani,K, Lickley,H, Vranic,M: Mechanism of glucoregulatory responses to stress and their deficiency in diabetes. Proceedings of the National Academy of Sciences U S A 88:1296-1300, 1991
170. Maher,T: Glucagon response to hypoglycemia in diabetic neuropathy. Hormone and Metabolic Research (Suppl) 9:87-89, 1980
171. Fukuda,M, Tanaka,A, Tahara,Y, Ikegami,H, Yamamoto,Y, Kumahara,Y, Shima,K: Correlation between minimal secretory capacity of pancreatic b-cells and stability of diabetic control. Diabetes 37:81-88, 1988
172. Raju,B, Cryer,P: Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes. Diabetes 54:757-764, 2005
173. Gosmanov,N, Szoke,E, Israelian,Z, Smith,T, Cryer,P, Gerich,J, Meyer,C: Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care 28:1124-1131, 2005
174. Shi,Z, Rastogi,K, Lekas,M, Efendic,S, Drucker,D, Vranic,M: Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats. Endocrinology 137:3193-3199, 1996
175. Taborsky Jr,G, Ahren,B, Havel,P: Implications for impaired a-cell responses in type 1 diabetes. Diabetes 47:995-1005, 1998
211
176. Taborsky,GJ, Ahren,B, Mundinger,T, Mei,Q, Havel,P: Autonomic mechanism and defects in the glucagon response to insulin-induced hypoglycemia. Diabetes Nutrition and Metabolism 15:318-322, 2002
177. McCall,A, Fixman,L, Fleming,N, Tornheim,K, Chick,W, Ruderman,N: Chronic hypoglycemia increases brain glucose transport. American Journal of Physiology Endocrinology and Metabolism 251:E442-E447, 1986
178. Boyle,P, Kempers,S, O'Connor,A, Nagy,R: Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. New England Journal of Medicine 333:1726-1731, 1995
179. Farhy,L, Du,Z, Zeng,Q, Veldhuis,P, Johnson,M, Brayman,K, McCall,A: Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats. American Journal of Physiology Endocrinology and Metabolism 295:E575-E585, 2008
180. Heller,S: Hypoglycaemia in Type 2 diabetes. Diabetes Research and Clinical Practice 82 Suppl 2:S108-S111, 2008
181. Briscoe,V, Davis,S: Hypoglycemia in type 1 and type 2 diabetes: Physiology, pathophysiology, and management. Clincal Diabetes 24:115-121, 2006
182. Boden,G, Soriano,M, Hoeldtke,R, Owen,O: Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients. Diabetes 32:1055-1059, 1983
183. Heller,S, Macdonald,I, Tattersall,R: Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis. Diabetologia 30:924-929, 1987
184. Polonsky,K, Herold,K, Gilden,J, Bergenstal,R, Fang,V, Moossa,A, Jaspan,J: Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes. Diabetes 33:1112-1119, 1984
185. Choudhary,P, Lonnen,K, Emery,C, Macdonald,I, MacLeod,K, Amiel,S, Heller,S: Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes. Diabetic Medicine 26:665-672, 2009
186. Shamoon,H, Friedman,S, Canton,C, Zacharowicz,L, Hu,M, Rossetti,L: Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest 93:2562-2571, 1994
187. Holstein,A, Hammer,C, Plaschke,A, Ptak,M, Kuhn,J, Diekmann,J, Kleesiek,K, Egberts,E: Hormonal counterregulation during severe hypoglycaemia under everyday conditions in patients with type 1 and insulin-treated type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes 112:429-434, 2004
212
188. Israelian,Z, Szoke,E, Woerle,J, Bokhari,S, Schorr,M, Schwenke,D, Cryer,P, Gerich,J, Meyer,C: Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus. Metabolism 55:593-598, 2006
189. Borg,M, Borg,W, Tamborlane,W, Brines,M, Shulman,G, Sherwin,R: Chronic hypoglycemia and diabetes impair counterregulation induced by localized 2-deoxy-glucose perfusion of the ventromedial hypothalamus in rats. Diabetes 48:584-587, 1999
190. Paranjape,S, Chan,O, Zhu,W, Horblitt,A, McNay,E, Cresswell,J, Bogan,J, McCrimmon,R, Sherwin,R: Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo. Diabetes 59:1521-1527, 2010
191. Zhu,W, Czyzyk,D, Paranjape,SA, Zhou,L, Horblitt,A, Szabo,G, Seashore,MR, Sherwin,R, Chan,O: Glucose prevents the fall in ventromedial hypothalamic GABA that is required for full activation of glucose counterregulatory responses during hypoglycemia. American Journal of Physiology Endocrinology and Metabolism 298:E971-E977, 2010
192. Chan,O, Lawson,M, Zhu,W, Beverly,J, Sherwin,R: ATP-sensitive K(+) channels regulate the release of GABA in the ventromedial hypothalamus during hypoglycemia. Diabetes 56:1120-1126, 2007
193. McCrimmon,R: Glucose sensing during hypoglycemia: lessons from the lab. Diabetes Care 32:1357-1363, 2009
194. Routh,V: Glucose-sensing neurons: are they physiologically relevant? Physiology and Behavior 76:403-413, 2002
195. Hardie,D, Carling,D: The AMP-activated protein kinase--fuel gauge of the mammalian cell? European Journal of Biochemistry 246:259-273, 1997
196. McCrimmon,R, Fan,X, Ding,Y, Zhu,W, Jacob,R, Sherwin,R: Potential role for AMP-activated protein kinase in hypoglycemia sensing in the ventromedial hypothalamus. Diabetes 53:1953-1958, 2004
197. Fan,X, Ding,Y, Brown,S, Zhou,L, Shaw,M, Vella,M, Cheng,H, McNay,E, Sherwin,R, McCrimmon,R: Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 296:R1702-R1708, 2009
198. White,N, Skor,D, Cryer,P, Levandoski,L, Bier,D, Santiago,J: Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. New England Journal of Medicine 308:485-491, 1983
199. Bolli,G, De,FP, De,CS, Perriello,G, Ventura,M, Benedetti,M, Santeusanio,F, Gerich,J, Brunetti,P: A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. Diabetes 33:732-737, 1984
213
200. Cersosimo,E, Garlick,P, Ferretti,J: Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes. Diabetes 50:2087-2093, 2001
201. Boden,G, Reichard Jr.,G, Hoeldtke,R, Rezvani,I, Owen,O: Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones. New England Journal of Medicine 305:1200-1205, 1981
202. Chan,O, Chan,S, Inouye,K, Shum,K, Matthews,S, Vranic,M: Diabetes impairs hypothalamo-pituitary-adrenal (HPA) responses to hypoglycemia, and insulin treatment normalizes HPA but not epinephrine responses. Diabetes 51:1681-1689, 2002
203. Dagogo-Jack,S, Craft,S, Cryer,P: Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 91:819-828, 1993
204. Hirsch,B, Shamoon,H: Defective epinephrine and growth hormone responses in type 1 diabetes mellitus are stimulus specific. Diabetes 36:20-26, 1987
205. Inouye,K, Shum,K, Chan,O, Mathoo,J, Matthews,S, Vranic,M: Effects of recurrent hyperinsulinemia with and without hypoglycemia on counterregulation in diabetic rats. American Journal of Physiology Endocrinology and Metabolism 282:E1369-E1379, 2002
206. Kinsley,B, Simonson,D: Evidence for a hypothalamic-pituitary versus adrenal cortical effect of glycemic control on counterregulatory hormone responses to hypoglycemia in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:684-691, 1996
207. Simonson,D, Tamborlane,W, DeFronzo,R, Sherwin,R: Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Annals of Internal Medicine 103:184-190, 1985
208. Benson,JJ, Johnson,D, Palmer,J, Werner,P, Ensinck,J: Glucagon and catecholamine secretion during hypoglycemia in normal and diabetic man. J Clin Endocrinol Metab 44:459-464, 1977
209. Davis,S, Goldstein,R, Jacobs,J, Price,L, Wolfe,R, Cherrington,A: The effects of differing insulin levels on the hormonal and metabolic response to equivalent hypoglycemia in normal humans. Diabetes 42:263-272, 1993
210. Davis,S, Goldstein,R, Price,L, Jacobs,J, Cherrington,A: The effects of insulin on the counterregulatory response to equivalent hypoglycemia in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77:1300-1307, 1993
211. Amiel,S, Sherwin,R, Simonson,D, Tamborlane,W: Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 37:901-907, 1988
214
212. Korzon-Burakowska,A, Hopkins,D, Matyka,K, Lomas,J, Pernet,A, Macdonald,I, Amiel,S: Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 21:283-290, 1998
213. Woerle,H, Meyer,C, Popa,E, Cryer,P, Gerich,J: Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes: further evidence for hepatorenal reciprocity. Diabetes 52:1386-1392, 2003
214. Meneilly,G, Cheung,E, Tuokko,H: Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 78:1341-1348, 1994
215. Meneilly,G, Cheung,E, Tuokko,H: Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 43:403-410, 1994
216. Kinsley,B, Widom,B, Utzschneider,K: Stimulus specificity of defects in counterregulatory hormone secretion in insulin-dependent diabetes mellitus: Effect of glycemic control. J Clin Endocrinol Metab 79:1383-1389, 1994
217. Marliss,E, Vranic,M: Intense exercise has unique effects on both insulin release and its roles in glucoregulation. Diabetes 51:S271-S283, 2002
218. Davis,M, Mellman,M, Friedman,S, Chang,C, Shamoon,H: Recovery of epinephrine response but not hypoglycemic symptom threshold after intensive therapy in type 1 diabetes. American Journal of Medicine 97:535-542, 1994
219. Davis,S, Mann,S, Briscoe,V, Ertl,A, Tate,D: Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes 58:701-709, 2009
220. Inouye,K, Chan,O, Yue,J, Matthews,S, Vranic,M: Effects of diabetes and recurrent hypoglycemia on the regulation of the sympathoadrenal system and hypothalamo-pituitary-adrenal axis. American Journal of Physiology Endocrinology and Metabolism 288:E422-E429, 2005
221. Fioramonti,X, Marsollier,N, Song,Z, Fakira,K, Patel,R, Brown,S, Duparc,T, Pica-Mendez,A, Sanders,N, Knauf,C, Valet,P, McCrimmon,R, Beuve,A, Magnan,C, Routh,V: Ventromedial hypothalamic nitric oxide production is necessary for hypoglycemia detection and counterregulation. Diabetes 59:519-528, 2010
222. Canabal,D, Song,Z, Potian,J, Beuve,A, McArdle,J, Routh,V: Glucose, insulin, and leptin signaling pathways modulate nitric oxide synthesis in glucose-inhibited neurons in the ventromedial hypothalamus. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 292:R1418-R1428, 2007
223. Ovalle,F, Fanelli,C, Paramore,D, Hershey,T, Craft,S, Cryer,P: Brief twice-weekly episodes of hypoglycemia reduce detection of hypoglycemia in type 1 diabetes mellitus. Diabetes 47:1472-1479, 1998
215
224. Fanelli,C, Pampanelli,S, Lalli,C, Del,SP, Ciofetta,M, Lepore,M, Porcellati,F, Bottini,P, Di,VA, Brunetti,P, Bolli,G: Long-term intensive therapy of IDDM patients with clinically overt autonomic neuropathy: effects on hypoglycemia awareness and counterregulation. Diabetes 46:1172-1181, 1997
225. Kleinbaum,J, Shamoon,H: Impaired counterregulation of hypoglycemia in insulin-dependent diabetes mellitus. Diabetes 32:493-498, 1983
226. Fanelli,C, Paramore,D, Hershey,T, Terkamp,C, Ovalle,F, Craft,S, Cryer,P: Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes. Diabetes 47:1920-1927, 1998
227. Davis,M, Mellman,M, Shamoon,H: Further defects in counterregulatory responses induced by recurrent hypoglycemia in IDDM. Diabetes 41:1335-1340, 1992
228. Frier,B, Fisher,B, Gray,C, Beastall,G: Counterregulatory hormonal responses to hypoglycaemia in type 1 (insulin-dependent) diabetes: evidence for diminished hypothalamic-pituitary hormonal secretion. Diabetologia 31:421-429, 1988
229. Shilo,S, Shamoon,H: Abnormal growth hormone responses to hypoglycemia and exercise in adults with type I diabetes. Israel Journal of Medical Sciences 26:136-141, 1990
230. Muggeo,M, Moghetti,P, Querena,M, Girotto,S, Bonora,E, Crepaldi,G: Effect of aging on growth hormone, ACTH and cortisol response to insulin-induced hypoglycemia in type I diabetes. Acta Diabetologica Latina 22:159-168, 1985
231. Amiel,S, Tamborlane,W, Simonson,D, Sherwin,R: Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. New England Journal of Medicine 316:1376-1383, 1987
232. Gerich,J, Mokan,M, Veneman,T, Korytkowski,M, Mitrakou,A: Hypoglycemia unawareness. Endocr Rev 12:356-371, 1991
233. Geddes,J, Schopman,J, Zammitt,N, Frier,B: Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabetic Medicine 25:501-504, 2008
234. Clarke,W, Gonder-Frederick,L, Richards,F, Cryer,P: Multifactorial origin of hypoglycemic symptom unawareness in IDDM. Association with defective glucose counterregulation and better glycemic control. Diabetes 40:680-685, 1991
235. Korytkowski,M, Mokan,M, Veneman,T, Mitrakou,A, Cryer,P, Gerich,J: Reduced beta-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Diabetes Care 21:1939-1943, 1998
236. Fernandez-Castaner,M, Webb,S, Levy,I, Rios,M, Casamitjana,R, Bergua,M, Figuerola,D, Rivera,F: Somatostatin and counterregulatory hormone responses to hypoglycemia in diabetes with and without autonomic neuropathy. Diabetes & Metabolism 11:81-86, 1985
216
237. Bremer,J, Jauch-Chara,K, Hallschmid,M, Schmid,S, Schultes,B: Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 32:1513-1517, 2009
238. Cranston,i, Lomas,J, Maran,A, Macdonald,I, Amiel,S: Restoration of hypoglycemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 344:283-287, 1994
239. Dagogo-Jack,S, Rattarasarn,C, Cryer,P: Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 43:1426-1434, 1994
240. Fanelli,C, Pampanelli,S, Epifano,L, Rambotti,A, Di,VA, Modarelli,F, Ciofetta,M, Lepore,M, Annibale,B, Torlone,E, Perruello,G, De Feo,P, anteusanio,F, runetti,P, Bolli,G: Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 37:1265-1276, 1994
241. Fritsche,A, Stefan,N, Harling,H, Gerich,J, Stumvoll,M: Avoidance of hypoglycemia restoires hypoglycemia awareness by increasing b-adrenergic sensitivity in type 1 diabetes. Annals of Internal Medicine 134:729-736, 2001
242. The DCCT Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
243. Ertl,A, Davis,S: Evidence for a vicious cycle of exercise and hypoglycemia in type 1 diabetes mellitus. Diabetes/Metabolism Research and Reviews 20:124-130, 2004
244. Cryer,P: Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM. A vicious cycle. Diabetes 41:255-260, 1992
245. Routh,V: Glucosensing neurons in the ventromedial hypothalamic nucleus (VMN) and hypoglycemia-associated autonomic failure (HAAF). Diabetes/Metabolism Research and Reviews 19:348-356, 2003
246. Goldberg,P, Weiss,R, McCrimmon,R, Hintz,E, Dziura,J, Sherwin,R: Antecedent hypercortisolemia is not primarily responsible for generating hypoglycemia-associated autonomic failure. Diabetes 55:1121-1126, 2006
247. Alquier,T, Kawashima,J, Tsuji,Y, Kahn,B: Role of hypothalamic adenosine 5'-monophosphate-activated protein kinase in the impaired counterregulatory response induced by repetitive neuroglucopenia. Endocrinology 148:1367-1375, 2007
248. Davis,M, Shamoon,H: Counterregulatory adaptation to recurrent hypoglycemia in normal humans. J Clin Endocrinol Metab 73:995-1001, 1991
249. Davis,S, Mann,S, Galassetti,P, Neill,R, Tate,D, Ertl,A, Costa,F: Effects of differing durations of antecedent hypoglycemia on counterregulatory responses to subsequent hypoglycemia in normal humans. Diabetes 49:1897-1903, 2000
217
250. Heller,S, Cryer,P: Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 40:223-226, 1991
251. Widom,B, Simonson,D: Intermittent hypoglycemia impairs glucose counterregulation. Diabetes 41:1597-1602, 1992
252. Davis,S, Shavers,C, Mosqueda-Garcia,R, Costa,F: Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. Diabetes 46:1328-1335, 1997
253. George,E, Harris,N, Bedfore,C, Macdonald,I, Hardisty,C, Heller,S: Prolonged but partial impairment of the hypoglycemic physiological response following short-term hypoglycemia in normal subjects. Diabetologia 38:1183-1190, 1995
254. Hvidberg,A, Fanelli,C, Hershey,T, Terkamp,C, Craft,S, Cryer,P: Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans. Diabetes 45:1030-1036, 1996
255. Paranjape,S, Briski,K: Recurrent insulin-induced hypoglycemia causes site-specific patterns of habituation or amplification of CNS neuronal genomic activation. Neuroscience 130:957-970, 2004
256. Sivitz,W, Herlein,J, Morgan,D, Fink,B, Phillips,B, Haynes,W: Effect of acute and antecedent hypoglycemia on sympathetic neural activity and catecholamine responsiveness in normal rats. Diabetes 50:1119-1125, 2001
257. McNay,E, Sherwin,R: Effect of recurrent hypoglycemia on spatial cognition and cognitive metabolism in normal and diabetic rats. Diabetes 53:418-425, 2004
258. Amiel,S: Cognitive function testing in studies of acute hypoglycaemia: rights and wrongs? Diabetologia 41:713-719, 1998
259. McNay,E, Williamson,A, McCrimmon,R, Sherwin,R: Cognitive and neural hippocampal effects of long-term moderate recurrent hypoglycemia. Diabetes 55:1088-1095, 2006
260. Puente,E, Silverstein,J, Bree,A, Musikantow,D, Wozniak,D, Maloney,S, Daphna-Iken,D, Fisher,S: Recurrent moderate hypoglycemia ameliorates brain damage and congitive dysfunction induced by severe hypoglycemia. Diabetes 59:1055-1062, 2010
261. Lingenfelser,T, Renn,W, Sommerwerck,U, Jung,M, Buettner,U, Zaiser-Kaschel,H, Kaschel,R, Eggstein,M, Jakober,B: Compromised hormonal counterregulation, symptom awareness, and neurophysiological function after recurrent short-term episodes of insulin-induced hypoglycemia in IDDM patients. Diabetes 42:610-618, 1993
218
262. George,E, Marques,J, Harris,N, Macdonald,I, Hardisty,C, Heller,S: Preservation of physiological responses to hypoglycemia 2 days after antecedent hypoglycemia in patients with IDDM. Diabetes Care 20:1293-1298, 1997
263. Powell,A, Sherwin,R, Shulman,G: Impaired hormonal responses to hypoglycemia in spontaneously diabetic and recurrently hypoglycemic rats. J Clin Invest 92:2667-2674, 1993
264. Rattarasarn,C, Dagogo-Jack,S, Zachwieja,J, Cryer,P: Hypoglycemia-induced autonomic failure in IDDM is specific for stimulus of hypoglycemia and is not attributable to prior autonomic activation. Diabetes 43:809-818, 1994
265. George,E, Harris,N, Bedford,C, Macdonald,I, Hardisty,C, Heller,S: Prolonged but partial impairment of the hypoglycaemic physiological response following short-term hypoglycemia in normal subjects. Diabetologia 38:1183-1190, 1995
266. Krulich,L, Dhariwal,A, McCann,S: Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783-790, 1968
267. Brazeau,P, Vale,W, Burgus,R, Ling,N, Butcher,M, Rivier,J, Guillemin,R: Hypothalamic peptide that inhibits the secretion of immunoreative pituitary growth hormone. Science 179:77-79, 1973
268. Meites,J: The 1977 Nobel Prize in physiology or medicine. Science 198:594-596, 1977
269. Pradayrol,L, Jornvall,H, Mutt,V, Ribet,A: N-terminally extended somatostatin: The primary structure of somatostatin 28. FEBS Letters 109:55-58, 1980
270. Pless,J: The history of somatostatin analogs. Journal of Endocrinological Investigation 28:1-4, 2005
271. Patel,Y: Somatostatin and its receptor family. Frontiers in Neuroendocrinology 20:157-198, 1999
272. Cone R, Low M, Elmquist J, Cameron J: Hypthalamus and Pituitary: Neuroendocrinology. In Williams Textbook of Endocrinology. Tenth ed. Larsen P, Koronenberg H, Melmed S, Polonsky K, Eds. Philadelphia, Saunders, 2003, p. 81-176
273. Weir,G, Bonner-Weir,S: Islets of Langerhans: The puzzle of intraislet interactions and their relevance to diabetes. J Clin Invest 85:983-987, 1990
274. Koerker,D, Ruch,W, Chideckel,E, Palmer,J, Goodner,C, Ensinck,J, Gale,C: Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 184:482-484, 1974
219
275. Taborsky Jr,G, Smith,P, Porte Jr,D: Differential effects of somatostatin analogues on alpha- and beta-cells of the pancreas. American Journal of Physiology Endocrinology and Metabolism 236:E123-E128, 1979
276. Orci,L, Unger,R: Functional subdivision of islets of Langerhans and possible role of D cells. Lancet 306:1243-1244, 1975
277. Kleinman,R, Gingerich,R, Wong,H, Walsh,J, Lloyd,K, Ohning,G, De,GR, Sternini,C, Brunicardi,F: Use of the Fab fragment for immunoneutralization of somatostatin in the isolated perfused human pancreas. American Journal of Surgery 167:114-119, 1994
278. Brelje,T, Scharp,D, Sorenson,R: Three-dimensional imaging of intact isolated islets of Langerhans with confocal microscopy. Diabetes 38:808-814, 1989
279. Barden,N, Lavoie,M, Dupont,A, Cote,J, Cote,J: Stimulation of glucagon release by addition of anti-somatostatin serum to islets of Langerhans in vitro. Endocrinology 101:635-638, 1977
280. Itoh,M, Mandarino,L, Gerich,J: Antisomatostatin gamma globulin augments secretion of both insulin and glucagon in vitro: evidence for a physiologic role for endogenous somatostatin in the regulation of pancreatic A- and B-cell function. Diabetes 29:693-696, 1980
281. Brunicardi,F, Kleinman,R, Ohning,G, Lloyd,K, Gingerich,R, Wong,H, Walsh,J: The inhibitory role of intraislet somatostatin on glucagon secretion in the isolated perfused human pancreas. Transplantation Proceedings 26:3451-3452, 1994
282. Kleinman,R, Ohning,G, Wong,H, Watt,P, Walsh,J, Brunicardi,F: Regulatory role of intraislet somatostatin on insulin secretion in the isolated perfused human pancreas. Pancreas 9:172-178, 1994
283. Liu,Y, Guth,P, Kaneko,K, Livingston,E, Brunicardi,F: Dynamic in vivo observation of rat islet microcirculation. Pancreas 8:15-21, 1993
284. Samols,E, Stagner,J: Islet somatostatin - microvascular, paracrine, and pulsatile regulation. Metabolism 39 (Suppl 2):55-60, 1990
285. Stagner,J, Samols,E: The vascular order of islet cellular perfusion in the human pancreas. Diabetes 41:93-97, 1992
286. Schusdziarra,V, Rouiller,D, Arimura,A, Unger,R: Antisomatostatin serum increases levels of hormones from the pituitary and gut, but not from the pancreas. Endocrinology 103:1956-1959, 1978
287. Schusdziarra,V, Zyznar,E, Rouiller,D, Boden,G, Brown,J, Arimura,A, Unger,R: Splanchnic somatostatin: a hormonal regulator of nutrient homeostasis. Science 207:530-532, 1980
220
288. Tannenbaum,G, McCarthy,G, Zeitler,P, Beaudet,A: Cysteamine-induced enhancement of growth hormone-releasing factor (GRF) immunoreactivity in arcuate neurons: morphological evidence for putative somatostatin/GRF interactions within hypothalamus. Endocrinology 127:2551-2560, 1990
289. Arimura,A, Schally,A: Increase in basal and thyrotropin-releasing hormone (TRH)-stimulated secretion of thyrotropin (TSH) by passive immunization with antiserum to somatostatin in rats. Endocrinology 98:1069-1072, 1976
290. Epelbaum,J: Somatostatin in the central nervous system: physiology and pathological modifications. Progress in Neurobiology 27:63-100, 1986
291. Patel Y: General aspects of the biology and function of somatostatin. In Basic and Clinical Aspects of Neuroscience. Weil C, Muller E, Thorner M, Eds. Berlin, Springer-Verlag, 1992, p. 1-16
292. Viollet,C, Lepousez,G, Loudes,C, Videau,C, Simon,A, Epelbaum,J: Somatostatinergic systems in brain: Networks and functions. Molecular and Cellular Endocrinology 286:75-87, 2008
293. Luft,R, Efendic,S, Hokfelt,T: Somatostatin--both hormone and neurotransmitter? Diabetologia 14:1-13, 1978
294. Luque,R, Gahete,M, Hochgeschwender,U, Kineman,R: Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways. American Journal of Physiology Endocrinology and Metabolism 291:E395-E403, 2006
295. Frohman,L: CNS peptides and glucoregulation. Annual Review of Physiology 45:95-107, 1983
296. Marco,J, Hedo,J, Villaneuva,M: Inhibition of intestinal glucagon-like immunoreactivity (GLI) secretion by somatostatin in man. J Clin Endocrinol Metab 44:695-698, 1977
297. Chisholm,C, Greenberg,G: Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. American Journal of Physiology Endocrinology and Metabolism 283:E311-E317, 2002
298. Baron,A, Wallace,P, Bretchtel,G, Prager,R: Somatostatin does not increase insulin-stimulated glucose uptake in humans. Diabetes 36:33-36, 1987
299. Luft,R, Efendic,S, Hokfelt,T, Johansson,O, Arimura,A: Immunohistochemical evidence for the localization of somatostatin--like immunoreactivity in a cell population of the pancreatic islets. Medical Biology 52:428-430, 1974
300. Steiner,D, Kim,A, Miller,K, Hara,M: Pancreatic islet plasticity: Interspecies comparison of islet architecture and composition. Islets 2:135-145, 2010
221
301. Brissova,M, Fowler,M, Nicholson,W, Chu,A, Hirshberg,B, Harlan,D, Powers,A: Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 53:1087-1097, 2005
302. Quesada,I, Tuduri,E, Ripoll,C, Nadal,A: Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. Journal of Endocrinology 199:5-19, 2008
303. Adeghate,E, Ponery,A: Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. Journal of Neuroendocrinolgy 14:555-560, 2002
304. Cabrera,O, Berman,D, Kenyon,N, Ricordi,C, Berggren,P, Caicedeo,A: The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proceedings of the National Academy of Sciences U S A 103:2334-2339, 2006
305. Braun,M, Ramracheya,R, Amisten,S, Bengtsson,M, Moritoh,Y, Zhang,Q, Johnson,R, Rorsman,P: Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia 52:1566-1578, 2009
306. Taborsky,GJ, Ensinck,J: Contribution of the pancreas to circulating somatostatin-like immunoreactivity in the normal dog. J Clin Invest 73:216-223, 1984
307. Patel,Y, Wheatley,T, Ning,C: Multiple forms of immunoreactive somatostatin: comparison of distribution in neural and nonneural tissues and portal plasma of the rat. Endocrinology 109:1943-1949, 1981
308. Noe,B: Synthesis of one form of pancreatic islet somatostatin predominates. Journal of Biological Chemistry 256:9397-9400, 1981
309. Amherdt,M, Patel,Y, Orci,L: Selective binding of somatostatin-14 and somatostatin-28 to islet cells revealed by quantitative electron microscopic autoradiography. J Clin Invest 80:1455-1458, 1987
310. Wang,X, Norman,M, Brunicardi,F: Somatostatin receptors and autoimmune-mediated diabetes. Diabetes/Metabolism Research and Reviews 21:15-30, 2005
311. Finley,J, Maderdrut,J, Roger,L, Petrusz,P: The immunocytochemical localization of somatostatin-containing neurons in the rat central nervous system. Neuroscience 6:2173-2192, 1981
312. Johansson,O, Hokfelt,T, Elde,R: Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience 13:265-339, 1984
313. Hokfelt,T, Efendic,S, Hellerstrom,C, Johansson,O, Luft,R, Arimura,A: Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special references to the A1-cells of the pancreatic islets and to the hypothalamus. Acta Endocrinologica 200:5-41, 1975
222
314. Liao,Z, Li,Z, Lu,Y, Wang,W: Microinjection of exogenous somatostatin in the dorsal vagal complex inhibits pancreatic secretion via somatostatin receptor-2 in rats. American Journal of Physiology Gastrointestinal and Liver Physiology 292:G746-G752, 2007
315. Guillemin,R: Somatostatin inhibits the release of acetylcholine induced electrically in the myenteric plexus. Endocrinology 99:1653-1654, 1976
316. Larsson,L, Goltermann,N, de,ML, Rehfeld,J, Schwartz,T: Somatostatin cell processes as pathways for paracrine secretion. Science 205:1393-1395, 1979
317. Brubaker,P, Drucker,D, Greenberg,G: Synthesis and secretion of somatostatin-28 and -14 by fetal rat intestinal cells in culture. American Journal of Physiology Gastrointestinal and Liver Physiology 258:G974-G981, 1990
318. Reichlin,S: Somatostatin. New England Journal of Medicine 309:1495-1501, 1983
319. Elliott,D, Blum,A, Li,J, Metwali,A, Weinstock,J: Preprosomatostatin messenger RNA is expressed by inflammatory cells and induced by inflammatory mediators and cytokines. Journal of Immunology 160:3997-4003, 1998
320. Aguila,M, Dees,W, Haensly,W, McCann,S: Evidence that somatostatin is localized and synthesized in lymphoid organs. Proceedings of the National Academy of Sciences U S A 88:11485-11489, 1991
321. Levite,M: Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proceedings of the National Academy of Sciences U S A 95:12544-12549, 1998
322. Patel,Y, Zingg,H, Dreifuss,J: Calcium-dependent somatostatin secretion from rat neurohypophysis in vitro. Nature 267:852-853, 1977
323. Goodman,R, Aron,D, Roos,B: Rat pre-prosomatostatin: structure and processing by microsomal membranes. Journal of Biological Chemistry 258:5570-5573, 1983
324. Shen,L, Rutter,W: Sequence of the human somatostatin I gene. Science 224:168-171, 1984
325. de Lecea,L, Criado,J, Prospero-Garcia,O, Gautvik,K, Schweitzer,P, Danielson,P, Dunlop,C, Siggins,G, Henriksen,S, Sutcliffe,J: A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381:242-245, 1996
326. Broglio,F, Grottoli,S, Arvat,E, Ghigo,E: Endocrine actions of cortistatin: In vivo studies. Molecular and Cellular Endocrinology 286:123-127, 2008
327. Spier,A, Fabre,V, de Lecea,L: Cortistatin radioligand binding in wild-type and somatostatin receptor-deficient mouse brain. Regulatory Peptides 124:179-186, 2005
223
328. van Hagen,P, Dalm,V, Staal,F, Hofland,L: The role of cortistatin in the human immune system. Molecular and Cellular Endocrinology 286:141-147, 2008
329. Samson,W, Zhang,J, Avsian-Kretchmer,O, Cui,K, Yosten,G, Klein,C, Lyu,R, Wang,Y, Chen,X, Yang,J, Price,C, Hoyda,T, Ferguson,A, Yuan,X, Chang,J, Hsueh,A: Neuronostatin encoded by the somatostatin gene regulates neuronal, cardiovascular, and metabolic functions. Journal of Biological Chemistry 283:31949-31959, 2008
330. Dun,S, Brailoiu,G, Tica,A, Yang,J, Chang,J, Brailoiu,E, Dun,N: Neuronostatin is co-expressed with somatostatin and mobilizes calcium in cultured rat hypothalamic neurons. Neuroscience 166:455-463, 2010
331. Lee,D, George,S, O'Dowd,B: Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends in Pharmacological Sciences 27:190-194, 2006
332. Lee,D, Cheng,R, Nguyen,T, Fan,T, Kariyawasam,A, Liu,Y, Osmond,D, George,S, O'Dowd,B: Characterization of apelin, the ligand for the APJ receptor. Journal of Neurochemistry 74:34-41, 2000
333. Schulz,C, Paulus,K, Lehnert,H: Adipocyte-brain: crosstalk. Results and Problems in Cell Differentiation 52:189-201, 2010
334. Guo,L, Li,Q, Wang,W, Yu,P, Pan,H, Li,P, Sun,Y, Zhang,J: Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B. Endrocrine Research 34:142-154, 2009
335. Ringstrom,C, Nitert,M, Bennet,H, Fex,M, Valet,P, Rehfeld,J, Friis-Hansen,L, Wierup,N: Apelin is a novel islet peptide. Regulatory Peptides 162:44-51, 2010
336. Boucher,J, Masri,B, Daviaud,D, Gesta,S, Guigne,C, Mazzucotelli,A, Castan-Laurell,I, Tack,I, Knibiehler,B, Carpene,C, Audigier,Y, Saulnier-Blache,J, Valet,P: Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146:1764-1771, 2005
337. Dray,C, Knauf,C, Daviaud,D, Waget,A, Boucher,J, Buleon,M, Cani,P, Attane,C, Guigne,C, Carpene,C, Burcelin,R, Castan-Laurell,I, Valet,P: Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metabolism 8:437-445, 2008
338. Dray,C, Debard,C, Jager,J, Disse,E, Daviaud,D, Martin,P, Attane,C, Wanecq,E, Guigne,C, Bost,F, Tanti,J, Laville,M, Vidal,H, Valet,P, Castan-Laurell,I: Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. American Journal of Physiology Endocrinology and Metabolism 298:E1161-E1169, 2010
339. O'Dowd,B, Heiber,M, Chan,A, Heng,H, Tsui,L, Kennedy,J, Shi,X, Petronis,A, George,S, Nguyen,T: A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136:355-360, 1993
224
340. O'Carroll,A, Don,A, Lolait,S: APJ receptor mRNA expression in the rat hypothalamic paraventricular nucleus: regulation by stress and glucocorticoids. J Neuroendocrinol 15:1095-1101, 2003
341. Meral,C, Tascilar,E, Karademir,F, Tanju,I, Cekmez,F, Ipcioglu,O, Ercin,C, Gocmen,I, Dogru,T: Elevated plasma levels of apelin in children with type 1 diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 23:497-502, 2010
342. Ashizawa,S, Brunicardi,F, Wang,X: PDX-1 and the pancreas. Pancreas 28:109-120, 2004
343. Vallejo,M, Miller,C, Beckman,W, Habener,J: Repression of somatostatin gene transcription mediated by two promoter silencer elements. Molecular and Cellular Endocrinology 113:61-72, 1995
344. Montminy,M, Brindle,P, Arias,J, Ferreri,K, Armstrong,R: Regulation of somatostatin gene transcription by cyclic adenosine monophosphate. Metabolism 45:4-7, 1996
345. Capone,G, Choi,C, Vertifuille,J: Regulation of the preprosomatostatin gene by cyclic-AMP in cerebrocortical neurons. Brain Research Molecular Brain Research 60:247-258, 1998
346. Efendic,S, Nylen,A, Roovete,A, Uvnas-Wallenstein,K: Effects of glucose and arginine on the release of immunoreactive somatostatin from the isolated perfused rat pancreas. FEBS Letters 92:33-35, 1978
347. Kanno,T, Gopel,S, Rorsman,P, Wakui,M: Cellular function in multicellular system for hormone-secretion: electrophysiological aspect of studies on alpha-, beta- and delta-cells of the pancreatic islet. Neuroscience Research 42:79-90, 2002
348. Brunicardi,F, Kleinman,R, Moldovan,S, Nguyen,T, Watt,P, Walsh,J, Gingerich,R: Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas. Pancreas 23:302-308, 2001
349. Brunicardi,F, Elahi,D, Andersen,D: Splanchnic neural regulation of somatostatin secretion in the isolated perfused human pancreas. Annals of Surgery 219:258-266, 1994
350. Goto,Y, Carpenter,R, Berelowitz,M, Frohman,L: Effect of ventromedial hypothalamic lesions on the secretion of somatostatin, insulin, and glucagon by the perfused rat pancreas. Metabolism 29:986-990, 1980
351. Julien,S, Laine,J, Morisset,J: Regulation of rat pancreatic CCKB receptor and somatostatin expression by insulin. Diabetes 53:1526-1534, 2004
352. El-Kouhen,K, Morriset,J: Control of somatostatin (SS) secretion by CCK-1 and CCK-2 receptors' occupation in RIN-14B cells, a rat pancreatic islet cell line. Pancreas 39:127-134, 2010
225
353. Berelowitz,M, Firestone,S, Frohman,L: Effects of growth hormone exccess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution. Endocrinology 109:714-719, 1981
354. Berelowitz,M, Szabo,M, Frohman,L, Firestone,S, Chu,L: Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 212:1279-1281, 1981
355. Chihara,K, Arimura,A, Schally,A: Effect of intraventricular injection of dopamine, noreprinephrine, acetylcholine, and 5-hydroxytryptamine on immunoreactive somatostatin release into rat hypophyseal portal blood. Endocrinology 104:1656-1662, 1979
356. Scarborough,D, Lee,S, Dinarello,C, Reichlin,S: Interleukin-1b stimulates somatostatin biosynthesis in primary cultures of fetal rat brain. Endocrinology 124:549-551, 1989
357. Quintela,M, Senaris,R, Dieguez,C: Transforming growth factor-bs inhibit somatostatin messenger ribonucleic acid levels and somatostatin secretion in hypothalamic cells in culture. Endocrinology 138:4401-4409, 1997
358. Quintela,M, Senaris,R, Helman,M, Casanueva,F, Dieguez,C: Leptin inhibits in vitro hypothalamic somatostatin secretion and somatostatin mRNA levels. Endocrinology 138:5641-5644, 1997
359. Arimura,A, Fishback,J: Somatostatin: regulation of secretion. Neuroendocrinology 33:256, 1981
360. Uvnas-Wallensten,K, Efendic,S, Luft,R: Vagal release of somatostatin into the antral lumen of cats. Acta Physiologica Scandinavica 99:126-128, 1977
361. Brubaker,P, Efendic,S, Greenberg,G: Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release. Endocrine 6:91-95, 1997
362. Schubert,M, Jong,M, Makhlouf,G: Bombesin/GRP-stimulated somatostatin secretion is mediated by gastrin in the antrum and intrinsic neurons in the fundus. American Journal of Physiology Gastrointestinal and Liver Physiology 261:G885-G889, 1991
363. Binimelis,J, Webb,S, Serrano,J, Codina,M, Corcoy,R, Perez,A, Peinado,M, Puig,M, de la Torre,W, Serrat,J, Gomez,J, Casamitjana,R, de Leiva,A: Plasma immunoreactive somatostatin is elevated in diabetic ketoacidosis and correlates with plasma non-esterified fatty acid concentration. Diabetic Medicine 4:221-224, 1987
364. Patel,Y, O'Neil,W: Peptides derived from cleavage of prosomatostatin at carboxyl- and amino-terminal segments. Characterization of tissue and secreted forms in the rat. Journal of Biological Chemistry 263:745-751, 1988
226
365. Baskin,D, Ensinck,J: Somatostatin in epithelial cells of intestinal mucosa is present primarily as somatostatin 28. Peptides 5:615-621, 1984
366. Schonbrunn,A, Tashjian Jr.,A: Characterization of functional receptors for somatostatin in rat pituitary cells in culture. Journal of Biological Chemistry 253:6473-6483, 1978
367. Yamada,Y, Post,S, Wang,K, Tager,H, Bell,G, Seino,S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in the brain, gastrointestinal tract, and kidney. Proceedings of the National Academy of Sciences U S A 89:251-255, 1992
368. Bruns,C, Raulf,F, Hoyer,D, Schloos,J, Lubbert,H, Weckbecker,G: Binding properties of somatostatin receptor subtypes. Metabolism 45:17-20, 1996
369. Patel,Y, Srikant,C: Somatostatin receptors. TRENDS in Endocrinology and Metabolism 8:398-405, 1997
370. Reisine,T: Somatostatin receptors. American Journal of Physiology Gastrointestinal and Liver Physiology 32:G813-G820, 1995
371. Evans,C, Keith,DJ, Morrison,H, Magendzo,K, Edwards,R: Cloning of a delta opiod receptor by functional expression. Science 258:1952-1955, 1992
372. Bruno,J, Xu,Y, Song,J, Berelowitz,M: Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proceedings of the National Academy of Sciences U S A 89:11151-11155, 1992
373. Bruno,J, Xu,Y, Song,J, Berelowitz,M: Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology 133:2561-2567, 1993
374. Kong,H, DePaoli,A, Breder,C, Yasuda,K, Bell,G, Reisine,T: Differential expression of messenger RNAs fo somatostatin receptor subtypes SSTR1, SSTR2 and SSTR3 in adult rat brain: analysis by RNA blotting and in situ hybridization histochemistry. Neuroscience 59:175-184, 1994
375. Breder,C, Yamada,Y, Yasuda,K, Seino,S, Saper,C, Bell,G: Differential expression of somatostatin receptor subtypes in brain. Journal of Neuroscience 12:3920-3934, 1992
376. Thoss,V, Perez,J, Probst,A, Hoyer,D: Expression of five somatostatin receptor mRNAs in the human brain and pituitary. Naunyn Schmiedeberg's Archives of Pharmacology 354:411-419, 1996
377. Panetta,R, Greenwood,M, Warszynska,A, Demchyshyn,L, Day,R, Niznik,H, Srikant,C, Patel,Y: Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Molecular Pharmacology 45:417-427, 1994
227
378. Kumar,U: Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. Journal of Comparative Neurology 504:185-205, 2007
379. Kumar,U, Laird,D, Srikant,C, Escher,E, Patel,Y: Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138:4473-4476, 1997
380. Day,R, Dong,W, Panetta,R, Kraicer,J, Greenwood,M, Patel,Y: Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology 136:5232-5235, 1995
381. O'Carroll,A, Krempels,K: Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endocrinology 136:5224-5227, 1995
382. Panetta,R, Patel,Y: Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 56:333-342, 1995
383. Le Romancer,M, Cherifi,Y, LEvasseur,S, Laigneau,J, Peranzi,G, Jasi,P, Lewin,M, Reyl-Desmars,F: Messenger RNA expression of somatostatin receptor subtypes in human and rat gastric mucosae. Life Sciences 58:1091-1098, 1996
384. Krempels,K, Hunyady,B, O'Carroll,A, Mezey,E: Distribution of somatostatin receptor messenger RNAs in the rat gastrointestinal tract. Gastroenterology 112:1948-1960, 1997
385. Kumar,U, Sasi,R, Suresh,S, Patel,A, Thangaraju,M, Metrakos,P, Patel,S, Patel,Y: Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48:77-85, 1999
386. Singh,V, Brendel,M, Zacharias,S, Mergler,S, Jahr,H, Wiedenmann,B, Bretzel,R, Plockinger,U, Strowski,M: Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 92:673-680, 2007
387. Mitra,S, Mezey,E, Hunyady,B, Chamberlain,L, Hayes,E, Foor,F, Wang,Y, Schonbrunn,A, Schaeffer,J: Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 140:3790-3796, 1999
388. Rossowski,W, Coy,D: Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochemical and Biophysical Research Communications 205:341-346, 1994
389. Strowski,M, Parmar,R, Blakde,A, Schaeffer,J: Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141:111-117, 2000
228
390. Kimura,N, Schindler,M, Kasai,N, Kimura,I: Immunohistochemical localization of somatostatin receptor type 2A in rat and human tissues. Endocrine Journal 48:95-102, 2001
391. Portela-Gomes,G, Stridsberg,M, Grimelius,L, Oberg,K, Janson,E: Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Applied Immunohistochemistry and Molecular Morphology 8:126-132, 2000
392. Cejvan,K, Coy,D, Efendic,S: Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 52:1176-1181, 2003
393. Strowski,M, Kohler,M, Chen,H, Trumbauer,M, Li,Z, Szalkowski,D, Gopal-Truter,S, Fisher,J, Schaeffer,J, Blake,A, Zhang,B, Wilkinson,H: Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Molecular Endocrinology 17:93-106, 2003
394. Fagan,S, Azizzadeh,A, Moldovan,S, Ray,M, Adrian,T, Ding,X, Coy,D, Brunicardi,F: Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery 124:254-258, 1998
395. Ludvigsen,E: Somatostatin receptor expression and biological functions in endocrine pancreatic cells: review based on a doctoral thesis. Upsala Journal of Medical Sciences 112:1-20, 2007
396. Ludvigsen,E, Stridsberg,M, Taylor,J, Culler,M, Oberg,K, Janson,E, Sandler,S: Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues. Regulatory Peptides 138:1-9, 2007
397. O'Carroll,A: Localization of messenger ribonucleic acids for somatostain receptor subtypes (sstr1-5) in the rat adrenal gland. The Journal of Histochemistry and Cytochemistry 51:55-60, 2003
398. Morel,G, Leroux,P, Garcia Caballero,T, Beiras,A, Gossard,F: Ultrastructural distribution of somatostatin-14 and -28 in rat adrenal cells. Cell and Tissue Research 261:517-524, 1990
399. Maurer,R, Reubi,J: Somatostatin receptors in the adrenal. Molecular and Cellular Endocrinology 45:81-90, 1986
400. Patel,Y, Greenwood,M, Kent,G, Panetta,R, Srikant,C: Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochemical and Biophysical Research Communications 192:288-294, 1993
401. Rosskopf,D, Schurks,M, Manthey,I, Joisten,M, Busch,S, Siffert,W: Signal transduction of somatostatin in human B lymphoblasts. American Journal of Physiology Cell Physiology 284:C179-C190, 2003
229
402. Taniyama,Y, Suzuki,T, Mikami,Y, Moriya,T, Satomi,S, Sasano,H: Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocrine Journal 52:605-611, 2005
403. Armani,C, Catalani,E, Balbarini,A, Bagnoli,P, Cervia,D: Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. Journal of Leukocyte Biology 81:845-855, 2007
404. Cervia,D, Casini,G, Bagnoli,P: Physiology and pathology of somatostatin in the mammalian retina: a current view. Molecular and Cellular Endocrinology 286:112-122, 2008
405. Guillermet-Guibert,J, Lahlou,H, Cordelier,P, Bousquet,C, Pyronnet,S, Susini,C: Physiology of somatostatin receptors. Journal of Endocrinological Investigation 28:5-9, 2005
406. Virgolini,I: Mack Forster Award Lecture. Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients. European Journal of Clinical Investigation 27:793-800, 1997
407. Virgolini,I, Pangerl,T, Bischof,C, Smith-Jones,P, Peck-Radosavljevic,M: Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? European Journal of Clinical Investigation 27:645-647, 1997
408. Casarini,A, Pinto,E, Jallad,R, Giorgi,R, Giannella-Neto,D, Bronstein,M: Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. Journal of Endocrinological Investigation 29:826-830, 2006
409. Pisarek,H, Pawlikowski,M, Kunert-Radek,J, Kubiak,R, Winczyk,K: SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochemica et Cytobiologica 48:142-147, 2010
410. Aguila,M, Rodriguez,A, Aguila-Mansilla,H, Lee,W: Somatostatin antisense oligodeoxynucleotide-mediated stimulation of lymphocyte proliferation in culture. Endocrinology 137:1585-1590, 1996
411. Karalis,K, Mastorakos,G, Chrousos,G, Tolis,G: Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 93:2000-2006, 1994
412. Weiss,R, Reddi,A, Nimni,M: Somatostatin can locally inhibit proliferation and differentiation of cartilage and bone precursor cells. Calcified Tissue International 33:425-430, 1981
413. Florio,T: Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases. Molecular and Cellular Endocrinology 286:40-48, 2008
230
414. Weckbecker,G, Lewis,I, Albert,R, Schmid,H, Hoyer,D, Bruns,C: Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Reviews Drug Discovery 2:999-1017, 2003
415. Sharma,K, Patel,Y, Srikant,C: Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688-1696, 1996
416. Kluxen,F, Bruns,C, Lubbert,H: Expression cloning of a rat brain somatostatin receptor cDNA. Proceedings of the National Academy of Sciences U S A 89:4618-4622, 1992
417. Vanetti,M, Kouba,M, Wang,X, Vogt,G, Hollt,V: Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Letters 311:290-294, 1992
418. Reynaert,H, Rombouts,K, Vandermonde,A, Urbain,D, Kumar,U, Bioulac-Sage,P, Pinzani,M, Rosenbaum,J, Geerts,A: Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 53:1180-1189, 2004
419. Dournaud,P, Gu,Y, Schonbrunn,A, Mazella,J, Tannenbaum,G, Beaudet,A: Localization of the somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody. Journal of Neuroscience 16:4468-4478, 1996
420. Fehlman,D, Langenegger,D, Schuepbach,E, Siehler,S, Feuerbach,D, Hoyer,D: Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery. Journal of Physiology (Paris) 94:265-281, 2000
421. Boudin,H, Sarret,P, Mazella,J, Schonbrunn,A, Beaudet,A: Somatostatin-induced regulation of SST(2A) receptor expression and cellsurface availability in central neurons: role of receptor internalization. Journal of Neuroscience 20:5932-5939, 2000
422. Kumar U, Grant M: Somatostatin and somatostatin receptors. In Results and Problems in Cell Differentiation : Cellular Peptide Hormone Synthesis and Secretory Pathways. Rehfeld J, Bundgaard J, Eds. Springer Berlin Heidelberg, 2010, p. 137-184
423. Beaudet,A, Greenspun,D, Raelson,J, Tannenbaum,G: Patterns of expression of SSTR1 and SSTR2 somatostatin receptor subtypes in the hypothalamus of the adult rat: relationship to neuroendocrine function. Neuroscience 65:551-561, 1995
424. Csaba,Z, Simon,A, Helboe,L, Epelbaum,J, Dournaud,P: Targeting sst2A receptor-expressing cells in the rat hypothalamus through in vivo agonist stimulation: neuroanatomical evidence for a major role of this subtype in mediating somatostatin functions. Endocrinology 144:1564-1573, 2003
425. Schindler,M, Sellers,L, Humphrey,P, Emson,P: Immunohistochemical localization of the somatostatin SST2(A) receptor in the rat brain and spinal cord. Neuroscience 76:225-240, 1997
231
426. Stepanyan,Z, Kocharyan,A, Pyrski,M, Hubschle,T, Watson,A, Schulz,S, Meyerhof,W: Leptin-target neurones of the rat hypothalamus express somatostatin receptors. Journal of Neuroendocrinolgy 15:822-830, 2003
427. Tannenbaum,G, Turner,J, Guo,F, Videau,C, Epelbaum,J, Beaudet,A: Homologous upregulation of sst2 somatostatin receptor expression in the rat arcuate nucleus in vivo. Neuroendocrinology 74:33-42, 2001
428. Tannenbaum,G, Zhang,W, Lapointe,M, Zeitler,P, Beaudet,A: Growth hormone-releasing hormone neurons in the arcuate nucleus express both Sst1 and Sst2 somatostatin receptor genes. Endocrinology 139:1450-1453, 1998
429. Goebel,M, Stengel,A, Wang,L, Coskun,T, Alsina-Fernandez,J, Rivier,J, Tache,Y: Pattern of Fos expression in the brain induced by selective activation of somatostatin receptor 2 in rats. Brain Research 1351:150-164, 2010
430. Stengel,A, Goebel,M, Wang,L, Rivier,J, Kobelt,P, Monnikes,H, Tache,Y: Selective central activation of somatostatin receptor 2 increases food intake, grooming behavior and rectal temperature in rats. Journal of Physiology and Pharmacology 61:399-407, 2010
431. Shimon,I, Taylor,J, Dong,J, Bitonte,R, Kim,S, Morgan,B, Coy,D, Culler,M, Melmed,S: Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99:789-798, 1997
432. Ren,S-G, Taylor,J, Dong,J, Yu,R, Culler,M, Melmed,S: Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 88:4239-4245, 2003
433. Lanneau,C, Bluet-Pajot,M, Zizzari,P, Csaba,Z, Dournaud,P, Helboe,L, Hoyer,D, Pellegrini,E, Tannenbaum,G, Epelbaum,J, Gardette,R: Involvement of the Sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: an in vitro and in vivo antisense study. Endocrinology 141:967-979, 2000
434. Stroh,T, Sarret,P, Tannenbaum,G, Beaudet,A: Immunohistochemical distribution and subcellular localization of the somatostatin receptor subtype 1 (sst1) in the rat hypothalamus. Neurochemical Research 31:247-257, 2006
435. Hukovic,N, Panetta,R, Kumar,U, Patel,Y: Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 137:4046-4049, 1996
436. Rocheville,M, Lange,D, Kumar,U, Sasi,R, Patel,R, Patel,Y: Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. Journal of Biological Chemistry 275:7862-7869, 2000
232
437. Patel,Y, Greenwood,M, Panetta,R, Hukovic,N, Grigorakis,S, Robertson,L, Srikant,C: Molecular biology of somatostatin receptor subtypes. Metabolism 45:31-38, 1996
438. Yang,S, Parkington,H, Epelbaum,J, Keating,D, Chen,C: Somatostatin decreases voltage-gated Ca2+ currents in GH3 cells through activation of somatostatin receptor 2. American Journal of Physiology Endocrinology and Metabolism 292:E1863-E1870, 2007
439. Orci,L, Baetens,D, Rufener,C, Amherdt,M, Ravazzola,M, Studer,P, Malaisse-Lagae,F, Unger,R: Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proceedings of the National Academy of Sciences U S A 73:1338-1342, 1976
440. Rahier,J, Goebbels,R, Henquin,J: Cellular composition of the human diabetic pancreas. Diabetologia 24:366-371, 1983
441. Ertan,A, Arimura,A, Akdamar,K, Shibata,T, Groot,K, Luciano,M, Mather,F, Degertekin,H, Agrawal,N, Ryan,J: Pancreatic immunoreactive somatostatin and diabetes mellitus. Digestive Diseases and Sciences 29:625-630, 1984
442. Segers,O, De,VM, Michotte,Y, Somers,G: Basal and tolbutamide-induced plasma somatostatin in healthy subjects and in patients with diabetes and impaired glucose tolerance. Diabetic Medicine 6:232-238, 1989
443. Skare,S, Dahl-Jorgensen,K, Hanssen,K, Norman,N: Increased peripheral venous somatostatin concentration and decreased glucagon response to arginine in patients with insulin dependent diabetes mellitus without residual B-cell function. Increased plasma SRIF in IDDM. Acta Endocrinologica 109:517-521, 1985
444. Jones,C, Reynolds,W, Hoganson,G: Streptozotocin diabetes in the monkey: plasma levels of glucose, insulin, glucagon, and somatostatin, with corresponding morphometric analysis of islet endocrine cells. Diabetes 29:536-546, 1980
445. Rastogi,K, Brubaker,P, Kawasaki,A, Efendic,S, Vranic,M: Increase in somatostatin to glucagon ratio in islets of alloxan-diabetic dogs: effect of insulin-induced euglycemia. Canadian Journal of Physiology and Pharamcology 71:512-517, 1993
446. Schusdziarra,V, Rouiller,D, Harris,V, Conlon,M, Unger,R: The response of plasma somatostatin-like immunoreactivity to nutrients in normal and alloxan diabetic dogs. Endocrinology 103:2264-2273, 1978
447. Patel,Y, Weir,G: Increased somatostatin content of islets from streptozotocin-diabetic rats. Clincal Endocrinology (Oxford) 5:191-194, 1976
448. Makino,H, Kanatsuka,A, Matsushima,Y, Yamamoto,M, Kumagai,A: Effect of streptozotocin administration on somatostatin content of pancreas and hypothalamus in rats. Endocrinologia Japonica 24:295-299, 1977
233
449. Patel,Y, Cameron,D, Bankier,A, Malaisse-Lagae,F, Ravazzola,M, Studer,P, Orci,L: Changes in somatostatin concentration in pancreas and other tissues of streptozotocin diabetic rats. Endocrinology 103:917-923, 1978
450. Matsushima,Y, Makino,H, Kanatsuka,A, Yamamoto,M, Kumagai,A: Immunohistochemical changes of somatostatin cells in the pancreatic islets of rats after streptozotocin administration. Endocrinologia Japonica 25:115, 1978
451. Kanatsuka,A, Makino,H, Matsushima,Y, Osegawa,M, Kasanuki,J, Miyahira,M, Yamamoto,M, Kumagai,A: Effect of glucose on somatostatin secretion from isolated pancreatic islets of normal and streptozotocin-diabetic rats. Endocrinology 109:652-657, 1981
452. Papachristou,D, Pham,K, Zingg,H, Patel,Y: Tissue-specific alterations in somatostatin mRNA accumulation in streptozotocin-diabetes. Diabetes 38:752-757, 1989
453. Kadowaki,S, Taminato,T, Chiba,T, Goto,Y, Nozawa,M, Seino,Y, Matsukura,S, Fujita,T: Reversal of the enhanced somatostatin release from the isolated, perfused diabetic rat pancreas after the amelioration of diabetes by whole pancreas transplantation. Diabetes 29:742-746, 1980
454. Brubaker,P, So,D, Drucker,D: Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes. Endocrinology 124:3003-3009, 1989
455. Kazumi,T, Utsumi,M, Yoshino,G, Ishihara,H, Hirose,Y, Makimura,H, Baba,S: Somatostatin concentration responds to arginine in portal plasma: effects of fasting, streptozotocin diabetes, and insulin administration in diabetic rats. Diabetes 29:71-73, 1980
456. Chiba,T, Taminato,T, Kadowaki,S, Chihara,K, Matsukura,S, Nozawa,M, Seino,Y, Fujita,T: Reversal of increased gastric somatostatin in streptozotocin-diabetic rats by whole pancreas transplantation. Diabetes 30:724-727, 1981
457. Ballmann,M, Conlon,J: Changes in the somatostatin, substance P and vasoactive intestinal polypeptide content of the gastrointestinal tract following streptozotocin-induced diabetes in the rat. Diabetologia 28:355-358, 1985
458. McEvoy,R, Hegre,O: Morphometric quantitation of the pancreatic insulin-, glucagon-, and somatostatin-positive cell populations in normal and alloxan-diabetic rats. Diabetes 26:1140-1146, 1977
459. Hara,M, Patton,G, Gerich,J: Increased somatostatin release from pancreases of alloxan diabetic rats perfused in vitro. Life Sciences 24:625-628, 1979
460. Matsushima,Y, Makino,H, Kanatsuka,A, Osegawa,M, Kumagai,A, Nishimura,M, Tochino,Y, Makino,S: Pancreatic somatostatin contents in spontaneously diabetic KK and non-obese diabetic (NOD) mice. Hormone and Metabolic Research 14:292-298, 1982
234
461. Trimble,E, Gerber,P, Renold,A: Abnormalities of pancreatic somatostatin secretion corrected by in vivo insulin treatment of streptozotocin-diabetic rats. Diabetes 30:865-867, 1981
462. Nie,Y, Nakashima,M, Brubaker,P, Li,Q-L, Perfetti,R, Janson,E, Zambre,Y, Pipeleers,D, Friedman,T: Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J Clin Invest 105:955-965, 2000
463. Unger,R, Orci,L: The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16, 1975
464. Unger,R: Letter: Glucagon in pathogenesis of diabetes. Lancet 1:1036-2, 1975
465. Unger,R: The Banting Memorial Lecture 1975. Diabetes and the alpha cell. Diabetes 25:136-151, 1976
466. Unger,R, Orci,L: Possible roles of the pancreatic D-cell in the normal and diabetic states. Diabetes 26:241-244, 1977
467. Shah,P, Basu,A, Basu,R, Rizza,R: Impact of lack of suppression of glucagon on glucose tolerance in humans. American Journal of Physiology Endocrinology and Metabolism 277:E283-E290, 1999
468. Reaven,G, Chen,Y, Golay,A, Swislocki,A, Jaspan,J: Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106-110, 1987
469. Busiguina,S, Argente,J, Garcia-Segura,LM, Chowen,JA: Anatomically specific changes in the expression of somatostatin, growth hormone-releasing hormone and growth hormone receptor mRNA in diabetic rats. Journal of Neuroendocrinolgy 12:29-39, 2000
470. Ramlal,T, Rastogi,S, Vranic,M, Klip,A: Decrease in glucose transporter number in skeletal muscle of mildly diabetic (streptozotocin-treated) rats. Endocrinology 125:890-897, 1989
471. Makino,H, Matsushima,Y, Kanatsuka,A, Kumagai,A, Nishimura,M: Changes in pancreatic somatostatin content in spontaneously diabetic mice, as determined by radioimmunoassay and immunohistochemical methods. Endocrinology 104:243-247, 1979
472. Joanny,P, Peyre,G, Steinberg,J, Guillaume,V, Pesce,G, Becquet,D, Oliver,C: Effect of diabetes on in vivo and in vitro hypothalamic somatostatin release. Neuroendocrinology 55:485-491, 1992
473. XiaoMing,Z, Xi,Z, Fang,S, Jilin,Z: Specific changes of somatostatin mRNA expression in the frontal cortex and hippocampus of diabetic rats. Journal of Anatomy 204:221-225, 2004
235
474. Iki,K, Pour,P: Distribution of pancreatic endocrine cells including IAPP-expressing cells in non-diabetic and type 2 diabetic cases. J Histochem Cytochem 55:111-118, 2007
475. Saito,K, Yaginuma,N, Takahashi,T: Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku Journal of Experimental Medicine 129:273-283, 1979
476. Vinik,A, Levitt,N, Pimstone,B, Wagner,L: Peripheral plasma somatostatin-like immunoreactive responses to insulin hypoglycemia and a mixed meal in healthy subjects and in noninsulin-dependent maturity-onset diabetics. J Clin Endocrinol Metab 52:330-337, 1981
477. Berelowitz,M, Coleman,D, Frohman,L: Temporal relationship of tissue somatostatin-like immunoreactivity to metabolic changes in genetically obese and diabetic mice. Diabetes 29:717-723, 1980
478. Pesce,G, Guillaume,V, Dutour,A, Dadoun, Joanny,P, Steinberg,J, Oliver,C: Effect of streptozotocin-induced diabetes on somatostatin receptors in the anterior pituitary, hypothalamus and cerebral cortex of the male rat. Life Sciences 54:1927-1933, 1994
479. Bruno,J, Xu,Y, Song,J, Berelowitz,M: Pituitary and hypothalamic somatostatin receptor subtype messenger ribonucleic acid expression in the food-deprived and diabetic rat. Endocrinology 135:1787-1792, 1994
480. Hilsted,J, Madsbad,S, Krarup,T, Tronier,B, Galbo,H, Sestoft,L, Schwartz,T: No response of pancreatic hormones to hypoglycemia in diabetic autonomic neuropathy. J Clin Endocrinol Metab 54:815-819, 1982
481. Baron,J: Dose response relationships of insulin hypoglycaemia and gastric acid in man. Gut 11:826-836, 1970
482. Greenberg,G, Pokol-Daniel,S, Fung,L: Influence of gastric acid on circulating somatostatin-14 and -28 released after insulin-induced hypoglycemia in conscious dogs. Endocrinology 131:1527-1533, 1992
483. Glaser,B, Vinik,A, Valtysson,G, Zoghlin,G: Truncal vagotomy abolishes the somatostatin response to insulin-induced hypoglycemia in man. J Clin Endocrinol Metab 52:823-825, 1981
484. Hermansen,K: Secretion of somatostatin from the normal and diabetic pancreas. Studies in vitro. Diabetologia 19:492-504, 1980
485. Muroyama,A, Uehara,S, Yatsushiro,S, Echigo,N, Morimoto,R, Morita,M, Hayashi,M, Yamamoto,A, Koh,D, Moriyama,Y: A novel variant of ionotropic glutamate receptor regulates somatostatin secretion from delta-cells of islets of Langerhans. Diabetes 53:1743-1753, 2004
236
486. Madsbad,S, Hilsted,J, Krarup,T, Tronier,B, Sestoft,L: Plasma somatostatin increases during hypoglycaemia in insulin-dependent patients with and without B-cell function. Clincal Endocrinology (Oxford) 19:47-51, 1983
487. Wass,J, Penman,E, Medbak,S, Dawson,A, Tsiolakis,D, Marks,V, Besser,G, Rees,L: Immunoreactive somatostatin changes during insulin-induced hypoglycaemia and operative stres in man. Clincal Endocrinology (Oxford) 12:269-275, 1980
488. Webb,S, Levy,I, Wass,J, Llorens,A, Penman,E, Casamitjana,R, Wu,P, Gaya,J, Martinez,M, Rivera,F: Studies on the mechanisms of somatostatin release after insulin induced hypoglycemia in man. Clincal Endocrinology (Oxford) 21:667-675, 1984
489. Gerich,J: Role of somatostatin and its analogues in the pathogenesis and treatment of diabetes mellitus. Metabolism 39 Suppl 2:52-54, 1990
490. Murao,K, Sato,M, Mizobuchi,M, Nimi,M, Ishida,T, Takahara,J: Acute effects of hypoglycemia and hyperglycemia on hypothalamic growth hormone-releasing hormone and somatostatin gene expression in the rat. Endocrinology 134:418-423, 1994
491. Lengyel,A, Grossman,A, Nieuwenhuyzen-Kruseman,A, Ackland,J, Rees,L, Besser,M: Glucose modulation of somatostatin and LHRH release from rat hypothalamic fragments in vitro. Neuroendocrinology 39:31-38, 1984
492. Berelowitz,M, Ting,N, Murray,L: Glucopenia-mediated release of somatostatin from incubated rat hypothalamus: monosaccharide specificity and role of glycolytic intermediates. Endocrinology 124:826-830, 1989
493. Baes,M, Vale,W: Characterization of the glucose-dependent release of growth hormone-releasing factor and somatostatin from superfused rat hypothalami. Neuroendocrinology 51:202-207, 1990
494. Sato,M, Murao,K, Matsubara,S, Niimi,M, Chihara,K, Takahara,J: Central glucopenia induced by 2-deoxy-D-glucose stimulates somatostatin secretion in the rat. Journal of Neuroendocrinolgy 7:801-805, 1995
495. Agnati,L, Fuxe,K, Eneroth,P, Zini,I, Harfstrand,A, Grimaldi,R, Zoli,M: Intravenous uridine treatment antagonizes hypoglycaemia-induced reduction in brain somatostatin-like immunoreactivity. Acta Physiologica Scandinavica 126:535-531, 1986
496. Rodriguez-Sanchez,M, Colas,B, Prieto,J, Arilla,E: Effects of insulin-induced hypoglycemia on somatostatin level and binding in rat cerebral cortex and hippocampus. Brain Research 494:36-41, 1989
497. Rodriguez-Sanchez,M, Arilla,E: Somatostatin concentration and binding in the rat hypothalamus and striatum during severe insulin-induced hypoglycemia. Bioscience Reports 9:199-206, 1989
237
498. Berelowitz,M, Dudlak,D, Frohman,L: Release of somatostatin-like immunoreactivity from incubated rat hypothalamus and cerebral cortex. Effects of glucose and glucoregulatory hormones. J Clin Invest 69:1293-1301, 1982
499. Karamanos,B, Tolis,G, Zoupas,C, Kardoyiannis,T, Benroubi,M, Alivisatos,J, Yotis,A: Effect of the long-acting somatostatin analogue SMS 201-995 on the glycaemic control in insulin-treated diabetics. Scandinavian Journal of Gastroenterology 21 (S119):262-266, 1986
500. Orskov,L, Moller,N, Bak,J, Porksen,N, Schmitz,O: Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism 45:211-217, 1996
501. Spinas,G, Bock,A, Keller,U: Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care 8:429-435, 1985
502. Davies,R, Miller,M, Turner,S, Watson,M, McGill,A, Orskov,H, Alberti,K, Johnston,D: Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes. Clincal Endocrinology (Oxford) 25:739-747, 1986
503. Plewe,G, Nolken,G, Krause,U, Del Pozo,E, Beyer,J: Somatostatin analogue SMS 201-995 in type 1 diabetes mellitus: initial experience after repeated administration. Scandinavian Journal of Gastroenterology 21 (S119):166-169, 1986
504. Osei,K, O'Dorisio,T, Malarkey,W, Craig,E, Cataland,S: Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy. Diabetes 38:704-709, 1989
505. Usenmez,T, Yildiz,O, Oktenli,C, Ozgurtas,T, Kutlu,M: Octreotide administration in diabetic rats: effects on renal function and morphology. Journal of Diabetes and Its Complications 14:53-59, 2000
506. Reisine,T, Bell,G: Molecular biology of somatostatin receptors. Endocr Rev 16:427-442, 1995
507. Taylor,J, Coy,D: The receptor pharmacology of somatostatin agonists and antagonists: implications for clinical utility. Journal of Endocrinological Investigation 29:8-10, 1997
508. Rossowski,W, Cheng,B, Jiang,N, Coy,D: Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin and adrenomedullin on gastric acid release using a new SRIF antagonist analogue. British Journal of Pharmacology 125:1081-1087, 1998
509. Hocart,S, Jain,R, Murphy,W, Taylor,J, Coy,D: Highly potent cyclic disulfide antagonists of somatostatin. Journal of Medicinal Chemistry 42:1863-1871, 1999
238
510. Cryer,P, Gerich,J: Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrine. Diabetes Care 6:95-99, 1983
511. Amiel,S, Tamborlane,W, Simonson,D, Sherwin,R: Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. New England Journal of Medicine 316:1376-1383, 1987
512. Bergenstal,R, Polonsky,K, Pons,G, Jaspan,J, Rubenstein,A: Lack of glucagon response to hypoglycemia in type I diabetics after long-term optimal therapy with a continuous subcutaneous insulin infusion pump. Diabetes 32:398-402, 1983
513. Bolli,G, Dimitriadis,G, Pehling,G, Baker,B, Haymond,M, Cryer,P, Gerich,J: Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. New England Journal of Medicine 310:1706-1711, 1984
514. Bolzan,A, Bianchi,M: Genotoxicity of streptozotocin. Mutation Research 512:121-134, 2002
515. Mansford,K, Opie,L: Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet 291:670-671, 1968
516. Szkudelski,T: The mechanism of alloxan and streptozoticin action in B cells of the rat pancreas. Physiological Research 50:536-546, 2001
517. Hosokawa,M, Dolci,W, Thorens,B: Differential selectivity of GLUT1- and GLUT2-expressing beta cells to streptozotocin. Biochemical and Biophysical Research Communications 289:1114-1117, 2001
518. Elsner,M, Guldbakke,B, Tiedge,M, Munday,R, Lenzen,S: Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 43:1528-1533, 2000
519. Shafrir E: Diabetes in animals: Contribution to the understanding of diabetes by study of its etiopathology in animal models. In Ellenberg and Rifkin's Diabetes Mellitus. Sixth ed. Porte Jr. D, Sherwin R, Baron A, Eds. New York, McGraw-Hill, 2003, p. 231-255
520. Turk,J, Corbett,J, Ramanadham,S, Bohrer,A, McDaniel,M: Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochemical and Biophysical Research Communications 197:1458-1464, 1993
521. Nukatsuka,M, Yoshimura,Y, Nishida,M, Kawada,K: Importance of the concentration of ATP in rat pancreatic beta cells in the mechanism of streptozotocin-induced cytotoxicity. Journal of Endocrinology 127:161-165, 1990
522. Marty,N, Dallaporta,M, Foretz,M, Emery,M, Tarussio,D, Bady,I, Binnert,C, Beermann,F, Thorens,B: Regulation of glucagon secretion by glucose transporter type 2 (glut2) and astrocyte-dependent glucose sensors. J Clin Invest 115:3545-3553, 2005
239
523. The DCCT Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 65:30-36, 1986
524. Dimitrakoudis,D, Vranic,M, Klip,A: Effects of hyperglycemia on glucose transporters of the muscle: use of renal glucose reabsorption inhibitor phloridzin to control glycemia. Journal of the American Society of Nephrology 3:1078-1091, 1992
525. Klee G: Laboratory techniques for recognition of endocrine disorders. In Williams Textbook of Endocrinology. Tenth ed. Larsen P, Kronenberg H, Melmed S, Polonsky K, Eds. Philadelphia, Saunders, 2003, p. 65-79
526. Livak,K, Schmittgen,T: Analysis of relative gene expression data using real-time quantitative PCR and the 2-Ct Method. Methods 25:402-408, 2001
527. Brown,M, Fisher,L: Central nervous system actions of somatostatin-related peptides. Advances in Experimental Medicine and Biology 188:217-228, 1985
528. Miles,P, Yamatani,K, Brown,M, Lickley,L, Vranic,M: Intracerebroventricular administration of somatostatin octapeptide counteracts the hormonal and metabolic responses to stress in normal and diabetic dogs. Metabolism 43:1134-1143, 1994
529. Inouye,K, Chan,O, Riddell,M, Akirav,E, Matthews,S, Vranic,M: Mechanisms of impaired hypothalamic-pituitary-adrenal (HPA) function in diabetes: reduced counterregulatory responsiveness to hypoglycemia. Diabetes Nutrition and Metabolism 15:348-355, 2002
530. Shulman G, Barrett E, Sherwin R: Integrated Fuel Metabolism. In Ellenberg & Rifkin's Diabetes Mellitus. Sixth ed. Porte JrD, Sherwin R, Baron A, Eds. New York, McGraw-Hill, 2003, p. 1-13
531. Hunyady,B, Hipkin,R, Schonbrunn,A, Mezey,E: Immunohistochemical Localization of Somatostatin Receptor SST2A in the Rat Pancreas. Endocrinology 138:2636-2639, 1997
532. Ludvigsen,E, Olsson,R, Stridsberg,M, Janson,E, Sandler,S: Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 52:391-400, 2004
533. Portela-Gomes,G, Stridsberg,M, Grimelius,L, Oberg,K, Janson,E: Expression of the Five Different Somatostatin Receptor Subtypes in Endocrine Cells of the Pancreas. [Miscellaneous Article]. Applied Immunohistochemistry and Molecular Morphology 8:126-132, 2000
534. Hauge-Evans,A, King,A, Carmignac,D, Richardson,C, Robinson,I, Low,M, Christie,M, Persaud,S, Jones,P: Somatostatin secreted by islet delta-cells fulfulls multiple roles as a paracrine regulatory of islet function. Diabetes 58:403-411, 2009
240
535. Reubi,J, Kappeler,A, Waser,B, Schonbrunn,A, Laissue,J: Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab 83:3746-3749, 1998
536. Tannenbaum,G, Colle,E, Wanamaker,L, Gurd,W, Goldman,H, Seemayer,T: Dynamic Time-Course Studies of the Spontaneously Diabetic BB Wistar Rat. II. Insulin-, Glucagon-, and Somatostatin-Reactive Cells in the Pancreas. Endocrinology 109:1880-1887, 1981
537. Patel,Y, Ruggere,D, Malaisse-Lagae,F, Orci,L: Alterations in somatostatin and other islet cell functions in the spontaneously diabetic BB Wistar rat: biochemical and morphological characterization. Metabolism 32 (7 Suppl 1):18-25, 1983
538. Papaccio,G, Mezzogiorno,V: Morphological aspects of glucagon and somatostatin islet cells in diabetic Bio Breeding and low-dose streptozotocin-treated Wistar rats. Pancreas 4:289-294, 1989
539. McCrimmon,R, Evans,M, Jacob,R, Fan,X, Zhu,Y, Shulman,G, Sherwin,R: AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. American Journal of Physiology Endocrinology and Metabolism 283:1076-1083, 2002
540. Seemayer,T, Colle,E, Tannenbaum,G, Oligny,L, Guttmann,R, Goldman,H: Spontaneous diabetes mellitus syndrome in the rat. III. Pancreatic alterations in aglycosuric and untreated diabetic BB Wistar-derived rats. Metabolism 32:26-32, 1983
541. Patel,Y, Wheatley,T, Malaisse-Lagae,F, Orci,L: Elevated portal and peripheral blood concentration of immunoreactive somatostatin in spontaneously diabetic (BBL) Wistar rats: suppression with insulin. Diabetes 29:757-761, 1980
542. Wilke,R, Hillard,C: Decreased adrenal medullary catecholamine release in spontaneously diabetic BB-Wistar rats. Role of hypoglycemia. Diabetes 43:724-729, 1994
543. Zhou,H, Zhang,T, Oseid,E, Harmon,J, Tonooka,N, Robertson,R: Reversal of defective glucagon responses to hypoglyemia in insulin-dependent autoimmune diabetic BB rats. Endocrinology 148:2863-2869, 2007
544. Shapiro,B, Berelowitz,M, Pimstone,B, Kronheim,S, Sheppard,M: Tissue and serum somatostatin-like immunoreactivity in fed, 15-h-fasted, and 72-h-fasted rats. Diabetes 28:182-184, 1979
545. Schauder,P, McIntosh,C, Arends,J, Frerichs,H: Effect of fasting on the release of insulin and somatostatin from perifused islets of Langerhans. Diabetes 28:204-207, 1979
241
546. Adeghate,E: Distribution of calcitonin-gene-related peptide, neuropeptide-Y, vasoactive intestinal polypeptide, cholecystokinin-8, substance P and islet peptides in the pancreas of normal and diabetic rats. Neuropeptides 33:227-235, 1999
547. Kim,A, Miller,K, Jo,J, Kilimnik,G, Wojcik,P, Hawa,M: Islet architecture: A comparative study. Islets 1:129-136, 2009
548. Brunicardi,F, Atiya,A, Moldovan,S, Lee,T, Fagan,S, Kleinman,R, Adrian,T, Coy,D, Walsh,J, Fisher,W: Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas. Pancreas 27:e84-e89, 2003
549. Yao,C, Gill,M, Martens,C, Coy,D, Hsu,W: Somatostatin inhibits insulin release via SSTR2 in hamster clonal beta-cells and pancreatic islets. Regulatory Peptides 129:79-84, 2005
550. Brown,M, Fisher,L: Corticotrpin-releasing factor: effects on the autonomic nervous system and visceral systems. Federation Proceedings 44:243-248, 1985
551. Brown,M, Fisher,L, Webb,V, Vale,W: Corticotropin-releasing factor: a physiologic regulator of adrenal epinephrine secretion. Brain Research 328:355-357, 1985
552. Bruhn,T, Plotsky,P, Vale,W: Effect of paraventricular lesions on corticotropin-releasing factor (CRF)-like immunoreactivity in the stalk-median eminence: Studies on the adrenocorticotrophin response to ether stress and exogenous CRF. Endocrinology 114:57-62, 1984
553. Engeland,W, Lilly,M, Bruhn,T, Gann,D: Comparison of corticotropin-releasing factor and acetylcholine on catecholamine secretion in dogs. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 253:R209-R215, 1987
554. Bruhn,T, Engeland,W, Anthony,E, Gann,D, Jackson,I: Corticotropin-releasing factor in the dog adrenal medulla is secreted in response to hemorrhage. Endocrinology 120:25-33, 1987
555. Munck,A: Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new eivdence, molecular mechanisms, and physiological significance. Perspectives in Biology and Medicine 14:265-269, 1971
556. Chrousos,G: The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. The International Journal of Obesity 24:S50-S55, 2000
557. Chan,O, Chan,S, Inouye,K, Vranic,M, Matthews,S: Molecular regulation of the hypothalamo-pituitary-adrenal (HPA) axis in streptozotocin-induced diabetes: Effects of insulin treatment. Endocrinology 142:4872-4879, 2001
558. Marti,O, Gavalda,A, Jolin,T, Armario,A: Effect of regularity of exposure to chronic immobilization stress on the circadian pattern of pituitary adrenal hormones, growth
242
hormone, and thyroid stimulating hormone in the adult male rat. Psychoneuroendocrinology 18:67-77, 1993
559. Velasco,A, Huerta,I, Granda,T, Cachero,T, Menendez,E, Marin,B: Circadian rhythms of plasma corticosterone at different times after induction of diabetes. Responses to corticoadrenal stimulation in light and dark phases. Life Sciences 52:965-974, 1993
560. Cameron,O, Kronfol,Z, Grenden,J, Caroll,B: Hypothalamic-pituitary-adrenocortical activity in patients with diabetes mellitus. Arch Gen Psychiatry 41:1090-1095, 1984
561. Ben-Shlomo,A, Melmed,S: Pituitary somatostatin receptor signaling. TRENDS in Endocrinology and Metabolism 21:123-133, 2010
562. Abbruscato,T, Thomas,S, Hruby,V, Davis,T: Blood-brain barrier permeability and bioavailability of a highly potent and -selective opioid receptor antagonist, CTAP: comparison with morphine. Journal of Pharmacology and Experimental Therapeutics 280:402-409, 1997
563. Chan,O, Inouye,K, Akirav,E, Park,E, Riddell,M, Matthews,S, Vranic,M: Hyperglycemia does not increase basal hypothalamo-pituitary-adrenal activity in diabetes but it does impair the HPA response to insulin-induced hypoglycemia. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 289:R235-R246, 2005
564. Chiodera,P, Coiro,V: Endogenous opioid mediation of somatostatin inhibition of arginine vasopressin release evoked by insulin-induced hypoglycemia in man. Journal of Neural Transmission 83:121-126, 1991
565. Viollet,C, Vaillend,C, Videau,C, Bluet-Pajot,M, Ungerer,A, L'Hertier,A, Potier,B, Billard,J-M, Schaeffer,J, Smith,R, Rohrer,S, Wilkinson,H, Zheng,H, Epelbaum,J: Involvement of sst2 somatostatin receptor in locomotor exploratory activity and emotional reactivity in mice. European Journal of Neuroscience 12:3761-3770, 2000
566. Zeyda,T, Diehl,N, Paylor,R, Brennan,M, Hochgeschwender,U: Impairment in motor learning of somatostatin null mutant mice. Brain Research 906:107-117, 2001
567. Epelbaum,J, Bertherat,J, Prevost,G, Kordon,C, Meyerhof,W, Wulfsen,I, Richter,D, Plouin,P: Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 80:1837-1844, 1995
568. Ueberberg,B, Tourne,H, Redman,A, Walz,M, Mchmid,K, Mann,K, Petersenn,S: Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Hormone and Metabolic Research 37:722-728, 2005
569. Pisarek,H, Pawlikowski,M: Immunohistochemical localization of the somatostatin receptor subtype 2A in the rat adrenal gland. Folia Histochemica et Cytobiologica 2002
243
570. Patel,D, Skau,K: Effects of chronic sodium salicylate feeding on the impaired glucagon and epinephrine responses to insulin-induced hypoglycaemia in streptozotocin diabetic rats. Diabetologia 32:61-66, 1989
571. Weir,G, Knowlton,S, Martin,D: Somatostatin inhibition of epinephrine-induced glucagon secretion. Endocrinology 95:1744-1746, 1974
572. Hahn,H, Gottschling,H, Woltanski,P: Effect of somatostatin on insulin secretion and cAMP content of isolated pancreatic rat islets. Metabolism 27:1291-1294, 1978
573. Schuit,F, Derde,M, Pipeleers,D: Sensitivity of rat pancreatic A and B cells to somatostatin. Diabetologia 32:207-212, 1989
574. Fehmann,H, Strowski,M, Goke,B: Functional characterization of somatostatin receptors expressed on hamster glucagonoma cells. American Journal of Physiology Endocrinology and Metabolism 268:E40-E47, 1995
575. Skroblin,P, Grossmann,S, Schafer,G, Rosenthal,W, Klussmann,E: Mechanisms of protein kinase A anchoring. International Review of Cellular and Molecular Biology 283C:235-330, 2010
576. Schuit,F, Pipeleers,D: Differences in adrenergic recognition by pancreatic A and B cells. Science 232:875-877, 1986
577. Gromada,J, Bokvist,K, Ding,W, Barg,S, Buschard,K, Renstrom,E, Rorsman,P: Adrenaline stimulates glucagon aecretion in pancreatic a-cells by increasing the Ca2+ current and the number of granules close to the L-type Ca2+ channels. The Journal of General Physiology 110:217-228, 1997
578. Vieira,E, Liu,Y, Gylfe,E: Involvement of alpha1 and beta-adrenoceptors in adrenaline stimulation of the glucagon-secreting mouse alpha-cell. Naunyn Schmiedeberg's Archives of Pharmacology 369:179-183, 2004
579. Gromada,J, Hoy,M, Bushchard,K, Salchi,A, Rorsman,P: Somatostatin inhibits exocytosis in rat pancreatic -cells by Gi2-dependent activation of calcineurin and depriming of secretory granules. Journal of Physiology 535:519-532, 2001
580. Gerich,J: Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 37:1608-1617, 1988
581. Melmed S, Kleinberg D: Anterior pituitary. In Williams Textbook of Endocrinology. Tenth ed. Larsen P, Koronenberg H, Melmed S, Polonsky K, Eds. Philadelphia, Saunders, 2003, p. 177-279
582. Gerich,J, Campbell,P: Overview of counterregulation and its abnormalities in diabetes mellitus and other conditions. Diabetes/Metabolism Reviews 4:93-111, 1988
583. Cryer,P: Role of growth hormone in glucose counterregulation. Hormone Research 46:192-194, 1996
244
584. Wurzburger,M, Prelevic,G, Sonksen,P, Balint-Peric,L: The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion. Hormone and Metabolic Research 24:329-332, 1992
585. Grant,M, Kumar,U: The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regulatory Peptides 159:3-8, 2010
586. Dimitriadis,G, Tessari,P, Gerich,J: Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependence diabetes mellitus. Metabolism 32:987-992, 1983
587. Vondra,K, Voborska,M, Kvapil,M, Weber,P, Dvorakova,H, Stanicka,S, Zamrazil,V: Somatostatin: Beneficial effects on remission in young adult patients with newly diagnosed diabetes mellitus type 1. Physiological Research 53:115-117, 2004
588. Strowski,M, Cashen,D, Birzin,E, Yang,L, Singh,V, Jacks,T, Nowak,K, Rohrer,S, Patchett,A, Smith,R, Schaeffer,J: Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist. Endocrinology 147:4664-4673, 2006
589. Gromada,J, Franklin,I, Wollheim,C: -Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84-116, 2007
590. Vieira,E, Salehi,A, Gylfe,E: Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia 50:370-379, 2007
591. de Heer,J, Rasmussen,C, Coy,D, Holst,J: Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263-2270, 2008
592. Singh,V, Grotzinger,C, Nowak,K, Zacharias,S, Gonez,E, Pless,G, Sauer,I, Eichhorn,I, Pfeiffer-Guglielmi,B, Hamprecht,B, Wiedenmann,B, Plockinger,U, Strowski,M: Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition. Endocrinology 148:3887-3899, 2007
593. Giaccari,A, Rossetti,L: Predominant role of gluconeogeneis in the hepatic glycogen repletion of diabetic rats. J Clin Invest 89:36-45, 1992
594. Albuquerque,G, Gazola,V, Garcia,R, Souza,K, Barrena,H, Curi,R, Bazotte,R: Gluconeogenesis and ketogenesis in perfused liver of rats submtited to short-term insulin-induced hypoglycemia. Cell Biochemistry and Function 26:228-232, 2008
595. Edgerton,D, Ramnanan,C, Grueter,C, Johnson,K, Lautz,M, Neal,D, Williams,P, Cherrington,A: Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo. Diabetes 58:2766-2775, 2009
245
596. Beale,E, Andreone,T, Koch,S, Granner,M, Granner,D: Insulin and glucagon regulate cytosolic phosphoenolpyruvate carboxykinase (GTP) mRNA in rat liver. Diabetes 33:328-332, 1984
597. Kraus-Friedmann,N: Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 64:170-259, 1984
598. Christ,B, Nath,A, Bastian,H, Jungermann,K: Regulation of the expression of the phosphoenolpyruvate carboxykinase gene in cultured rat heptocytes by glucagon and insulin. European Journal of Biochemistry 178:373-379, 1988
599. Sasaki,K, Cripe,T, Koch,S, Andreone,T, Petersen,D, Beale,E, Granner,D: Mulithormonal regulation of phosphoenolpyruvate carboxylase gene transcription. Journal of Biological Chemistry 259:15242-15251, 1984
600. Nordlie,R, Arion,W, Glende Jr,E: Liver microsomal glucose 6-phosphatase, inorganic pyrophosphate, and pyrophosphate-glucose. IV. Effects of adrenalectomy and cortisone administration on activities assayed in the absence and presence of deoxycholate. Journal of Biological Chemistry 240:3479-3484, 1965
601. Segal,H, Washko,M: Studies of liver glucose-6-phosphate. Journal of Biological Chemistry 234:1937-1941, 1959
602. Klover,P, Monney,R: Hepatocytes: critical for glucose homeostasis. The International Journal of Biochemistry and Cell Biology 36:753-758, 2004
603. Argaud,D, Zhang,Q, Pan,W, Miatra,S, Pilkis,S, Lange,A: Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5`-flanking sequence. Diabetes 45:1563-1571, 1996
604. O'Brien,R, Streeper,R, Ayala,J, Stadelmaier,B, Hornbuckle,L: Insulin-regulated gene expression. Biochemical Society Transactions 29:552-558, 2001
605. Modaressi,S, Christ,B, Bratke,J, Zahn,S, Heise,T, Jungermann,K: Molecular cloning, sequencing and expression of the cDNA of the mitochondrial form of phosphoenolpyruvate carboxykinase from human liver. Biochem J 315:807-814, 1996
606. Ito,J, Kuzumaki,T, Otsu,K, Iuchi,Y, Ishikawa,K: Hormonal regulation of aldolase B gene expression in rat primary cultured hepatocytes. Archives of Biochemistry and Biophysics 350:291-297, 1998
607. Lins,P, Wajngot,A, Adamson,U, Vranic,M, Efendic,S: Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia. Diabetes 32:633-636, 1983
608. Friedman,J, Yung,J, Patel,Y, McGrane,M, Hanson,R: Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. Journal of Biological Chemistry 268:12952-12957, 1993
246
609. Saker,F, Ybarra,J, Leahy,P, Hanson,R, Kalhan,S, Ismail-Beigi,F: Glycemia-lowering effect of cobalt chloride in the diabetic rat: role of decreased gluconeogenesis. American Journal of Physiology Endocrinology and Metabolism 274:E984-E991, 1998
610. Davies,G, Crosson,S, Khandelwal,R, Roesler,W: The Phosphorylation State of the cAMP Response Element Binding Protein Is Decreased in Diabetic Rat Liver. Archives of Biochemistry and Biophysics 323:477-483, 1995
611. van Schaftingen,E, Gerin,I: The glucose-6-phosphatase system. Biochem J 362:513-532, 2002
612. Barzilai,N, Rossetti,L: Role of glucokinase and glucose-6-phosphatase in the acute and chronic regulation of hepatic glucose fluxes by insulin. Journal of Biological Chemistry 268:25019-25025, 1993
613. Burchell,A, Cain,D: Rat hepatic microsomal glucose-6-phosphatase protein levels are increased in streptozotocin-induced diabetes. Diabetologia 28:852-856, 1985
614. Mithieux,G, Vidal,H, Zitoun,C, Bruni,N, Daniele,N, Minassian,C: Glucose-6-phosphatase mRNA and activity are increased to the same extent in kidney and liver of diabetic rats. Diabetes 45:891-896, 1996
615. Samuel,V, Beddow,S, Iwasaki,T, Zhang,X-M, Chu,X, Still,C, Gerhard,G, Shulman,G: Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes. Proceedings of the National Academy of Sciences U S A 106:12121-12126, 2009
616. Cherrington,A, Caldwell,M, Dietz,M, Exton,J, Crofford,O: The effect of somatostatin on glucose uptake and production by rat tissues in vitro. Diabetes 26:740-748, 1977
617. Fleig,W, Noether-Fleig,G, Roeben,H, Ditschuneit,H: Hormonal regulation of key gluconeogenic enzymes and glucose release in cultured hepatocytes: effects of dexamethasone and gastrointestinal hormones on glucagon action. Archives of Biochemistry and Biophysics 229:368-378, 1984
618. Cherrington,A, Lacy,W, Chiasson,J: Effect of glucagon on glucose production during insulin deficiency in the dog. J Clin Invest 62:664-677, 1978
619. Abell,T, Richards,A, Yandle,T, Espiner,E, Frampton,C, Ikram,H: Competitive peptide antagonists of ANF-induced cyclic guanosine monophosphate production. Biochemical and Biophysical Research Communications 164:108-113, 1989
620. Holmes,C, Hayford,J, Gonzales,J, Weydert,J: A survery of conitive functioning at difference glucose levels in diabetic persons. Diabetes Care 6:180-185, 1983
621. Frier,B: Defining hypoglycaemia: what level has clinical relevance? Diabetologia 52:31-34, 2009
247
622. Swinnen,S, Mullins,P, Miller,M, Hoekstra,J, Holleman,F: Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia 52:38-41, 2009
623. Cryer,P: Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia 52:35-37, 2009
624. Mokan,M, Mitrakou,A, Veneman,T, Ryan,C, Korytkowski,M, Cryer,P, Gerich,J: Hypoglycemia unawareness in IDDM. Diabetes Care 17:1397-1403, 1994
625. Fanelli,C, Epifano,L, Rambotti,A, Pampanelli,S, Di Vicenzo,A, Modarelli,F, Lepore,M, Anniballe,B, Ciofetta,M, Bottini,P, Porcellati,F, Scionti,L, Santeusanio,F, Brunetti,P, Bolli,G: Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 42:1683-1689, 1993
626. Liu,D, McManus,R, Ryan,E: Improved counter-regulatory hormonal and symptomatic responses to hypoglycemia in patients with insulin-dependent diabetes mellitus after 3 motnhs of less strict glycemic control. Clinical and Investigative Medicine 19:72-82, 1996
627. van Loon,G, Appel,N: beta-Endorphin-induced hyperglycemia is mediated by increased central sympathetic outflow to adrenal medulla. Brain Research 204:236-241, 1981
628. Brown,M, Rivier,J, Vale,W: Somatostatin: central nervous system actions on glucoregulation. Endocrinology 104:1709-1715, 1979
629. Cherrington,A, Chiasson,J, Liljenquist,J, Jennings,A, Keller,U, Lacy,W: The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. J Clin Invest 58:1407-1418, 1976
630. Sacks,H, Waligora,K, Matthews,J, Pimstone,B: Inhibition by somatostatin of glucagon-induced glucose release from the isolated perfused rat liver. Endocrinology 101:1751-1759, 1977
631. Oliver,J, Wagle,S: Studies on the inhibition of insulin release, glycogenolysis and gluconeogenesis by somatostatin in the rat islets of langerhans and isolated hepatocytes. Biochemical and Biophysical Research Communications 62:772-777, 1975
632. Taylor,J, Theveniau,M, Bashirzadeh,R, Reisine,T, Eden,P: Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 15:1229-1236, 1994
633. Bergman,R, Ader,M, Finegood,D, Pacini,G: Extrapancreatic effect of somatostatin infusion to increase glucose clearance. American Journal of Physiology Endocrinology and Metabolism 247:E370-E379, 1984
248
634. Moller,N, Bagger,J, Schmitza,O, Jorgensen,J, Ovesen,P, Moller,J, Alberti,K, Orskov,H: Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm. J Clin Endocrinol Metab 80:1789-1793, 1995
635. Peng,M, Conforti,L, Millhorn,D: Expression of somatostatin receptor genes and acetylcholine receptor development in rat skeletal muscle during postnatal development. International Journal of Molecular Medicine 1:841-848, 1998
636. O'Carroll,A, Raynor,K, Lolait,S, Reisine,T: Characterization of cloned human somatostatin receptor SSTR5. Molecular Pharmacology 46:291-298, 1994
637. Davis,S, Shavers,C, Mosqueda-Garcia,R, Costa,F: Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. Diabetes 46:1328-1335, 1997
638. Heller,S, Cryer,P: Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 40:223-226, 1991
639. Widom,B, Simonson,D: Intermittent hypoglycemia impairs glucose counterregulation. Diabetes 41:1597-1602, 1992
640. Davis,M, Shamoon,H: Counterregulatory adaptation to recurrent hypoglycemia in normal humans. J Clin Endocrinol Metab 73:995-1001, 1991
641. Inouye,K, Yue,J, Chan,O, Kim,T, Akirav,E, Park,E, Riddell,M, Matthews,S, Vranic,M: Effects of insulin treatment without and with recurrent hypoglycemia on hypoglycemic counterregulation and adrenal catecholamine-synthesizing enzymes in diabetic rats. Endocrinology 147:1860-1870, 2006
642. Wilke,R, Riley,D, Lelkes,P, Hillard,C: Decreased catecholamine secretion from the adrenal medullae of chronically diabetic BB-Wistar rats. Diabetes 42:862-868, 1993
643. Fisher,D, Brown,M: Somatostatin analog: plasma catecholamine suppression mediated by the central nervous system. Endocrinology 107:714-718, 1980
644. Role,L, Leeman,S, Perlman,R: Somatostatin and substance P inhibit catecholamine secretion from isolated cells of guinea-pig adrenal medulla. Neuroscience 6:1813-1821, 1981
645. Mizobe,F, Kozousek,V, Dean,D, Livett,B: Pharmacological characterization of adrenal paraneurons: substance P and somatostatin as inhibitory modulators of the nicotinic response. Brain Research 178:555-566, 1979
646. Havel P, Taborsky GJ: Stress-induced activation of the neuroendocrine system and its effects on carbohydrate metabolism. In Ellenberg and Rifkin's Diabetes Mellitus. Sixth ed. Porte JrD, Sherwin R, Baron A, Eds. New York, McGraw-Hill, 2003, p. 127-149
249
647. Inoue,M, Kuriyama,H: Somatostatin inhibits the nicotinic receptor-activated inward current in guinea pig chromaffin cells. Biochemical and Biophysical Research Communications 174:750-757, 1991
648. Livett,B, Boksa,P, Dean,D, Mizobe,F, Lindenbaum,M: Use of isolated chromaffin cells to study basic release mechanisms. Journal of the Autonomic Nervous System 7:59-86, 1983
649. Livett,B, Boksa,P: Receptors and receptor modulation in cultured chromaffin cells. Canadian Journal of Physiology and Pharamcology 62:467-476, 1984
650. Saito,H, Saito,S, Ohuchi,T, Oka,M, Sano,T, Hosoi,E: Co-storage and co-secretion of somatostatin and catecholamine in bovine adrenal medulla. Neuroscience Letters 52:43-47, 1984
651. Brown,M, Fisher,L, Spiess,J, Rivier,C, Rivier,J, Vale,W: Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology 111:928-931, 1982
652. Brown,M, Rivier,J, Vale,W: Somatostatin-28: selective action on the pancreatic -cell and brain. Endocrinology 108:2391-2393, 1981
653. Maggs,D, Jacob,R, Rife,F, Caprio,S, Tamborlane,W, Sherwin,R: Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue. Diabetes 46:70-76, 1997
654. Brown,M, Fisher,L: Brain peptide regulation of adrenal epinephrine secretion. American Journal of Physiology Endocrinology and Metabolism 247:E41-E46, 1984
655. Inouye,K, Chan,O, Yue,J, Andrews,M, Li,Q, Vranic,M, Matthews,S: The effect of long-term insulin treatment with and without antecedent hypoglycemia on neuropeptide and corticosteroid receptor expression in the brains of diabetic rats. Brain Research Bulletin 77:149-157, 2008
656. Brown,M, Rivier,C, Vale,W: Central nervous system regulation of adrenocorticotropin secretion: role of somatostatstatins. Endocrinology 114:1546-1549, 1984
657. Tizabi,Y, Calogero,A: Effect of various neurotransmitters and neuropeptides on the release of corticotropin-releasing hormone from the rat cortex in vitro. Synapse 10:341-348, 1992
658. Axelrod,J, Reisine,T: Stress hormones: their interactions and regulation. Science 224:452-459, 1984
659. Fioramonti,X, Contie,S, Song,Z, Routh,V, Lorsignol,A, Penicaud,L: Characterization of glucosensing neuron subpopulations in the arcuate nucleus: integration in neuropeptide Y and pro-opio melanocortin networks? Diabetes 56:1219-1227, 2007
250
660. Song,Z, Routh,V: Recurrent hypoglycemia reduces the glucose sensitivity of glucose-inhibited neurons in the ventromedial hypothalamus nucleus. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 291:R1283-R1287, 2006
661. Chan,O, Cheng,H, Herzog,R, Czyzyk,D, Zhu,W, Wang,A, McCrimmon,R, Seashore,M, Sherwin,R: Increased GABAergic tone in the ventromedial hypothalamus contributes to suppression of counterregulatory responses after antecedent hypoglycemia. Diabetes 57:1363-1370, 2008
662. Dunn,J, Cranston,i, Marsden,P, Amiel,S, Reed,L: Attenuation of amydgala and frontal cortical responses to low blood glucose concentration in asymptomatic hypoglycemia in type 1 diabetes: a new player in hypoglycemia unawareness? Diabetes 56:2766-2773, 2007
663. Arbelaez,A, Powers,W, Videen,T, Price,J, Cryer,P: Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes 57:470-475, 2008
664. Veneman,T, Mitrakou,A, Mokan,M, Cryer,P, Gerich,J: Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes 43:1311-1317, 1994
665. Maran,A, Crepaldi,C, Trupiani,S, Lucca,T, Jori,E, Macdonald,I, Tiengo,A, Avogaro,A, Del Prato,S: Brain function rescue effect of latate following hypoglycaemia is not an adaptation process in both normal and Type I diabetic subjects. Diabetologia 43:733-741, 2000
666. Boyle,P, Nagy,R, O'Connor,A, Kempers,S, Yeo,RA, Qualls,C: Adaptation in brain glucose uptake following recurrent hypoglycemia. Proceedings of the National Academy of Sciences U S A 91:9352-9356, 1994
667. Koranyi,L, Bourey,R, James,D, Mueckler,M, Fiedorek,FJ, Permutt,M: Glucose transporter gene expression in rat brain: Pretranslational changes associated with chronic insulin-induced hypoglycemia, fasting, and diabetes. Molecular and Cellular Neurosciences 2:244-252, 1991
668. Simpson,I, Appel,N, Hokari,M, Oki,J, Holman,G, Maher,F, Koehler-Stec,E, Vannucci,S, Smith,Q: Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. Journal of Neurochemistry 72:238-247, 1999
669. Segel,S, Fanelli,C, Dence,C, Markham,J, Videen,T, Paramore,D, Powers,W, Cryer,P: Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 50:1911-1917, 2001
670. Evans,M, McCrimmon,R, Flanagan,D, Keshavarz,T, Fan,X, McNay,E, Jacob,R, Sherwin,R: Hypothalamic ATP-sensitive K + channels play a key role in sensing
251
hypoglycemia and triggering counterregulatory epinephrine and glucagon responses. Diabetes 53:2542-2551, 2004
671. McCrimmon,R, Fan,X, Cheng,H, McNay,E, Chan,O, Shaw,M, Ding,Y, Zhu,W, Sherwin,R: Activation of AMP-activated protein kinase within the ventromedial hypothalamus amplifies counterregulatory hormone responses in rats with defective counterregulation. Diabetes 55:1755-1760, 2006
672. Kumagai,A, Kang,Y, Boado,R, Pardridge,W: Upregulation of blood-brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes 44:1399-1404, 1995
673. Chan,O, Inouye,K, Riddell,M, Vranic,M, Matthews,S: Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinologica 28:87-102, 2003
674. Bernard C: Leçons sur les phénomènes de la vie. Cours de physiologies generale du Museum d'Histoir Naturelle. Paris, Librairie Delagrave, 1859,
675. Betancur,C, Azzi,M, Rostene,W: Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy. Trends in Pharmacological Sciences 18:372-386, 1997
676. Mayer,E: Some of the challenges in drug development for irritable bowel syndrome. Gut 48:585-586, 2001
677. Reubi,J, Schaer,J, Wenger,S, Hoeger,C, Erchegyi,J, Waser,B, Rivier,J: SST3-selective potent peptidic somatostatin receptor antagonists. Proceedings of the National Academy of Sciences U S A 97:13973-13978, 2000
678. Ouyang,H, Andersen,T, Chen,W, Nofsinger,R, Steffansen,B, Borchardt,R: A comparison of the effects of p-glycoprotein inhibitors on the blood-brain barrier permeation of cyclic prodrugs of an opioid peptide (DADLE). Journal of Pharmaceutical Sciences 98:2227-2236, 2009
679. Hukovic,N, Rocheville,M, Kumar,U, Sasi,R, Khare,S, Patel,Y: Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail. Journal of Biological Chemistry 274:24550-24558, 1999
680. Liu,Q, Cescato,R, Dewi,D, Rivier,J, Reubi,J, Schonbrunn,A: Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Molecular Pharmacology 68:90-101, 2005
681. Presky,D, Schonbrunn,A: Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. Journal of Biological Chemistry 263:714-721, 1988
682. Roettger,B, Ghanekar,D, Rao,R, Toledo,C, Yingling,J, Pinon,D, Miller,L: Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Molecular Pharmacology 51:357-362, 1997
252
683. Pheng,L, Dumont,Y, Fournier,A, Chabot,J, Beaudet,A, Quirion,R: Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells. British Journal of Pharmacology 139:695-704, 2003
684. Cescato,R, Schulz,S, Waser,B, Eltschinger,V, Rivier,J, Wester,H, Culler,M, Ginj,M, Liu,Q, Schonbrunn,A, Reubi,J: Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. Journal of Nuclear Medicine 47:502-511, 2006
685. Rossowski,W, Gu,Z, Akarca,U, Jensen,R, Coy,D: Characterization of somatostatin receptor subtypes controlling rat gastric acid and pancreatic amylase release. Peptides 15:1421-1424, 1994
686. Martinez,V, Curi,A, Torkian,B, Schaeffer,J, Wilkinson,H, Walsh,J, Tache,Y: High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice. Gastroenterology 114:1125-1132, 1998
687. Zhao,C, Martinez,V, Piqueras,L, Wang,L, Tache,Y, Chen,D: Control of gastric acid secretion in somatostatin receptor 2 deficient mice: shift from endocrine/paracrine to neurocrine pathways. Endocrinology 149:498-505, 2008
688. Fery,F, Tappy,L, Schneiter,P, Deviere,J, Balasse,E: Effect of somatostatin on duodenal glucose absorption in man. J Clin Endocrinol Metab 90:4163-4169, 2005
689. Ruggere,M, Patel,Y: Hypersecretion of gastric somatostatin in spontaneously diabetic BB rats. Diabetes 36:849-852, 1987
690. Young,A: Inhibition of glucagon secretion. Advances in Pharmacology 52:151-171, 2005
691. Kawamori,R, Shichiri,M, Kikuchi,M, Yamasaki,Y, Abe,H: The mechanism of exaggerated glucagon response to arginine in diabetes mellitus. Diabetes Research and Clinical Practice 1:131-137, 1985
692. Raskin,P, Aydin,I, Unger,R: Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. Diabetes 25:227-229, 1976
693. Unger,R, Aguilar-Parada,E, Muller,M, Eisentraut,A: Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837-848, 1970
694. Muller,M, Faloona,G, Aguilar-Parada,E, Unger,R: Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. New England Journal of Medicine 283:109-115, 1970
695. Purdon,C, Brousson,M, Nyveen,S, Miles,P, Halter,J, Vranic,M, Marliss,E: The roles of insulin and catecholamines in the glucoregulatory response during intense exercise and early recovery in insulin-dependent diabetic and control subjects. J Clin Endocrinol Metab 76:566-573, 1993
253
696. Sigal,R, Purdon,C, Fisher,S, Halter,J, Vranic,M, Marliss,E: Hyperinsulinemia prevents prolonged hyperglycemia after intense exercise in insulin-dependent diabetic subjects. J Clin Endocrinol Metab 79:1049-1057, 1994
697. Wasserman D, Shi Z, Vranic M: Metabolic implications of exercise and physical fitness in physiology and diabetes. In Ellenberg & Rifkin's Diabetes Mellitus. Sixth ed. Porte JrD, Sherwin R, Baron A, Eds. New York, McGraw-Hill, 2003, p. 453-480